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The role of protein kinase C (PKC) in luteinizing hormone-releasing
hormone (LHRH)-induced luteinizing hormone (LH) release and in the priming effect
of LHRH (the unique ability of LHRH to increase pituitary responsiveness to itself)
was examined. Using pro-oestrous rat anterior pituitary pieces, incubated in vitro, the
PKC inhibitors, staurosporine, Ro 31-8220 and l-(5-isoquinolinesulphonyl)-2-
methylpiperazine (H7) inhibited the induction of LHRH priming, but had no effect on
initial, unprimed LHRH-induced release of LH. Although the primed response was
readily inhibited by staurosporine and Ro 31-8220, it was unusually resistant to block
by H7, suggesting that the induction of LHRH priming may involve activation of an
H7-resistant form of PKC or PKC-like kinase.
Since the PKC(s) which control LH release may have a distinct
pharmacological profile, the effect of PKC inhibitors and activators (phorbol 12,13-
dibutyrate (PDBu) 1,2-dioctanoyl-sn-glycerol (DOG) and mezerein) on hormone
release was examined in more detail. Mezerein and PDBu both induced LH and
growth hormone (GH) release, whereas LH, but not GH, release could be induced by
DOG. Thus DOG may activate at least some of the PKC forms which induce LH
release, but not those which induce GH release. Although PKC activator-induced LH
and GH release were readily inhibited by staurosporine, PDBu- and mezerein-induced
GH release were resistant to block by H7. Furthermore, PKC activator-induced LH
release displayed both H7-sensitive and H7-resistant components. Cytosolic PKC
activity, partially purified from anterior pituitary, was measured in a mixed micelle
assay. A PDBu-induced, Ca2+-independent, histone kinase activity was detected
which was relatively resistant to H7. In contrast, Ca2+-dependent PKC activity
displayed the expected sensitivity to H7. Therefore, the H7-resistant PKCs which
have a role in LHRH priming, LH release and GH release may be of the Ca2+-
independent type. Further attempts to characterise the H7-resistant kinase(s) by H7
displacement of [3H]-dimethylstaurosporine binding to sites in different tissues were
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made, but only limited conclusions could be drawn since the binding sites on PKC for
these two inhibitors appear to be non-identical.
The cellular targets of the PKCs which control anterior pituitary hormone
release were investigated. The induction of LHRH priming, but not LHRH-induced
LH release from unprimed tissue, was inhibited by a number of inhibitors of
phospholipase A2 (PLA2). Phorbol 12,13-dibutyrate-induced LH release was
inhibited by PLA2 inhibitors, suggesting that PLA2 is a target (not necessarily
directly) for the PKC(s) which control LH release. Consistent with this hypothesis,
PDBu elicited [3H]-arachidonic acid (AA) release from prelabelled pituitary tissue, a
response which showed partial H7-resistance. Furthermore, LHRH-induced [3H]-AA
release was relatively H7-resistant, suggesting that the form of PKC responsible for
induction of LHRH priming can activate PLA2. Additional studies indicated that
PKC modulation of PLA2 activity was dependent upon protein synthesis. In contrast,
the PKC(s) which induced GH release did not appear to do so by a mechanism
involving PLA2.
Investigations into the steroidal control of PKCs and their influences in
anterior pituitary tissue showed that the expression and actions of certain PKC forms
in gonadotrophs measured, in vitro, can be modulated by prior treatment with
oestradiol-17(3 (E2), in vivo. Oestrogen treatment of ovariectomised rats enhanced
tissue responsiveness to LHRH and PDBu-induced LH, but not GH release measured
in vitro. This action of E2 seemed to involve synthesis of addition kinases. The E2-
induced increase in gonadotroph responsiveness (in particular the magnitude of the
LHRH priming effect) thus appears to involve LHRH receptor stimulus-secretion
coupling and, in particular, a facilitation of the increased expression of the PKC
form(s) that are crucial for the induction of priming.
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1.1 Signal Transduction Through Phospholipid Hydrolysis
Experiments performed by Hokin and Hokin (1953) showed that carbachol
stimulation of pigeon pancreatic slices enhanced the incorporation of 32P
orthophosphate into the head groups of the membrane phospholipids,
phosphatidylinositol (Ptdlns), and its metabolic precursor, phosphatidate (PtdOH).
These experiments pioneered a number of studies which lead to the hypothesis that
the stimulation of certain cell surface receptors initiates Ptdlns breakdown, and that
this action is important for the control of physiological responses such as cell
division, secretion, contraction and neural activity (Michell, 1975).
More recently, compelling evidence for receptor-induced breakdown of
phosphatidylcholine (PtdCho) and phosphatidylethanolamine has also been provided
and this mechanism has also been suggested to have a physiological role (see
Loffelholz, 1989; Billah and Anthes, 1990; Exton, 1990 for reviews).
1.1.1 Receptor controlled phosphoinositide hydrolysis
Receptor-mediated breakdown of inositol-containing phospholipids
occurs mainly by the catalytic action of the phospholipase C (PLC) enzyme family
(Figure 1.1). A number of reports have suggested that the polyphosphoinositides,
rather than Ptdlns, are the preferred substrates of PLC. For example, in experiments
performed by Irvine and co-workers (1984), a mixture of brain PLCs was incubated
with a lipid mixture which had inositol lipids as a minor component, similar to the
composition of the inner leaflet of the plasma membrane. Phosphatidylinositol 4,5-
bisphosphate (PtdIns(4,5)P2) was hydrolysed 100 times more rapidly than Ptdlns
suggesting that Ptdlns (4,5)P2 is the preferred substrate. Immunological analysis of
purified proteins, biochemical investigations and molecular cloning studies have
revealed that PLC exists as several different classes of isoform (a, (3, y and 8) and that
each class has several related members (see Meldrum et al, 1991 for review).
However, recent studies suggest that the putative PLCa cDNA encodes a protein
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which is devoid of PLC activity (Srivastava et al, 1991). Nevertheless, it is possible
that the authentic (3, y and 8 PLC isoforms have distinct properties, are differentially
regulated and that such differential control is of physiological importance.
Receptor-induced activation of PLC can be mediated via the actions of
guanine nucleotide-binding proteins (G-proteins). In general, receptor-regulated G-
proteins are heterotrimeric structures, consisting of a, (3 and y subunits, which
transduce signals from agonist-occupied receptors to their effector enzymes in a GTP-
dependent manner. For example, in permeabilized rat mast cells, the non-
hydrolysable analogue of GTP, GTP-y-S (which causes prolonged G-protein
activation), induced both histamine release and inositol phospholipid hydrolysis
(Cockcroft and Gomperts, 1985; Cockcroft et al, 1987) indicating G-protein
involvement in agonist-induced histamine release. Further evidence for G-protein
control of PLC activity has come from additional studies which showed that GTP
could modulate agonist binding to PLC-linked receptors and that GTP could activate
PLC in plasma membranes from blowfly salivary glands (Litosch et al, 1985). A
considerable number of G-protein a subunits have been identified (see Simon et al,
1991 for review), some of which have been implicated in the control of PLC activity.
The majority of receptors which couple to PLC do so via pertussis toxin-insensitive
G-proteins, including, for example, the platelet thromboxane A2 receptor which may
couple to certain members of the Gq class (Shenker et al, 1991). Interestingly, a Gq
protein from bovine liver selectively activates the (3i, but not the y or 8 forms of PLC
(Taylor et al, 1991), suggesting that these multiple forms of G-protein may
selectively control the coupling of receptors to specific isoforms of PLC.
It is clear that G-proteins are not the sole means by which receptors can
couple to PLC. In Swiss 3T3 cells, platelet-derived growth factor (PDGF) can
activate the intrinsic tyrosine kinase (TK) activity of the receptor and induce inositol
phosphate production (Berridge et al, 1984). However, PDGF-induced inositol
phospholipid hydrolysis is not modulated by GTP analogues (Cattaneo and
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Vincentini, 1989), suggesting that PLC activation may not be a G-protein dependent
process. Mutant growth factor receptors which are defective in TK activity fail to
elicit inositol phospholipid turnover (Moolenaar et al, 1988) and TK inhibitors
prevent inositol phosphate production by some agonists (Margolis et al, 1989). Thus,
agonist stimulation of certain growth factor receptors may activate PLC in a TK-
dependent manner. The y isoform of PLC can directly associate with the epidermal
growth factor receptor and becomes phosphorylated on specific tyrosine residues, an
effect which correlates with activation of the enzyme (Margolis et al, 1989;
Meisenhelder et al, 1989). However, IgE receptor-induced tyrosine phosphorylation
and activation of PLCy in rat basophilic leukaemia cells appears to involve a non¬
receptor TK (Park et al, 1991). Thus, multiple mechanisms exist for the receptor
control of PLC activity, each of which may selectively control the involvement of
certain PLC forms in receptor responses.
Phospholipase C-catalysed hydrolysis of PtdIns(4,5)P2 generates two
products, inositol (1,4,5) triphosphate (Ins(l,4,5)P3) and 1,2-diacylglycerol (DAG),
both of which serve as second messengers: Ins(l,4,5)P3 mobilises Ca2+ from
intracellular pools (Streb et al, 1983) and DAG activates the phospholipid-dependent
serine/threonine-specific kinase, protein kinase C (PKC) (Nishizuka, 1984) (see
section 1.2).
An important cellular function for Ins(l,4,5)P3 was implied by early
studies which showed that activation of Ca2+-mobilising receptors was accompanied
by the rapid formation of Ins(l,4,5)P3 (Berridge, 1983) and that a specific
Ins(l,4,5)P3 5-phosphatase existed (Downes et al, 1982). The Ca2+ mobilising action
ofIns(l,4,5)P3 was then demonstrated by adding Ins(l,4,5)P3 to permeabilized
pancreatic acinar cells, which caused rapid Ca2+ release (Streb et al, 1983).
Following Ca2+ release, Ca2+ is resequestered, and this coincides with the rapid
degradation of Ins(l,4,5)P3 (Joseph et al, 1984). Since these early experiments, the
Ca2+ mobilising action of Ins(l,4,5)P3 has been demonstrated in a number of
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different cell types including anterior pituitary GH3 cells (Berridge and Irvine, 1984).
Inositol 1,4,5-trisphosphate releases Ca2+ from non-mitochondrial Ca2+ pools
(probably the endoplasmic reticulum) by binding to specific receptors (Berridge and
Irvine, 1989). However, a proportion of the intracellular Ca2+ pool (approximately
50 - 70%) is insensitive to Ins(l,4,5)P3. The Ins(l,4,5)P3-insensitive pools may
contribute to the Ins(l,4,5)P3-induced Ca2+ signal by acting as a store of Ca2+ which
can refill depleted Ins(l,4,5)P3-sensitive pool in a GTP-dependent manner (Ghosh et
al, 1989).
A large number of different inositol phosphates have been identified in
agonist-stimulated eukaryotic cells and putative physiological roles for each have
been sought. Most mono- and bis-inositol phosphates appear to be products of
Ins(l,4,5)P3 degradation and have no known second messenger function. The levels
of inositol pentakisphosphates and inositol hexakisphosphates change very slowly
during agonist stimulation suggesting that they do not have an acute second
messenger role (Tilly etal, 1987). Inositol 1,3,4,5-tetrakisphosphate has been
suggested to enhance Ins(l,4,5)P3 responses by interacting with specific intracellular
recognition sites to control the transfer of Ca2+ between different intracellular pools
(Irvine, 1990).
A number of novel inositol phospholipids have been identified which are
formed during stimulation of certain receptors. For example, in thrombin-stimulated
platelets, there is a time dependent production of PtdIns(3,4)P2 and PtdIns(3,4,5)P3,
probably due to the activity of a phosphatidylinositide 3-kinase (PI-3 kinase) (Kucera
and Rittenhouse, 1990). A physiological role for these novel inositol-containing
phospholipids has yet to be elucidated, but an involvement of growth factor TK
receptors in this potential signal transduction pathway is implicated by the co-
association of these receptors with the Src homology-2 (SH2) domains of the p85
subunit of PI-3 kinase (Heldin, 1991).
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1.1.2 Receptor-controlled phosphatidylcholine hydrolysis
During stimulation of certain agonists there is a major quantitative
discrepancy between the level of PtdInsP2 breakdown and DAG accumulation. For
example, in hepatocytes, Ca2+-mobilising agonists elicited a rapid, transient release of
Ins(l,4,5)P3, but a sustained accumulation of DAG (Bocckino et al, 1985; Charest et
al, 1985). Determination of the fatty acid species in the DAG by HPLC showed a
higher content of palmitic, oleic and linoleic acids than would have been expected for
the breakdown of PtdInsP2 and suggested that some of this DAG probably came from
the hydrolysis of PtdCho. Direct evidence for agonist-induced PtdCho breakdown
has come from experiments in which cells were pre-labelled with either [3H]-choline
or l-0-[3H] alkyl-2-lyso-s«-glycero-3-phosphocholine. Analysis of the labelled
products of agonist stimulation indicate that PtdCho hydrolysis is probably mediated
by either a PtdCho-specific PLC, which is distinct from the Ptdlns-specific enzyme
(Irving and Exton, 1987), or by phospholipase D (PLD) (Cabot et al, 1988; Pai etal,
1988). The action of both phospholipases liberate DAG from PtdCho; the PLC
catalysed reaction directly releases DAG, whereas the actions of PLD liberates
PtdOH (Figure 1.1) which can be further metabolised to DAG by the action of
phosphatidate phosphohydrolase (PPH). Not only DAG but also PtdOH appears to
have a number of cellular actions which may be of functional significance (see
below).
In a series of studies, similar to those used to examine G-protein
involvement in receptor-induced inositol phospholipid hydrolysis, agonist-induced
PtdCho hydrolysis by both PLC and PLD was shown to be dependent upon G-protein
action (Irving and Exton, 1987). In some cell types, agonist-induced PtdCho
hydrolysis by means of PLD can be blocked by PKC inhibitors and mimicked by
PKC activators, suggesting that receptor-controlled PLD activation can occur by a
PKC-dependent route (Exton, 1990). Therefore, PLC (and the activation of PKC by
means of the DAG it produces) may be involved in the control of PLD action.
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However, some receptor types may couple to PLD, independently of PLC activation.
For example, stimulation of PLD activity in rat-1 fibroblasts expressing the platelet
0C2 adrenergic receptor is inhibited by pertussis toxin but is independent of inositol
phosphate production and is unaffected by PKC inhibitors (MacNulty etal, 1992).
Thus, some receptors may couple to PLD by directly interacting with G-proteins,
although further studies are required to determine if this mechanism of PLD control is
of physiological relevance. Activation of PLD by fMet-Leu-Phe in cytochalasin-
primed neutrophils is apparently independent of PtdInsP2-specific PLC and instead
may require tyrosine phosphorylation of presently unknown targets (Uings et al,
1992). Therefore, certain parallels exist in the mechanism of receptors coupling to
the phospholipases which catalyse PtdIns(4,5)P2 and PtdCho hydrolysis.
Agonist-induced PtdCho breakdown provides an alternative route for the
production of species of DAG which can effectively activate PKC in vitro (Go et al,
1987) and may therefore have important functional effects. If an agonist induces
PtdCho breakdown, independently of inositol phospholipid hydrolysis, DAG levels
will increase, but in the absence of Ins(l,4,5)P3-induced Ca2+ mobilisation. Since
PKC isoforms show differences in their activation profiles with respect to various
DAGs and Ca2+ (1.2.1 and 1.2.2), it is possible that PtdCho hydrolysis may promote
activation of specific PKC isoforms. Alternatively, receptor-mediated PtdCho
hydrolysis may occur in a sequence involving PLC-action and PKC activation,
causing a sustained release of DAG, first from the breakdown of PtdIns(4,5)P2 and
later from PLD-catalysed PtdCho hydrolysis, which may promote prolonged PKC
activation. In this process, PLD could potentially have effects on its own activity by
inducing DAG release which can have positive feedback actions on PKC. Such
control of PLD activity has yet to be demonstrated but could contribute to bringing
about sustained activation of PLD which may be important for long-term
physiological and pathophysiological states. However, since the types of DAG
released by PtdCho hydrolysis might activate PKC forms which are distinct from
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those activated by PtdIns(4,5)P2-derived DAG, it is conceivable that such feedback
effects may not be permitted. Diacylglycerol has a number of putative cellular
actions, in addition to activating PKC. In crude tissue homogenates and in
reconstituted enzyme-membrane models, DAG can induce translocation of DAG
kinase from the cytosol to the cell membrane (Besterman et al, 1986). Furthermore,
certain species of DAG are enriched with arachidonic acid (AA), which has biological
activity (section 1.3.5). Phosphatidic acid also has a number of biological actions
and, in human carcinoma cells, can mobilise Ca2+ from intracellular stores
(Moolenaar et al, 1986), and may induce inositol phospholipid hydrolysis in vitro by
activating a PtdIns(4,5)P2-specific PLC (Jackowski and Rock, 1989). Phosphatidic
acid-dependent phosphorylation of certain proteins in extracts from rat liver, brain,
lung and testis has been observed, suggesting that a phosphatidic acid-dependent
protein kinase may exist (Bocckino et al, 1991). Any combination of these cellular
actions of DAG and PtdOH may be important for the functional actions of PtdCho-
metabolising receptors.
1.2 Cellular Targets and Actions of Protein Kinase C
Protein kinase C was first identified in 1977 by Nishizuka's group as a
proteolytically activated protein kinase, present in many different mammalian tissues
which, at that time, had no obvious role in signal transduction (Inoue et al, 1977).
Further experiments showed that PKC was a Ca2+-activated, phospholipid-dependent
enzyme (Takai et al, 1979) and that DAG, one of the products of PLC and PLD-
catalysed phospholipid hydrolysis, increased the affinity of the enzyme for Ca2+,
thereby activating it (Kishimoto et al, 1980). These studies linked PKC activation to
signal transduction mechanisms. Since these early studies, PKC has been shown to
exist as a family of different enzymes which have a role in many different aspects of
cellular function, including secretion and exocytosis, cell proliferation, gene
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expression, smooth muscle contraction, ion channel function and regulation of other
aspects of signal transduction systems (Nishizuka, 1984, 1988).
1.2.1 Protein kinase C isoenzymes
Screening of various complementary DNA (cDNA) libraries has shown
that PKC exists of a family of at least 10 isoenzymes which are encoded by separate
genes (a, y, 5, e, £, r|, X and 0 isoforms) or are splice variants of a single mRNA
transcript (Pi and Pn isoforms) (Nishizuka, 1988; Parker et al, 1989; Osada et al,
1990; Y Nishizuka, personal communication). The a, P, and y (group A) PKC
isoform cDNA sequences have five variable regions (Vi- V5) and four conserved
regions (C] - C4) (Figure 1.2) and are responsive to Ca2+, phospholipid (particularly
phosphatidylserine), DAG and phorbol esters. The carboxy terminal half of the
enzyme contains the C3 and C4 regions, constitutes the catalytic domain and has
sequence similarity with other protein kinases. The C3 region of each enzyme has a
putative ATP binding sequence. Interestingly, the C4 region of the a and P but not
the y isoform has a second putative ATP-binding sequence, the significance of which
is unknown. The amino terminal Ci and C2 regions constitute the regulatory domain,
and are proposed to contain the Ca2+, DAG and phospholipid binding sites and a
pseudosubstrate region. Transfection of COS cells with cDNA encoding the A series
isoforms show that the a, p^Pn and y gene products correspond to the III, II and I
subtypes, respectively, which are separated biochemically by hydroxyapatite column
chromatography (Kikkawa et al, 1987). The 8, e, £, T] and the recently identified X
and 0 (group B) PKC isoforms do not contain the C2 region, and since these PKCs do
not show Ca2+ dependence, this region has been suggested to contain the Ca2+
binding site. The £ and X isoforms contain only one of two cysteine-rich tandem
sequences present in the Ci region of the N-terminal regulatory domain. Since these
cysteine-rich sequences are suggested to be essential for DAG/phorbol ester binding,
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it is perhaps not surprising that the £ and X isoforms are shown to be unresponsive to
phorbol esters (Liyanage et al, 1992; Y. Nishizuka, personal communication).
Northern blot analysis with specific oligonucleotide probes, in situ mRNA
hybridisation techniques and immunohistochemical studies using antibodies specific
to certain PKC isoforms have shown that each isoform has a distinct tissue
distribution. The a, (3 and 8 PKC isoforms have been identified in many cells and
tissues examined so far, whereas the y isoform is located in the CNS only (Nishizuka,
1988; Ogita et al, 1992). The e isoform is expressed predominantly in brain tissue,
with only trace amounts in the heart, lung, spleen, thymus and testis (Koide et al,
1992) and high levels of T] PKC are detected in the skin and lung (Osada et al, 1990).
The 0 isoform is found in skeletal muscle and PKC-A, is located in the testis and ovary
(Y. Nishizuka, personal communication). Many cell types contain more than one
PKC isoform, and these may have different subcellular localisations (Nishizuka,
1988). This raises the possibility that each form of PKC has a distinct physiological
function and that, within a cell, targets may exist which are specifically
phosphorylated by different isoenzymes.
1.2.2 Activation of protein kinase C
When PKC is extracted from rat brain in the presence of Ca2+ chelators, it
is found mainly in the soluble fraction, in an inactive form (Kikkawa et al, 1982).
The inactive state of the enzyme may be conferred by the interaction of the
pseudosubstrate sequence with the protein substrate binding site (Bell and Bums,
1991). During hormone or PKC activator stimulation, PKC is translocated to the
membrane fraction in a Ca2+-dependent manner (for the A series isoforms at least)
where it is activated; a process which requires sn-1,2 DAG, Mg2+ ions, anionic
phospholipid and ATP (Kishimoto etal, 1980; Nishizuka 1984, 1988; Huang, 1989).
Studies of PKC activity in mixed micelle assay systems have led to a
proposed model of PKC activation for the A series PKC isoforms (Burns and Bell,
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1991). In this model, soluble, inactive PKC binds Ca2+ and, as a result, becomes
membrane associated, interacting with anionic phospholipids such as
phosphatidylserine but still has relatively low kinase activity (Bazzi and Nelsestuen,
1988). The activity of this translocated PKC form is increased by phorbol esters or
DAGs, which probably induce a conformational change in the enzyme, perhaps by
dislocating the pseudosubstrate site from the active site. Once activated, PKC can
phosphorylate itself, increasing its sensitivity to proteolytic breakdown (Ohno et al,
1990). Initially, the fully active catalytic subunit, protein kinase M (PKM) is released
(Nishizuka, 1984), but further proteolysis at a number of different sites in the protein,
causes the complete loss of activity (Schaap et al, 1990). Autophosphorylation and
proteolysis of PKC may have an important role in the termination of PKC action.
Since the B series PKC isoforms do not translocate in response to changes
in Ca2+, they must be activated by a mechanism which differs from the one described
above. Most of the 5 isoform is suggested to be membrane associated in unstimulated
cells (Ogita et al, 1992), indicating that an initial, Ca2+-dependent translocation step
is unnecessary. Instead, the activity of the already membrane bound 5 isoform can be
altered by phosphatidylserine and DAG alone (Ogita et al, 1992). The mechanism by
which the cytosolic Ca2+-independent PKC forms are encouraged to translocate is
less clear.
The PKC isoforms differ in their susceptibility to DAG; the (3 form is
highly DAG-sensitive, whereas the a isoform is less susceptible to DAG activation
and yPKC is relatively DAG-resistant (Naor et al, 1988). In addition to the effects of
DAG on PKC activity, it is now clear that arachidonic acid (AA) can activate the
PKC isoforms, but to different extents under different conditions of Ca2+ and DAG.
The a isoform is activated by high concentrations of AA in the presence of Ca2+,
whereas, the pi and Pn isoforms respond poorly to AA (Sekiguchi etal, 1987).
However, purified Pn, prepared by expression in baculovirus, is maximally activated
by micromolar concentrations of AA in the absence of Ca2+, phosphatidylserine and
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DAG (Burns et al, 1990). The yPKC isoform is activated by low, possibly
physiological concentrations of AA (~ 10 fiM), in the absence of Ca2+,
phosphatidylserine and DAG (Naor et al, 1988). More recent evidence shows that
DAG can act synergistically with relatively low concentrations of AA (20 - 50 (iM) to
activate purified a, p and y isoforms such that the activity of each was nearly
maximal at nearly basal levels of Ca2+ (Shinomura et al, 1991). The effect of AA on
the activity of the B series isoforms has yet to be studied in detail. A recent report
shows that, in the presence of phosphatidylserine and DAG, AA can markedly
activate e PKC, expressed and purified from COS cells, but has inhibitory effects on 8
isoform activity under the same conditions (Koide et al, 1992). Other cis-unsaturated
fatty acids can also alter PKC activity, but are less active than AA (Sekiguchi et al,
1987). The biochemical mechanism of AA activation of PKC is poorly understood,
but may involve an allosteric action on a site other than the DAG binding site.
It is clear that the activity of each PKC isoform can be under complex
control by a number of different intracellular factors. Since different PKC isoforms
have differing sensitivities for various species of DAG and cis-unsaturated fatty acids
and Ca2+, it is possible that the activity of each may be controlled with a degree of
selectivity. For example, during PLC-catalysed inositol phospholipid hydrolysis,
those isoforms which are readily affected by DAG and Ca2+, i.e. the a and P forms,
may be activated. Diacylglycerol released from routes that are not accompanied by
intracellular Ca2+ mobilisation, for example, by PLD and PtdCho-specific PLC
pathways, may preferentially activate the B series PKC isoforms. Arachidonic acid,
which can be released by either the phospholipase A2 (PLA2) pathway (section 1.3)
or by the sequential actions of PLC/DAG lipase, may preferentially activate the y
isoform, but inhibit the 5 isoform, or in the additional presence of DAG, may
preferentially activate PKC-e. Since there is evidence that certain receptors can
modulate PLA2 action, independently of inositol phospholipid turnover (section
1.3.2.3) some agonists may preferentially activate the y, over the P or a isoforms.
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Alternatively, if PLC and PLA2 are activated in sequence, then the initial release of
DAG and Ca2+ may, at first, activate the a and p PKCs whilst the later release of AA
may activate the yform in a Ca2+-independent manner (Naor et al, 1988). This action
may be important for the later phase of hormone action where Ca2+ levels are
decreasing and may be only slightly above basal. Such sustained PKC activation may
be necessary for transcriptional activation and cell proliferation (Berry and Nishizuka,
1990).
1.2.3 Cellular actions of protein kinase C
A number of different cellular responses may be mediated by PKC
activation, for example, PKC may have a crucial role in the feedback regulation of the
Ca2+ mobilising pathway. In the GH3 clonal pituitary cell line, phorbol ester pre¬
incubation decreases basal and thyrotrophin-releasing hormone-induced inositol
phospholipid turnover (Drummond, 1985) suggesting that PKC may have negative
effects on the mechanisms involved in PtdIns(4,5)P2 hydrolysis. It is also possible
that PKC may attenuate the Ca2+ signal by altering the activity of an IP3 phosphatase
leading to increased Ins(l,4,5)P3 degradation, or by activating the Ca2+ extrusion
apparatus (see Shearman et al, 1989b for review). The Ins(l,4,5)P3 receptor can be
phosphorylated by PKC in vitro (Ferris et al, 1991) and although the functional
consequence of this action has still to be determined, this would provide an additional
mechanism by which Ins(l,4,5)P3 responses could be modulated. In thymocytes,
however, phorbol esters can enhance inositol phospholipid turnover (Taylor et al,
1984), indicating that PKC can also have positive effects on the inositol
phospholipid/Ca2+ signal. Protein kinase C activation can also have positive effects
on other signal transduction pathways. For example, PKC can enhance PLA2
activity, by acting synergistically with Ca2+ in some systems (1.3.2.2), and can
modulate PLD action (1.2.2).
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A number of receptor and membrane proteins, contractile and cytoskeletal
proteins and are substrates for PKC in vitro (Nishizuka, 1984, 1988).
Phosphorylation of one or more of these substrates in vivo may have important
functional consequences. For example, phorbol 12,13-dibutyrate (PDBu) treatment
of rat hippocampal pyramidal cells can increase Ca2+ currents in these cells (Baraban
et al, 1985); an effect which may be due to direct phosphorylation of the ion channel
(Campbell et al, 1988). This action of PKC on pyramidal cell channel activity may
be functionally important since PKC activation in these cells can elicit some of the
characteristics of long-term potentiation (Hu et al, 1987).
When measured in cell-free assays, each PKC isoform shows different
activities towards various exogenous substrates. The A series, but not the B series,
isoforms can readily phosphorylate histone, myelin basic protein and protamine
(Koide et al, 1992; Liyanage et al, 1992). Therefore, in vivo, different isoforms may
phosphorylate distinct cellular targets and may have specific physiological actions. A
number of studies have shown that distinct PKC isoforms can control or influence
different cellular processes. For example, when purified rat brain PKC was
introduced into permeabilized cultured anterior pituitary cells, the a and (3, but not the
y, isoform could induce luteinizing hormone release (Naor et al, 1989). In SH-Y5Y
neuroblastoma cells, down regulation of certain PKC isoforms is associated with cell
differentiation. Antibodies for a, (3, y, 8 and e PKCs were introduced into
permeabilized SH-Y5Y cells, but only those targeted against the a and £ forms could
induce cell differentiation, suggesting that a and £ PKCs are involved in this process
(Leli et al, 1992). Further studies using antibodies specific to certain isoforms,
together with genetic manipulation of the sequences encoding certain isoforms, may
help to elucidate the role of PKC isoforms in cellular responses in the future.
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1.2.4 Pharmacological regulation of protein kinase C activity
1.2.4.1 Protein kinase C activators
Both 1,2-DAGs and the tumour-promoting phorbol esters can directly
activate PKC in cell-free assays and in intact cells by increasing the affinity of the
enzyme for Ca2+ and/or phospholipid (Castagna et al, 1982; Ogita et al, 1992). The
phorbol ester receptor co-purifies with PKC (Niedel et al, 1983), providing additional
evidence that these agents act on PKC. Furthermore, 1,2-DAGs displace the binding
of 12,13-phorbol esters to PKC (Leach et al, 1983), suggesting that phorbol esters
mimic DAG by activating PKC at the DAG binding site.
It is now clear that there are a number of differences in the biological
effects of various DAGs, phorbol esters and phorbol ester-related compounds. These
differences may relate to the ability of some of these compounds to selectively
activate certain PKC isoforms. The synthetic DAG, 1,2-dioctanoyl .v/z-glycerol
(DOG), can mimic only some of the modulatory actions of phorbol esters on heart
and anterior pituitary 'L'-type Ca2+ channel activity (Lacerda et al, 1988; MacEwan
and Mitchell, 1991). Furthermore, phorbol ester-stimulated interleukin 1(3 mRNA
production and protein phosphorylation patterns in human leukaemia cells were only
partially mimicked by DOG (Strulovici et al, 1989). The ability of DOG to mimic
only some of the actions of phorbol esters may indicate that DOG is a selective
activator of distinct PKC forms. Certainly, purified PKCy is more sensitive to DOG
than the a isoform (Sekiguchi et al, 1988) and there is evidence that DOG has
relatively low affinity for displacement of [3H]-PDBu binding to a-PKC in
comparison to the (3 and y isoforms (MacEwan et al, 1992a). The actions of DOG on
the activity of other PKC isoforms merits further investigation. The phorbol ester-
related diterpene, mezerein, can mimic only some of the tumour-promoting actions of
phorbol esters such as phorbol 12-myristate 13-acetate (PMA) (Slaga et al, 1980).
Jaken and her co-workers (1983) suggested that mezerein may act on a subset of the
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phorbol ester receptor, perhaps a down-modulated form of PKC. However, following
the identification of the PKC isoforms, the actions ofmezerein described in this study
seem likely to be explained by selective effects of this agent at certain isoforms.
Certainly, mezerein shows selective binding to some of the multiple phorbol ester
binding sites in mouse skin (Dunn and Blumberg, 1983) which may represent one or
more PKC isoform. Short chain deoxyphorbols, e.g. 12-deoxyphorbol 13-isobutyrate
and some phorbols with unsaturated side chains, e.g. phorbol 12-retinoate 13-acetate
may also be able to discriminate subpopulations of phorbol ester recognition sites
(Dunn and Blumberg, 1983). However, it is possible that these agents can act at least
in part, on other (as of yet unidentified) kinases, which may be closely related to
PKC.
Purified PKC subspecies do show heterogeneity in their responsiveness to
different phorbol esters and phorbol ester-related compounds. Evans and his co¬
workers (1991) showed that the (3 isoform could be selectively activated by 12-
deoxyphorbol 13-phenylacetate 20-acetate (DOPPA) over the a, y and 5 isoforms.
However, in this study, the effect of DOPPA on e, £, rj, X and 0 isoform activity was
not examined and it was admitted that the (3 isoform preparation may be contaminated
by B series isoforms. Further investigations into the effect of DOPPA on the activity
of purified isoforms, prepared, for example, using the baculovirus-insect cell
expression system, will clarify any isoform-selective nature of DOPPA. Other
phorbol ester analogues, such as thymeleatoxin and sapintoxin-A are also reported to
show selectivity towards certain isoforms. Thymeleatoxin (a close congener of
mezerein) is a relatively poor activator of the 5 and e PKC isoforms, but can activate
the A series PKCs (although in a manner which is highly dependent upon Ca2+), and
sapintoxin-A is a potent activator of the a, (3 and y forms, but fails to activate the 8
and e isoforms effectively (Evans et al, 1991; Ryves et al, 1991).
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Further development of selective activators of different PKC isoforms will
be useful for future studies into the of involvement of these enzymes in specific
cellular responses.
1.2.4.2 Protein kinase C inhibitors
Protein kinase C inhibitors have been widely used to study the
involvement of this enzyme in responses to various agonists. These agents may
inhibit PKC activity by interfering with the Ca2+/phospholipid interaction, phorbol
ester/DAG binding or ATP or substrate binding.
Inhibitors that prevent the interaction of PKC with Ca2+ include,
dibucaine, adriamycin, polymyxin B and melittin (Huang 1989). However, since
these agents block the activity of other Ca2+-dependent enzymes, they are rarely used
as PKC inhibitors. Other agents that interact with the PKC regulatory domain include
calphostin C and sphingosine. Calphostin C inhibits PKC activity by interfering with
DAG/phorbol binding and has reasonable selectivity for PKC over other protein
kinases (Kobayashi et al, 1989). However, calphostin C seems to cause permanent
inactivation of phorbol ester binding and this may limit its usefulness in some studies.
Sphingosine is an 18-carbon chain lipid base which potently inhibits PKC activity by
interacting competitively with DAG/Ca2+ and phosphatidylserine binding (Hannun
and Bell, 1987), but also has effects on other biological processes which are
independent of its ability to inhibit PKC (Hidaka and Kobayashi, 1992). Potent
peptide inhibitors of PKC activity have been developed which resemble the
pseudosubstrate region of PKC (House and Kemp, 1987; Eichholtz etal, 1990).
Since this region varies between different isoforms, it may be possible to develop
isoform-selective peptide inhibitors which act at this site. However, these inhibitors
are not cell permeable, limiting their usefulness.
Compounds which inhibit PKC activity by interacting with the catalytic
domain include the isoquinolinesulphonamides, such as l-(5-isoquinolinesulphonyl)-
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2- methyl piperazine (H7), and compounds which contain the indole carbazole
moiety, e.g. staurosporine, K252a. Kinetic studies have revealed that the action of H7
on PKC activity is reversible and competitive with ATP. However, since the ATP
binding sites of a number of serine/threonine kinases show considerable sequence
homology, it is not surprising that H7 only shows modest selectivity for PKC over
other protein kinases. For example, H7 can inhibit PKC, cGMP-dependent protein
kinase (PKG) and cAMP-dependent protein kinase (PKA) activities all with Ki values
in a range of 3 - 6 (J.M (Hidaka and Kobayashi, 1992). Since the H7 analogue, HA
1004, has similar inhibitory effects on a number of serine/threonine-specific protein
kinases, but has reduced affinity for PKC, this compound is a useful control for
determining the actions of PKC (Hidaka et al, 1984). Staurosporine and K252a also
appear to inhibit PKC activity by interacting with the catalytic domain, perhaps by
competing with the ATP binding site (Kase et al, 1986; Nakadate et al, 1988; Huang,
1989). However, both compounds inhibit the activity of other kinases by similar
mechanisms and cannot be considered as a selective inhibitors of PKC (Riiegg and
Burgess, 1989). Davis et al (1989) have developed more selective analogues of
staurosporine. One such bis-indolyl maleimide compound, Ro 31-8220, has 100 fold
greater selectivity than staurosporine for PKC over PKA. More recently, further
development of these compounds has produced a series of new drugs with even
greater selectivity for PKC. One such compound, Ro 31-8425, is 350 fold more
selective for PKC than PKA (Nixon et al, 1992), but has yet to become commercially
available. A natural product, chelerythrine, is 250 fold more potent at inhibiting PKC
than PKA (Herbert et al, 1990a), and has very recently become commercially
available.
Although PKC inhibitors which interact with the catalytic domain are
generally regarded to be unable to distinguish between different PKC isoforms, H7, in
particular, can selectively inhibit some cellular actions of phorbol esters, but not
others. In mouse epidermal cells, H7 inhibited PMA-stimulated ornithine
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decarboxylase induction, but not the PMA-induced decrease in epidermal growth
factor binding. Sphingosine, on the other hand, could inhibit both PMA-mediated
responses (Nakadate et al, 1989). The phorbol ester-stimulated activity of a protein
kinase purified from porcine spleen was less sensitive to block by K252a than PKCs
purified from mouse brain (Gschwendt et al, 1989). This K252a-resistant PKC may
be a form of the 5 isoform (Uchida et al, 1991). However, these PKC-inhibitor
resistant actions of phorbol esters may represent effects on processes which are
independent of PKC involvement. Alternatively, PKM has been reported by some to
show reduced potency for H7 and staurosporine (Junco et al, 1990), although
Nakadate et al (1988) reported that such potency shifts did not occur. The
phenomenon observed by Junco and co-workers may therefore be due to further,
deleterious proteolysis of the catalytic subunit. Alternatively, PKM originating from
different PKC isoforms may have different pharmacological properties. Nevertheless,
the possibility that PKC isoform-specific inhibitors may exist is an interesting
prospect. Selective inhibitors of certain PKC isoforms will provide a greater
understanding regarding isoform-specific functions and may have novel therapeutic
actions since PKC is implicated in pathological states such as cancer, inflammation,
and neuronal damage (Nishizuka, 1988).
1.3. Receptor-Controlled Arachidonic acid Release
Phospholipids (and certain species of PtdCho and phosphoinositides in
particular) possess stearate on the 1 carbon and arachidonate on the 2 carbon of the
src-l,2-DAG backbone (Billah and Anthes, 1990; Meldrum et al, 1991). Agonist-
stimulation of a number of receptor types can enhance arachidonic acid (AA)
liberation from these membrane phospholipids (Irvine 1982); the action of PLA2 is
implicated as an important route of AA release. Phospholipase A2 catalyses the
hydrolysis of the 2-position of the phospholipid, liberating equimolar amounts of free
fatty acid and lysophospholipid (Irvine, 1982) (Figures 1.1 and 1.3) and since the
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majority of AA in mammalian cells is esterfied in the 2-acyl position of certain
phospholipids (Irvine, 1982), this will have the effect of increasing free AA levels.
Alternatively, PLC- or PLD-mediated phosphoinositide or phosphatidylcholine
breakdown may produce arachidonyl-diglycerides (Figure 1.3). The AA present in
these DAGs can be liberated either by the action of DAG lipase (Bell et al, 1979;
Irvine, 1982) at the 2-position, or by the sequential action of DAG-lipase at the 1-
position, followed by monoacylglycerol lipase (MAG lipase) action on the 2-
monoacylglycerol (Prescott and Majerus, 1983) (Figure 1.3).
Arachidonic acid has a range of biological effects (see section 1.3.5), and
can be metabolised further to prostaglandin, leukotriene and epoxygenase products
which also have biological activity (Needleman et al, 1986). Subsequently, the
receptor control of AA release has been suggested to be functionally important.
1.3.1 The phospholipase A2 enzyme family
A variety of extracellular and intracellular forms of PLA2 have been
described. The secreted PLA2 forms are of low molecular weight (12 - 18 kDa) and
function in phospholipid digestion and inflammatory responses, whereas the high
molecular weight (30 - 110 kDa) PLA2S are cytosolic and are probably involved in
receptor-linked signal transduction mechanisms.
In the gastro-intestinal tract, PLA2 action is required for phospholipid
breakdown and digestion, for example, in the pancreas, where PLA2 is secreted as an
inactive zymogen which is converted to the active form by proteases (Chang et al,
1987a). The protein structures of the pancreatic PLA2 enzymes have been well
characterised and are related to the PLA2 enzymes found in snake venom, bee venom
(Verheij et al, 1981) and rat stomach (Yasuda et al, 1990). In aqueous solution, these
PLA2S exist as dimers and are rich in disulphide bonds which are essential for their
stability and activity (Verheij et al, 1981). These secreted forms of PLA2 are
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dependent upon millimolar levels of Ca2+ for full activity (Ono et al, 1988) and have
a putative Ca2+ binding domain (van Sharrenburg et al, 1985).
High levels of PLA2S are found in arthritic joints (Vadas et al, 1985) and
when purified PLA2 protein is injected intradermally, it can cause an acute
inflammatory reaction (Murakami et al, 1990), suggesting that PLA2 has a role in
inflammatory disease. Phospholipase A2 has also been implicated in the pathogenesis
of asthma, where it hydrolyses PtdCho in the lung surfactant, and may be the cause of
acute respiratory distress syndrome (Heath et al, 1985). The inflammatory PLA2
forms are of low molecular weight but have different primary structures from the
digestive and snake venom enzyme (Henrikson et al, 1977). Nevertheless, the
inflammatory and pancreatic PLA2S show close similarity in their Ca2+-binding
regions (Wery et al, 1991) and are also dependent upon millimolar Ca2+ levels for
activation (Vadas et al, 1985). Related forms are found in liver (Aarsman et al,
1989), rat spleen (Ono et al, 1988) and in rat platelets (Hayakawa et al, 1988).
Cytosolic, high molecular weight PLA2S have been described in various
different cell types including rat kidney (Gronich et al, 1990) and sheep platelets
(Loeb and Gross, 1986). Unlike the low molecular weight forms, the high molecular
weight forms are active over a range of concentrations of Ca2+ (300 - 800 nM) which
are equivalent to those in agonist-stimulated cells. The cytosolic PLA2 forms in the
human monocytic U937 cell line are amongst those best characterised where a PLA2
with a molecular mass of approximately 100 kDa has been identified (Clark et al,
1990, 1991a). This PLA2 prefers substrates with AA at the 2-position and is activated
by Ca2+ at levels equivalent to those found in stimulated cells, which led to the
suggestion that this PLA2 is responsible for agonist-induced eicosanoid production in
U937 cells. Molecular cloning and expression studies have revealed that this PLA2
has no detectable sequence homology with the characterised secretory PLA2 forms.
Most interestingly this PLA2 has an N-terminal 140 amino acid fragment which
translocates to natural membrane vesicles in a Ca2+-dependent fashion. This portion
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of the enzyme has sequence homology with the Ca2+-binding domain of PKC-y, to
the synaptic vesicle protein p65 (which has been implicated in vesicle fusion with the
plasmalemma), with the GTPase activating protein and with PLC-y. Such a domain
may have an important regulatory role and may control the association of PLA2 with
the membrane substrate, in a Ca2+-dependent manner, during a stimulus.
The various high molecular weight PLA2S have distinct specificities for
different phospholipid substrates. A cytosolic PLA2, partially purified from RAW
264.7 macrophage cells, preferentially hydrolyses PtdCho (Leslie et al, 1988), whilst
a form in rat kidney hydrolyses PtdCho and phosphatidylethanolamine equally well
(Gronich et al, 1990). In platelets, a PLA2 form has been reported to specifically
hydrolyse PtdOH (Lapetina et al, 1981). The physiological significance of the
substrate preference of these different PLA2 forms has yet to be determined, although
such actions would generate different species of lysophospholipid which may, in
principle, have varying degrees of biological activity. Nevertheless, these cytosolic
PLA2S, in general, selectively hydrolyse substrate with AA at the sn-2 position (Kim
et al, 1988; Leslie et al, 1988; Clark et al, 1990; Channon and Leslie, 1990; Dietz and
Mong, 1990) and their actions would be expected to influence free AA levels,
irrespective of the species of lysophospholipid produced.
1.3.2 Hormonal regulation of phospholipase A2 activity
The low molecular weight forms of PLA2 are unlikely to be directly
controlled by receptor activation since they require Ca2+ levels which are higher than
those found within a cell following receptor activation. Furthermore, these enzymes
are located within secretory granules and are unlikely to be affected by changes in the
intracellular environment. In any case, the reducing environment of the cytosol
would inactivate the disulphide rich secreted PLA2 forms. In contrast, the high
molecular weight cytosolic PLA2 forms are resistant to the reducing environment of
the cytosol, are active at agonist-induced levels of Ca2+ and are the likely candidates
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for the receptor controlled enzyme. It has been suggested that the cytosolic PLA2
forms may be activated by second messengers generated by the PtdIns(4,5)P2-PLC
pathway or may be directly activated via specific G-proteins.
1.3.2.1 Role of calcium in phospholipase A2 activation
In certain cell types, PLA2 activation was found to be closely linked to the
occupancy of Ca2+ mobilising receptors. In human platelets, thrombin-induced AA
release was reduced in presence of the Ca2+ chelator, quin 2, and in the absence of
extracellular Ca2+ (Simon et al, 1986), suggesting that PLA2 activity is controlled by
changes in intracellular Ca2+ levels. These studies supported the hypothesis that
receptor activation of PLA2 may be secondary to PLC-catalysed inositol phospholipid
hydrolysis and Ca2+ mobilisation. However, in a number of different cell types,
including HL60 cells, an increase in intracellular Ca2+ levels alone was found to be
insufficient to activate PLA2 (Billah et al, 1986). Furthermore, the mechanism of
receptor-induced AA release can be dissociated from inositol phospholipid turnover
in FRTL5 rat thyroid cells (Burch et al, 1986, see also section 1.3.2.3), spinal cord
neurons (Kanterman et al, 1990) and Madin-Darby canine kidney cells (Slivka and
Insel, 1987), indicating that factors other than or in addition to changes in intracellular
Ca2+ levels may control PLA2 activity.
1.3.2.2 Role of protein kinase C in phospholipase A2 activation
Several studies show that PKC can have an important regulatory role in
the control of PLA2 activity by certain agonists. In cultured astrocytes, the PKC
activator PMA can elicit prostaglandin E (PGE) release, supporting a role for PKC in
the control of PLA2 activity (Hartung and Toyka, 1987). Furthermore, in Madin-
Darby canine kidney cells, PKC down regulation reduces bradykinin-induced AA
release suggesting that PKC may modulate PLA2 activity in these cells (Godson et al,
1990). More direct evidence for PKC control of PLA2 activity came from studies
which showed that PMA treatment of intact rat renal mesangial cells caused an
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increase in PLA2 activity measured in cell-free extracts (Gronich et al, 1988).
Interestingly, treatment with PMA alone could not mimic the level of AA release
measured from intact mesangial cells stimulated with the physiological agonist,
arginine vasopressin (AVP) (Gronich et al, 1988). However, in intact cells, PMA
could facilitate Ca2+ ionophore-induced PLA2 activity, as assessed by measuring
PGE2 release, to levels that mimicked those obtained by stimulation with AVP
(Bonventre and Swidler, 1988). Therefore, both PKC activation and Ca2+ may act
synergistically to activate PLA2 in these cells. Alternatively, raised intracellular Ca2+
may promote the activation of some PKCs by PMA although it is not clear whether
this contributes to the synergy observed in these studies.
Protein kinase C has been proposed to modulate PLA2 activity by a
number of different mechanisms. For example, PKC may activate PLA2 by
phosphorylating the enzyme or by altering the activity of inhibitory or stimulatory
influences on PLA2 action. Purified PKC-[3 can phosphorylate a cytosolic PLA2
purified from macrophage cells in vitro, but without any effect on the catalytic
activity of PLA2 on phospholipids from macrophage membranes (Wiljkander and
Sunder, 1991). It has yet to be determined if direct phosphorylation of PLA2 by other
PKC isoforms can occur in intact cells and whether this is related to PLA2 activation.
The lipocortins are putative endogenous inhibitors of PLA2 activity whose
actions are suggested to be modulated by PKC phosphorylation. In platelets, both
thrombin and PMA increase the phosphorylation state of a lipocortin-related protein
and this was suggested to decreases its anti-PLA2 activity (Tourqui et al, 1986).
Protein kinase C phosphorylation and inactivation of lipocortin would be a suitable
mechanism by which PLA2 activity could be controlled. However, a study by Crouch
and Lapetina (1986) showed that, although both a and y-thrombin induced
phosphorylation of this protein, only oc-thrombin could induce AA release. Thus,
there was a clear dissociation between the ability of an agonist to phosphorylate this
protein and release AA. Furthermore, in cell-free assays, the actions of lipocortin can
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be overcome by high phospholipid substrate concentrations (Davidson et al, 1987),
indicating that lipocortins do not interact directly with PLA2, as was first suggested,
but exert their action by binding to the phospholipid substrate. Such actions may
account for the ability of these agents to inhibit purified PLC and PLD activity in
vitro (Hirata, 1981). These observations question the specificity of lipocortins and
their significance as regulators of cytosolic PLA2 activity.
Recently, protein kinase C has been suggested to modulate the activity of a
phospholipase A2-activating protein (PLAP) which has functional and antigenic
properties related to the PLA2 stimulatory peptide, melittin (Clark et al, 1987a;
Crooke et al, 1989). In the leukotriene D4 receptor signal transduction system, PKC
regulates the transcription, translation and synthesis of a PLAP which can activate a
PtdCho-specific PLA2, but has no effect on PLC activity or on pancreatic or snake
venom PLA2 (Clark et al, 1987a; 1991b). Thus, PLAP may be a regulator of
cytosolic PLA2 activation in response to an agonist.
In other cell types both PKC-dependent and -independent pathways of AA
release have been described. For example, in endothelial cells, bradykinin-induced
AA release was not reduced by the PKC inhibitor, staurosporine, whereas PMA-
induced AA release was, suggesting that bradykinin activates PLA2 in a PKC-
independent manner. Furthermore, bradykinin- and PMA-induced AA release were
additive suggesting that each stimulus induces AA release by a distinct mechanism
(Buckley etal, 1991).
Diacylglycerols may activate PLA2 by a PKC-independent mechanism.
Partially purified human platelet PLA2 activity was stimulated by DAG in cell-free
assay (Kramer et al, 1987; Burch, 1988). Although PKC contamination was present
in the PLA2 preparation, the PKC inhibitor, H7 had no effect on DAG-induced PLA2
activation (Burch, 1988), suggesting that DAG may activate PLA2 independently of
PKC involvement. Diacylglycerol may activate PLA2 by having a physico-chemical
action on the structure and stability of the phospholipid bilayer which may enhance
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the access of the protein to the substrate. Alternatively, DAG may induce
conformational changes in PLA2 itself. However, any possible physiological
significance of this action of DAG has yet to be verified.
1.3.2.3 G-protein control of phospholipase A2 activity
The possible coupling of PLA2 to receptors via G-proteins was initially
indicated by studies from Burch and his co-workers (1986). Prior treatment of intact
FRTL 5 cells with pertussis toxin inhibited noradrenaline- and GTP-analogue-induced
AA release, suggesting that a1-adrenergic receptors in these cells are to coupled to
PLA2 via a G-protein. However, GTP analogues are potent activators of all G-protein
dependent processes, including PLC activation, and since many receptors couple to
both PLC and PLA2, this could indicate that the second messenger products of PLC
action can stimulate PLA2 activity (see sections 1.3.2.1 and 1.3.2.2). As a
consequence, further evidence was sought to support the coupling of receptors to
PLA2 via G-proteins. Additional experiments showed that; (1) pertussis toxin, which
ADP ribosylates and inactivates certain G-protein a subunits, selectively inhibited
noradrenaline- and GTP-y-S-induced AA release but not inositol phosphate
accumulation; (2) the PLC inhibitor, neomycin, blocked GTP-y-S-induced inositol
phosphate formation but not AA release; and (3) that AA release could be induced
from [3H]-arachidonoyl PtdCho by GTP-y-S using FRTL 5 cell membranes (Burch et
al, 1986). These results suggested that the ai-adrenergic receptor in FRTL 5 cells is
associated with 2 G-proteins; a pertussis toxin-sensitive form which activates PLA2
and a pertussis toxin-insensitive form which controls PLC activity. Although
activation of PLA2 and PLC may be controlled by distinct G-proteins, it is clear that
the G-protein control of PLA2 activity in some systems may still depend upon PLC
action to some extent. In neutrophils, fMet-Leu-Phe activation of PLA2 is probably
under dual control from a Ca2+/PKC-dependent pathway and a G-protein dependent
pathway (Cockcroft et al, 1991) with approximately 50% of AA arising via a G-
26
protein-dependent route. However, micromolar Ca2+ levels are required for G-
protein-dependent AA release, indicating that this pathway may still require prior
activation of PLC.
Further studies on the G-protein control of PLA2 activity have been
carried out using rod outer segment of the bovine retina. In this system, the light
receptor for the rod outer segments couples to both PLA2 and cyclic GMP-dependent
phosphodiesterase by a G-protein known as transducin (Jelsema, 1987). When
purified a and Py transducin subunits were added to membranes, the a subunit
stimulated the cyclic GMP-dependent phosphodiesterase. Surprisingly, PLA2 activity
was stimulated by the Py complex, but not by the a subunit (Jelsema and Axelrod,
1987). Thus, the Py subunit complex was suggested to modulate PLA2 activity.
Similarly, patch clamp studies have show that purified Py subunits open cardiac
plasma membrane K+ channels apparently by stimulating PLA2 activity (Kim et al,
1989). However, although the Py/PLA2 response in heart was attenuated by the
lipoxygenase inhibitor, nordihydroguaiaretic acid (NDGA), the actions of the
physiological regulator of these channels, acetylcholine, was unaffected by this drug.
These results question the role of the Py subunits and PLA2 activation in the
physiological control of these channels. Furthermore, the concentration of Py
subunits that activated these K+ channels was over 200 fold higher than the
concentration of oq subunit reported by another group to elicit the same effect
(Codina et al, 1987; Logothetis et al, 1987). This evidence supports a role for the a
but not the py subunits in the agonist-control of heart K+ channel opening. Thus, the
a subunit is a more likely candidate as the main G-protein effector of agonist-induced
PLA2 activation although the Py subunits, at higher concentrations, may also be
effective.
Attempts to identify an a subunit type which activates PLA2 show that
both pertussis toxin and cholera toxin (which causes sustained activation of Gsa) can
inhibit and stimulate PLA2 activity (Jelsema, 1987), suggesting that multiple forms of
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G-protein may couple to PLA2. In one study, Gupta et al (1990) found that, in
Chinese hamster ovary (CHO) cells, thrombin and type 2-purinergic receptor agonists
stimulated PLA2 activity through a Gj-type G-protein. In an attempt to identify the
functional domain of the a subunit, chimeric cDNAs were constructed, with different
lengths of Gsa subunit cDNA being replaced with corresponding bases from Gja, and
the chimeric constructs were expressed in CHO cells. These experiments showed that
the last 36 amino acids of Gjoc were critical for G-protein regulation of PLA2 activity.
This type of approach has the advantage over pharmacological studies in that one can
examine the involvement of certain G-protein a subunits in receptor-effector coupling
with greater selectivity. Such studies, together with reconstitution experiments using
specific G-protein a subunits, receptors and effector enzymes, may clarify the nature
of the G-proteins which couple to PLA2. Microinjection of H-ras (which encodes a
21 kDa monomelic G-protein) into fibroblasts can activate PLA2, without having an
effect on inositol phospholipid metabolism (Bar-Sagi and Feramisco, 1986),
indicating that monomelic G-proteins may also control PLA2 activity.
1.3.3. Pharmacological regulation of phospholipase A2 activity
Since PLA2 activation has an important role in receptor signalling and
inflammatory disease, selective PLA2 inhibitors may be effective therapeutic agents.
Inhibitors of PLA2 can affect enzyme activity by a number of different mechanisms;
by either interacting with the enzyme itself, or by interfering with the
enzyme/substrate interaction or by altering Ca2+ availability.
Compounds which make the membrane more fluid (e.g. halothane) or
rigid (cholesterol) disturb the architecture of the lipid-water interface, and in doing so,
may physically prevent PLA2 action. Other drugs, such as local anaesthetics,
polyamines, antipsychotic agents, antibiotics, organic solvents, and antimalarial
agents interact with the phospholipid substrate and prevent enzyme interaction
(Chang et al, 1987a). The antimalarial drugs chloroquine and quinacrine (mepacrine)
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are amongst those which have been most widely used to inhibit PLA2 activity. In
addition to their actions on the phospholipid substrate, these agents may also inhibit
enzyme activity by altering Ca2+ availability (Chang et al, 1987a). Clearly, a number
of cellular processes require Ca2+ and any agent which alters Ca2+ availability will
not be selective. Such actions may account for the ability of quinacrine to inhibit
platelet PLC activity, although at concentrations that are 10 times greater than those
which are required to block PLA2 activity (Hofmann, 1982).
The lipoxygenase and cyclo-oxygenase inhibitors, indomethacin,
5,8,11,14-eicosatetraynoic acid (ETYA) and NDGA can inhibit PLA2 activity from
neutrophil extracts although at concentrations 2 or more fold greater than those
needed to inhibit the relevant pathways of AA metabolism (Franson et al, 1980;
Lanni and Becker, 1985). Since agonist-induced eicosanoid production is dependent
upon both PLA2 and lipoxygenase/cyclo-oxygenase activity, it is important to
interpret the actions of these drugs with due care.
Various agents can inhibit PLA2 activity by directly interacting with the
enzyme. p-Bromophenacyl bromide inhibits PLA2 activity by covalently modifying
essential histidine residues which are associated with the catalytic site of the enzyme
(Volwerk et al, 1974; Drenth et al, 1976; Roberts et al, 1977). However, this drug
can also modify a variety of other proteins and can inhibit platelet PLC activity by
modifying sulfhydryl groups (Hofmann et al, 1982; Kyger and Franson, 1984).
Manoalide covalently modifies lysine residues near the PLA2 active site, inhibiting
enzyme activity, but can inhibit the actions of other phospholipases by similar
mechanisms (Lombardo and Dennis, 1985).
A number of alternative PLA2 inhibitors have been recently developed.
The structure of the Roche PLA2 inhibitors, Ro 31-4493 and Ro 31-4639, has been
based on the X-ray crystal structure of the porcine PLA2 active site (Davis et al,
1988) and can inhibit PLA2 activity in ram sperm sonicates (Roldan and Mollendo,
1991). These compounds appear to block activity by interacting either directly or
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allosterically with the enzyme active site and, therefore, may have a degree of
specificity. Other new PLA2 inhibitors, such as ONO-RS-082 and aristolochic acid,
can block PLA2 activity without altering PLC activity (Banga et al, 1986; Rosenthal
et al, 1989). The exact mechanism of action of these two agents has still to be
determined, although aristolochic acid can interact directly, but non-covalently with
isolated PLA2. Such agents may prove useful for examining the involvement of
PLA2 in physiological responses.
The bee venom peptide, melittin can activate PLA2 (Habermann, 1972)
without altering PLC and lysophospholipase activity (Shier, 1979). The exact
mechanism by which melittin activates PLA2 is unknown, although melittin can
intercalate into cell membranes (Mix et al, 1984) which may render the phospholipid
substrate more susceptible to PLA2 hydrolysis. Melittin can also increase
intracellular Ca2+ levels, possibly by forming ion-permeable 'channels' (Tosteson and
Tosteson, 1981), and this action of melittin may also, in part, contribute to activation
of PLA2. However, at high concentrations, melittin can lyse cells by disrupting cell
membrane integrity (Mix et al, 1984). These actions of melittin may account for its
non-specific effects (Metz, 1986).
1.3.4 Alternative pathways of arachidonic acid release
In platelets, thrombin can induce a rapid release of radioactive AA from
pre-labelled cells. However, when PLA2 activity was measured in platelet extracts,
this activity was too low to account for the rapid release of AA observed with
thrombin (Bell et al, 1979). This observation led to the hypothesis that AA may be
released from phospholipids by a route other than that involving PLA2. Further
experiments showed that upon thrombin stimulation of platelets, the levels of 1-
stearoyl-2-arachidonoyl containing phospholipids, but not other types of
phospholipid, were decreased (Broekman et al, 1979) and that a rapid increase in 1-
stearoyl-2-arachidonoyl diglyceride occurred (Bell et al, 1979). Arachidonate was
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released from this diglyceride by the action of diglyceride lipase in the particulate
fraction of platelet sonicates (Bell et al, 1979). Thus, the sequential actions of an
inositol phospholipid-specific PLC, liberating arachidonyl diglyceride, followed by
the action of a DAG lipase (Figure 1.3) may be an important route of agonist-induced
AA release in some cell types. Since certain species ofPtdCho are enriched in AA at
the sn-2 position (Billah and Anthes, 1990), it is of course, possible that arachidonyl-
containing diglycerides can be produced by the actions of either a PtdCho-specific
PLC or by the action of PLD, followed by PPH (section 1.1.2) and that DAG lipase
action can generate AA from this DAG. However, the physiological significance of
the PtdCho-PLC/DAG lipase and PLD/DAG lipase pathways of AA release has still
to be determined.
More recent studies have shown that 1,2-DAG, produced in response to
thrombin, was preferentially hydrolysed at the sn-1 position over the sn-2 position,
since a 2-monoacylglycerol intermediate, but no 1-monoacylglycerol was detected
(Prescott and Majerus, 1983). Thus, in this model, it would seem that DAG lipase
will catalyse the removal of stearate at the 1-position. Arachidonate will then be
cleaved from the 2-monoacylglycerol by MAG lipase action (Figure 1.3). The MAG
lipase activity can be separated from the DAG lipase activity on DEAE-Sepharose
(Prescott and Majerus, 1983), suggesting that these activities may represent distinct
enzymes.
In the F-l 1 dorsal root ganglia x neuroblastoma hybrid cell line,
bradykinin could induce a significant increase in [3H]-AA release from prelabelled
cells (Morell et al, 1991). Since bradykinin was unable to induce the appearance of
lysophospholipid, it was suggested that PLA2 was not involved in the mechanism of
AA release by this agonist. However, it is now clear that some high molecular weight
cytosolic forms of PLA2 exhibit lysophospholipase activity (Leslie, 1991). Thus, the
lack of appearance of lysophospholipid in agonist-stimulated cells may not indicate
conclusively the involvement of PLA2 in the mechanism of AA release. The
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involvement of either the PLA2 or DAG lipase pathways in agonist-induced AA
release may be further assessed using PLA2 inhibitors (section 1.3.3) and the DAG
lipase inhibitor, l,6-di((9-(carbamoyl)cyclohexaneoxime)hexane (RHC 80267). For
example, luteinizing hormone-releasing hormone (LHRH) induced luteinizing
hormone (LH) release from rat anterior pituitary cells was reduced by RHC 80267, at
a concentration known to selectively inhibit DAG lipase action (10 (iM), to levels
approximately 60% of control. The remaining response to LHRH was blocked by the
PLA2 inhibitor, quinacrine (Chang et al, 1988), suggesting that the actions of both
PLA2 and DAG lipase may be important for secretory responses to LHRH. However,
RHC 80267 clearly lacks specificity at higher concentrations and can inhibit the
activity of PLA2, PLC and cyclo-oxygenase at concentrations of 100 jiM and above
(Oglesby and Gorman, 1984). As a consequence, care must be taken when
interpreting the effect of this agent on cellular responses.
Arachidonic acid release may also be increased by inhibiting the activity
of the enzymes involved in the re-esterification of AA. Phorbol esters and
diglycerides can increase AA release from platelets by a mechanism which involves
inhibition of the activity of arachidonoyl CoA synthetase and arachidonoyl
lysophosphatidate acyltransferase (Fuse et al, 1989). Although the exact mechanism
by which this inhibition of enzyme activity occurs is unknown, PKC may have either
direct or indirect actions on enzyme activity. Any inhibitory action ofPKC on
arachidonoyl CoA synthetase and arachidonoyl lysophosphatidate acyltransferase
activities would provide another hypothetical mechanism by which an agonist could
induce an increase in free AA levels.
1.3.5 Cellular actions of arachidonic acid and arachidonic acid metabolites
Arachidonic acid has a putative role as an intracellular messenger in
mammalian cells and can be metabolised further, leading to the formation of
biologically active eicosanoids; cyclo-oxygenase and associated enzymes form both
32
prostaglandins (PGs) and thromboxanes (TXs); lipoxygenases form leukotrienes
(LTs) and hydroxyeicosatetraenoic acids (HETEs); and the cytochrome P-450
epoxygenases generate various epoxide metabolites (Figure 1.3) (see Needleman et
al, 1986 for review).
In vitro, AA and its metabolites can have many different cellular actions
which may contribute to their physiological effects. For example, AA can stimulate
guanylate cyclase activity (Gerzer et al, 1986), adenylate cyclase activity (Poon et al,
1981) and can increase inositol phospholipid turnover by activating PLC (Irvine et al,
1979). Thus, AA can have positive actions on a number of different second
messenger pathways which may serve to stimulate or amplify them, possibly having
important functional consequences. For example, in placental cells, AA induces
human placental lactogen secretion, probably by stimulating PLC activity and inositol
phospholipid hydrolysis in these cells (Zeitler and Handwerger, 1985). Since AA and
certain AA metabolites can induce Ca2+ release from intracellular Ca2+ pools,
including those which are sensitive to Ins(l,4,5)P3 (Beaumier etal, 1987), and PLC
may be a Ca2+-stimulated enzyme (Meldrum et al, 1991), a Ca2+ mobilising action of
AA could alter PLC activity. Arachidonic acid can also induce prolactin secretion
from pituitary GH3 cells by a mechanism which is not prevented by inhibitors of
lipoxygenase or cyclo-oxygenase pathways (Kolesnick et al, 1984). In contrast, using
dispersed anterior pituitary cells, the inhibitors of AA metabolism, ETYA and
NDGA, can inhibit LHRH-induced LH release (Hulting et al, 1984, 1985) suggesting
that AA metabolites are involved in this process.
Arachidonic acid, itself, and some of its metabolites, notably 12-(S)-
hydroxy-5,8,10,14-eicosatetraenoic acid (12-HPETE) and 5(S),6(R),15(S)-
trihydroxy-7,9,13-trans,l 1-cis eicosatetraenoic acid (Lipoxin A4), can activate the y
(and to a lesser extent, the a and (3 isoforms) of PKC (Naor et al, 1988; Shearman,
1989a, section 1.2.2). In platelets, AA can induce phosphorylation of certain
endogenous substrates; a response which can be prevented by the PKC inhibitor, H7,
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and by immunodepletion of PKC, but which is mimicked by phorbol esters,
suggesting that AA induces this response by modulating PKC activity (Khan et al,
1991). Furthermore, AA may induce platelet aggregation by directly stimulating
PKC activity (Nishikawa et al, 1988).
Arachidonic acid and its metabolites may also have an important role in
the control of neurotransmitter release. Electrophysiological experiments have shown
that AA and the lipoxygenase metabolite, 12-HPETE, increased the opening
probability of a subclass of K+ channels in Aplysia that are suggested to participate in
presynaptic inhibition of neurotransmitter release by Phe-Met-Arg-Phe-NH2
(FMRFamide) (Piomelli and Greengard, 1990). Furthermore, AA and 12-HPETE
could inhibit the activity of Ca2+/calmodulin-dependent protein kinase II (Piomelli et
al, 1989), an enzyme whose actions are important for synaptic vesicle release. Thus,
the combined action of 12-HPETE on Aplysia K+ channel activity and
Ca2+/calmodulin-dependent protein kinase II activity have been suggested to inhibit
neurotransmitter release (Piomelli and Greengard, 1990). Arachidonic acid and LTC4
can also directly activate K+ channels in atrial myocytes (Kurachi et al, 1989) which
would presumably cause cell hyperpolarization and thereby inhibit smooth muscle
excitation.
Arachidonic acid and its metabolites can diffuse out of the cell and act,
either on the cell from which they are released, or on adjacent cells. By having such
an action, AA has been proposed as a retrograde messenger for long-term potentiation
(LTP) in the hippocampus. Experiments by Williams and collaborators (1989) show
that following N-methyl D-aspartate-activation of the dentate gyrus, AA is released
from post-synaptic cells. Perifusion with AA, together with a weak stimulation of the
fibres connecting the entorhinal cortex to the dentate gyrus of the hippocampus,
caused a long-term enhancement of synaptic transmission in the dentate gyrus of the
anaesthetised rat, similar to LTP. However, the cellular site and mode of action of
AA in the mechanism of LTP is uncertain.
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Several membrane associated receptors for prostaglandins, thromboxanes
and leukotrienes are now well established, underlying the importance of these
eicosanoids in cell to cell signalling. Leukotrienes have a number of biological
actions, many of which may be mediated by their interactions with specific receptors.
For example, LTB4 and LTC4 can cause constriction of the bronchi, arterioles,
dilation of the venules and can cause arrhythmia (Needleman et al, 1986).
Leukotriene B4 is also a potent chemotactic agent for neutrophils and eosinophils
(Needlemann et al, 1986). Thus, the leukotrienes have been implicated as mediators
of asthma, inflammatory reactions and myocardial infarction. Prostaglandins can also
act at specific receptors, causing a number of cellular effects. For example, PGD2 can
induce smooth muscle contraction, sleep induction, hypothermia, transmitter release,
antiaggregation of blood platelets and growth inhibition (Shimizu and Wolf, 1990).
Thus, AA metabolites have a wide range of cellular actions which can be mediated by
their interaction with specific membrane bound receptors.
1.4 TheMolecular Mechanisms of Luteinizing Hormone-
Releasing Hormone Action in the Anterior Pituitary
The anterior pituitary gland consists of at least 5 different cell types which
release different hormones; the gonadotrophins, luteinizing hormone (LH) and
follicle-stimulating hormone (FSH) are released from gonadotrophs; prolactin is
released from lactotrophs; growth hormone (GH) is released from somatotrophs;
adrenocorticotrophic hormone is released from corticotrophs and thyroid-stimulating
hormone (TRH) is released from thyrotrophs. The release of these hormones is under
the control of a number of factors, many of which are released from the nerve endings
of the median eminence of the hypothalamus, and are carried to the pituitary gland by
the hypophysial-portal blood vessels. Hypothalamo-pituitary function is important
for controlling physiological processes such as growth, stress, water retention, fertility
and metabolic rate (Fink, 1988).
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The hypothalamic decapeptide, luteinizing hormone releasing hormone
(LHRH, pyro-Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) has four main
actions on the anterior pituitary gland; (1) it can induce LH and FSH release; (2) it
can increase gonadotroph responsiveness to itself - an effect known as LHRH priming
(Aiyer et al, 1974a; Edwardson and Gilbert, 1976; Pickering and Fink, 1976; 1979);
(3) it can regulate LHRH receptor number and; (4) it can induce gonadotrophin
synthesis (Fink, 1988). These actions of LHRH are important for maintaining the
reproductive cycle in the mammal. In particular, in the female rat in vivo LHRH
priming acts in co-ordination with the cyclic surge of LHRH in the hypophysial portal
blood, producing a massive release of LH, leading to ovulation on a day of the cycle
known as pro-oestrus.
1.4.1 Luteinizing hormone-releasing hormone actions on gonadotrophin
release
The first evidence for a priming action of LHRH came from in vivo studies
in pro-oestrous rats in which the LH response to the second of two injections with
LHRH was significantly greater than the response to the first LHRH injection (Aiyer
et al, 1974). In later experiments, LHRH priming was demonstrated in pro-oestrous
rat anterior pituitary tissue in vitro and a number ofmajor differences between the
priming and releasing actions of LHRH were detected (Table 1.1). For example,
LHRH-induced LH release, but not LHRH priming, is dependent upon extracellular
Ca2+ and can be elicited by Ca2+ ionophores and depolarising concentrations of K+
(Pickering and Fink, 1979). Ultrastructural studies have shown that priming is
accompanied by a change in orientation and length of the gonadotroph microfilaments
and movement of the secretory granules to the plasma membrane. This action may
explain why there is an increase in size of the readily releasable pool of LH prior to
the LH surge (Fink, 1988). The priming response, but not the releasing action of
LHRH, requires synthesis of a protein, other than additional hormone (Edwardson
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and Gilbert, 1976; Pickering and Fink, 1976, 1979). This protein may be a 70 kDa,
heat-shock protein (Curtis et al, 1985), whose exact function in priming has yet to be
clarified. Luteinizing hormone-releasing hormone priming is associated with an
increased production of IP3 and facilitated Ca2+ mobilisation (Mitchell et al, 1988),
thus the priming response is associated with an increase in stimulus-secretion
coupling. Pre-treatment with PKC activators can augment LHRH-induced hormone
release (Turgeon and Waring, 1986), raising the possibility that PKC may modulate
LHRH priming. Consistent with this hypothesis, in a preliminary study,
staurosporine inhibited the priming actions, but not the releasing effects of LHRH
(Fink etal, 1990). However, in another study (Johnson et al, 1988), H7 was unable to
inhibit either the priming or releasing actions of LHRH. Nevertheless, the possibility
that PKC activation may be required for LHRH priming requires further
investigation.
In vivo, the LH surge is preceded by a surge of oestrogen (E2) and is
accompanied and followed by an increase in plasma progesterone levels. There is
good evidence that E2 is required to maintain the LH surge and that this modulatory
action of E2 is partly due to an indirect effect on the LHRH-releasing neurones,
facilitating LHRH release (Fink, 1988). Oestrogen also facilitates LHRH-induced LH
release by having direct effects on gonadotroph responsiveness (Drouin et al, 1976;
Debeljuk et al, 1978). This action may be due to an effect of E2 on the intracellular
mechanisms which control gonadotrophin release. For example, long-term E2
treatment of ovariectomised rats and of cultured anterior pituitary cells can facilitate
LH responses to PKC activators measured in vitro (Liu and Jackson, 1988; Bourne et
al, 1989; Fahmy etal, 1989), probably by inducing synthesis of additional PKCs
(Drouva et al, 1990). Progesterone can also enhance LHRH responses, possibly by
having effects on gonadotroph stimulus-secretion coupling (Mann and Barraclough,
1973; Turgeon and Waring, 1981, 1990). The ovary releases a number of non¬
steroidal factors, including inhibin, that have a negative influence on LHRH
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responses (de Konig et al, 1987; Koppenaal et al, 1991). For example, inhibin
treatment of rat anterior pituitary cell cultures for 5 days reduced subsequent secretory
responses to phorbol esters (Wang et al, 1990), suggesting that inhibin may suppress
responses to LHRH by having an effect on PKC, or some mechanism subsequent to
PKC activation. Thus, both gonadal steroids and non-steroidal factors may modulate
gonadotrophin release and LHRH priming by affecting post-receptor signalling
events.
1.4.2 The role of calcium in LHRH receptor responses
Preliminary studies suggested that LH release occurred by a Ca2+-
dependent mechanism, since Ca2+ ionophores could induce LH release from pituitary
cultures (Conn et al, 1979; Naor and Eli, 1985; Chang et al, 1986b), LHRH-induced
LH release coincided with an increase in 45Ca2+ flux from pre-loaded anterior
pituitary pieces (Williams, 1976) and secretory responses to LHRH were, in part,
dependent upon the presence of extracellular Ca2+ (Marian and Conn, 1979). More
recent studies have shown that LHRH induced inositol phospholipid breakdown both
in dispersed anterior pituitary cells (Snyder and Bleasdale, 1982) and in cell
populations enriched in gonadotrophs (Raymond etal, 1984; Andrews and Conn,
1986) and that this was followed by an increase in Ins(l,4,5)P3 and DAG
accumulation (Schrey, 1985; Andrews and Conn, 1986). Inositol (1,4,5)
trisphosphate production and Ca2+ mobilisation may, therefore, be a major pathway
for LHRH-induced LH release. Since G-protein analogues induced an increase in
inositol phosphate production and LH release from ATP-permeabilized dispersed rat
anterior pituitary cells (Andrews et al, 1986), the LHRH receptor is probably coupled
to PLC via a G-protein.
In cultured anterior pituitary cells, the pattern of LHRH-induced
gonadotrophin release is biphasic, consisting of an initial rapid peak of hormone
release within the first 10 minutes of stimulation, followed by a more sustained
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release (Borges et al, 1983; Tasaka et al, 1988). This temporal pattern of hormone
release correlated with changes in the requirement of the response for Ca2+ from
intracellular and extracellular sources. Using fluorescent indicators to measure
cytosolic free Ca2+ levels in single cell populations of enriched gonadotrophs, LHRH
stimulation was shown to induce an initial spike of Ca2+ which is followed by a more
sustained increase in Ca2+ (Clapper and Conn, 1985). Removal of the extracellular
Ca2+ reduced the initial Ca2+ spike by 35 - 60% and prevented the prolonged increase
in intracellular Ca2+ (Chang et al, 1986b; Limor et al, 1987; Tasaka et al, 1988).
Thus, approximately half of the spike phase of Ca2+ release comes from intracellular
stores, the remaining Ca2+ apparently entering from extracellular sources through
dihydropyridine (DHP)-insensitive Ca2+ channels (Smith et al, 1987; Tasaka et al,
1988). Calcium entry through the DHP-insensitive channels continues into the later
phase of LH release, during which, Ca2+ entry (approximately 30% of the later phase)
also occurs through DHP-sensitive Ca2+ channels (Chang et al, 1986b; Shangold et
al, 1988).
The LHRH-mediated increase in intracellular Ca2+ levels may induce
gonadotrophin release by modulating the activity of a number of different Ca2+-
dependent processes. In particular, LHRH treatment of ovariectomized rats causes a
redistribution of calmodulin from the cytosol to the plasma membrane (Conn et al,
1981a), a process which may have functional significance since the activities of
calmodulin-dependent enzymes may be altered. Indeed, a component of LHRH-
induced LH release can be inhibited by calmodulin antagonists (Conn et al, 1981b),
suggesting a role for Ca2+/calmodulin-dependent enzymes in this process.
1.4.3 The role of protein kinase C in LHRH receptor responses
Although LHRH receptor activation also liberates DAG (Andrews and
Conn, 1986) which can activate PKC (section 1.2), the involvement of PKC in LHRH
responses is controversial (see Conn, 1989 for review). Luteinizing hormone-
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releasing hormone can induce PKC translocation to the cell membrane (Hirota et al,
1985; Naor et al, 1985; McArdle and Conn, 1986), with a time-course and dose-
dependency similar to that of LHRH-induced LH release. Furthermore, DAGs and
phorbol esters induced gonadotrophin release from anterior pituitary cells in culture
(Smith and Vale, 1980; Conn et al, 1985; Nigro-Villar and Lapetina, 1985; Chang et
al, 1987b) and anterior pituitary pieces in vitro (Turgeon and Waring, 1986; Johnson
and Mitchell, 1989). Introduction of purified rat brain PKC into permeabilized
anterior pituitary cells also induced LH release (Naor et al, 1989), consistent with a
role for PKC in LH release responses. Notably, Ca2+ ionophores and PKC activators
mimicked the early and late secretory responses to LHRH respectively (Harris et al,
1985; Naor and Eli, 1985; Turgeon and Waring, 1986; Chang etal, 1987b). Although
some studies show that LHRH-induced LH release, and the later secretory response in
particular, are prevented by PKC inhibitors (Hirota et al, 1985; Chang et al, 1987b;
Stojilkovic et al, 1991), others have reported that LHRH responses are not prevented
by these drugs (van der Merwe et al, 1990b). Thus, further studies are required to
clarify the role of PKC in LHRH response.
Attempts to elucidate the involvement of PKC in LHRH responses by
phorbol ester-induced down regulation of pituitary PKC levels have also produced
conflicting results. For example, after down regulation of PKC in dispersed anterior
pituitary cells, some have reported that both LHRH and phorbol ester secretory
responses are attenuated (Stojilkivic etal, 1988b, 1991). In contrast, similar studies
show that, although phorbol ester-induced hormone release is reduced, the response to
LHRH is unaffected (McArdle and Conn, 1986; McArdle et al, 1987). The
discrepancies between these down-regulation studies may be accounted for by
differences in the down-regulation protocols. For example, in a study by McArdle et
al (1987), anterior pituitary PKC levels were down regulated by PMA treatment for 6
hours, a protocol which can down-regulate PKC levels by only approximately 50%
(Stojilkovic et al, 1991). It is likely that the PKC(s) involved in LHRH responses
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may not be down-regulated completely by this method. In another study (Stojilkovic
et al, 1991), anterior pituitary cells were treated with PMA over a longer time-scale
(24 hours), during which, PKC was down regulated by 90% and LHRH secretory
responses were attenuated. Several problems can arise from using chronic phorbol
ester treatment as a method of down-regulating PKC. Firstly, since PKC can
phosphorylate a number of different cellular targets, prolonged phorbol ester
treatment may causes long-term changes in cell function, which can alter cell
responsiveness. In addition, phorbol esters can release LH and, on sustained
application, may reduce gonadotroph^ levels by 70 - 80% (Stojilkovic et al, 1988a,
1988b). Ideally, gonadotroph PKC levels should be down-regulated under conditions
that will not affect gonadotrophin secretory capacity. As a consequence, PKC down-
regulation by prolonged phorbol ester treatment is not an ideal system in which to
study PKC involvement in LHRH responses.
In a large number of studies, dispersed anterior pituitary cells, maintained
in culture, have been used to examine LHRH action. Although cultured cells respond
to LHRH, it is clear that they function differently than tissue in vivo and to anterior
pituitary pieces incubated in vitro. For example, LHRH can induce LH biosynthesis
in gonadotrophs in vivo and in tissue pieces incubated in vitro, but is unable to do so
in cultured cells. In addition, LHRH is unable to induce a priming response in
dispersed cells (Speight and Fink, 1981; Chang et al, 1987b) whilst priming does
occur in tissue pieces (Edwardson and Gilbert, 1976; Pickering and Fink, 1976, 1979;
Turgeon and Waring, 1981). There are several reasons why cultured cells may not
function in an entirely physiological way. First of all, it is clear that steroids can have
modulatory effects on a number of factors which may contribute to LHRH responses
and LHRH priming in particular. Oestrogen, for example, can influence PKC
expression in cultured anterior pituitary cells, enhancing LH secretory responses to
phorbol esters (Drouva et al, 1990) and LHRH (Audy et al, 1990). Therefore, it is
possible that any PKCs which function in the LHRH signal may be down-regulated in
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cells which have been cultured in steroid-free conditions, explaining why a number of
workers have been unable to find any PKC involvement in LHRH receptor signalling
using this system. Secondly, enzymatic dispersion may cause changes in LHRH
receptor properties (Naor et al, 1980). Thirdly, dispersed pituitary cells are incubated
in the absence of LHRH, whereas in vivo the pituitary is under the continual influence
of LHRH pulses. Finally, gonadotrophs are suggested to specifically associate with
lactotrophs via gap junctions (Nakane et al, 1970) and physiological interactions,
such as the exchange of inorganic and organic molecules, may take place between
these cell types (Denef and Andres, 1983). Dispersed cells in culture, therefore, are
not an ideal system for studying the involvement of PKC (or, indeed, other cellular
signals) in LHRH responses.
Anterior pituitary tissue pieces and cells in culture consist of populations
of different cell types, only approximately 10% of which are gonadotrophs and unless
a cell specific response, such as LH/FSH release, is measured, problems may arise
with regards to interpreting certain studies. Some groups have carried out studies
using gonadotrophs from dispersed anterior pituitaries which have been purified by
elutriation (Raymond etal, 1984; Hirota et al, 1985; Andrews and Conn, 1986). An
alternative approach has been to use clonal cell lines but, until very recently, no
gonadotroph cell line existed. However, recently, Mellon and her colleagues have
produced a clonal cell line from transgenic mice, the a T3-1 cell line, which
expresses high affinity LHRH receptors (Windle et al, 1990; Horn et al, 1991). Like
dispersed anterior pituitary cells, a T3-1 cells mobilise intracellular and extracellular
Ca2+ in response to LHRH (McArdle et al, 1992). However, these cells do not
synthesis or secrete the (3 LH or FSH subunits (Windle et al, 1990), limiting their
usefulness as a model of LHRH action in gonadotrophs. Although future
development of similar cell lines, which function more physiologically, may help to
characterise the molecular mechanism of LHRH action, these cell lines, like dispersed
cells, will probably suffer from the drawbacks described above. Of all of the
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described systems, anterior pituitary tissue pieces incubated in vitro seem to function
most similarly to anterior pituitaries in vivo and are therefore, a more physiological
system in which to characterise the role of effectors, such as PKC, in LHRH
responses.
1.4.4 The role of arachidonic acid and it metabolites in LHRH responses
Arachidonic acid and its lipoxygenase and epoxygenase metabolites may
have a second messenger function in LHRH receptor signalling. Using cultured
anterior pituitary cells, AA can induce LH release and LHRH can induce an increase
in [3H]-AA release from pre-labelled cells (Naor and Catt, 1981; Chang et al, 1986a,
1987b). Addition of melittin or exogenous PLA2 can induce LH release from
cultured anterior pituitary cells (Kiesel et al, 1985). The PLA2 inhibitor, quinacrine,
can inhibit 40% of the LH/FSH secretory response to LHRH; the remaining release of
hormone being blocked by the DAG lipase inhibitor, RHC 80267 (Chang et al, 1988).
These results suggest that LHRH may induce AA release by a route involving both
DAG lipase and PLA2 action. The mechanism by which LHRH receptors couple to
PLA2 and DAG lipase is poorly understood.
Luteinizing hormone-releasing hormone-induced LH release from
dispersed anterior cells is prevented by lipoxygenase inhibitors, including NDGA and
BW 755C and by the more selective lipoxygenase inhibitors, L-656,224 and MK 886,
but not cycloxygenase inhibitors (Naor and Catt, 1981; Naor et al, 1983; Dan-Cohen
et al, 1992) suggesting a role for lipoxygenase metabolites as mediators of LHRH
responses. Consistent with this hypothesis, LHRH induces an increase in leukotriene
production (Vanderhoek et al, 1984; Kiesel etal, 1991). Different lipoxygenase
metabolites have been shown to induce LH release from dispersed anterior pituitary
cells, but with conflicting results. 5-Hydroxy-6,8,l 1,14-eicosatetraenoic acid (5-
HETE) can induce LH release from cultured cells, but at concentrations which are
unlikely to be physiological (> 1 (iM) (Naor et al, 1983; Kiesel et al, 1987). In some
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investigations, LTC4 and LTB4 have been shown to induce LH release at
concentrations which may be physiologically relevant (Catt et al, 1985; Naor et al,
1985; Dan-Cohen et al, 1992). However, a second report suggests that LTC4 only is
effective (Hulting et al, 1985) and yet a third report indicates that neither LTC4 nor
LTB4 can induce LH release (Naor et al, 1983). Clearly, these results do not provide
a definitive conclusion as to the role of specific lipoxygenase metabolites in LHRH
responses. Nevertheless, leukotriene receptor antagonists, compounds like FPL
55,712, ICI 198 615 and LY 171 883, can partially inhibit LHRH-induced LH release
from dispersed rat anterior pituitary cells at concentrations where they are known to
selectively antagonise LTD4, LTC4 and LTE4 receptor actions (Kiesel et al, 1991;
Dan-Cohen et al, 1992). It would seem, therefore, that lipoxygenase metabolites, and
certain leukotrienes in particular, may play a role, at least in part, in the mechanism of
LHRH-induced LH release from dispersed rat anterior pituitary cells.
The epoxygenase metabolite 5,6-epoxyeicosatrienoic acid can also induce
LH release from dispersed anterior pituitary cells but at a concentration (100 nM) that
may not be physiological (Snyder et al, 1983). However, these experiments do not
discount the possibility that certain epoxygenase metabolites may function in the
process of LHRH-induced LH release. Additional experiments examining the effect
of epoxygenase inhibitors on secretory responses to LHRH will be of interest since
they may clarify the role of these AA metabolites in the LHRH receptor signal.
1.5 The Aim of This Study
The aim of this research project has been to elucidate the pharmacology,
cellular targets and physiological actions of PKC forms in rat anterior pituitary tissue,
particularly in the context of the priming effect of LHRH. Thus, a number of
questions were addressed: (1) is PKC activation required for gonadotrophin release in
response to LHRH and/or the LHRH priming effect? (2) if so, what are the
pharmacological profiles of the PKC forms that control these responses? (3) is PLA2
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a cellular target of these PKC forms? (4) do gonadal steroids, such as oestrogen,




Phospholipid breakdown by different forms of phospholipase
Agonist-stimulated phospholipid breakdown can occur by the actions of
one or more type of phospholipase. Both phospholipase C (PLC) and phospholipase
D (PLD) catalyse the hydrolysis of phosphodiester linkages. The catalytic actions of
PLC would release 1,2-diacylglycerol and the polar head group of the phospholipid,
whereas PLD-induced phospholipid hydrolysis would liberate phosphatidic acid and a
free base (depicted here as R2). The R2 position base may be either inositol or
choline. Phospholipase A2 (PLA2) catalyses the hydrolysis of the sn-2 bond of the
phospholipid backbone, releasing free fatty acid, such as arachidonic acid (as shown







































Protein kinase C enzyme family
This figure is a schematic representation of the cDNA sequences of the
known PKC isoforms. The A series (a, (3 and y) are the Ca2+-dependent forms
whereas the B series (y, e, rj, 0 and X) are the Ca2+-independent forms. The boxed
regions represent the conserved regions of PKC (Ci - C4) whilst the variable regions
are shown by V1 - V5. Analysis of the functions of these domains has been based
upon deletion/mutagenesis studies, construction of chimeric PKCs, sequence analysis
and by making biochemical comparisons with other enzymes. This figure has been























Comparison between the releasing and priming actions of LHRH in the pro-
oestrous rat
(Based on Fink (1986)).
Releasing Priming
Can be repeated frequently
Enhanced by oestrogen
Dependent on extracellular Ca2+
Mimicked by high K+
Mimicked by Ca2+ ionophores
Dependent on protein synthesis
Dependent on integrity of
microfilaments
Elicited in dispersed cells
Cyclic AMP acts as a mediator
Ins (1,4,5)P3 acts as a mediator
PKC acts as a mediator
AA and/or its metabolites act as
mediators















[5,6,8,9,11,12,14,15-3H(N)]-Arachidonic acid (specific activity
approximately 240 Ci/mmol), adenosine 5'-[y-35S-thio] triphosphate (ATP-y-35S)
(specific activity approximately 240 Ci/mmol) and [20-3H(N)]-phorbol 12,13-
dibutyrate (specific activity =19 Ci/mmol) [3H]-N,N-dimethylstaurosporine (specific
activity =160 Ci/mmol) were purchased from Du Pont, Dreieich, Germany.
Luteinizing hormone-releasing hormone (LHRH), phorbol 12,13-dibutyrate (PDBu),
l,2-dioctanoyl-^«-glycerol (DOG), mezerein, quinacrine dihydrochloride, p-
bromophenacyl bromide (BrPheBr), 4, 8, 11, 14-eicosatetraynoic acid (ETYA),
nordihydroguaiaretic acid (NDGA), indomethacin, arachidonic acid sodium salt
(AA), arachidic acid, oestradiol 17(3 (E2), bovine serum albumin (BSA; essential fatty
acid free), deoxyribonuclease, hyaluronidase, docosahexaenoic acid, penicillin,
streptomycin, trans-epoxysuccinyl-L-leucylamido-(4-guanidino) butane (E64), 2-
mercaptoethanol (EtSH), phenylmethylsulphonyl fluoride (PMSF), lysine-rich histone
HIS, Dulbecco's modification of Minimal Essential Medium powder (without phenol
red, but with 1000 mg/ml glucose and 1-glutamine) were all purchased from Sigma
Chemical Company Ltd, Poole, Dorset, UK. K252a was purchased from Kyowa
Medex Co, Tokyo, Japan, ionomycin, staurosporine and Nonidet P-40 were
purchased from Novabiochem, Nottingham, UK and aristolochic acid sodium salt was
purchased from Biomol Research Laboratories, c/o Semat, St Albans, Herts, UK. 4-
Chloro-/V-(p-pentylcinnamoyl) anthraniric acid (ONO-RS-082) was a gift from ONO
Pharmaceuticals, Osaka, Japan. Ro 31-8220, Ro 31-4639 and Ro 31-4493 were gifts
from Roche Products Ltd, Welwyn Garden City, Herts, UK. 1,6-Di(0-(carbamoyl)
cyclohexaneoxime) hexane (RHC 80267) was a gift from Wellcome Research
Laboratories, Beckenham, Kent, UK. Foetal calf serum was purchased from Sera
Lab, Crawley Down, Sussex, UK. Leupeptin and collagenase were obtained from
Boehringer Mannheim, Lewes, UK and phosphatidylserine (sodium salt) from Lipid
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Products, Nutfield, Surrey. Hepes-buffered minimal essential medium containing
Earle's salts (MEM), Dulbecco's modified Eagle's medium (DMEM) with sodium
pyruvate and glutamine, Earle's balanced salt solution (EBSS) with magnesium but
without phenol red and l-(5-isoquinolinesulphonyl-2 methylpiperazine)
dihydrochloride (H7) were obtained from Gibco Brl, Paisley, Scotland, UK.
Analar grade laboratory chemicals were obtained from BDH, Dagenham,
Essex, UK. COB-Wistar rats were purchased from Charles River UK Ltd, Margate,
Kent, UK or were obtained from a colony bred in this department which were derived
from Charles River Wistar rats. The a T3-1 cell line was a gift from Dr Pamela
Mellon, the Salk Institute, USA. Radioimmunoassay materials were gifts from Dr S
Raiti of the NHPP, University ofMaryland School of Medicine, Baltimore, MD,
USA, Drs GD Niswender, LE Reichert Jr and the Pituitary Hormone Distribution
Agency of the NIADKK, Baltimore, MD, USA and the Scottish Antibody Production
Unit, Carluke, Lanarkshire, UK.
2.2 Methods
2.2.1 Animals
Adult female (~ 200 g) or male (~ 250 g) COB Wistar rats were
maintained under controlled lighting (lights on from 05.00 to 19.00 h) and
temperature (22°C) with free access to food pellets (CRM, Labsure, Manea, Cambs,
UK) and tap water.
Female rats were assessed for a minimum of two 4 day oestrous cycles (as
determined by vaginal lavage) before being anaesthetised with Sagatal (30 mg ml/kg
body weight; sodium pentabarbitone; May and Baker, Dagenham, Essex) by 11.00 -
11.30 am on the appropriate day of the cycle. The cytological characteristics of the
vaginal smears in 4-day cyclic rats were as follows;
Metoestrus: large numbers of leucocytes, epithelial cells and cornified epithelial
cells.
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Dioestrus: leucocytes, epithelial cells and cornified epithelial cells, but in smaller
amounts than metoestrous animals.
Pro-oestrus: mainly nucleated epithelial cells.
Oestrus: predominantly cornified epithelial cells.
To study the effects of oestrogen (E2) treatment on anterior pituitary
responsiveness, female rats, at random stages of the oestrous cycle, were bilaterally
ovariectomised under halothane anaesthesia and left over a period of 4 weeks before
being randomly divided into two experimental groups. The E2-treated group received
subcutaneous implants in the dorsal neck with 1 cm long silicone elastomer capsules
(Dow-Coming Corporation, Michigan, USA), with an internal diameter of 0.078
inches and an external diameter of 0.125 inches, containing 0.5 cm of crystallised
oestradiol 17(3 and the control (i.e. E2 untreated) group received equivalent implants
but with empty capsules (Dzuik & Cook, 1966; Henderson et al, 1977). On the
morning of the 5th day after implantation, vaginal smears were examined.
Ovariectomised animals which had been implanted with empty capsules had smears
similar in characteristic to those seen dioestrus whereas those animals which had been
implanted with E2-containing capsules had smears similar to those seen on oestrus.
Animals were anaesthetised and decapitated by 11.30 am on the 5th day after
implantation.
2.2.2 Anterior pituitary cell dispersion and cell culture
Anterior pituitary pieces were removed from 5-6 female rats using, as far
as possible, sterile technique and placed into a sterile petri dish containing
approximately 5 ml of sterile Earle's balanced salts solution (EBSS) and cut into 8
pieces of approximately equal size. The tissue pieces were then transferred to a
second sterile petri dish containing 5 ml of sterile EBSS containing 0.2% collagenase,
0.2% hyaluronidase and 2 fig/ml deoxyribonuclease. The tissue was then left to
incubate with the enzymes for 1 hour at 37°C under an atmosphere of 95% air/5%
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C02. The cells were dispersed by tritutating the enzyme-treated tissue with a sterile
glass pasteur pipette. The cells were separated from the enzyme solution and cell
debris by centrifugation (room temperature, 750 g, 10 min). The supernatant was
discarded and the pellet was resuspended in 5 ml of EBSS containing 2 |lg/ml
deoxyribonuclease. The cell suspension was pipetted onto fibronectin-treated 12 well
plates (0.2 ml/well) along with 1 ml of pre-warmed DMEM (made from DMEM
powder as described in Appendix 1.2) containing 10% steroid-stripped foetal calf
serum (see Appendix 1.1), 100 U/ml penicillin and 100 (ig/ml streptomycin. Cells
were incubated for 4 days in a humified atmosphere of 95% 02/5% C02 at a constant
temperature of 37°C, after which, the medium was replaced.
a T3-1 cells were grown in Dulbecco's modified Eagle's medium
(DMEM) with sodium pyruvate (110 mg/1) containing 10% foetal calf serum, 2 mM
glutamine, 100 U/ml penicillin and 100 |ig/ml streptomycin, under a humidified
atmosphere of 95% air/5% C02 at 37°C and received fresh medium every 3-4 days.
Cells were allowed to grow to 100% confluency and were split and either seeded, at
low density, in fresh flasks or in 12 well plates for assay purposes. Cells were
harvested by trypsin digestion; the medium was removed and replaced with 5 ml of
0.25% (v/v) trypsin solution (37°C). After 15-30 seconds, the trypsin solution was
removed and the flasks were incubated for a further 5 minute period (37°C). Cells
were detached from the culture flask by agitation in fresh DMEM. The cell
suspension was split into new flasks.
For storage, harvested cells were resuspended in 95% foetal calf serum +
5% dimethylsulphoxide (~ 107 cells/ml) and aliquoted into cryostat tubes, which were
then sealed. The cells were frozen at -70°C for 3 - 5 h before being placed in liquid
N2. Cells were recovered from storage by placing the frozen cryostat tube into a
beaker of water (37°C) for 2 minutes. The defrosted cell suspension was transferred
into a flask containing pre-warmed (37°C) DMEM using a sterile syringe and wide
gauge needle.
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All tissue culture was carried out using sterile apparatus and in sterile flow
hoods.
2.2.3 Hormone secretion experiments
The methods were based upon those used by Pickering and Fink (1976)
(Figure 2.1). Anterior pituitary glands were hemisected and randomly distributed into
25 ml conical flasks containing 2 ml of pre-gassed and pre-warmed (37°C) Hepes-
buffered minimal essential medium with Earle's salts (MEM). The hemipituitary
pieces were pre-incubated for 30 min in a shaking water bath at 37°C under an
atmosphere of 95% 02/5% CO2, after which, the medium was discarded and replaced
hourly with fresh pre-warmed and pre-gassed MEM. To examine the actions of
various secretagogues on hormone release, the tissue was incubated for an initial,
basal hour in the presence ofMEM only, followed by consecutive hours in the
presence of either LHRH, a PKC activator or ionomycin as appropriate. In the
experiments where the effects of PKC/PLA2 inhibitors were examined, the inhibitor
was present in the basal hour as well as the 1st, 2nd and 3rd hours, together with the
appropriate secretagogue. The medium was collected at the end of each hourly
incubation and was stored at -20°C until it was radioimmunoassayed for LH, FSH or
GH (Niswender et al, 1968; Daane and Parlow, 1971, see Appendix II). Where drugs
were made up as stock solutions in dimethylformamide (DMF) or ethanol, the
maximum concentration of each solvent was used in control experiments.
The mean intra- and inter-assay variables in the LH and GH
radioimmunoassays were less than 5% and 7% respectively. Luteinizing hormone
was assayed using either NIH-LH-S18 or NIADDK-rat LH-RP2 and data were
normalised for comparison. Other minor factors which may affect the reproducibility
of the experimental data include small differences between pituitaries, such as
minimal variations in size.
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2.2.4. Cytosolic protein kinase C activity assay
Anterior pituitary PKC activity was determined as the phosphatidylserine -
dependent, histone HIS kinase activity induced by PKC activators using methods
modified from those described by Wise et al (1982) and Huang et al (1988) (Figure
2.2). Anterior pituitary tissue was homogenised in 2 volumes (volume = lml/g of
tissue, wet weight) of 20 mM Tris HC1 (pH 7.5) containing 50 mM 2-
mercaptoethanol, 2 mM ethylenediaminetetraacetic acid (EDTA), 1 mM
phenylmethylsulphonyl fluoride (PMSF), 0.01% (w/v) leupeptin and 20 (iM E64.
The homogenate was centrifuged (16,000 g, 20 min, 4°C) and the supernatant was
collected and recentrifuged (16,000 g, 5 min, 4°C). The supernatant from the second
spin was taken to represent cytosol and was partially purified by loading onto 1.5 ml
DE52 diethylaminoethyl (DEAE) cellulose (Whatman International Ltd, Maidstone,
Kent, UK) in a Bio-Rad Poly-Prep chromatography column (Bio-Rad Laboratories,
Richmond, CA, USA) at 4°C. The cytosol was then washed with 6 column volumes
of homogenisation buffer before eluting the partially purified PKC with 3 column
volumes of buffer containing 150 mM NaCl. Partially-purified cytosolic PKC
activity was measured in an assay mixture containing (final concentrations): 12.5 mM
MgCl2, 100 (ig/ml phosphatidylserine (sodium salt) + 0.04% Nonidet P-40, 1.25
mg/ml histone HIS, 100 pM ATP-y-35S (0.595 pCi/tube) and cytosol (final volume =
100 pi). All assay components and drugs were dissolved in 20 mM Tris HC1 (pH 7.5)
+ 0.5 mM EGTA. Assay tubes additionally contained either 600 pM CaCl2 (100 pM
free Ca2+) or 5 mM ethyleneglycol-bis-(P-aminoethyl ether) N, N, N', N'-tetraacetic
acid (EGTA) to give Ca2+-dependent and Ca2+-independent conditions respectively .
Phosphatidylserine vesicles were prepared by drying the lipid from chloroform/
methanol under a stream of N2. The subsequent film of phosphatidylserine was
scraped into 20 mM Tris HC1 (pH 7.5) + 0.5 mM EGTA at a stock concentration of
400 pg/ml, sonicated, then 0.16% Nonidet P-40 was added. The mixture was
vortexed before use. Protein kinase C activity was measured either in the absence of
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activator (i.e. basal activity) or in the presence of 1 |J.M PDBu or 100 (iM DOG or in
the presence of activator and an appropriate PKC inhibitor. DOG which was added to
each assay tube in 1 pi DMF using a Hamilton microsyringe. Reactions were carried
out at 30°C for 15 min and were stopped by quenching with 20 pi of 0.1 M ATP in
0.1 M EDTA (pH 7.0). The quenched reaction mixture (50 pi) was spotted onto a
4 cm2 piece of P-81 cellulose phosphate ion-exchange paper (Whatman International
Ltd) and washed (3 x 10 ml, 2 min, room temperature) in 75 mM H3PO4.
Kinase activity measured in the presence of phosphatidylserine, 5 mM
EGTA (i.e. low free Ca2+) and in the absence of PKC activator was taken to represent
basal activity and was subtracted from all activator-stimulated levels. Calcium-
independent kinase activity was taken to be the activity measured in the presence of 5
mM EGTA and PKC activator. The additional kinase activity measured with samples
containing CaCl2 + PKC activator was taken to represent calcium-dependent kinase
activity. ATP-y-35S (rather than ATP-y-32P) was used because, whilst it is still a
good substrate for many types of protein kinase (Eckstein, 1985), the
thiophosphorylated products are more resistant to phosphatase action (Coyne et al,
1987).
2.2.5 [3H]-Arachidonic acid release measurements
The release of [3H]-arachidonic acid ([3H]-AA) from pre-labelled anterior
pituitary tissue or dispersed cells in culture was measured by reverse-phase liquid
chromatography on octadecyl silica cartridges (ODS) (sep-pak Cis cartridge, Waters
Chromatography, Watford, Hertfordshire, UK) using the solvent system described by
Powell (1982) (Figure 2.3). Anterior pituitary glands were removed, hemisected and
each hemipituitary cut into two equal quarters. Pairs of pituitary quarters were then
placed into a silanised flask containing 1 ml of pre-warmed (37°C) and pre-gassed
(95% 02/5% CO2) MEM and pre-incubated in a shaking water bath (37°C, 95%
02/5% CO2) for 30 minutes. The medium was then replaced with fresh MEM
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containing 0.5 (iCi of [3H]-AA and the tissue incubated with the label for 2 hours.
The tissue was then washed three times in MEM containing 1% fatty acid-free bovine
serum albumin (BSA) to remove unesterified [3H]-AA.
Dispersed anterior pituitary cells or a T3-1 cells were cultured in 12 well
plates for 4 days as described in section 2.2.2. The culture medium was removed and
replaced with fresh pre-warmed MEM containing 0.5 (iCi of [3H]-AA. The cells
were incubated for 18 hours in an incubator at 37°C under a humidified atmosphere
of 95% air/5% CO2. The cells were then washed three times in MEM containing 1%
BSA.
For studies of [3H]-AA release, after washing, the tissue or cells were
incubated in MEM + 0.5% BSA (as a trap for released [3H]-AA) containing either no
drug (basal) or an appropriate stimulus. After 15 min, the incubation medium was
removed and placed in 2 ml ice-cold ethanol, and 3.7 ml of distilled H2O was added
(to give a final ethanol concentration of 30%) and this was retained for [3H]-AA
determination. The cells/tissue were washed twice in pre-warmed and pre-gassed
MEM +1% BSA then a final 1 ml aliquot of pre-warmed and pre-gassed MEM +
0.05% BSA was added to each. The cells were scraped into the medium. The tissue
pieces/cells suspension were transferred to a silanised hand held tissue grinder along
with the medium and homogenised. The homogenate was added to 2 ml of ice-cold
ethanol and was then diluted with distilled water (3.7 ml) to give a final ethanol
concentration of 30%.
Both tissue/cell homogenates and medium were centrifuged (10', 5°C,
3000 g) and the supernatant from each was retained and acidified to pH 3 with 1M
HC1. To measure medium and tissue [3H]-AA levels, a 4 ml aliquot of the acidified
supernatant from each was loaded onto an ODS column (pre-washed with 5 ml
ethanol followed by 5 ml of CIH2O). Solvents were then passed through the columns
in the following order: (a) 30% ethanol (20 ml) to elute polar substances such as
polar lipids; (b) distilled H2O (20 ml) to remove the ethanol; (c) petroleum ether (10
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ml) to remove the water; (d) petroleum ether: CHCI3 (1:1, 20 ml) to elute fatty acids;
(e) methyl formate (10 ml) to elute prostaglandins and leukotrienes; (f) 80% ethanol
(20 ml); (g) 100% ethanol (20 ml); and (h) distilled H2O (20 ml) to regenerate the
matrix. A 4 ml aliquot of the petroleum ether: CHCI3 fraction was allowed to
evaporate off overnight, then the radioactivity in 4 ml aliquots of each solvent
fraction was counted by liquid scintillation counting. The radioactivity in 200 p.1
samples of the acidified tissue homogenate and the incubation medium supernatants
were also determined to give a measurement total amount of label incorporated into
the tissue/cells. The amount of [3H]-AA released could then be expressed as a
percentage of the total amount of label incorporated into the tissue/cells.
To examine the effects of inhibitors on [3H]-AA release responses, the
tissue was preincubated for 15 min in pre-warmed and pre-gassed MEM containing
the appropriate inhibitor or no drug as appropriate. The medium was then removed
and discarded, and the tissue incubated with the appropriate stimulus together with
the inhibitor as described above.
Since PLA2 can be markedly activated by raised Ca2+ levels (Irvine, 1982;
Rosenthal et al, 1989; section 1.3.2.1), we tested the effect of the Ca2+ ionophore,
ionomycin, as a trial stimulus on [3H]-AA release from pre-labelled anterior pituitary
tissue. Figure 2.4 shows the effect of ionomycin (30 (J.M) treatment of [3H]-AA pre-
labelled male rat pituitary pieces on the changes in radioactivity in each solvent
fraction. After a 15 minute incubation with ionomycin the radioactivity levels in each
solvent fraction obtained from ODS-extraction of the medium were increased (Figure
2.4a). In particular, ionomycin treatment significantly enhanced the levels of
radioactivity in fraction D (petroleum ether:CHCl3) (p < 0.05, n = 5; Mann-Whitney
U-test). Additional experiments showed that when [3H]-AA was incubated with
anterior pituitary tissue which had been previously inactivated by homogenising in 1
ml MEM, diluted in ethanol to a final concentration of 30% and carried through the
extraction procedure, over 83% authentic [3H]-AA was detected in the petroleum
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ether:CHCl3 fraction. This observation correlates with those made by Powell (1982)
who showed that, whereas the more polar phospholipids were probably passed
through the column without being retained, fatty acids, such as AA, and
monohydroxy fatty acids were eluted by mixtures of petroleum ether and CHCI3. The
radioactivity in fraction E (methyl formate) of the medium extract was also slightly
increased following ionomycin treatment. Since methyl formate can elute
prostaglandins and thromboxanes from the ODS column, it would seem, therefore,
that ionomycin treatment of anterior pituitary also induces an increase in medium AA
metabolite levels. The radioactivity levels in fractions F, G and H (80% ethanol,
100% ethanol and distilled H2O respectively) from the medium were also increased
following ionomycin treatment. These fractions are believed to contain moderately
polar hydrophilic substances whose exact identity is uncertain (Powell, 1982).
Ionomycin treatment had no significant effect on the levels of radioactivity
in the solvent fractions obtained form ODS-extraction of the tissue homogenate
(Figure 2.4b). Interestingly, the radioactivity in fraction F (80% ethanol) was
decreased in the ionomycin-treated tissue samples. The reason for this decrease in
unknown but may simply be a reflection of the relatively small sample size used in
this study.
In summary, ionomycin treatment of [3H]-AA pre-labelled male rat
anterior pituitary tissue increases medium [3H]-AA levels, as assessed by the levels of
radioactivity in the petroleum ether:CHCl3 fraction from ODS extraction. This
technique of measuring [3H]-AA release from pre-labelled anterior pituitary tissue is
a useful approach to assess the involvement of AA-releasing enzymes, such as PLA2
or DAG lipase in agonist responses, but must be used with restricted interpretation
and in internally controlled comparative experiments. It is unclear as to how
measurements made using this assay reflect cytosolic [3H]-AA levels during a
stimulus since there is, of course, no information on absolute [3H]-AA concentrations,
just relative levels of radioactivity. Mass assay measurements of cellular AA levels
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have been described (Currie et al, 1992), but such measurements are impossible here
due to the low abundance of the cell type relevant to this research project (i.e.
gonadotrophs).
To investigate the source of the baseline release of [3H]-AA, pro-oestrous
rat anterior pituitary tissue, which had been pre-labelled with [3H]-AA, was incubated
for 15 min in MEM containing either no drug (baseline), or the PLA2 inhibitor
quinacrine (50 |iM) or the DAG lipase inhibitor, RHC 80267 (200 |iM), and the
medium [3H]-AA levels were determined (Table 2.1). Neither quinacrine nor RHC
80267 had any significant inhibitory effect on baseline [3H]-AA release suggesting
that neither PLA2 nor DAG lipase plays any significant role in the basal turnover of
AA in this tissue. Baseline [3H]-AA release may represent the leak of unesterified
fatty acid from the tissue.
Since the main aim of this research project has been to elucidate the
targets and actions of the PKC(s) involved in anterior pituitary hormone release, the
effects of DAG lipase and PLA2 inhibitors were examined on phorbol 12,13-
dibutyrate (PDBu)-induced [3H]-AA release from pre-labelled pro-oestrous rat
anterior pituitary tissue (Table 2.2). In the presence of PDBu (300 nM), [3H]-AA
release was significantly increased above baseline levels. When used at a
concentration that is known to block PLA2 activity with minimal side-effects on other
cellular processes, quinacrine (50 |J.M) inhibited PDBu-induced [3H]-AA release to
levels that were not significantly different from baseline. However, RHC 80267, at a
concentration (80 p.M) which has been shown to inhibit the cellular actions of DAG
lipase with little side-effect (Sutherland and Amin, 1982), had no significant
inhibitory effect on PDBu-induced [3H]-AA release. Within the limits of the
pharmacological specificity of these tools, these results suggest that, in pro-oestrous
rat anterior pituitary tissue, PKC activation induces [3H]-AA release by a route
involving activation of PLA2, but not DAG lipase.
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2.2.6 Cytosolic [3H]-phorbol 12,13-dibutyrate binding studies
The number of PKC molecules in E2-treated and -untreated pituitary
cytosol and their affinity for PDBu were assessed using a [3H]-PDBu binding method
described previously (Leach et al, 1983, Figure 2.5). Anterior pituitaries were
homogenised in 2 vol 50 mM Tris HC1 (pH 9.0) containing 1 mM PMSF and 1 mM
MnCl2 then centrifuged (100,000 g, 1 h, 4°C). The supernatant was collected and re-
centrifuged (120,000 g, 1 h, 4°C) and the supernatant from the second spin was
regarded as cytosol and stored at -40°C until use. Cytosol was diluted in assay buffer
(50 mM Tris HC1 (pH 7.4), 4 mg/ml BSA (essential fatty acid free), 1 mM CaCl2 and
75 mM magnesium acetate) to a concentration which gave total binding of
approximately 5 - 10% of total radioactivity present. The assay constituents were
1 mg/ml phosphatidylserine (sodium salt), [3H]-PDBu (0.2 - 50 nM final
concentration) and 25 |il of diluted cytosol. Phosphatidylserine vesicles were prepared
by dissolving the lipid in chloroform, drying under N2, reconstituting into assay
buffer, vortexing and sonicating. Total binding was measured in the presence of
0.5% DMF whilst non-specific binding was measured in the presence of 20 pM
PDBu (with DMF vehicle to 0.5%). After a 30 min incubation (37°C), protein was
precipitated at 4°C by adding 100 pi of 12 mg/ml bovine gamma-globulin and 300 pi
of 24% polyethyleneglycol 8000 in 50 mM Tris HC1 (pH 7.4) (1.8 mg/ml and 11%
final concentrations respectively) (4°C, 20 min). The precipitate was pelleted by
centrifugation (12,000 g, 5 min, 4°C), the supernatant aspirated off and the
radioactivity in each pellet determined by being dissolved overnight in 10 ml
scintillation fluid, then liquid scintillation counted for P-radioactivity.
2.2.7 [3H]-N,N-Dimethylstaurosporine binding studies
The method used was based on that described by Gross et al, 1990 (Figure
2.6). Tissue was homogenised in buffer containing Tris-HCl (20 mM), EtSH
(50 mM), EDTA (2 mM) and PMSF (1 mM), pH 7.5. Tissue homogenate was
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centrifuged (12,000g, 4°C, 20 min), the supernatant was removed and respun
(12,000g, 4°C, 20 min). The supernatant from the second spin was regarded as
cytosol and was used in the [3H]-N,N-dimethylstaurosporine ([3H]-DMS) binding
studies. Cytosol was diluted in homogenisation buffer to a concentration which gave
total binding of approximately 10% of total radioactivity present. The assay
constituents were (final concentrations) Tris-HCl (20 mM pH 8.0), 0.2 (ig/ml bovine
gamma globulin, 1 mM dithiothreitol, 0.5 nM [3H]-DMS, unlabelled PKC inhibitor
and diluted cytosol. After 30 minutes incubation at 4°C, the protein was precipitated
by adding 12 mg/ml bovine gamma globulin and 24% polyethylene glycol 8000 (final
concentrations of 1.8 mg/ml and 11% respectively) (4°C, 20 min). The precipitate
was pelleted by centrifugation (12,000 g, 5 min, 4°C), the supernatant aspirated off
and the radioactivity in each pellet counted.
Total binding (TB) was measured in the absence of unlabelled PKC
inhibitor and in the presence of 0.5% DMF. Non-specific binding (NSB, which was
approximately 25% of TB) was determined in the presence of 3 pM staurosporine in a
final DMF concentration of 0.5%.
2.2.8 Protein assay
Protein content in anterior pituitary cytosol, and in DEAE cellulose-
purified cytosol was measured using a Pierce protein assay kit (Pierce, Chester, UK).
This method uses an assay reagent based on the Bradford method (1976) consisting of
Coomassie Blue G-250, phosphoric acid, methanol, water and solubilizing agents.
When Coomassie Blue binds to proteins in an acidic solution, an absorbance shift
from 465 to 595 nm occurs. Protein standard was BSA (essential fatty acid free)
diluted in the appropriate assay medium. The protein concentrations for the unknown
samples were determined against the standard curve, which was consistently linear
with the standard protein concentration used.
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2.2.9 Data analysis
All values are expressed as mean ± standard error of the mean (SEM) from
data obtained from a number (n) of independent, individual determinations which
were performed either on the same day or on two consecutive days. Statistical
analyses were carried out using the Mann-Whitney U-test unless otherwise stated.
The time-course data in Chapter 5 were analysed by both 2-way and 1-way analysis
of variance, followed by Duncan's New Multiple Range test on statistically different
groups. The concentration of drug which could produce 50% of the maximal
response (EC50 value) and the concentration of inhibitors which could inhibit 50% of
a stimulus-evoked response (IC50 value) were assessed by fitting the data with a non¬
linear, error-weighted, iterative curve-fitting programme, P.fit (Biosoft, Cambridge,
UK) and represented as means ± SEM.
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Figure 2.1
Flow diagram of the method used to measure anterior pituitary hormone release
from rat anterior pituitary pieces in vitro
Figure 2.1
adult COB Wistar rats
anterior pituitaries hemisected






Basal h 1st h 2nd h 3rd h









MEM removed at the end of each h
medium removed stored at -20°C
RIA for LH & GH
Figure 2.2
Flow diagram of the methodology used to determine cytosolic protein kinase C
activity
Figure 2.2
rat anterior pituitary tissue
homogenise in 2 vols of buffer
(20 mM Tris.HCl (pH 7.5), 50 mM 2-EtSH, 2 mM EDTA, ImM PMSF)
+0.01% leupeptin + 20 [lM E64
1.
spin (20 mins then 5mins, 16000g, 4°C)
I.
supernatant onto 1.5 ml DE52 (pH 7.5) column
prewashed with buffer + 0.01% leupeptin + 20 pM E64
I
collect 0-150 mM NaCl fraction
thiophosphorylation assay
20 mM Tris.HCl (pH 7.5)
0.5 mM EGTA
12.5 mM MgCl2





± 0.6 mM CaCl2
±5 mM EGTA
reaction started with bench-top centrifuge, then 15 mins, 30°C
stop with addition of ice-cold 0.1 mM ATP in 0.1 M EDTA (pH7.0)
i
spot 50 pi sample onto 4cm^ P81 cellulose phosphate paper
I
wash for 3x2 mins in 75mM H3PO4, dried
and counted by liquid scintillation counting
Figure 2.3
Flow diagram of the methods used to measure [3H]-arachidonic acid release






label (2x1/4 per flask)



































Levels of radioactivity in solvent fractions from (a) medium and (b) tissue from
control and ionomycin-treated male rat anterior pituitary pieces
Male rat tissue was incubated in medium containing either no drug
(baseline) or ionomycin (30 (iM) for 15 min. The radioactivity in the solvent
fractions of the medium (a) and tissue (b) from each treatment was determined. The
fractions are as follows; A: distilled H2O; B: 30% ethanol; C: petroleum ether;
D: petroleum ether: CHCI3 (1:1); E: methyl formate; F: 80% ethanol; G: 100%
ethanol; H: distilled H2O. The statistical significance of the effects of ionomycin

























Flow diagram of the method used to measure [3H]-phorbol 12,13-dibutyrate
binding in these studies
Figure 2.5
ovariectomised ± E2 rats
anterior pituitaries
homogenised in 2 vol of 50 mM Tris HC1 (pH 9.0),
1 mM PMSF, ImM MnCl2
pellet
(membrane)
supernatant from 2nd spin
(cytosol)-stored at -40°C until use
50 mM Tris HC1 (pH 7.4)
4 mg/ml BSA
ImM CaCl2, 75 mM Mg acetate
1 mg/ml phosphatidylserine
(mixed micelle)
0.2- 50 nM [3H]-PDBu (final
concentration)
DMF (<0.1 % final)
or 20 (J.M PDBu in DMF (for total
and non-specific binding respectively)
capped, vortexed and incubated (30
min 37°C)
proteins precipitated on ice with 12
mg/ml bovine gamma globulin + 24%
polyethylene glycol 8000
spin tubes (12,000 g, 5 min, 4 °C)
supernatant aspirated and pellet [3H]-
PDBu counted the next day by liquid
scintillation.
20 min (4 °C)
Figure 2.6









centrifuge 12,000 g, 4°C, 20 min
retain supernatant
centrifuge 12,000g, 4°C, 20 min
binding assay
20 mM Tris-HCl (pH 8.0)
0.2 p.g/ml bovine gamma globulin
1 mM dithiothreitol




add 12 mg/ml bovine gamma globulin
and 24 % polyethyleneglycol 800
4°C, 15 min
precipitate protein
centrifuge 12,000g, 4°C, 5 min
discard supernatant
wash pellet with 1 ml ice-cold Tris-HCl
count pellet
Table 2.1
The effect of quinacrine and RHC 80267 on baseline [3H]-arachidonic acid
([3H]-AA) release from pre-labelled pro-oestrous rat anterior pituitary pieces
Anterior pituitary pieces, which had been pre-labelled with [3H]-AA and
extensively washed, were incubated for 15 min in medium containing either no drug
(baseline), quinacrine (50 |lM) or RHC 80267 (200 (iM). Medium [3H]-AA levels
were determined as described in section 2.2.5. Data are means ± SEM and the
number of determinations are shown in parentheses.
[3H]-AA
(% of total label incorporated)
baseline 0.69 ± 0.07 (8)
quinacrine 0.61 ± 0.02 (4)
RHC 80267 0.69 ± 0.08 (4)
Table 2.2
The effect of quinacrine and RHC 80267 on phorbol 12,13-dibutyrate (PDBu)-
induced [3H]-arachidonic acid ([3H]-AA) release from pre-labelled pro-oestrous
rat anterior pituitary pieces
[3H]-Arachidonic acid-labelled pairs of anterior pituitary quarters were
pre-incubated for 15 minutes in medium only, or with quinacrine (50 jiM) or RHC
80267 (80 (J.M), the medium was discarded and replaced with fresh medium
containing either no drug (basal) or PDBu (300 nM), or PDBu and either quinacrine
or RHC 80267. After a second 15 min incubation, the medium was removed and the
[3H]-AA released was extracted. The statistical significance of the effects of
quinacrine and RHC 80267 on PDBu-induced [3H]-AA release was determined
(*p < 0.05, Mann-Whitney U-test). Values shown are the means ± SEM and the
number of determinations are shown in parentheses.
[3H]-AA release
(% of total label incorporated)
basal 1.59 ±0.07 (10)






+ 2.53 ± 0.22 (4)
RHC 80267
CHAPTER 3




Although LHRH receptor activation in rat anterior pituitary gonadotrophs
is associated with rapid metabolism of phosphoinositides (Snyder and Bleasdale,
1982; Raymond etal, 1984) and production of DAG (Andrews and Conn, 1986),
which can activate PKC, the exact involvement of PKC in LHRH responses is
controversial (see Conn, 1989 for review). Luteinizing hormone-releasing hormone
can induce PKC translocation to the cell membrane (Hirota et al, 1985; Naor et al,
1985; McArdle and Conn, 1986) and PKC activators induce gonadotropin release, in
vitro (Smith and Vale, 1980; Conn et al, 1985; Nigro-Villar and Lapetina, 1985;
Turgeon and Waring, 1986), consistent with a role for PKC in gonadoptrophin
release. Some studies have shown that LHRH-induced LH release can be prevented
by PKC inhibitors (Hirota et al, 1985; Chang et al, 1987b), whilst others have
reported that LHRH responses are unaffected by these drugs (Johnson et al, 1988;
Beggs and Millar, 1989). Investigations into the effect of PKC down-regulation on
secretory responses to LHRH in cultured gonadotrophs have also produced
conflicting results; some have reported PKC down-regulation attenuates responses to
LHRH (Stojilkivic et al, 1988b, 1991), whereas others suggest that LHRH-induced
LH release is unaffected (McArdle and Conn, 1986; McArdle etal, 1987). Clearly,
additional studies are required to examine a possible role for PKC in responses to
LHRH.
Evidence suggests that the gonadotropin release response to LHRH is
probably under the influence of several different, cellular factors. For example, the
biphasic pattern of LHRH-induced gonadotropin release observed in cultured cells
(Borges et al, 1983) correlates with changes in the requirement of the response for
Ca2+ from intracellular and extracellular sources (Bourne and Baldwin, 1980;
Shangold et al, 1988; Smith et al, 1987;Tasaka et al, 1988; see Davidson et al, 1991
for review). In addition, acute LHRH responses measured in vitro are independent of
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protein synthesis whereas later responses to LHRH, including the LHRH priming
response, (Aiyer et al, 1974a), can be prevented by protein synthesis blockers
(Edwardson and Gilbert, 1976; Pickering and Fink, 1976; Bourne and Baldwin,
1980). Since the release of gonadotrophin induced by LHRH may be under the
influence of different factors at any one particular time, it is likely that PKC
activation is only one of a number of intracellular changes that occur following
LHRH receptor activation and will, therefore, have a select role in the temporal
pattern of gonadotrophin release.
In an attempt to clarify the role of PKC activation in LHRH receptor
signalling, the effects of a number of putative inhibitors of this kinase were examined
on initial responses to LHRH and on the later LHRH priming effect which is
observed in pro-oestrous rat anterior pituitary pieces. There is now evidence which
suggests that distinct PKC isoforms show different sensitivities to various PKC
activators and inhibitors (Evans et al, 1991; Ryves et al, 1991). Therefore, to
investigate the possibility that pharmacologically distinct PKCs are involved in
LHRH priming, LH release, and, as a contrast, growth hormone (GH) release, the
effects of PKC inhibitors were also examined on hormone release induced by various
pharmacological activators of PKC.
3.2 SpecificMethodology
Stimulus-induced hormone release was measured from anterior pituitary
pieces as described in section 2.2.3. Pro-oestrous female rat hemipituitaries were
incubated for an initial hour (basal h) in medium only, followed by consecutive hours
(1st, 2nd, 3rd h) in the presence of either LHRH or a PKC activator (phorbol 12,13-
dibutyrate (PDBu), 1,2-dioctanoyl-sn-glycerol (DOG) or mezerein) or a Ca2+
ionophore (ionomycin). To examine the effects of PKC inhibitors (staurosporine,
K252a, H7, Ro 31-8220) on hormone release, the appropriate inhibitor was included
in the basal h incubation and in the 1st h, 2nd h, 3rd h, together with the secretagogue.
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To control for the effects of each PKC inhibitor on baseline hormone release, some
tissue samples were incubated for consecutive hourly periods in the presence of
inhibitor only. Phorbol 12,13-dibutyrate, mezerein, DOG, ionomycin, staurosporine,
K252a and Ro 31-8220 were all made up as stock solutions in dimethylformamide
(DMF) and kept in the dark, on ice, before final dilution in MEM for experiments. A
fresh stock of DOG was made for every experiment. The maximum concentration of
DMF used was 0.5% v/v and this was shown in control experiments to have no effect.
H7 and LHRH were made up as stock solutions in distilled H2O.
To examine the role of PKC in LHRH priming in more detail, a number of
different experiments were carried out. In a first experiment, staurosporine was
included in the basal h and in the 1st h together with LHRH. The tissue was then
washed in MEM only, in a shaking water bath (under 95% 02/5% CO2, at 37°C) for 2
consecutive 5 minute periods, to remove the staurosporine. At the end of each 5 min
wash, the medium was discarded and replaced with fresh MEM. Following
staurosporine washout, tissue was incubated for a final h (2nd h) with LHRH only.
Control treatments were incubated with LHRH, as above, but in the absence of
staurosporine, followed by an identical washing procedure and a 2nd h incubation
with LHRH. The effectiveness of the staurosporine washout procedure was tested by
incubating tissue with the radiolabeled derivative of staurosporine, [3H]-N, N-
dimethylstaurosporine ([3H]-DMS), over 2 consecutive hours. The medium was then
removed, and the tissue washed as described above, but each wash was retained.
After washing, the tissue was homogenised in 1 ml of fresh MEM and the
radioactivity in the tissue homogenate and the two 5 ml washes was measured by
liquid scintillation counting. The tissue concentration of [3H]-DMS remaining after
washout was calculated as a % of the total radioactivity in the tissue prior to washout.
In a second experiment, the effect of staurosporine on LHRH responses in
pre-primed tissue was examined. The tissue was incubated for one hour in medium
only (basal h), followed by a 1st h incubation in the presence of LHRH (1 nM),
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during which, LHRH priming occurs. The tissue was then incubated either with
LHRH only (control) for 2 further consecutive hours (2nd, 3rd), or with LHRH and
staurosporine (300 nM).
In a third experiment, the effect of staurosporine on ionomycin-induced
gonadotropin release from preprimed tissue was examined. Tissue was either
incubated in medium only (basal h), followed by LHRH (1 nM) for a 1st h then with
ionomycin (30 }iM) for a 2nd h or together with staurosporine throughout each of
these hourly incubations.
All statistical analyses were carried out using the Mann-Whitney U-test.
The standards used were NIADDK-rat FSH-RP2 for all FSH data, NIADDK-rat-GH-
RP-2 for all GH data, NIH-LH-S18 for LH data in Figures 3.2a, 3.2b, 3.5, 3.6, 3.8,
3.9a, and NIADDK-rat LH-RP2 for the remaining figures and tables.
3.3 RESULTS
The effect of PKC inhibitors on initial LHRH-induced gonadotrophin release
and LHRH priming in pro-oestrous rat anterior pituitary tissue
Figure 3.1 shows the effect of consecutive hourly incubations of LHRH
(1 nM) on (a) LH and (b) FSH release from pro-oestrous rat anterior pituitary tissue.
During the 1 st h incubation with LHRH, LH release was significantly increased from
a basal h level of 6.3 ±1.5 (ig/1 (n = 6) to 29.9 ±8.1 p.g/1 (n = 6). With a 2nd h
incubation with LHRH, LH release was greatly enhanced with respect to that
measured during the 1st h (162.0 ± 20.4 |ig/l). This enhanced LHRH-induced LH
release occurs as a result of LHRH priming (Aiyer et al, 1974). Similarly, LHRH
treatment induced a significant increase in initial acute FSH release followed by an
further enhanced FSH release response in the 2nd h.
To investigate the role of PKC in LHRH responses, the PKC inhibitor,
staurosporine (300 nM), was included throughout each hourly incubation (Figure 3.1).
In the presence of staurosporine (hatched bars), neither basal h nor 1st h LHRH-
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induced LH or FSH release were significantly different from control levels (open
bars). However 2nd h LHRH-induced LH and FSH were both significantly inhibited
by staurosporine (p < 0.05). Interestingly, at staurosporine concentrations of 300 nM
and above, 2nd h LH (Figure 3.2a) and FSH release (Figure 3.3a) were only ever
decreased to levels seen in the 1st h with LHRH, but not to basal h levels. Thus, it
appears that staurosporine blocks the enhanced secretory response to LHRH, that
occurs as a consequence of LHRH priming, without affecting acute, 1st h LHRH-
induced release. Similarly, the staurosporine congener, K252a, inhibited the 2nd h,
primed LH and FSH response without altering initial LHRH-induced gonadotrophin
release (Figures 3.2b and 3.3b).
Recently, a staurosporine derivative, Ro 31-8220, has been developed with
considerably greater selectivity for PKC (Davis et al, 1989) than staurosporine itself.
Similar to the effects of staurosporine, Ro 31-8220 was found to significantly inhibit
the 2nd h of LHRH-induced LH (Figure 3.2c) without altering either basal or 1st h
LHRH-induced gonadotrophin release. The inhibitory effects of Ro 31-8220 on 2nd
h LHRH-induced LH release further suggest that activation of PKC (or a closely
related kinase), is required for LHRH priming.
It has been reported that another PKC inhibitor, H7, at a concentration of
10 |iM, is unable to prevent LHRH priming (Johnson et al, 1988). Since
staurosporine and H7 are both thought to inhibit kinase activity by interacting with, or
near to, the ATP binding site of the enzyme, the dissociated effects of these
compounds on priming may be unexpected. However, it has been suggested that
certain actions of PKC may be less sensitive to blockade by H7 than has been
generally reported (Watson etal, 1988; Nakadate et al, 1989; MacEwan and Mitchell,
1991). To investigate the possiblity that LHRH priming involves a PKC which is
relatively H7-resistant, the effect ofH7 on LHRH responses was examined in more
detail (Figures 3.2d and 3.3c). Consistent with a previous report (Johnson et al,
1988), 10 |iM H7 had no significant effect on either 1st h or 2nd h LHRH-induced LH
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or FSH release. However, at H7 concentrations of 100 |lM and above, 2nd h LHRH-
induced LH and FSH release were significantly inhibited (p < 0.05). Neither baseline
nor 1st h LH release was affected by H7 (10 - 300 |iM).
Evidence that PKC activation is required for the induction of LHRH priming,
but not for LHRH-induced gonadotrophin release
Since staurosporine, K252a, Ro 31-8220 and H7 reduced 2nd h LHRH-
induced gonadotrophin release to 1st h levels only, PKC activation may be essential
for enhanced pituitary responsiveness to LHRH only, but not for initial responses to
LHRH. It is possible that PKC activation is required either for the induction of
LHRH priming, or for the mechanism that directly mediates an increased rate of
hormone release which is needed to express priming. To distinguish between these
possible roles for PKC in LHRH responses, the mode of involvement of PKC in
LHRH priming was examined in a series of experiments (Figure 3.4). Since there
was no discernible difference between the effects of PKC inhibitors on LH and FSH
release (see above), in these remaining experiments, LH release only was determined.
In a first experiment, after a basal h incubation with staurosporine (300
nM), the inhibitor was included throughout the 1st h of incubation, together with
LHRH (1 nM) (i.e. that hour during which priming occurs). The tissue was then
washed extensively to remove the staurosporine, and incubated for a 2nd h in the
presence of LHRH only. In this experiment, staurosporine did not alter either basal h
or initial 1st h LHRH-induced LH release (Figure 3.4a), similar to the effects of
staurosporine shown previously (see Figures 3.1 and 3.2). Although staurosporine
was not present in the 2nd h of LHRH incubation, LHRH-induced LH release during
this hour was still significantly inhibited (p < 0.05). When tissue was incubated for 2
consecutive hours with [3H]-N, N-dimethylstaurosporine ([3Hj-DMS), and subjected
to an identical washing procedure, the tissue concentration of [3H]-DMS remaining
was reduced to 8 ± 2% (n = 4) of the initial level. Furthermore, to test that PKC was
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still active following washout, tissue was incubated with staurosporine for 2 h,
washed and the PDBu facilitation of K+-induced 45Ca2+ influx was measured as
described by MacEwan and Mitchell (1991). Following staurosporine washout,
PDBu enhancement of K+-induced 45Ca2+ influx was not significantly different from
that in control tissue (108 ± 10% of the facilitation measured in vehicle-incubated
controls). Thus, anterior pituitary PKC(s) are still active after staurosporine treatment
and subsequent washout.
In a second experiment, the effect of staurosporine on LHRH responses in
pre-primed tissue was tested (Figure 3.4b). In this experiment, tissue was primed by
incubating with LHRH (1 nM) for a 1st h, then staurosporine (300 nM) was included
during the 2nd and 3rd h incubations together with LHRH. Staurosporine had no
significant inhibitory effect on LHRH-induced LH or FSH release from pre-primed
anterior pituitary tissue, even over a period of two hours which would allow for the
expression of any possible slow-developing inhibitory effect.
Finally, to confirm that staurosporine has no inhibitory action on the
general secretory apparatus of the gonadotroph, the effect of staurosporine on
ionomycin-induced gonadotrophin release was examined (Table 3.1). Luteinizing
hormone release was significantly increased over all hours of incubation with
ionomycin (30 |lM), but did not exhibit a pattern of release typical of a 'primed'
response. Ionomycin-induced LH release was not significantly blocked by
staurosporine at any hour of incubation with the Ca2+ ionophore (1st h, 2nd h),
indicating that staurosporine has no inhibitory action on the general, Ca2+-triggered
secretory mechanisms in the gonadotroph. When pituitary tissue was incubated with
LHRH (1 nM) during the 1st h followed by ionomycin (30 |iM) in the 2nd h, the 2nd
h ionomycin-induced LH release response was enhanced with respect to 1st h LHRH-
induced LH release. These results are consistent with previous observations which
show that, although induction of priming is specific to LHRH, an increased
gonadotrophin release from previously primed tissue can be elicited by a non-specific
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secretagogue, such as ionomycin (Pickering and Fink, 1979). When staurosporine
was included throughout each incubation, 1 st h LHRH-induced LH release was
unaffected but the subsequent 2nd h ionomycin-induced LH release was significantly
blocked. This staurosporine block of the 2nd h ionomycin response following LHRH
treatment suggests that PKC activation must be important for the induction of LHRH
priming, but not for LH release, since LH release induced over consecutive hours
with ionomycin only is unaffected by staurosporine.
The effect of PKC activators on luteinizing hormone and growth hormone
release from pro-oestrous rat anterior pituitary pieces
When rat hemipituitary pieces were incubated for consecutive hours
together with PDBu (100 nM) both LH and GH release were significantly increased,
but with very different time courses (Figure 3.5). Release of GH was maximal in the
1st h of phorbol treatment, having increased from a basal h level of 370 ± 89 p.g/1 (n =
5) to 766 ± 95 |ig/l (n = 5) in the 1st h. In contrast, LH release measured during 1st h
of PDBu incubation was not significantly different from basal hour levels of LH
release. However, LH release was significantly increased (p < 0.05) during the 2nd h
of PDBu incubation in comparison to basal h levels, and increased further during the
3rd h of PDBu incubation.
Mezerein induced both LH and GH release with a similar temporal pattern
to that observed using PDBu. Increasing the concentrations of either PDBu or
mezerein was accompanied by a concentration-dependent increase in the magnitude
of both LH (Figure 3.6a) and GH release (Figure 3.6b). Growth hormone release was
induced by mezerein and PDBu with similar potency. Mezerein was equally effective
at releasing both LH (EC50 = 152.2 ± 69.8 nM) and GH (EC50 = 74.3 ± 62.0 nM).
However, PDBu was less effective than mezerein on LH release suggesting that the
PKC(s) involved in this process may less susceptible to activation by PDBu.
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During the 2nd and 3rd, but not the 1st, consecutive hours of DOG (200
pM) incubation, there was a small, but significant, increase of LH release above
baseline levels from pro-oestrous rat anterior pituitary tissue (Figure 3.7a). However,
DOG was much less effective at inducing LH release than either PDBu or mezerein.
In contrast to the effects on LH release, DOG was unable to induce significant
amounts of GH release during any hour of incubation with the diglyceride (Figure
3.7b).
The effect of PKC inhibitors on PKC-activator-induced luteinizing hormone and
growth hormone release
The PKC inhibitor staurosporine, caused a concentration-dependent
inhibition of 100 nM PDBu-induced LH and GH release with similar potency (IC50 =
44.0 ± 17.2 nM and 74.3 ± 62 nM for LH and GH respectively) (Figure 3.8). At
staurosporine concentrations of 100 nM and above, both LH and GH release were
blocked to levels not significantly different from levels of hormone release measured
in the absence of a PDBu stimulus.
Luteinizing hormone release induced by 100 nM PDBu was significantly
inhibited by another PKC inhibitor, H7, at concentrations of 3 |iM and above and
with an IC50 value of 1.7 ± 1.5 pM (Figure 3.9a). In contrast, 100 nM PDBu-induced
GH release was unaffected by H7, even at concentrations of 30 - 300 pM which
caused over 80% inhibition of LH release induced by 100 nM PDBu. However, when
the effect of H7 (30 pM) was examined on LH release measured over a range of
PDBu concentrations (Figure 3.10), it was clear that an H7-resistant component of
this response could also be detected, especially at higher levels of phorbol ester. That
is, LH release induced by 30 nM PDBu was completely inhibited by 30 pM H7,
whereas, approximately 20% of LH release measured at 1 pM PDBu was insensitive
to H7 (30 pM). Similarly, mezerein-induced LH release also consisted of H7-
sensitive and -resistant components (Figure 3.9b). Approximately 40% of the LH
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secretory response to mezerein was inhibited by H7 at concentrations as low as 1 pM.
However, further inhibition of this response was not seen until H7 concentrations of
30 pM and above. Furthermore, at H7 concentrations as high as 100 pM, mezerein-
induced LH release was not completely inhibited, with 20% of the response
remaining. Mezerein (300 nM) -induced GH release was completely insensitive to
inhibition by H7 at concentrations as high as 100 pM (Figure 3.9b). Both mezerein-
induced LH and GH release, however, were readily blocked by staurosporine (300
nM) to levels that were not significantly different from baseline levels of release
(Table 3.2).
Although DOG (200 (iM)-induced LH release was readily inhibited by
staurosporine (300 nM), to levels that were not significantly different from baseline,
this response was entirely resistant to inhibition by 30 pM H7 (see Table 3.3).
Therefore, DOG may be a selective activator of at least some of the H7-resistant
PKC(s) which can elicit LH release.
Neither H7 (30 pM) nor staurosporine (2 pM) K252a (10 pM), nor Ro 31-
8220 (30 pM) had any effect on baseline LH, FSH and GH release from anterior
pituitary tissue when added alone to the incubation medium over a period of 3
consecutive hours .
The effect of PKC inhibitors on PDBu-induced anterior pituitary PKC activity
The effects ofH7 and staurosporine were further examined on anterior
pituitary PKC activity, measured in a mixed micelle assay. Calcium-independent
cytosolic PKC activity was stimulated by PDBu with an EC50 of 916 ± 150 nM and
the additional activity evoked in the presence of Ca2+ had an EC50 for PDBu of 261
± 86 nM. All activity was entirely dependent on the presence of phosphatidylserine.
Calcium-dependent activity induced by PDBu (1 pM) was potently inhibited by
staurosporine and H7 (Table 3.4) with IC50 values similar to those found for PKC
activity measured in a range of other peripheral and central tissues. For example,
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Ca2+-dependent cytosolic PKC activity from rat midbrain was inhibited by
staurosporine and H7 with IC50 values of 100 ± 40 nM and 34 ± 5 |iM respectively.
In contrast, Ca2+-independent anterior pituitary PKC activity was distinctly less
sensitive to H7 than the Ca2+-dependent activity measured in the same experiment
(Table 3.4). However, in experiments using rat midbrain, Ca2+-independent activity
had the expected sensitivity to H7 and staurosporine (IC50 = 27 ± 9 |lM and 120 ± 6
nM respectively). The Ca2+-independent activity in anterior pituitary, however,
showed the expected potency of block by staurosporine (Table 3.4).
3.4 discussion
The results presented in this chapter demonstrate that activation of PKC
(or a closely related kinase) is required for the induction of LHRH priming, but not
for initial LHRH-induced gonadotrophin release from pro-oestrous rat anterior
pituitary tissue in vitro. These results also provide evidence for the existence of
several pharmacologically distinguishable PKC forms in anterior pituitary cells and
suggest that one or more of these forms have distinct roles in the control of LHRH
responses and in PKC activator-induced LH or GH release.
Several lines of evidence presented here, together with observations made
by other workers, indicate that the facilitation of gonadotrophin release which is
brought about by LHRH priming is dependent upon the activation of a PKC-like
kinase and not another known species of protein kinase. Firstly, the LHRH priming
response was readily inhibited by staurosporine at concentrations (IC50 = 26.3 ± 7.0
nM) typical for inhibition of other PKC-mediated cellular responses (Davis et al,
1989; Dunn and Rang, 1990), including the block of 100 nM PDBu-induced LH
release (IC50 = 44.0 ± 17.2 nM) reported here (Figure 3.8), and for partially- or
extensively-purified PKC activity measured in cell free assays (Table 3.4) (Nakadate
et al, 1988). The potency ratio for the inhibitory effects of staurosporine and its less
active congener, K252a, on LHRH priming (62- and 111-fold for FSH and LH
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respectively) is of a similar order to that reported for their inhibition of PKC in cell-
free systems (36-fold), but not cyclic nucleotide-dependent protein kinases
(approximately 2-fold for both PKA and PKG) (Kase et al, 1986; Tamaoki et al,
1986). In addition, LHRH priming was inhibited by Ro 31-8220 (which has been
reported by Davis and colleagues (1989) to be 2 - 3 orders of magnitude more
effective at inhibiting PKC than PKA or Ca2+/calmodulin-dependent protein kinase)
and this inhibition of priming occurred at similar concentrations (IC50 = 19.0 ± 6.8
|lM) to the inhibition of 100 nM PDBu-induced LH release (IC50 = 15.6 ± 4.5 (iM).
Inhibitors that show selectivity for other protein kinases over PKC, such as tyrosine
kinase inhibitors, calmodulin antagonists and inhibitors of the myosin light chain
kinase family are unable to prevent the LHRH priming response when used at
concentrations greater than their respective IC50 values in whole cells (Johnson et al,
1992a). In fact, in these experiments, LHRH-induced secretion was enhanced in the
presence of the calmodulin antagonists, and others have shown that these drugs can
facilitate PMA-induced LH release (Iwashita et al, 1984). Although certain
calmodulin inhibitors can inhibit LHRH responses in dispersed cells (Conn et al,
1981b), these agents can also alter surface membrane potential (McLaughlin and
Whitaker, 1988) and bind to proteins other than calmodulin (Moor and Dedman,
1982), and these non-specific actions may contribute to the effects of these drugs on
LHRH responses (Van der Merwe et al, 1990a). Circumstantial evidence also
suggests that the cyclic nucleotide-dependent kinases are not involved in LHRH
responses. Both LHRH-induced LH release and priming can be uncoupled from
changes in gonadotroph cAMP levels and can only be mimicked by very high,
possibly toxic levels of dibutyryl cAMP (Naor et al, 1975b, 1978; Conn et al, 1979;
Pickering and Fink, 1979), arguing against PKA involvement in LHRH responses.
Cyclic GMP analogues do not induce LH release from anterior pituitary (Naor and
Catt, 1980; Liu and Jackson, 1981), arguing against a role for PKG in LHRH
responses. Finally, PKC activator-induced LH release was seen to develop with each
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consecutive hourly incubation (Figures 3.5 and 3.7), thus activation of PKC with
phorbol esters can mimic the temporal profile of LHRH priming response.
Protein kinase C translocation and activation can occur within minutes of
an LHRH stimulus (Hirota et al, 1985). However, several pieces of evidence
presented in this chapter suggest that PKC activation is not essential for initial
responses to LHRH, but is required for the induction of LHRH priming in pro-
oestrous rat hemipituitaries. Firstly, PKC inhibitors had no effect on initial LHRH-
induced gonadotropin release, but inhibited primed release to a level equivalent to
the initial response, but never to basal levels (Figures 3.2 and 3.3). In a similar
manner, staurosporine and another putative PKC inhibitor, retinal, can block late
response to LHRH in dispersed anterior pituitary cells without having any effect on
acute LHRH-induced LH release (Chang et al, 1987b; Stojilkovic et al, 1991). In
pro-oestrous rat hemipituitaries, staurosporine exerted its inhibitory effects on primed
gonadotropin release if present during the hour in which LHRH priming had taken
place (i.e. the 1st h, Figures 3.1, 3.2, 3.3, 3.4a), indicating that PKC activation is most
likely to be required for the induction of LHRH priming. Furthermore, the response
of previously-primed tissue to LHRH was unaltered by staurosporine (Figure 3.4b),
further suggesting that PKC activation is not required for the expression, but instead,
is needed for the induction of priming. Staurosporine did not inhibit LH release
induced by ionomycin (Table 3.1), indicating that this inhibitor did not have a
delayed, non-specific action on the secretory apparatus of the gonadotroph. However,
staurosporine could prevent the LHRH-induced change in pituitary responsiveness,
even when LH release from previously-primed cells was elicited by ionomycin rather
than a second LHRH challenge, further indicating that PKC activation is specifically
required for the induction of priming. These results are consistent with observations
made by other workers who have found acute LHRH-induced LH release to be
independent of PKC activation (McArdle et al, 1987; Stojilkovic etal, 1991). One
isolated report has suggested that staurosporine can enhance early responses to LHRH
74
(Van der Merwe et al, 1990b). However, this result may be explained by the way the
authors expressed LH release, i.e. as a percentage of the total LH present after an
initial stimulus. Luteinizing hormone-releasing hormone can induce a PKC-
dependent synthesis of additional LH, elevating total pituitary gonadotropin content
(Andrews et al, 1988; Stojilkovic et al, 1988b). Staurosporine may, therefore,
prevent LHRH-induced gonadotropin synthesis, but not initial secretory responses to
LHRH and as a consequence, the response to LHRH, may appear to be enhanced in
the presence of this inhibitor.
Activators of PKC can mimic the late component of LHRH-induced LH
release in pro-oestrous pituitary pieces (Figure 3.4; Turgeon and Waring, 1986)
consistent with PKC involvement in later responses to LHRH. Furthermore, pre-
treatment of anterior pituitary pieces with PKC activators can enhance subsequent
responses to LHRH (Johnson et al, 1988), suggesting that activation of PKC can
increase pro-oestrous rat gonadotroph responsiveness, perhaps by inducing the
priming mechanism independently of LHRH receptor activation. The delay between
PKC activation and expression of the primed response indicates that there may be
several steps in the process by which PKC activation can result in LHRH priming.
The data presented in Figure 3.2 show that LHRH priming is attenuated by
H7, but with lower potency (IC50 = 71.6 ± 13.3 |iM) than has been reported
previously for the actions of this drug on PKC-mediated cellular responses (Hidaka et
al, 1984). The simplest interpretation of these results would be that LHRH priming
involves a PKC-like kinase which is relatively H7-resistant. Additional evidence to
support this hypothesis was obtained by examining the effect ofH7 on PKC activator-
induced LH and GH release. In these experiments, mezerein- and PDBu-induced LH
release consisted of both H7-sensitive and -insensitive components (Figures 3.9 and
3.10) and DOG-induced LH release consisted of the H7-resistant component only
(Table 3.3). Mezerein and PDBu may, therefore, activate H7-sensitive PKCs, in
addition to the H7-resistant PKC(s) that is involved in priming, to induce LH release.
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Although LHRH priming involves the H7-resistant PKC(s) only, the H7-sensitive
PKC forms may indirectly contribute to LH release by modulating other factors
which are involved in the LH release process. For example, PKC activators can
promote Ca2+ entry through voltage-sensitive Ca2+ channels of gonadotrophs and
thereby affect hormone release in general (Stojilkovic et al, 1988a, 1991; Izumi et al,
1990). Protein kinase C activators can also induce synthesis of new gonadotrophin
(Andrews et al, 1988; Stojilkovic et al, 1988b).
Phorbol 12,13-dibutyrate-induced GH release from pro-oestrous rat
anterior pituitary tissue was also resistant to block by H7 at concentrations up to 30
jiM. Although H7 inhibits other serine-threonine kinases in addition to PKC (IC50
values: PKG, 6 pM; PKA, 3 |lM; myosin light chain kinase, 97 (J.M; and PKC, 6 |lM)
(Hidaka et al, 1984) there is no explicit evidence to suggest that DAGs, phorbol esters
or phorbol-related compounds, such as mezerein, can directly activate protein kinases
other than PKC. As a consequence, the H7-resistant kinase observed in these
experiments is most probably PKC or a PKC-like kinase. Additional evidence that
pro-oestrous rat anterior pituitary cells express H7-resistant PKCs has come from
experiments where partially purified cytosolic PKC activity was measured in a mixed
micelle assay using histone as a substrate (Table 3.4). Phosphatidylserine-dependent,
PDBu-stimulated kinase activity consisted of a Ca2+-independent component which
was relatively H7-resistant, but readily blocked by staurosporine. In contrast, Ca2+-
dependent PDBu-induced PKC activity displayed the expected sensitivities to
inhibition by H7 and staurosporine. Several other reports have also described phorbol
ester responses which display high resistance to inhibition by H7, but not
staurosporine (Watson et al, 1988; Johnson and Mitchell, 1989; Johnson et al, 1989;
Nakadate et al, 1989; Fink et al, 1990; MacEwan and Mitchell, 1991) and since H7
and its closely related congener, HA 1004, show relative selectivity between different
classes of kinases (Hidaka and Hagiwara, 1987), it would be reasonable to postulate
that H7 might also distinguish between different subtypes of PKC.
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Although H7 and staurosporine are structurally different, both compounds
are thought to inhibit PKC activity by binding at or near to the ATP binding site,
hence the contrast between the effects of H7 and staurosporine on LHRH priming and
on PKC activator-induced GH and LH release is, at first, unexpected. However,
several lines of evidence suggest that the sites of action of these two inhibitors are not
identical. Firstly, H7, but not staurosporine, has been reported to act in a kinetically
competitive manner with ATP (Hidaka et al, 1984; Tamaoki et al, 1986; Riiegg and
Burgess, 1989) although other evidence does show apparent competitive mechanisms
for staurosporine and K252a (Kase et al, 1986; Davis et al, 1989). Secondly, the
binding of [3H]-DMS is displaced by H7 with extremely low potency (IC50 > 500
|iM) (see Chapter 6). Furthermore, the a and (3 PKC isoforms have both been
reported to have a second consensus recognition motif for ATP (Huang, 1989),
indicating that the interactions between H7 and these isoforms may be complex.
Several earlier reports have shown that different classes of PKC activator
can induce LH and GH release from anterior pituitary tissue in vitro and from anterior
pituitary cells in culture (Smith and Vale, 1980; Conn et al, 1985; Nigro-Villar and
Lapetina, 1985; Turgeon and Waring, 1986; Boyd and Wallis, 1989). However, the
data presented here indicates that the kinases which induce LH and GH release have
distinct pharmacological profiles with respect to different PKC activators. Growth
hormone release was induced by mezerein and PDBu with equal potency suggesting
that the PKC(s) involved are similarly activated by both of these compounds. In
contrast, LH release was induced more effectively by mezerein than PDBu,
suggesting that the PKCs involved in this process are more readily activated by
mezerein. Differences in the tumour promoting effects of phorbol esters, such as
PMA, and mezerein have been reported previously (Slaga et al, 1980) and may reflect
the ability of these compounds to preferentially activate certain PKC forms.
1,2-Dioctanoyl-Srt-glycerol was unable to induce any significant release of
GH and although DOG could enhance LH release, the secretory response to DOG was
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much smaller than that measured using either PDBu or mezerein. In certain other
models of PKC function in pituitary cells, for example, the facilitation of
depolarisation-induced 45Ca2+ influx into anterior pituitary prisms, a DOG
concentration of 100 (iM elicited effects of equivalent magnitude to 300 nM PDBu or
mezerein. The low potency of DOG on LH release, and in the 45Ca2+ model suggests
that DOG may selectively activate certain PKC forms (MacEwan and Mitchell,
1991). Indeed, in other physiological models of PKC action, DOG has been shown to
mimic some, but not all, actions of phorbol esters (Lacerda et al, 1988, see also
Chapters 4 and 5). Certainly, it appears that DOG can activate an H7-resistant
PKC(s) that is involved in PKC activator-induced LH release. Reduced potency of
DOG as an activator of a-PKC isoform has been reported (Sekiguchi et al, 1988;
MacEwan et al, 1992a); an effect which is most marked under conditions of basal
cytosolic Ca2+ (<100 |iM). However, DOG, unlike PDBu and mezerein, is
susceptible to intracellular degradation by DAG lipases (Kaibuchi et al, 1983), which
may also partly contribute the low efficacy of DOG on LH release, especially in the
relatively long incubation periods used here.
Different PKC isoforms have been implicated as having distinct roles in
certain cellular responses. For example, during thyrotrophin-releasing hormone
(TRH) stimulation of the anterior pituitary derived GH4 Ci cell line (Kiley et al,
1991, 1992) the a, (3, 5 and e PKC isoforms associate with the cytoskeleton causing
cytoskeletal changes. However, selective down-regulation of the £ isoform did not
alter the regulatory effects of TRH on actin filament organisation, suggesting that an
isoform, other than e PKC, is involved in this process. The relationship of the PKC(s)
forms involved in LHRH priming, and LH and GH release in pro-oestrous anterior
pituitary tissue to the characterized PKC isoforms is not entirely clear from the results
presented here. Of the known PKC types, the a, Pn, £, but not y nor Pi isoforms are
expressed in anterior pituitary (Naor et al, 1988; Naor, 1990). Northern blot analysis
has indicated that the mRNA for the e and also the C, but perhaps not the 8 isoform are
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present in significant levels (Lutz, Ison and Mitchell, personal communication) but it
is unclear whether or not anterior pituitary cells express the rj, X or 0 PKC isoforms.
When added to permeabilized pituitary cells, both a and (3 isoforms can stimulate LH
release (Naor et al, 1989). Certainly, the H7-sensitive PKC(s) involved in LH release
in pro-oestrous rat tissue may be one or more of the Ca2+-dependent types, such as
the a and [3 isoforms. However, Ca2+-independent, H7-resistant PKCs are also
involved in LH release, GH release, and LHRH priming and therefore, may include
one or more of the (8), e, rj, X or 0 isoforms. Data obtained using expressed and
purified enzymes have shown that the e and 5-isoforms of PKC display the expected
degree of sensitivity to H7 (Schaap and Parker, 1990; Uchida et al, 1991), indicating
that neither e nor 8 PKC may be the H7-resistant PKC(s) shown here. In addition, the
C, and X PKC isoforms are reported to be phorbol ester-insensitive (Liyanage et al,
1992; Y. Nishizuka, personal communication) suggesting that neither of these
isoforms represents the PDBu-induced, H7-resistant kinase activity detected in
anterior pituitary cytosol (Table 3.4). Since histone has been reported to be a poor
substrate for the characterised Ca2+-independent isoforms (Ohno etal, 1988; Huang,
1989; Schaap et al, 1989; Schaap and Parker, 1990; Olivier and Parker, 1991), the
H7-resistant, Ca2+-independent, histone kinase activity in anterior pituitary cytosol
seems unlikely to represent any of the known Ca2+-independent isoforms. There are
a number of complicating factors, however, since there is increasing evidence that the
degree of Ca2+-dependency of the a, (3 and y isoforms, may alter in the presence of
certain fatty acids (Murakami and Routtenberg, 1985; Naor et al, 1988; Shinomura et
al, 1991) and that the Ca2+ dependency of the (3 isoform can be altered by its
phosphorylation state (Pelech et al, 1991). Using purified/expressed enzyme
preparations, the known PKC isoforms also differ in their PKC activator
pharmacology (Evans et al, 1991; Ryves et al, 1991), but it is difficult to relate these
observations made under fixed assay conditions with differences seen in whole cells
(as has been shown in this study). For example, the choice of substrate used in an
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assay can determine the Ca2+ dependency of the a, (3 and y isoforms and can alter the
potency of DAGs and phorbol esters as PKC activators (Wolf et al, 1984; Bazzi and
Nelsestuen, 1987). In addition, DAGs stimulate various PKC isozymes with different
potency in assays containing different phospholipids (Huang et al, 1988). Therefore
the activator pharmacology of cellular PKCs will probably vary according to the
phospholipid environment and substrate.
In comparison to LHRH receptor signalling, the intracellular changes
which occur upon GH-releasing hormone (GHRH) receptor activation are much less
well understood. Growth hormone-releasing hormone does not stimulate inositol
phospholipid turnover (Collado Escobar et al, 1986; French et al, 1990) and PKC
activation is not required for the actions of GHRH (Ohmura and Friesen, 1985;
French et al, 1989). Growth hormone-RH stimulation of somatotrophs is
accompanied, instead, by stimulation of adenylate cyclase activity (Labrie et al, 1983)
and a subsequent increase in cAMP levels (Bilezikjian and Vale, 1983). Although
PKC activation may not be essential for the actions of GHRH, PKC may facilitate
cAMP production and GH release in response to GHRH (Summers et al, 1985; Cheng
et al, 1991). Thus, the actions of PKC in GHRH receptor signalling may bear some
analogy to the facilitatory effects of PKC on LHRH-induced gonadotrophin release
reported here.
In summary, it has been shown here that several pharmacologically
distinct PKC forms exist in anterior pituitary tissue and these forms differentially
control LH release, GH release and LHRH priming in pro-oestrous rat tissue pieces in
vitro. Although these experiments provide preliminary evidence regarding the
relationship of these pharmacologically distinct forms to the known PKC isoforms,
further studies are required to define their precise identity. Since the known PKC
isoforms have distinct tissue distributions, it may be possible to correlate the
distribution of the H7-resistant kinase(s) described here with the tissue distribution of
the known PKC forms. For example, the H7-sensitivity of PKC activity purified from
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different tissue sources may be determined and compared using the kinase assay
method described here. However, since the H7-resistant PKC may represent a
modified version of a known PKC isoform, an alternative approach may be required
to identify this kinase. Using isoform-specific antibodies, one could immunodeplete
certain PKC isoforms from cell free preparations of anterior pituitary PKC in an
attempt to identify an H7-resistant activity. One could also attempt to inhibit LHRH
priming using PKC isoform-selective antibodies, although this approach requires
dispersed, permeabilised cells which clearly do not function in an identical manner to
whole tissue (see section 1.4.3). Antisense oligonucleotides to specific PKC isoforms
may also be used to inhibit LHRH priming although this approach is limited since it is
dependent upon the gene encoding the kinase being active. Since the structure of the
pseudosubstrate region of different PKC isoforms may show heterogeneity, it is
possible that isoform-selective inhibitors may be developed which target this region.
Such compounds may, potentially, help to clarify the identity of the PKC involved in
LHRH priming. However, it is possible that some of the pharmacological differences
that we are observing here may represent the involvement of new, as of yet
unidentified PKC isoforms or PKC-like kinase.
The different temporal pattern of PKC activator-induced LH and GH
release indicates that these distinct PKCs may also phosphorylate different cellular
targets. Further experiments to determine the cellular targets of the PKC forms
involved in LHRH priming and PKC activator-induced LH and GH release will be of
interest (see Chapter 4).
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Figure 3.1
The effect of staurosporine on LHRH-induced (a) LH and (b) FSH release from
pro-oestrous rat hemipituitaries
Control treatments (open bars) were incubated for consecutive hours in the
presence of medium only (basal h) followed by consecutive periods (1st h, 2nd h) in
the presence of LHRH (1 nM). Including staurosporine (300 nM) throughout each
hour (hatched bars) had no significant effect on basal h or 1 st h LHRH-induced LH or
FSH release. The release of both LH and FSH measured during the 2nd h was
significantly inhibited in the presence of staurosporine (*p < 0.05). Data are mean ±










Concentration-effect curves for the action of the PKC inhibitors, (a)
staurosporine, (b) K252a, (c) Ro 31-8220 and (d) H7 on LHRH-induced LH
release from pro-oestrous rat hemipituitaries
After a basal hour incubation with PKC inhibitor only, tissue was
incubated for consecutive hours (1st h, 2nd h) in the presence of LHRH (1 nM) and
PKC inhibitor. First h LHRH-induced LH release was unaffected by either
staurosporine (10 - 1000 nM), K252a (0.03 - 10 pM), Ro 31-8220 (0.1 - 50 pM) or
H7 (10 - 300 pM). However, 2nd h LHRH-induced LH release was significantly
inhibited by all four compounds when compared to 2nd h LHRH-induced LH release
in the absence of PKC inhibitor (*p < 0.05). The IC50 values for inhibition of the 2nd
h response were 26.3 ± 7.0 nM for staurosporine, 2.9 ± 0.4 pM for K252a, 19.0 ± 6.8
pM for Ro 31-8220 and 71.6 ± 13.3 pM for H7. Each point represents the mean ±



















































































Concentration-effect curves for the action of the PKC inhibitors (a)
staurosporine, (b) K252a and (c) H7 on LHRH-induced FSH release from pro-
oestrous rat hemipituitaries
After a basal hour incubation with PKC inhibitor only, tissue was
incubated for consecutive hours (1st h, 2nd h) in the presence of LHRH (1 nM) and
PKC inhibitor, first h LHRH-induced FSH release was unaffected by staurosporine
(10 - 300 (iM), K252a (0.03 - 10 nM) or H7 (10 - 300 ^M). However, 2nd h LHRH-
induced FSH release was significantly inhibited by all three compounds when
compared to 2nd h LHRH-induced FSH release in the absence of PKC inhibitor (*p <
0.05). The IC50 values for inhibition of the 2nd h response were 37.0 ±7.1 nM for
staurosporine, 2.3 ± 0.5 |iM for K252a and 88.1 ± 20.4 (J.M for H7. Each point
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Figure 3.4
The effect of staurosporine on the development of LHRH priming in pro-
oestrous rat hemipituitaries
In part a, tissue was incubated with staurosporine (300 nM) for an initial
basal h and in the 1st h together with LHRH (1 nM) (hatched bars). Tissue was then
extensively washed before receiving a final hour incubation (2nd h) in the presence of
LHRH only (open bars). Although staurosporine was not present during the 2nd h,
primed release was significantly inhibited (*p < 0.05). Control samples received
LHRH only in the 1st h and 2nd h. Part b shows the effect of staurosporine on
LHRH-induced LH release from pre-primed pro-oestrous rat hemipituitaries.
Following a basal h incubation in medium only, tissue was primed by incubating with
LHRH (1 nM) for lh. Tissue was then exposed to two further consecutive hourly
incubations (2nd h, 3rd h) either with LHRH only (open bars) or LHRH and
staurosporine (hatched bars). Staurosporine (300 nM) had no significant inhibitory
effect on LHRH-induced LH release from previously primed tissue. Data are mean ±




Temporal profile of the effect of phorbol 12,13-dibutyrate (PDBu) on LH and
GH release from pro-oestrous rat anterior pituitary tissue
Hemipituitary pieces were incubated for an initial hour in the presence of
medium only (basal h) followed by consecutive hours with 100 nM PDBu (1st h, 2nd
h, 3rd h). The release of GH (hatched bars) was maximal in the 1st h of incubation
with PDBu whereas release of LH (open bars) was only significantly different (*p <
0.05) from basal in the 2nd h with PDBu and continued to rise in the 3rd h (**p <
















Concentration response curves for the effect of phorbol 12,13-dibutyrate (■)
and mezerein (•) on (a) LH and (b) GH release from pro-oestrous rat
hemipituitaries
Tissue was incubated for a basal h in medium only followed by
consecutive hours in the presence of either PDBu (0.03 - 1 (iM) or mezerein (0.03 - 1
(lM). These graphs show LH release measured in the 3rd h of incubation and GH
release during the 1st h of incubation. Data are expressed as the fold of release that
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Figure 3.7
The temporal pattern of 1,2-dioctanoyl-sn-glycerol (DOG)-induced (a) LH and
(b) GH release from pro-oestrous rat anterior pituitary pieces
Tissue was incubated for 4 consecutive hours in the presence ofmedium
only (baseline, open bars) followed by consecutive hours in the presence of 200 (iM
DOG (hatched bars). Luteinizing hormone, but not GH, release was significantly
greater than baseline levels throughout the 2nd and 3rd h incubation with DOG (*p <
0.05). However, GH release was not significantly different from baseline levels














Concentration-response curves for the effects of (a) staurosporine on phorbol
12,13-dibutyrate (PDBu)-induced LH (•) and GH release (■) from pro-oestrous
rat anterior pituitary tissue
Tissue was incubated for a basal hour in medium only or together with
staurosporine (10 - 300 nM), followed by consecutive hourly incubations (1st h, 2nd
h, 3rd h), in addition, with PDBu (100 nM). These graphs show LH release measured
in the 3rd h of incubation and GH release during the 1st h of incubation.
Staurosporine blocked 100 nM PDBu-induced LH and GH release with similar














Concentration-response curves for the effect of (a) H7 on phorbol 12,13-
dibutyrate (PDBu)-induced LH and GH release and (b) H7 on mezerein-induced
LH and GH release from pro-oestrous rat anterior pituitary tissue
Tissue was incubated for consecutive hours (basal h, 1st h, 2nd h, 3rd h) in
the presence of various concentrations of H7. In addition, either 100 nM PDBu (a) or
300 nM mezerein (b) was also present throughout the 1st h, 2nd h and 3rd h
incubations. The data show GH (■) release measured during the 1st h and LH release
(•) measured in the 3rd h of incubation with PKC activators. The statistical
significant inhibition of hormone release by H7 is shown by *(p < 0.05). The
corresponding basal release of LH during the 3rd h of drug-free controls was 2.5 ± 0.3
pg/1 (a) and 3.9 ± 0.4 jj.g/1 (b). H7 alone had no effect on basal release of LH or GH
at any of the concentrations tested. Each point on the graphs represents the mean ±






























































The effect of H7 on LH release induced from pro-oestrous rat anterior pituitary
tissue by increasing concentrations of phorbol 12,13-dibutyrate (PDBu)
Tissue was incubated for consecutive hours with various concentrations of
PDBu (3 - 1000 nM) either in the presence or absence ofH7 (30 (iM). The data
shows the % of the LH response, measured during the 3rd h of PDBu incubation, that























The effect of staurosporine on ionomycin-induced LH release from untreated
and LHRH-pretreated pro-oestrous rat anterior pituitary tissue
Hemipituitaries were incubated in vitro for 3 hours. In the basal hour
there was medium alone (controls) or staurosporine (300 nM). In the 1st hour there
was (in addition to staurosporine) ionomycin (50 (J.M, Ii). or LHRH (1 nM, Li),
followed by a 2nd h with ionomycin (I2). The statistical significance of the inhibitory
actions of staurosporine were determined (*p < 0.05). Values given are the mean ±
SEM with the number of separate determinations in parentheses.
LH release
(fold of basal h)





19.2 ±2.5 (7) 13.0 ±2.4 (7)





3.7 ±0.2 (6) 18.7 ±2.5 (6)
3.3 ±0.7 (6) *10.3 ± 0.9 (6)
Table 3.2
The effect of staurosporine on mezerein-induced LH and GH release from pro-
oestrous rat anterior pituitary tissue
Hemipituitaries were incubated in vitro for 4 hours. In the basal hour
there was medium alone (baseline) or staurosporine (300 nM). In the following 3
consecutive hours the incubations contained the same and/or mezerein (300 nM).
Values are for LH release measured in the 3rd h and GH release measured in the 1st h
with mezerein. The statistical significance of the actions of staurosporine on
mezerein-induced hormone release are shown as *p < 0.05. Values given are the





baseline 3.9 ± 0.4 (4) 480.7 ± 105.5 (4)
mezerein 39.1 ±4.3 (5) 1820.3 ±234.7 (5)
mezerein
+ *2.9 ± 0.4 (4) *510.0 ±38.7 (4)
staurosporine
Table 3.3
The effect of PKC inhibitors on 1,2-dioctanoyl-s/i-glyceroI (DOG)-induced LH
release from pro-oestrous rat anterior pituitary tissue
Hemipituitaries were incubated in vitro for 4 consecutive hours. In the
basal hour, tissue was incubated in medium only (baseline), or with staurosporine
(300 nM) or H7 (30 jiM). In the following 3 consecutive hours in addition to these
drugs, tissue was incubated with DOG (200 (iM) as appropriate. Values are for LH
release measured during the 3rd h of incubation with DOG with and without the
appropriate PKC inhibitor. Net LH release was significantly enhanced above baseline
levels in the presence of DOG (tp < 0.05). Staurosporine, but not H7, significantly
inhibited DOG-induced LH release (*p < 0.05,) when compared to release in the
presence of DOG only. Values are means ± SEM and the number of determinations
are shown in parentheses.
net LH release
(ltg/0
baseline 3.6 ±0.3 (5)
DOG t8.5 ± 0.8 (6)
DOG
+ *2.4 ± 0.4 (6)
staurosporine
DOG
+ 7.7± 0.3 (6)
H7
Table 3.4
The effect of PKC inhibitors on phorbol 12,13-dibutyrate-induced PKC activity
partially purified from rat anterior pituitary cytosol
Phorbol 12,13-dibutyrate (1 |iM)-induced histone HIS kinase activity was
measured in the presence of phosphatidylserine, with either the presence (100 (iM






101 ± 39 17 ±4
171+46 121 ±18
CHAPTER 4
Evidence for a Role of Phospholipase a2 in
Luteinizing Hormone-Releasing Hormone
Receptor Signalling in RatAnterior
Pituitary Tissue
4.1 Introduction
In Chapter 3, it was suggested that pharmacologically distinct forms of
PKC or a PKC-like kinase may be involved in the induction of LHRH priming and
PKC activator-induced LH release and GH release from pro-oestrous rat anterior
pituitary tissue. Since the temporal patterns of phorbol ester-induced LH and GH
release were different (Figure 3.5), the sequence of events that lead from PKC
activation to hormone release in gonadotrophs is probably very different from that in
somatotrophs. Thus, different PKC forms may induce LH and GH release and LHRH
priming by phosphorylating different cellular targets. One potential target for the
PKC(s) which induce LH release, and possibly those which mediate LHRH priming,
may be phospholipase A2 (PLA2), or an intermediate factor which leads to the
activation of PLA2.
The release of LH can be induced from primary cultures of rat
gonadotrophs by the PLA2 activator, melittin, and by exogenously added snake
venom PLA2 (Kiesel et al, 1985). The actions of LHRH are accompanied by an
increased release of AA and its metabolites (Vanderhoek et al, 1984; Catt et al, 1985)
and exogenously added AA, and several AA metabolites, can induce LH release from
dispersed anterior pituitary cell cultures (Naor and Catt, 1981; Naor et al, 1983;
Hulting et al, 1984; Conte et al, 1986; Kiesel et al, 1987). Since these observations
suggest that cellular responses to LHRH may involve PLA2 activation, a possible role
of PLA2 in LH responses to LHRH and PKC activators was determined using pro-




4.2.1 Hormone release measurements
Hemipituitaries were removed from adult female COB Wistar rats that had
been anaesthetised and decapitated by 11.00 am on pro-oestrus and hormone release
was measured using the methods described in section 2.2.3. The medium was
radioimmunoassayed for LH, FSH and GH (Niswender et al, 1968; Daane and
Parlow, 1971). The standards used were NIH-LH-S18 for the data in Figures 4.1, 4.2
and for some of the data in Figure 4.9 and Table 4.10 and NIADDK-rat LH-RP2 for
the remaining figures and tables, NIADDK-rat-GH-RP-2 and NIADDK-rat FSH-RP2.
4.2.2 [3H]-Arachidonic acid release measurements
[3H]-Arachidonic acid release was measured from pre-labelled pro-
oestrous anterior pituitary pieces and a T3-1 cells as described in section 2.2.5. After
labelling with [3H]-AA, pairs of pituitary quarters or 12 well plates of confluent
a T3-1 cells were incubated for 15 min in the presence or absence of the appropriate
drugs. The incubation medium was removed and the [3H]-AA released was measured
by lipid extraction and reverse-phase liquid chromatography on octadecyl silica
(ODS) using the solvent system described by Powell (1982).
4.2.3 Drugs
Luteinizing hormone-releasing hormone, quinacrine dihydrochloride,
aristolochic acid sodium salt, Ro 31-4493, Ro 31-4639, H7, cycloheximide and
melittin were made up as stock solutions in distilled H2O. Ionomycin, phorbol 12,13-
dibutyrate (PDBu), 4-chloro-N-(p-pentylcinnamoyl) anthraniric acid (ONO-RS-082)
RHC 80267, staurosporine, Ro 31-8220, nordihydroguaiaretic acid (NDGA), and
indomethacin were made up as stock solutions in DMF. Arachidonic acid, arachidic
acid, p-bromophenacyl bromide (BrPheBr), 7, 7-dimethyleicosadienoic acid (DEDA)
and 4, 8, 11, 14-eicosatetraynoic acid (ETYA) were made up as stock solutions in
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ethanol. The maximum concentration of DMF or ethanol (0.05% v/v) was used in
control experiments and had no effect on either hormone release or [3H]-AA release.
4.2.4 Data analysis
All statistical analysis was carried out using the Mann-Whitney U-test
unless otherwise stated.
4.3 Results
The effect of phospholipase A2 inhibitors on LHRH responses measured in pro-
oestrous rat hemipituitary pieces
Figure 4.1 shows the effect of the PLA2 inhibitor, quinacrine (50 pM)
(Markus and Ball, 1969; Loffler et al, 1985) on LH (Figure 4.1a) and FSH (Figure
4.1b) release from pro-oestrous rat hemipituitaries, measured over consecutive hourly
incubations with LHRH (1 nM). Neither basal h, nor 1st h LHRH-induced LH
release was significantly altered in the presence of quinacrine. However, 2nd h
LHRH-induced LH release, where LHRH priming is expressed, was significantly
inhibited by quinacrine (50 pM; p < 0.05) to levels that were 44.5 ± 3.1% of control.
Similarly, 2nd h, but not basal h or 1st h, LHRH-induced FSH release was
significantly inhibited by quinacrine (Figure 4.1b). Quinacrine, at concentrations up
to 100 pM, caused a dose-dependent inhibition of 2nd h LHRH-induced LH release to
levels approaching those measured during the 1st h of LHRH stimulation, but never
to basal h levels (Figure 4.2a). Another PLA2 inhibitor, p-bromophenacyl bromide
(BrPheBr) (Drenth et al, 1976) also blocked LHRH-induced LH release from primed
tissue to levels approaching those measured in the 1st h of LHRH incubation, without
affecting 1st hour LH release (Figure 4.2b). However, at BrPheBr concentrations of
50 pM and above, basal h LH release was elevated above control levels, suggesting
that this compound may have non-specific actions at high concentrations.
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Other putative inhibitors of PLA2 activity such as aristolochic acid (50
pM) (Vishwanath etal, 1988) and ONO-RS-082 (10 pM) (Banga etal, 1986)
inhibited 2nd h LHRH-induced LH release without altering either basal h or 1st h
LHRH-induced LH release. The inhibitory effects of these compounds on the 2nd,
but not the 1st h of LHRH-induced LH release from pro-oestrous rat hemipituitaries
indicate that PLA2 activation may be required for LHRH priming, but not for initial
responses to the peptide. However, other putative PLA2 inhibitors, Ro 31-4493 (100
pM), Ro 31-4639 (100 pM) (Davis et al, 1988) and 7,7-dimethyleicosadienoic acid
(DEDA) (30 pM) (Cohen et al, 1984) had no significant inhibitory effect on LHRH-
induced LH release at any hour of incubation, when used at concentrations greater
than those reported to cause 50% inhibition of PLA2 activity (Table 4.1).
Neither quinacrine (100 pM), ONO-RS-082 (10 pM), aristolochic acid
(150 pM), DEDA (30 pM), Ro 31-4493 (100 pM) nor Ro 31-4639 (100 pM) had any
significant effect on baseline gonadotrophin release when measured over several
hours of incubation.
Evidence that phospholipase A2 activation is required specifically for the
induction of LHRH priming in pro-oestrous rat anterior pituitary pieces
To examine the role ofPLA2 in LHRH priming in more detail, a number
of experiments were carried out, similar to those which were used to ascertain the role
of PKC in LHRH responses (see Chapter 3, section 3.3). A first experiment
examined the effect of quinacrine on changes in pituitary responsiveness which occur
during the 1st h of LHRH incubation (Figure 4.3a). Hemipituitary pieces were
incubated for a basal h in medium only or with quinacrine (50 pM), followed by a 1st
h incubation with, in addition, LHRH (1 nM). After the 1st h incubation, quinacrine
was removed by washing the tissue three times in fresh pre-warmed and pre-gassed
MEM and the washed tissue was incubated for a final hour (2nd h) with LHRH only.
Control treatments received identical incubations with LHRH and washing, but in the
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absence of quinacrine. Consistent with the results shown in Figures 4.1 and 4.2,
quinacrine did not inhibit either basal h or 1st h LHRH-induced LH release (Figure
4.3a). However, following a 1st h incubation with LHRH and quinacrine, 2nd h
LHRH-induced LH release was significantly reduced in comparison to the controls,
although the tissue had been washed to remove the inhibitor from the 2nd h
incubation period. These results indicate that quinacrine may inhibit the induction of
LHRH priming, reducing the 2nd h response to LHRH as a consequence. However, it
is possible that the washout procedure was not completely effective and that a
significant amount of quinacrine remained in the tissue during the 2nd h of LHRH
incubation. Consequently, additional experiments were carried out to further examine
the effects of quinacrine on the induction LHRH priming.
In a second experiment, the effect of quinacrine was examined on LHRH-
induced LH release from pituitary tissue which had been previously primed (Figure
4.3b). Hemipituitaries were incubated for a 1st h with LHRH followed by a further 2
consecutive hourly incubations with LHRH, either in the presence or absence of
quinacrine (50 (iM). Quinacrine had no significant inhibitory action on LHRH-
induced LH release from pre-primed tissue, even over two hours of incubation which
would allow for any possible slow-developing inhibitory effect on the mechanism of
hormone release.
To test the action of quinacrine on the secretory apparatus of the
gonadotroph, the effect of this drug was examined on LH release induced by raising
intracellular Ca2+ levels (Table 4.2). In the presence of ionomycin (30 (iM), LH
release was significantly increased (p < 0.05, Mann-Whitney U-test) above basal h
levels, but with a temporal pattern that did not exhibit 'priming'. Quinacrine (50 pM)
had no significant inhibitory effect on ionomycin-induced LH release measured
during any hour of incubation indicating that the inhibitor did not alter the general
Ca2+-induced secretory apparatus of the gonadotroph. In addition, these results
suggest that PLA2 is not involved in the mechanism of Ca2+-induced LH release. In
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contrast, ionomycin-induced LH release from tissue which had been previously
primed by a 1st h incubation with LHRH was significantly inhibited when quinacrine
was present during the LHRH incubation period. This is consistent with the idea that,
although priming relates specifically to a cascade of intracellular signals elicited by
LHRH, the consequential facilitation of release to any given stimulus in primed tissue
applies not only to LHRH as a secretagogue but to other general post-priming stimuli,
such as Ca2+ ionophore (Pickering and Fink, 1979).
In summary, PLA2 inhibitors blocked LHRH responses only when present
during the time when LHRH priming takes place, i.e. the 1st h of LHRH treatment
(Figures 4.1, 4.2, 4.3 and Table 4.1, 4.2). In addition, quinacrine did not inhibit the
actions of secretagogues that do not evoke a priming response. These results,
therefore, indicate an involvement of PLA2 in the induction, but not in the expression
of LHRH priming.
Is an H7-resistant form of PKC involved in the mechanism of phospholipase A2
activation during LHRH priming?
The analogous effects of PKC inhibitors and PLA2 inhibitors on LHRH
priming imply a possible connection between PKC and PLA2 activation in the
induction of this response. In one possible sequence of events, AA produced by
PLA2 action may directly activate PKC (section 1.2.2 and 1.3.5). To test this
hypothesis, the effect of PKC inhibitors was examined on secretory responses to AA.
Arachidonic acid (300 (iM) could induce a significant increase in LH release during
the 2nd and 3rd h of incubation with the fatty acid (Figure 4.4a). However, neither
staurosporine nor H7 had any significant inhibitory effect on AA (300 |lM)-induced
LH release (Table 4.3) suggesting that AA does not induce LH release by a
mechanism that involves PKC. Furthermore, the saturated congener of AA, arachidic
acid (300 p.M), which lacks many of the biological actions of AA (Beaumier et al,
1987; Negishi et al, 1990), could also induce a significant increase in LH release
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during the 2nd and 3rd h of incubation (Figure 4.4b). It would seem, therefore, that
the direct actions of AA on LH release may be non-specific.
In an alternative sequence of events, PKC activation may modulate PLA2
activity. To test this possibility, the effect of PLA2 inhibitors was examined on
PDBu-induced LH release and as a contrast, PDBu-induced GH release (Figure 4.5
and Table 4.4). Phorbol 12,13-dibutyrate (300 nM)-induced LH release was dose-
dependendy inhibited by quinacrine (IC50 = 20 ± 9 jiM). In contrast, PDBu-induced
GH release measured was unaltered by quinacrine (Figure 4.5b), even at
concentrations as high as 100 |iM where PDBu-induced LH release was decreased to
levels which were approximately 10% of control. Aristolochic acid (100 (iM) and
BrPheBr (50 p.M) also inhibited PDBu-induced LH release but not PDBu-induced GH
release (Table 4.4). The actions of these inhibitors suggest that PLA2 activation may
be involved in the mechanism by which the PKC(s) induces LH release, but not GH
release.
The influence of LHRH on gonadotroph PLA2 activity was examined,
more directly, by measuring [3H]-AA release from pre-labelled anterior pituitary
tissue. After a 15 min incubation with LHRH (1 nM), medium [3H]-AA levels
increased by approximately 2-fold over basal levels (Table 4.5). To determine the
pathway of LHRH-induced [3H]-AA release, the effects of quinacrine and the DAG
lipase inhibitor, RHC 80267 were examined. These inhibitors were used at
concentrations reported to inhibit the activity of their target enzymes with minimal
side effects (Hoffman et al, 1982; Sutherland and Amin, 1982). [3H]-Arachidonic
acid release induced by LHRH was inhibited by quinacrine (50 (iM), but not by RHC
80267 (80 (J.M) (Table 4.5), indicating that the main route of [3H]-AA release
induced by LHRH is via a pathway involving PLA2.
To test for the possible involvement of the H7-resistant PKC-like priming
kinase in the mechanism of LHRH-induced activation of PLA2, the effects ofH7 and
staurosporine were examined on LHRH-induced [3H]-AA release (Table 4.6). [3H]-
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Arachidonic acid release induced by LHRH was readily inhibited by staurosporine
(300 nM), a concentration which similarly inhibits LHRH priming (Chapter 3), to
levels that were not significantly different from basal. However, LHRH-induced
[3H]-AA release was relatively resistant to inhibition by H7 at a concentration (30
pM) which is unable to significantly inhibit LHRH priming (Chapter 3) (Table 4.6).
Thus, during LHRH action on the gonadotroph, the action of an H7-resistant form of
PKC may be instrumental in increasing PLA2 activity, an event which may
participate in bringing about a primed state.
The pharmacology of the [3H]-AA release response, with respect to PKC
inhibitors, was analysed further. Phorbol 12,13-dibutyrate (300 nM) induced a dose-
dependent increase in [3H]-AA release from pre-labelled pro-oestrous rat anterior
pituitary tissue (Figure 4.6), a response which was readily inhibited by quinacrine (50
pM) but not RHC 80267 (80 pM) (Chapter 2, Table 2.2). This result is consistent
with the hypothesis that PKC may induce [3H]-AA release by modulating anterior
pituitary PLA2 activity, rather than by other possible routes of free AA production.
Both staurosporine and Ro 31-8220 completely inhibited 300 nM PDBu-induced
[3H]-AA release from pre-labelled tissue with IC50 values of 28.4 ± 17.9 nM and 5.1
± 7.8 pM respectively (Figure 4.7a and 4.7b). Phorbol ester-induced [3H]-AA release
was also inhibited by H7, but in a biphasic manner (Figure 4.7c). Although more
than 50% of the response to PDBu was blocked by H7 concentrations as little as 1
pM, no further inhibition was observed until the H7 concentration was then further
increased by over 30-fold, suggesting that the PKC form(s) mediating over 40% of
the response was highly resistant to H7. Thus, although H7-resistant forms of PKC
are involved in LHRH-induced modulation of PLA2 activity, both H7-resistant and
-sensitive forms may be involved in the mechanism of PDBu-induced [3H]-AA
release. Neither staurosporine (300 nM), H7 (100 pM), Ro 31-8220 (30 pM),
quinacrine (50 pM) nor RHC 80267 (200 pM) had any significant effect on baseline
[3H]-AA release (Table 2.1).
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The priming effect of LHRH measured in pro-oestrous rats in vivo and in
vitro, is dependent upon protein synthesis (Pickering and Fink, 1976; Debeljuk et al,
1978). It is unlikely that this protein synthesis-dependent step represents the
synthesis of new LH as there is no change in total pituitary LH content during
priming (Pickering and Fink, 1979; Speight and Fink, 1981). The relationship of
protein synthesis to PKC and to PLA2 activation in the mechanism of LHRH priming
was therefore investigated. The protein synthesis inhibitor, cycloheximide (Obrig et
al, 1971), at a concentration of 50 |iM, significandy inhibited PDBu (300 nM)-
induced LH release, but not GH release during all hours of incubation (Figure 4.8).
Cycloheximide also inhibited LHRH- and PDBu-induced [3H]-AA release (Table
4.6). In contrast, cycloheximide had no effect on LH release induced by the PLA2
activator, melittin (Habermann, 1972), during any hour of incubation (Figure 4.9).
Thus, it appears that in the LHRH receptor signal transduction system, protein
synthesis may be required for a process following PKC activation, but prior to the
action of PLA2. These results are consistent with a model of LHRH receptor
signalling in which PKC modulates PLA2 activity, in a protein synthesis-dependent
manner, to induce priming.
Arachidonic acid as a possible mediator of LHRH priming
Since PLA2 activation may be required for the induction of LHRH
priming, and the actions of LHRH are accompanied by an increase in free [3H]-AA
levels, AA may be a mediator of the priming effect. As shown earlier (Figure 4.4),
AA could induce LH release from pro-oestrous hemipituitaries but probably by a non¬
specific effect. Since PLA2 activation is important for the induction of priming, but
not for LH release, a more probable action of AA may be to alter gonadotroph
responsiveness. To test the actions of AA on gonadotroph responsiveness, pro-
oestrous rat hemipituitaries were pre-incubated for 1 h with AA (300 (iM), or
arachidic acid (300 |iiM), followed by 2 further consecutive hourly incubations (1st h,
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2nd h) with LHRH only (1 nM) (Table 4.8). To allow for the direct effects of AA and
arachidic acid on LH release, control treatments contained the appropriate fatty acid
in the basal h, but were incubated in medium only during the 1st and 2nd h. Hormone
release measured throughout these control incubations was subtracted from values
obtained in the presence of LHRH. Prior incubation with AA, but not arachidic acid,
significantly enhanced net LHRH-induced LH release measured over 2 consecutive
hours (p < 0.05) (Table 4.8). Since AA treatment could increase pituitary
responsiveness to LHRH, analogous to a priming effect, in a manner that was distinct
from its non-specific actions on gonadotrophin release, it seems possible that the
generation of AA may contribute to bringing about priming.
The effect of inhibitors of arachidonic acid metabolism on LHRH responses
measured in pro-oestrous rat hemipituitaries
Since previous reports have suggested that metabolites of AA may
modulate gonadotrophin release (Naor et al, 1983; Snyder et al, 1983; Catt et al,
1985; Kiesel et al, 1987), a possible role for AA metabolites in LHRH responses in
pro-oestrous rat hemipituitary pieces was examined using a number of inhibitors of
the pathways of AA metabolism. At a concentration of 10 pM, where 4,8,11,14-
eicosatetraynoic acid (ETYA) is reported to inhibit the lipoxygenase and cyclo-
oxygenase pathways of AA metabolism (Hamberg and Samuelson, 1974), LHRH-
induced LH release was unaltered during any hour of incubation (Table 4.9)
suggesting that neither lipoxygenase nor cyclo-oxygenase metabolites are required for
LHRH responses in pro-oestrous rat hemipituitaries. However, ETYA, at a
concentration of 30 pM, inhibited 2nd h, but not 1st h, LHRH-induced LH release to
levels that were not significantly different from basal h measurements. Although
ETYA can inhibit the epoxygenase pathway of AA metabolism at this higher
concentration (Capdevilla et al, 1988), it can also block PLA2 activity (Lanni and
Becker, 1985). Nordihydroguiaretic acid (NDGA), when used at a concentration (10
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pM) reported to inhibit the epoxygenase and lipoxygenase pathways (Smith and
Bowman, 1982; Capdevilla et al, 1988), had no effect on LHRH responses during any
hour (Table 4.9). However, when used at a concentration of 30 pM, NDGA inhibited
both 1st h and 2nd h LHRH-induced LH release to baseline levels, but at this level
NDGA can also inhibit PLA2 activity (Lanni and Becker, 1985). The cyclo-
oxygenase inhibitor, indomethacin, had no effect on LHRH-induced LH release
during any hour (Figure 4.10) when used at concentrations up to 30 pM. However,
300 |iM indomethacin inhibited 2nd h LHRH-induced LH release to basal h levels of
release, suggesting that this inhibitor may have a slow-developing toxic effect on
hormone release at high concentrations.
Neither ETYA (10 pM), NDGA (30 pM) nor indomethacin (30 pM) had
any significant effect on baseline LH release measured over several hours of
incubation.
The involvement of phospholipase A2 in LHRH receptor signalling in a T3-1 cells
The anterior pituitary gland consists of a heterogeneous cell population,
only around 10% of which are gonadotrophs. It is therefore difficult to determine the
contribution of this small population of cells in responses measured in whole
pituitary. A clonal cell line has recently been developed from anterior pituitary
tumours generated in transgenic mice (Windle et al, 1990), and in the following
experiments, this a T3-1 cell line was used to further investigate and compare the
effects of phorbol esters and LHRH on gonadotroph PLA2 activity. When [3H]-AA
pre-labelled a T3-1 cells were incubated with LHRH for 15 min, there was a
significant increase in [3H]-AA release (Table 4.10). However, LHRH-induced AA
release from a T3-1 cells was not inhibited by either staurosporine (300 nM) or H7
(30 pM). Furthermore, PDBu (300 nM) did not induce any significant release of
[3H]-AA from a T3-1 cells. The effects of PDBu and PKC inhibitors on LHRH
responses in a T3-1 cells contrast strongly with their actions on pro-oestrous rat
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pituitary [3H]-AA release (Table 4.6 and Figure 4.6), suggesting that quite different
cellular signalling pathways may be involved in these transformed cells, limiting then-
usefulness as a model of gonadotrophs in vivo.
4.4 DISCUSSION
Previous reports suggest that stimulation of rat gonadotroph and rat
granulosa cell LHRH receptors can lead to activation of PLA2 (Naor and Catt, 1981;
Minegishi et al, 1987). The present evidence suggests that, in pro-oestrous rat
hemipituitary pieces, activation of PLA2 may be required for the induction of LHRH
priming, but not for initial LHRH-induced gonadotrophin release. Quinacrine,
BrPheBr, aristolochic acid and ONO-RS-082 blocked 2nd h LHRH-induced release
of primed LH, but not 1st h LHRH-induced LH release (Figures 4.1, 4.2 and Table
4.1), with potencies similar to their effects on PLA2-mediated responses in other cell
types (Loffler et al, 1985; Banga et al, 1986; Rosenthal et al, 1989; Tohmatsu et al,
1989). Notably, the concentration of quinacrine which was reported to inhibit long-
term secretory responses to LHRH in primary cultures of rat anterior pituitary cells
(IC50 = 20 |iM) (Naor and Catt, 1981) is within the range described here for the
inhibition of the LHRH priming (IC50 = 34.0 ± 10.3 pM). Using pro-oestrous rat
tissue, the 2nd h response to LHRH was reduced by these inhibitors to levels that
approached 1 st h levels of LHRH-induced LH release, but never to baseline levels,
suggesting that PLA2 activation may be required for enhanced gonadotroph
responsiveness. Consistent with this hypothesis, LHRH-induced LH release was
inhibited only if quinacrine was present throughout the time when LHRH priming
occurred, i.e. during the 1st h of LHRH incubation, whereas LHRH-induced LH
release from pre-primed tissue was not blocked by quinacrine (Figure 4.3).
Therefore, the induction, but not the expression, of priming may well be dependent
upon PLA2 activation. Quinacrine did not appear to inhibit the release of LH from
previously primed tissue by affecting the general mechanism of gonadotrophin release
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since this drug did not alter ionomycin-induced LH release. However, if the tissue
was primed by exposure to LHRH, facilitated LH release in response to Ca2+-
ionophores was blocked by quinacrine to 'non-primed' levels (Table 4.2).
Interestingly, long-term secretory responses to LHRH measured in dispersed rat
anterior pituitary cells, which do not exhibit an obvious priming response, are also
dependent upon PLA2 action (Naor and Catt, 1981). It seems, therefore, that
although PLA2 activation is involved in the later stages of hormone release in both
the dispersed cell and intact tissue models of LHRH action, some other factor may
limit the expression of priming in dispersed cells. For example, the products of PLA2
action may have paracrine effects on adjacent cells in situ, an action which will be
altered by the process of cell dispersal.
The specificity of both quinacrine and BrPheBr as inhibitors of PLA2
action has been questioned in a number of studies (Irvine, 1982; Dise et al, 1982;
Chang et al, 1987a). Quinacrine may inhibit PLA2 activity by interacting with the
hydrophobic regions of the phospholipid substrate and, at high concentrations, may
perturb membrane architecture and alter cell function (Dise et al, 1982). However,
quinacrine did not alter the LH release induced by elevating intracellular Ca2+ levels
through the use of iomomycin (Table 4.2), suggesting that a non-specific action of
this drug is unlikely to be responsible for its effects on LHRH responses.
Furthermore, quinacrine attenuated PDBu-induced LH release without any significant
effect on corresponding GH release (Figure 4.5). Bromophenacyl bromide inhibited
PLA2 activity by forming a covalent bond with a histidine residue which is situated
near the Ca2+-binding site of the enzyme (Volwerk et al, 1974; Drenth et al, 1976;
Roberts et al, 1977), but can also alkylate thiol and amine groups ofmany different
proteins (Erlanger et al, 1965) which may account for the effects of high
concentrations of BrPheBr on baseline LH release. Although BrPheBr and quinacrine
are putative inhibitors of PLC activity (Hofmann et al, 1982), these compounds were
unable to prevent the presumed PLC-dependent, 1st h LHRH-induced LH release. In
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addition, at the concentrations used here, these compounds have been reported to
inhibit PLA2 in other systems without affecting PLC activity (Lazarewicz et al,
1988). Furthermore, ONO-RS-082, which can inhibit PLA2 activity in platelets
without affecting PLC activity (Tohmatsu et al, 1989; Banga et al, 1986), blocked the
primed response to LHRH.
Although the LHRH priming phenomenon was inhibited by quinacrine,
BrPheBr, aristolochic acid and ONO-RS-082, a number of other putative PLA2
inhibitors (DEDA, Ro 31-4493 and Ro 31-4639) had no effect on LH release
measured over any hour of incubation with LHRH (Table 4.1). Other workers have
shown that DEDA can inhibit PLA2 activity in vitro, but not in vivo, and have
suggested that the efficacy ofDEDA as an inhibitor in vitro may relate to the
characteristics of the enzyme in isolation (Cohen et al, 1984). Both Ro 31-4493 and
Ro 31-4639 can block PLA2 action in intact cells with an IC50 value of 10 - 25 (iM
(Roldan and Mollinedo, 1991; Henderson et al, 1989). In certain cell types, therefore,
these compounds do appear to gain access to the cell interior although it is not certain
whether all cell types are readily permeable to these compounds (Roche Products pic,
unpublished observations). Both Ro PLA2 inhibitors were designed to interact with
polar amino acid side chains in the active site of porcine pancreatic PLA2 (Davis et
al, 1988). However, this enzyme has no detectable sequence homology with
cytosolic (presumably hormonally-regulated) PLA2S (Clark et al, 1990, 1991b). As a
consequence, both compounds may be weak inhibitors of the PLA2(s) that has a role
in LHRH receptor signal transduction. In agreement with both of these hypotheses
regarding the failure of the Ro compounds to inhibit priming, experiments from our
laboratory have shown that quinacrine, but neither Ro 31-4493 nor Ro 31-4639 can
inhibit PDBu-induced [3H]-AA release from pro-oestrous rat anterior pituitary tissue
(87 ±7% and 90 ± 4% of the control response to PDBu in the presence of Ro 31-4493
and Ro 31-4639, respectively). Pharmacological differences between enzymes
isolated from different tissue sources have been reported previously (Loffler et al,
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1985; Nixon et al, 1985). For example, another PLA2 inhibitor, WY-48, 489, readily
inhibits membrane-associated PLA2 isolated from human platelets but has little effect
on pancreatic PLA2 activity (Marshall and Chang, 1990). It is possible that inhibitors
which display selectivity for different forms of PLA2 may be developed as
therapeutic agents in the future.
In agreement with the pharmacological evidence presented here which
suggests that activation of LHRH receptors modulate gonadotroph PLA2 activity,
LHRH induces a relatively rapid (15 min) increase in a quinacrine-sensitive, but RHC
80267-insensitive release of [3H]-AA from pro-oestrous rat anterior pituitary pieces
(Table 4.5). Unfortunately, due to the small population of gonadotrophs in anterior
pituitary tissue, it was not possible to measure the cellular content of [3H]-AA after
stimulation. The exact relationship between medium [3H]-AA levels (as measured in
these experiments) and cellular-free AA is therefore unclear. Although a time-course
of LHRH-induced [3H]-AA release from pro-oestrous rat tissue was not studied in
detail, in dispersed pituitary cells LHRH induces a significant release of AA by 10
minutes of treatment which gradually increases over a period of an hour (Naor and
Catt, 1981), and this correlates with the time-course of the development of priming in
vitro (Pickering and Fink, 1976). However, in contrast with these results, a previous
report has shown that RHC 80267, at concentrations that block DAG lipase activity
with little or no effect on PLA2, inhibited approximately 40% of LHRH-induced LH
release from dispersed anterior pituitary cells (Chang et al, 1988). The reason why
DAG lipase is apparently involved in LHRH responses in dispersed cells but not in
pro-oestrous rat pituitary tissue is uncertain, but may reflect an alteration in
gonadotroph function which occurs following cell dispersal and culture (see section
1.4.3).
The involvement of PLA2 in LHRH responses in pro-oestrous rat anterior
pituitary tissue may have been further demonstrated by the generation of
lysophospholipid following agonist stimulation. However, it is now clear that certain
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cytosolic PLA2 forms exhibit lysophospholipase activity (Leslie, 1991). Therefore,
the absence of lysophospholipid production in LHRH-stimulated cells may not
indicate conclusively that PLA2 is not involved in agonist-induced AA release.
Alternatively, following LHRH treatment, changes in anterior pituitary PLA2 activity
may have been determined by measuring partially-purified PLA2 activity in a cell-
free assay using either a fluorogenic or radiolabeled PLA2 substrate (Clark et al,
1990; Gronich et al, 1990; Piomelli and Greengard, 1991). However, since
gonadotrophs are a relatively small proportion (-10%) of the cell types in anterior
pituitary tissue, any change in gonadotroph PLA2 activity may be difficult to detect
using this method. Although changes in a T3-1 cell PLA2 activity may be more
readily detected in cell free assays, it is clear that LHRH-induced [3H]-AA may be
under different intracellular control in this clonal cell line than responses to LHRH
measured in pro-oestrous rat anterior pituitary tissue (Figure 4.6, Tables 4.6 and
4.10). Thus, it is uncertain as to how stimulus-induced changes in a T3-1 cell PLA2
activity will relate to changes in PLA2 activity determined in pro-oestrous rat anterior
pituitary tissue.
During the LHRH receptor signal, modulation of gonadotroph PLA2
activity may be dependent upon the activity of a PKC-like kinase, suggesting that
PLA2 activation may occur down-stream from the action of PLC which, presumably,
was the origin of the DAG which led to PKC activation. An initial indication of a
possible link between PLA2 and PKC activation came from the comparable actions of
PLA2 inhibitors (quinacrine, BrPheBr, ONO-RS-082 and aristolochic acid) and PKC
inhibitors (staurosporine, K252a, Ro 31-8220 and H7) on the induction of the priming
effect (see also Chapter 3). In addition, staurosporine and H7 inhibited LHRH-
induced [3H]-AA release at concentrations which are equivalent to their effects on
LHRH priming (Figures 3.2 and 3.3 and Table 4.5). Thus, LHRH receptor-mediated
activation of an H7-resistant, PKC-like kinase may participate in modulating PLA2
activity and ultimately result in priming. In agreement with this sequence of events,
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PLA2 inhibitors blocked PDBu-induced LH release (Figure 4.5) and PDBu treatment
enhanced [3H]-AA release (Figure 4.6). Although PKC-dependent phorbol ester-
modulation of PLA2 activity has been described in other cell types (Hartung and
Toyka, 1987; Parker et al, 1987), there are some reports that phorbol esters may
directly activate phospholipases (Billah etal, 1989; Billah and Anthes, 1990). It is
unlikely that direct activation of PLA2 can account for the effects of PDBu on
anterior pituitary [3H]-AA release since this effect required protein synthesis (Table
4.7), implying that the mechanism of PLA2 activation is complex. Furthermore,
PDBu-induced [3H]-AA release from hemipituitaries was readily inhibited by
staurosporine and Ro 31-8220 (Figure 4.7), indicating the involvement of PKC in this
response. Phorbol 12,13-dibutyrate-induced [3H]-AA release was inhibited by H7 in
a biphasic manner suggesting that, in addition to a set of relatively H7-resistant
PDBu-activated kinases, which presumably modulate PLA2 activity in LHRH
receptor signalling, a set ofmore conventional H7-sensitive PKC(s) are capable of
activating PLA2. These H7-sensitive PKC(s) which control PLA2 activity may be
involved in some function of the gonadotroph, other than priming, or may have a
function in the control of AA release from other anterior pituitary cell types.
Modulation of PLA2 activity by PKC requires protein synthesis and it
seems quite possible that this process may represent the protein synthesis-dependent
step in the LHRH priming response. Luteinizing hormone-releasing hormone-
induced [3H]-AA release, PDBu-induced [3H]-AA release and PDBu-induced LH
release were very markedly inhibited by cycloheximide (Table 4.7 and Figure 4.8).
Therefore, protein synthesis may occur subsequent to PKC activation, consistent with
a previous observation (Bourne et al, 1989). Melittin-induced LH release was not
affected by cycloheximide (Figure 4.9), indicating that the processes beyond PLA2
activation do not require protein synthesis. However, melittin can cause cell lysis and
induce voltage-dependent ion conductances in planar lipid bilayers (Tosteson and
Tosteson, 1981; Metz, 1986), thus melittin-induced LH release may not occur by an
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entirely PLA2-dependent process. Nevertheless, these results do suggest that PKC
modulates PLA2 activity in a protein synthesis-dependent manner. In smooth muscle
and epithelial cells, PKC can regulate the rapid synthesis of an endogenous, melittin-
like protein which activates PLA2 (Clark et al, 1987a, 1991b) This PLA2 activating
protein (PLAP) has been shown to have a role in the leukotriene D4 receptor
signalling system (see Crooke et al, 1989 for review). Preliminary evidence obtained
by Northern blot analysis has indicated that LHRH may modulate PLAP mRNA
levels in pro-oestrous rat anterior pituitary tissue (Lutz and Mitchell, unpublished
observations). Indeed, during LHRH receptor signalling, PKC-induced synthesis of a
PLAP and subsequent PLA2 activation could represent an appropriate protein
synthesis-dependent mechanism by which LHRH priming may occur. Further
investigations are required to examine the involvement of PKC in the control of
PLAP expression by LHRH, perhaps by studying the effects of PKC inhibitors on
LHRH induction of PLAP mRNA by Northern blotting, and on PLAP expression,
using PLAP-selective antibodies.
Of the potential products of PLA2-catalysed phospholipid hydrolysis, AA,
may be a mediator of priming. Both AA and its biologically inactive congener,
arachidic acid, could induce LH release, but only AA could enhance pituitary
responsiveness (Table 4.8). Arachidic acid lacks many of the cellular actions of AA,
for example, AA, but not arachidic acid, can induce Ca2+ release from intracellular
stores (Beaumier et al, 1987) and can induce inositol phospholipid hydrolysis
(Negishi et al, 1990). It is possible, therefore, that AA and arachidic acid may induce
LH release by having a non-specific detergent-like action on the gonadotroph cell
membrane (Karnovsky et al, 1982; Kaye et al, 1992). In dispersed anterior pituitary
cells, LH release in response to AA and LHRH are additive (Chang et al, 1987b),
suggesting that the mechanism by which AA induces LH release is separate from the
mode of action of LHRH. Certainly, AA, at concentrations higher than those used
here, can cause lysis of dispersed anterior pituitary cells (Liu and Jackson, 1989).
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However, 300 (iM AA, as used here, was unable to induce a significant increase in
GH release from rat anterior pituitary pieces when measured over several hours of
incubation, suggesting that a lytic effect of AA is unlikely to account for the actions
of this fatty acid on LH release responses shown here. In addition, AA is readily
metabolised (Needleman et al, 1986) and can be re-incorporated into cellular
phospholipids (Irvine, 1982) and at high concentrations, AA can assume a miceller
form in an aqueous environment (MacEwan et al, 1991), so it is likely that the free
concentration of AA is considerably less than the empirical value. In other cell types,
endogenous AA production can be dissociated from exocytosis (Churcher et al, 1990;
Morgan and Burgoyne, 1990; Cockcroft, 1991) suggesting that AA may not be a
direct mediator of secretion. This is probably also true in gonadotrophs where PLA2
activation and AA production are not required for LH release, but for enhancing
gonadotroph responsiveness. This effect of AA on gonadotroph responsiveness was
not mimicked by arachidic acid, suggesting that the effect of AA was probably not
due to a non-specific action of the fatty acid. However, AA was unable to completely
mimic the degree of priming induced by LHRH and an additional increment in
LHRH-dependent priming occurred following AA incubation, suggesting that AA
may not be the sole mediator of priming. Lyso-phospholipid, the co-product of PLA2
action, can have a number of biological actions and can be further metabolised to 1-
alkyl-2 (R)-acetyl-glycerol-3-phosphorylcholine, (platelet-activating factor (PAF)).
Platelet-activating factor can act on specific membrane bound receptors and, itself,
can induce inositol phospholipid turnover, having either a paracrine effect on other
cells in the anterior pituitary or an autocrine action on the cell from which it was
released (see Shukla, 1991 for review). A possible role of both PAF and
lysophospholipid as mediators of LHRH priming requires further investigation,
perhaps by studying the effect ofmetabolically-stable species of PAF on gonadotroph
responsiveness and of PAF receptor antagonists on LHRH responses. Other
intracellular factors, such as raised Ca2+ levels, may contribute by acting in parallel,
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or synergistically, with AA to achieve a maximal 'primed' secretory response. Indeed,
in cell-free systems, AA can enhance fusion of secretory granules into membranes, in
a Ca2+-dependent manner, modulating exocytosis (Creutz, 1981). An equivalent
action of AA in gonadotrophs may enhance Ca2+-induced LH release.
The LHRH priming affect may not be dependent upon AA metabolism
since neither ETYA nor NDGA had any effect on LHRH responses when either
compound was used at a concentration (10 |iM) which is reported to inhibit
lipoxygenase, cyclo-oxygenase and epoxygenase activity (Hamberg and Samuelson,
1984; Smith and Bowman, 1981; Capdevilla et al, 1988) (Table 4.9). At a higher
concentration (30 |iM), ETYA and NDGA did inhibit priming, but at this
concentration, both drugs also block PLA2 activity (Lanni and Becker, 1985) so no
clear interpretation can be made regarding these results. Indomethacin, did not alter
LHRH-responses except at high, non-specific concentrations (Franson et al, 1980;
Snyder et al, 1983) (Figure 4.10), consistent with previous reports which suggest that
cyclo-oxygenase products do not have a role in LHRH receptor signalling (Naor et al,
1975a; Sundberg et al, 1975; Naor and Catt, 1981; Catt etal, 1985). Therefore, we
could find no evidence to suggest that AA metabolites have a role in LHRH responses
in pro-oestrous rat anterior pituitary tissue. However, both ETYA and NDGA can
inhibit LHRH-induced LH release from primary cultures of anterior pituitary cells
(Naor et al, 1983; Catt et al, 1985) suggesting a role for lipoxygenase metabolites in
this system. In some studies, however, high, possibly non-specific concentrations of
these inhibitors were used (Chang et al, 1986a, 1987b), so no clear conclusions can be
made regarding these observations. Studies into the actions of several different
lipoxygenase metabolites on LH release have produced conflicting results (section
1.4.4) and as a consequence, a distinct conclusion as to the role of specific
leukotrienes as mediators in LHRH responses cannot be made. Nevertheless,
selective leukotriene receptor antagonists can partially inhibit LHRH-induced LH
release from primary cultures (Catt et al, 1985; Kiesel et al, 1991; Bito et al, 1992).
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It is possible that these discrepancies may be accounted for by differences in the
model of pituitary function chosen in each study (see Conn et al, 1992 for review)
and that lipoxygenase products have a different function in LHRH receptor-signalling
in pro-oestrous rat pituitary pieces than in dispersed pituitary cells that have been
maintained in culture for several days. A role for leukotrienes as hypothalamic
transmitters which are co-released with LHRH has been suggested (Lindgren et al,
1984). However, the physiological relevance of this possible hormonal action of
leukotrienes has yet to be determined.
Epoxygenase metabolites, including 5, 6-epoxyeicosatrienoic acid, have
been shown to induce LH release from primary cultures of anterior pituitary cells.
However, these effects on LH release only occur at concentrations that are unlikely to
be physiologically relevant (> 1 p,M) (Snyder et al, 1983), and may reflect the ability
of epoxygenase metabolites to act as Ca2+ ionophores (Snyder et al, 1986). Further
studies using new, highly selective inhibitors of epoxygenase and lipoxygenase
enzymes will help to clarify the role of these pathways of AA metabolism in LHRH
responses in pro-oestrous rat anterior pituitary tissue.
Luteinizing hormone-releasing hormone induced release of [3H]-AA from
the male mouse gonadotroph a T3-1 cell line (Table 4.10), consistent with a role for
PLA2 in LHRH receptor signalling in these cells. However, in contrast to the results
observed using pro-oestrous hemipituitaries, PDBu did not induce any significant
release of [3H]-AA from a T3-1 cells and PKC inhibitors were unable to block
LHRH-induced LH release (Table 4.10). These results are most interesting since they
suggest that LHRH receptors in a T3-1 cells may be coupled to different intracellular
mechanisms than those which are linked to LHRH receptors in pro-oestrous rat
gonadotrophs. Stimulation of a T3-1 cells with LHRH causes a number of
intracellular changes that also occur in rat primary cell cultures and anterior pituitary
pieces, including the production of inositol phosphates, PKC translocation,
enhancement of voltage-sensitive Ca2+-channel activity, an increase in gonadotrophs
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a-subunit mRNA levels and PLD stimulation (Horn et al, 1991; Netiv et al, 1991).
However, these cells do not express the (3-gonadotrophin subunit (Windle et al, 1990)
indicating that some functions of these cells are abnormal. The different responses of
a T3-1 cells in comparison to pro-oestrous rat hemipituitaries may, in part, be due to
the abnormal functioning of these cells, species differences and/or the differences in
steroid influences. Certainly, dispersed anterior pituitary cells from pro-oestrous rats
do not release [3H]-AA in response to PDBu unless they have been treated with
oestrogen (see Chapter 5), suggesting that steroids are required to maintain the
pathway by which PKC activation leads to modulation of PLA2 activity.
Nevertheless, in contrast to its actions on pro-oestrous rat hemipituitaries, LHRH does
not appear to modulate [3H]-AA release from a T3-1 cells in a PKC-dependent
manner. One possibility is that, in a T3-1 cells, LHRH activates PLA2 by a
mechanism which is independent of PLC-mediated inositol phospholipid turnover and
PKC activation, perhaps by direct G-protein coupling of the LHRH receptor to PLA2.
Experiments examining the effect of the PLC inhibitor, neomycin, on LHRH-induced
[3H]-AA release from a T3-1 cells will help clarify the possible involvement of a
PLC-independent pathway of [3H]-AA release in these cells. Alternatively, LHRH
may induce [3H]-AA release from a T3-1 cells by a PLA2-independent mechanism,
but by a pathway involving DAG lipase/MAG lipase action. Studies into the effect of
RHC 80267 on LHRH-induced [3H]-AA from a T3-1 cells will, therefore, be of
interest. Clearly, further investigations are required to clarify the intracellular
mechanisms involved in LHRH-induced [3H]-AA release from a T3-1 cells.
Neither cycloheximide (Figure 4.9) nor quinacrine (Figure 4.5) inhibited
PDBu-induced GH release indicating that neither protein synthesis nor PLA2
activation is required for the mechanism of PKC activation-induced GH release.
Instead, PDBu-induced GH release is suggested to occur by a route which is
dependent upon 'L'-type voltage-sensitive Ca2+ channel activation (Johnson et al,
1991). Thus, the PKCs that induce LH and GH release have distinct cellular targets
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which may, in part, account for the difference in the time course of PDBu release for
each of these hormones.
In conclusion, these experiments show that the induction of LHRH
priming requires PLA2 activation. The form of PLA2 which is controlled by the
LHRH receptor may be related to the cytosolic PLA2S which associate with the cell
membrane, in response to a stimulus, in a Ca2+-dependent manner (Gronich et al,
1988, 1990; Channon and Leslie, 1990; Clark et al, 1991a; Leslie, 1991). However,
changes in Ca2+ levels alone are not sufficient for full activation of the gonadotroph
PLA2 since ionomycin-induced LH release was unaltered by PLA2 inhibitors (Table
4.2). In addition, the action of an H7-resistant PKC-like kinase also appears to be
involved in LHRH modulation of PLA2 activity. Arachidonic acid may induce
priming by a mechanism which is independent on the metabolism of the fatty acid.
The exact mechanism by which AA enhances gonadotroph responsiveness is unclear,
however AA can enhance inositol phospholipid breakdown (Irvine et al, 1979), which
may account for the facilitated stimulus-secretion coupling which is associated with
LHRH priming (Mitchell et al, 1988), and can induce Ca2+ release from non-
mitochondrial stores (Wolf et al, 1986; Beaumier et al, 1987) which may potentially
enhance Ca2+-dependent processes such as gonadotrophin release. Arachidonic acid
can synergise with DAG to activate certain PKC isoforms (Shearman et al, 1991;
Shinomura etal, 1991; Chen and Murakami, 1992), possibly causing long-term
activation of the 'priming' kinase. However, a sustained action of AA is unlikely to
occur during the expression of LHRH priming since PKC inhibitors had no effect on
responses to LHRH in pre-primed tissue (Chapter 3). The relevance of these actions




The effect of quinacrine on LHRH-induced LH (a) and FSH (b) release from
pro-oestrous rat anterior pituitary tissue
Tissue was incubated for 3 consecutive hours. In the basal h, tissue was
incubated in either medium only (open bars) or with quinacrine (50 |lM) (hatched
bars) then, in addition, with LHRH (1 nM) during the following 1st and 2nd h
incubations. Quinacrine had no significant effect on either basal or 1st h
gonadotrophin release, but significandy inhibited 2nd h, LHRH-primed LH and FSH
release (*p < 0.05). Data are means ± SEM for 4 - 6 determinations.
Figure 4.1
□ LHRH







Concentration-response curves for the effect of (a) quinacrine and (b) p-
bromophenacyl bromide on initial LHRH-induced LH release and LHRH
priming in pro-oestrous rat anterior pituitary tissue
Tissue was incubated for an initial, basal h (•) in medium only or with
increasing concentrations of either quinacrine (10 - 100 (J.M) or p-bromophenacyl
bromide (BrPheBr) (10 - 100 |iM) followed by 2 further consecutive hourly
incubations (1st h (■) and 2nd h (A)) with, in addition, LHRH (1 nM). Both
quinacrine and BrPheBr dose-dependently inhibited 2nd h primed release of LH
induced by LHRH, without having any significant inhibitory effect on 1 st h LHRH-
induced LH release (*p < 0.05). Basal h LH release, however, was significantly
increased in the presence of BrPheBr at concentrations of 50 - 100 pM. Data are





















The effect of quinacrine on the development of LHRH priming in pro-oestrous
rat anterior pituitary tissue
Hemipituitary pieces were incubated for consecutive hours (basal h, 1st h,
2nd h, 3rd h). In part a, tissue was incubated for a basal h with either quinacrine
(hatched bars), or with no drug (open bars), followed by a 1st h with, in addition,
LHRH (1 nM). The tissue was then washed in MEM and all treatments were
incubated with LHRH only during the final 2nd h. Second h LHRH-induced LH
release was significantly inhibited (*p < 0.05) in the quinacrine treated tissue. In part
b, tissue was incubated for a basal h in medium only followed by a 1st h with 1 nM
LHRH (open bars), during which LHRH priming takes place. Throughout the 2nd
and 3rd h, tissue was then incubated with LHRH only (open bars) or with LHRH and
quinacrine (50 (iM) (hatched bars). Quinacrine had no significant inhibitory effect on























The effect of (a) arachidonic acid and (b) arachidic acid on LH release from pro-
oestrous rat anterior pituitary pieces
Hemipituitary pieces were incubated for a basal h in medium only
followed by 3 consecutive hourly incubations either in medium only (baseline) or
with (a) arachidonic acid ( 300 |iM) or (b) arachidic acid (300 p.M). Luteinizing
hormone release was significantly increased above baseline during the 2nd and 3rd h
of both arachidonic acid and arachidic acid incubation (*p < 0.05). Values are means






































The effect of quinacrine on phorbol 12,13-dibutyrate (PDBu)-induced LH and
GH release from pro-oestrous rat hemipituitaries
Hemipituitaries were incubated for a basal h in either medium only or with
various concentrations of quinacrine (2-100 |iM). Over the following consecutive
hourly incubations, the medium contained, in addition, PDBu (300 nM). The data
represents LH release measured during the 3rd h of PDBu incubation and GH
measured throughout the 1st h of phorbol incubation. Quinacrine dose-dependently
inhibited PDBu-induced LH but not GH release (*p < 0.05). Each point on the graph
represents the mean ± SEM for 4 - 8 determinations.
LH release (fold of basal h)
GH release (fold of basal h)
Figure 4.6
Concentration response curve for the effect of phorbol 12,13-dibutyrate (PDBu)
on [3H]-arachidonic acid ([3H]-AA) release from pre-labelled pro-oestrous rat
anterior pituitary tissue
Pairs of pro-oestrous rat anterior pituitary quarters were pre-labelled with
[3H]-AA and extensively washed. Tissue was then incubated in medium containing
either no drug or various concentrations of PDBu (30 - 1000 nM) for 15 min. Medium
[3H]-AA levels were determined. The statistical significance of the effect of PDBu











































Concentration-response curves of the effect of (a) staurosporine, (b) Ro 31-8220
and (c) H7 on phorbol 12,13-dibutyrate (PDBu)-induced [3H]-arachidonic acid
([3H]-AA) release from pro-oestrous rat anterior pituitary tissue
Pairs of pre-labelled anterior pituitary quarters were pre-incubated for 15
minutes with medium only or the appropriate concentration of PKC inhibitor
(staurosporine (30 - 1000 nM), Ro 31-8220 (3 -30 pM), H7 (3 - 100 pM)). The
medium was discarded and replaced with fresh medium containing either no drug
(basal) or PDBu (300 nM) only or PDBu and various concentrations of the
appropriate inhibitor. After 15 minutes, [3H]-AA release was determined. Both
staurosporine and Ro 31-8220 fully reversed the effect of PDBu. However, PDBu-
induced [3H]-AA release apparently displayed 2 components of inhibition by H7. A
highly sensitive component of [3H]-AA release was inhibited by H7 at concentrations
of < 3 pM, but H7 concentrations from 3 - 30 pM caused little further inhibition and
concentrations as high as 100 pM were unable to fully reverse the effects of PDBu.
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The effect of cycloheximide on phorbol 12,13-dibutyrate (PDBu)-induced (a) LH
and (b) GH release from pro-oestrous rat anterior pituitary tissue
Hemipituitaries were incubated for a basal h in either medium only (open
bars) or with cycloheximide (50 |iM) (hatched bars). Over a further 3 consecutive
hourly incubations, the medium contained, in addition, PDBu (300 nM).
Cycloheximide (CHX) inhibited 2nd and 3rd h PDBu-induced LH but not GH release
(*p < 0.05). Each point on the graph represents the mean ± SEM for 6
determinations. The SEM values for LH release measured in the CHX-treated
samples were within the range of 0.2 - 0.4 ng/ml and were too small to be














The effect of cycloheximide on melittin-induced LH release from pro-oestrous
rat hemipituitaries
Hemipituitaries were incubated for a basal h in medium containing either
with no drug (open bars) or cycloheximide (CHX, 50 pM) (hatched bars). In the
following consecutive hourly incubations, the medium contained, in addition, melittin
(3 pM). Melittin-induced LH release was clearly unaffected by the presence of




















Concentration response curve for the effect of indomethacin on LHRH-induced
LH release from pro-oestrous rat hemipituitaries
Hemipituitary pieces were incubated for an initial, basal h (•) in medium
only or with increasing concentrations of indomethacin (0.6 - 300 |lM) followed by 2
further consecutive hourly incubations (1st h (■) and 2nd h (A)) with, in addition,
LHRH (1 nM). Indomethacin had no inhibitory effect on either basal h or 1st h
LHRH-induced LH release over the concentration range used. Second h LHRH-
induced LH release was not affected by indomethacin, except at the highest



























The effect of PLA2 inhibitors on initial LHRH-induced LH release and LHRH
priming in pro-oestrous rat anterior pituitary tissue
Hemipituitaries were incubated in vitro for 3 h. In the basal h there was
medium alone or a PLA2 inhibitor (ONO-RS-082 (10 pM), Ro 31-4493 (100 |iM), Ro
32-4639 (100 pM), 7, 7-dimethyleicosadienoic acid (DEDA, 30 pM) or aristolochic
acid (50 pM)). In the 1st and 2nd h there was, in addition, LHRH (1 nM). The
statistical significance of the inhibitory actions of the PLA2 inhibitors tested was
determined (*p < 0.05). Values given are the mean ± S.E.M. with the number of
determinations in parentheses.
LH release (pg/1)
basal h 1st h 2nd h




















10.6 ± 1.9 (4) 25.6 ± 1.8 (4) 96.2 ± 11.6(4)
Table 4.2
The effect of quinacrine on ionomycin-induced LH release from primed or
unprimed pro-oestrous rat anterior pituitary tissue
Hemipituitary pieces were incubated for consecutive hours, initially in the
presence of medium only or with quinacrine (50 |i.M) (basal h). In addition, the 1st h
incubation had ionomycin (30 (iM, Ii) or LHRH (1 nM, Lj), followed by a 2nd h
incubation with ionomycin (I2). Quinacrine had no significant inhibitory effect on
ionomycin-induced LH release during any hour of incubation. However, ionomycin-
induced LH release from tissue which had been pre-primed by a 1st h incubation with
LHRH was significantly inhibited (*p < 0.05). All values are means ± SEM and the
number of determinations are shown in parentheses.
basal h
LH release (|ig/l)
1st h 2nd h
I1-I2 4.5 ± 1.0 (5) 26.7 ± 2.0 (5) 26.8 ± 2.8 (5)
I1-I2










75.1 ± 1.0 (5)
*30.8 ± 1.4 (4)
Table 4.3
The effect of PKC inhibitors on arachidonic acid (AA)-induced LH release from
pro-oestrous rat anterior pituitary tissue
Hemipituitaries were incubated in vitro for consecutive hours. In the basal
h, tissue was incubated in medium only, or with staurosporine (300 nM) or H7 (30
|lM)). In the following hours (1st h, 2nd h, 3rd h), the incubation medium contained,
in addition, AA (300 |iM). The data shown here represent LH release measured
during the 3rd h of incubation with AA, during which, LH release was increased
significantly with respect to baseline (*p < 0.05, Student's t-test). Neither H7 nor
staurosporine had any significant inhibitory effects on AA-induced LH release
(Student's t-test). Values shown are for means ± SEM and the number of
determinations are shown in parentheses.
LH release (|ig/l)
baseline 3.4 ± 0.4 (4)
AA *6.3 ± 1.3 (4)
AA + staurosporine 5.8 ± 0.6 (6)
AA + H7 5.1 ±0.7 (6)
Table 4.4
The effect of PLA2 inhibitors on phorbol 12,13-dibutyrate (PDBu)-induced LH
and GH release from pro-oestrous rat anterior pituitary tissue
Hemipituitaries were incubated for a basal h either in with no drug or with
a PLA2 inhibitor (p-bromophenacyl bromide (BrPheBr, 50 (iM)) or aristolochic acid
(100 |lM). In the following hours (1st h, 2nd h, 3rd h), the incubation medium
contained, in addition, PDBu (300 nM) or no drug (baseline). The data shown here
represent LH release measured during the 3rd h of incubation and GH release
measured during the 1st h of incubation with PDBu. In the presence of PDBu alone,
both LH and GH release were increased to levels that were significantly greater than
baseline (tp < 0.05). The statistical significance of the effects of PLA2 inhibitors on
PDBu-induced hormone release is shown by * (p < 0.05). Values shown are the
means ± SEM and the number of determinations are shown in parentheses.
LH release (p.g/1) GH release Qig/1)
baseline 4.9 ± 0.9 (4) 259 ± 14 (4)
PDBu t32.3 ± 2.7 (6) tl964± 109(6)
PDBu + BrPheBr *15.8 ±2.1 (4) 2072 ± 369 (4)
PDBu + aristolochic acid *14.2 ± 1.5 (4) 2239 ± 208 (4)
Table 4.5
The effect of quinacrine and RHC 80267 on LHRH-induced [3H]-arachidonic
acid ([3H]-AA) release from pre-labelled pro-oestrous rat anterior pituitary
pieces
Pairs of pre-labelled anterior pituitary quarters were pre-incubated for 15
minutes in medium only, or with quinacrine (50 (iM) or RHC 80267 (80 p.M). The
medium was discarded and replaced with fresh medium containing either no drug
(basal) or LHRH (1 nM) only or LHRH together with either quinacrine or RHC
80267. After a second 15 min incubation, the medium was removed and the [3H]-AA
was extracted. [3H]-Arachidonic acid release was increased in the presence of LHRH
to levels that were significantly greater than baseline (tp < 0.01). The statistical
significance of the inhibitory effects of quinacrine and RHC 80267 on LHRH-induced
[3H]-AA release was determined (*p < 0.05). Values shown are the means ± SEM
and the number of determinations are shown in parentheses.
[3H]-AA release
(% of total label incorporated)
baseline 0.85 ± 0.06 (8)
LHRH t2.17 ±0.16(8)
LHRH
+ *0.92 ± 0.07 (6)
quinacrine
LHRH
+ 2.14 ±0.31 (6)
RHC 80267
Table 4.6
The effect of PKC inhibitors on LHRH-induced [3H]-arachidonic acid ([3H]-AA)
release from pre-labelled pro-oestrous rat anterior pituitary pieces
Pairs of [3H]-AA labelled anterior pituitary quarters were pre-incubated
for 15 minutes with either no drug, or H7 (30 jiM) or staurosporine (300 nM). The
medium was replaced and fresh medium contained either no drug (basal), LHRH (1
nM), LHRH and H7, or LHRH and staurosporine. [3H]-Arachidonic acid release was
increased in the presence of LHRH to levels that were significantly greater than
baseline (tp < 0.05). Staurosporine, but not H7, significantly inhibited LHRH-
induced [3H]-AA release (*p < 0.05). Values shown are the means ± SEM and the
number of determinations are shown in parentheses.
[3H]-AA release
(% of total label incorporated)
baseline 1.03 ±0.09 (10)
LHRH t2.33 ± 0.30 (10)
LHRH
+ *0.95 + 0.04(10)
staurosporine
LHRH
+ 1.79 ±0.07 (8)
H7
Table 4.7
The effect of cycloheximide on LHRH- and phorbol 12,13-dibutyrate (PDBu)-
induced [3H]-arachidonic acid ([3H]-AA) release from pro-oestrous rat anterior
pituitary pieces
Pairs of pituitary quarters, pre-labelled with [3H]-AA, were pre-incubated
for 15 min in medium containing either no drug or cycloheximide (50 JiM). The
medium was discarded and replacement medium contained, in addition, either no
drug (baseline) or LHRH (1 nM) or PDBu (300 nM). After a 15 minute incubation,
the medium was removed and [3H]-AA release was determined. [3H]-Arachidonic
acid release was increased in the presence of either LHRH or PDBu alone to levels
that were significantly greater than baseline (tp < 0.05, ttp < 0.01). Both LHRH- and
PDBu-induced [3H]-AA release were significantly inhibited by cycloheximide (*p <
0.05). Values are means ± SEM for the number of determinations shown in the
parentheses.
[3H]-AA release
(% of total label incorporated)
baseline 1.04 ±0.07 (10)
LHRH tt2.46 ± 0.07 (5)
LHRH + cycloheximide *1.04 ±0.09 (6)
PDBu 11.65 ± 0.10 (8)
PDBu + cycloheximide *1.16 ±0.09 (8)
Table 4.8
The effect of arachidonic acid and arachidic acid pre-treatment on secretory
responses to LHRH measured in pro-oestrous rat anterior pituitary tissue
Hemipituitaries were pre-incubated for a basal h with either arachidonic
acid (300 pM), arachidic acid (300 pM) or with no drug (no drug pre-incubation).
Following the basal h incubation, all treatments were incubated over 2 consecutive
hours (Li, L2) with LHRH only (1 nM). Control treatments were pre-incubated with
either arachidonic acid or arachidic acid or no drug followed by 2 consecutive hourly
incubations in medium only. Luteinizing hormone release during the control
incubations was subtracted from corresponding release measured during LHRH
treatment. Pre-treatment with arachidonic acid, but not arachidic acid, significantly
enhanced net LHRH-induced LH release measured during both 1 st and 2nd h
incubation periods (p < 0.05). Values shown are means ± SEM and the number of
determinations are shown in parentheses.





18.9 ±2.7 (4) 60.6 ±8.3 (4)
*48.5 ±6.3 (6) *115.0 ±11.3 (6)
23.9 ±4.2 (4) 60.1 ±9.1 (4)
Table 4.9
The effect of inhibitors of arachidonic acid (AA) metabolism on secretory
responses to LHRH measured in pro-oestrous rat anterior pituitary
Hemipituitaries were incubated in vitro for consecutive hours. In the basal
h, tissue was incubated in medium only, or in the presence ofETYA (10 pM or 30
p.M), or NDGA (10 fiM or 30 pM). In the following hours (1st h, 2nd h), the
incubation medium contained, in addition, LHRH (1 nM). The statistical significance
of the effects of each inhibitor was determined (*p < 0.05). Values shown are for
means ± SEM and the number of determinations are shown in parentheses.
LH release (p.g/1)
basal h 1st h 2nd h
















3.7 ± 0.4 (4) *6.3 ± 1.2 (4) *6.32 ±3.16 (4)
Table 4.10
The effect of LHRH and phorbol 12,13-dibutyrate (PDBu) on [3H]-arachidonic
acid (AA) release from a T3-1 cells
a T3-1 cells which had been pre-labelled with [3H]-AA and extensively
washed,were pre-incubated for 15 minutes with either no drug, staurosporine (300
nM), or H7 (30 (iM). The medium was replaced and the cells were incubated for a
further 15 minutes with, in addition either no drug (basal), LHRH (100 nM) or PDBu
(300 nM) and medium [3H]-AA levels were determined. [3H]-Arachidonic acid
release was significantly increased in the presence of LHRH, but not PDBu when
compared to baseline (*p < 0.05). Neither staurosporine nor H7 had any significant
inhibitory effect on LHRH-induced [3H]-AA release. Data are shown as means ±
SEM and the number of determinations are shown in parentheses.
[3H]-AA release
(% label incorporated)
baseline 0.80 ±0.15 (8)
LHRH *5.12 ±0.35 (6)
LHRH + staurosporine 5.76 ±0.13 (6)
LHRH + H7 4.06 ± 0.35 (6)
PDBu 0.73 ± 0.22 (8)
CHAPTER 5
TheEffect ofGonadal Steroids on Protein
Kinase C and Phospholipase A2 Mediated
Responses inRat Anterior PituitaryCells
5.1 INTRODUCTION
The responsiveness of gonadotrophs to secretagogues, such as LHRH
(Arimura and Schally, 1974; Aiyer and Fink, 1974; Drouin et al, 1976; Kamel et al,
1987a; Turgeon and Waring, 1981), depolarising concentrations of potassium (Liu
and Jackson, 1988) and activators of PKC (Fahmy et al, 1989; Liu and Jackson, 1988;
Audy et al, 1990; Drouva et al, 1990) can be markedly altered by the prior presence of
gonadal steroids, suggesting that steroids modulate several aspects of stimulus-
secretion coupling in these cells. Since the magnitude of priming is altered during the
oestrous cycle (Waring and Turgeon, 1980), it seems that gonadal steroids may have a
modulatory influence upon the mechanism of priming. The experiments that are
described in Chapters 3 and 4 suggest that the induction of LHRH priming is
dependent upon the actions of an H7-resistant PKC-like kinase which modulates the
activity of PLA2. We therefore investigated the possibility that steroid modulation of
pituitary responsiveness may involve an effect on the pharmacologically distinct
forms of PKC that are involved in mediating LH release and inducing LHRH priming
and, as a consequence, on LHRH activation of PLA2.
5.2 SpecificMethodology
5.2.1 Hormone Secretion Experiments
Female COB Wistar rats were anaesthetised and decapitated by 11.30 am
on the appropriate day of the oestrous cycle. Long-term ovariectomised rats were
anaesthetised and decapitated by 11.30 am on the 5th day after implantation with
silicone elastomer capsules containing either no steroid or oestrogen (E2). Anterior
pituitary glands were removed, hemisected and hormone release was measured as
described in Chapter 2 (section 2.2.3). Hormone release was determined as described
in Chapter 2. The medium that was collected at the end of each hourly incubation and
was stored at -20°C until it was radioimmunoassayed for LH and GH (Niswender et
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al, 1968; Daane and Parlow, 1971). The standards used were NIADDK-rat LH-RP2
and NIADDK-rat-GH-RP-2.
5.2.2 Cytosolic protein kinase C activity assay
Anterior pituitary PKC activity was determined as the phosphatidylserine-
dependent, histone HIS kinase activity induced by PKC activators using methods
described in Chapter 2, section 2.2.4. Protein kinase C activity was measured either
in the absence of activator (i.e. basal activity) or in the presence of 1 (iM PDBu or
100 |iM DOG. Kinase activity measured in the presence of phosphatidylserine, 5 mM
EGTA (i.e. low free Ca2+) and in the absence of PKC activator was taken to represent
basal activity and was subtracted from all activator-stimulated levels. Calcium-
independent kinase activity was taken to be the activity measured in the presence of 5
mM EGTA and PKC activator. The additional kinase activity measured with samples
containing CaCl2 + PKC activator was taken to represent calcium-dependent kinase
activity.
5.2.3 Cytosolic [3H]-phorbol 12,13-dibutyrate binding
The number of PKC molecules in E2-treated and -untreated pituitary
cytosol and their affinity for PDBu were assessed using the [3H]-PDBu binding
method described in Chapter 2, section 2.2.6.
5.2.4 [3H]-Arachidonic acid release measurements
Long-term ovariectomised female COB Wistar rats were implanted with
capsules containing either E2 or no steroid (Chapter 2, section 2.2.2). On the 5th day
after implantation, rats were anaesthetised, decapitated and anterior pituitaries were
removed and bisected. Each hemipituitary was cut into 2 equal pieces and tissue was
labelled with [3H]-AA. [3H]-Arachidonic acid release from pre-labelled tissue was
determined using the methods described in Chapter 2, section 2.2.5.
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To examine the effects of steroids on responses measured in primary
cultures of anterior pituitary cells, anterior pituitary glands, removed from female rats
at random stages of the oestrous cycle, were enzymatically dispersed and the cells
cultured for 4 days in steroid-free DMEM, without phenol red (see Appendix 1.1 and
1.2), as described in Chapter 2, section 2.2.2. Cells were then incubated in DMEM
with either no steroid or 1 nM E2 for 48 h. [3H]-Arachidonic acid release from pre-
labelled cells was determined as described in Chapter 2, section 2.2.5.
5.2.5 Drugs
Phorbol 12,13-dibutyrate, DOG, ionomycin and staurosporine were made
up as stock solutions in DMF. The maximum concentration of DMF (0.5% v/v) was
used in control experiments and had no effect on either hormone or [3H]-AA release.
Quinacrine, LHRH, H7, leupeptin and E64 were all made up as stock solutions in
distilled H2O.
All PKC assay components and drugs were dissolved in 20 mM Tris HC1
(pH 7.5) + 0.5 mM EGTA except for DOG which was added to each assay tube in 1
p.1 DMF using a Hamilton microsyringe.
5.2.6 Data analysis
The statistical analysis of the time course data of hormone release obtained
from the experiments using tissue from ovariectomised animals, with or without E2
treatment, was carried out by both 2-way and 1-way analysis of variance, followed by
Duncan's New Multiple Range test on significantly different groups. All other
statistical analysis were carried out using the Mann-Whitney U-test or Student's t-test
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5.3 RESULTS
The effect of PDBu and LHRH on hormone release from rat anterior pituitary
tissue removed at different stages of the oestrous cycle
Table 5.1 shows the effect of consecutive hourly incubations of LHRH
(1 nM) on LH release from rat hemipituitaries removed at different stages of the
oestrous cycle. Basal h LH release did not alter significantly with the stage of the
cycle. However, the magnitude of both 1st h and 2nd h LHRH-induced LH release
were oestrous cycle day-dependent. Tissue taken on the morning ofmetoestrus was
the least responsive to a 1st h incubation with LHRH, and tissue responsiveness
gradually increased over dioestrus, reached a maximum on the morning of pro-
oestrus, and decreased by the morning of oestrus. Similarly, 2nd h LHRH-induced
LH release, where LHRH priming is expressed, was smallest in tissue removed at
metoestrus, increased over dioestrus and was maximal by pro-oestrus. Neither basal h
nor 1st h LHRH-induced LH release, measured at any stage of the oestrous cycle, was
inhibited by staurosporine. However, at all stages of the cycle, the 2nd h primed
release of LH was significantly inhibited by staurosporine to 1st h levels of LHRH-
induced LH release. Thus, the LHRH priming response measured at all stages of the
oestrous cycle may be dependent upon activation of a protein kinase, in particular, a
form of PKC.
Since the magnitude of priming is oestrous cycle-dependent, any of the
factors which participate in the induction of the priming response, such as PKC, may
be modulated in a cycle-dependent manner. To examine the possibility that PKC
action in gonadotrophs may alter over the oestrous cycle, the effect of consecutive
hourly incubations with PDBu (300 nM) was examined on LH release, and as a
comparison, GH release from tissue removed from female rats at different stages of
the cycle (Figure 5.1). The magnitude of PDBu-induced LH release was found to
alter with the stage of the oestrous cycle. Tissue removed on the morning of
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metoestrus was least responsive, with 3rd h PDBu-induced LH release increasing
only to around 2-fold of basal h levels. The magnitude of PDBu-induced LH release
increased over dioestrus, and was maximal on pro-oestrus, on which, 3rd h LH release
was 7-fold of basal h levels. Tissue removed on the morning of oestrus was slightly
less responsive to PDBu than tissue removed at pro-oestrus. Interestingly, PDBu-
induced LH release from oestrous tissue displayed a slightly different temporal
pattern from that measured on other days of the cycle. That is, PDBu-induced LH
release from oestrous rat tissue, but not from tissue taken at any other stage of the
cycle, was increased above basal h levels by the 1st h of incubation with PDBu. It is
also interesting to note that the relative responsiveness to PDBu throughout the
oestrous cycle (with respect to LH release) does not linearly parallel the capacity to
prime in response to LHRH. Therefore, although PKC may be an important
component in the induction of LHRH priming, other steroid-regulated factors may
also play a significant role in this response. In contrast to PDBu-induced LH release,
neither the magnitude nor time-course of PDBu-induced GH release altered
significantly with the oestrous cycle. Therefore, factors (such as ovarian steroids)
which control the reproductive cycle of the rat may modulate the transduction
pathways, possibly PKC or subsequent targets, through with phorbol esters can
induce LH, but not GH, release.
The effect of E2 treatment of long-term ovariectomised rats on anterior pituitary
responses to LHRH measured in vitro
The changes in the magnitude of PDBu-induced LH release and LHRH
priming measured over the oestrous cycle correlate with the changes in circulating E2
levels that are measured in the rat, in vivo (Turgeon andWaring, 1981; Evans et al,
1983). That is, during metoestrus, when rat plasma E2 levels are at their lowest,
pituitary LH responses are at their smallest. As the circulating E2 levels increase over
dioestrus and reach a peak on pro-oestrus, pituitary responsiveness to PDBu and
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LHRH increases accordingly. Therefore, it appears that E2 can somehow enhance
stimulus-secretion coupling in gonadotrophs. To test for a possible action of E2 on
LHRH receptor responses, the effects of in vivo E2 treatment of long-term
ovariectomised rats was examined on anterior pituitary responses to LHRH, in vitro
(Table 5.2). Throughout both hours of LHRH incubation, LH release from
ovariectomised rat hemipituitaries was increased above basal h levels. However, the
magnitude of 1st and 2nd h LHRH-induced LH release was not significantly different
indicating that ovariectomised rat tissue may lack the ability to prime. Following E2
treatment, both 1st h and 2nd h LHRH-induced LH release were potentiated in
comparison to release measured from untreated ovariectomised rat tissue.
Furthermore, following E2 treatment, the ability of the tissue to exhibit a form of
priming was apparently restored, with the 2nd h secretory response to LHRH being
approximately 2-fold greater than 1st h LHRH-induced LH release. However, it
should be noted that this priming ratio of 2nd h/lst h release is still somewhat smaller
than the LHRH priming ratio of around 7-fold that was seen on pro-oestrus (Table
5.1).
In the presence of staurosporine (300 nM), neither basal h nor 1st h
LHRH-induced LH release was inhibited, irrespective of the steroid exposure of the
tissue. However, 2nd h LHRH-induced LH release from both E2-treated and
-untreated tissue appeared to be partially inhibited by staurosporine, although, due to
the small sample size of the E2-treated group, the statistical significance of this effect
could not be determined. In contrast, LHRH-induced LH release measured during
any hour was unaffected by H7 (30 fiM) in tissue removed from either E2-treated or
-untreated ovariectomised animals. These preliminary results further suggest that
later secretory responses to LHRH in tissue removed from either E2-treated or
-untreated ovariectomised animals are dependent upon activation of staurosporine-
sensitive but H7-resistant kinase, perhaps the H7-resistant PKC activity that was
detected in pro-oestrous rat anterior pituitary cytosol (Chapter 3). Furthermore, E2
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treatment may facilitate the expression of LHRH priming during the later phase of
hormone release, possibly by modulating the actions of this kinase.
The effect of E2 treatment of long-term ovariectomised rats on anterior pituitary
responses to PKC activators measured in vitro
To test the hypothesis that changes in E2 levels throughout the oestrous
cycle may be a cause of the variation in magnitude of PKC responses in rat
gonadotrophs, long term ovariectomised rats were implanted with capsules containing
either E2 or no steroid for 5 days, and secretory responses to PKC activators were
measured in vitro. The baseline release of both hormones was determined in parallel
control incubations for 4 consecutive hours and the corresponding values were
subtracted form all stimulated values to allow presentation of net stimulus-induced
responses. Consecutive hourly incubations with PDBu (300 nM) significantly
increased net LH and GH release from anterior pituitary tissue taken from both E2-
treated and -untreated ovariectomised rats (Figures 5.2 and 5.3). The magnitude of
PDBu-induced LH release from pituitary tissue removed from E2-treated rats was
very markedly greater than that seen using tissue from untreated ovariectomised
animals (p < 0.05, p < 0.01, Mann-Whitney U-test). For example, in the 3rd h of
PDBu incubation, net LH release from E2-treated and -untreated ovariectomised rats
was 265.7 ±31.6 (J.g/1 (n = 10) and 20.7 ± 3.9 pg/1 (n = 10) respectively (Figure 5.2a).
Furthermore, the time course of PDBu-induced LH release altered with E2 treatment.
In tissue from E2-treated, but not -untreated rats, there was a time-dependent increase
in LH release in response to PDBu (F(3,36) = 37.35, p < 0.0001 and F(3,36) = 1.73, p
= 0.178, respectively). Statistically significant increments in LH release from E2-
treated tissue occurred progressively at each hour ofPDBu incubation (p < 0.05,
Duncan's New Multiple Range test). Thus, LH release from untreated tissue reached
maximal levels by the 1st h of PDBu incubation, whereas LH output from E2-treated
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tissue increased progressively with each successive PDBu incubation (in a manner
similar to that seen with pro-oestrous tissue (see Chapter 3).
The release of GH was increased by PDBu in both E2-treated and
-untreated tissue (F(3,36) = 9.17, p < 0.0001 and F(3,36) = 5.47, p < 0.0034
respectively) with statistically significant increments over basal in the 1st, 2nd and
3rd h of PDBu incubation in each group (Duncan's New Multiple Range test) (Figure
5.3a). However, in contrast to PDBu-induced LH release, the magnitude of PDBu-
induced GH release was not significantly different between any hour of incubation in
other group or between E2-treated and -untreated tissue respectively (Mann-Whitney
U-test). These data are consistent with E2 having a facilitatory action on the
mechanism by which phorbol ester activators of PKC can induce LH but not GH
release.
In a manner similar to PDBu, DOG (200 |iM) also induced a significant
increase in LH release from pituitary tissue from both untreated and E2-treated
animals (Figure 5.2b). Analysis of raw data failed to show a statistically significant
time-dependent increase in overall LH output form either E2-treated or -untreated
tissue in the presence of DOG. However, the corresponding basal LH release in each
hour (assessed in parallel control incubations), showed a time-dependent decrease.
When these basal values were subtracted to yield net DOG-induced LH release, non-
parametric analysis (Mann-Whitney U-test) revealed a significant increment in LH
release at each hour of incubation with DOG (p < 0.05). There were no significant
differences between DOG-induced LH release from E2-treated or -untreated tissue at
any time point. Using pituitary tissue from untreated ovariectomised rats, DOG-
induced LH release was similar in magnitude to PDBu-induced LH release at all
hours of incubation with PKC activator (Figure 5.2). However, DOG was unable to
mimic the facilitatory actions of PDBu on LH release from E2-treated tissue in that
the magnitude of DOG-induced LH release from E2-treated and -untreated tissue was
similar. In contrast to the effects of PDBu, DOG (at concentrations up to 200 |lM)
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was unable to induce GH release from either E2-treated or -untreated tissue (Figure
5.3), similar to pro-oestrous rat tissue (see Chapter 3), suggesting that the PKC(s)
which mediate GH and LH release differ in their susceptibility to activation by DOG.
The effect ofH7 and staurosporine on PKC activator-induced LH and GH
release from anterior pituitary tissue removed from ovariectomised rats treated
with or without E2
In a further set of experiments, the effects of staurosporine and H7 were
examined on PKC activator-induced hormone release from pituitary tissue from E2-
treated and -untreated ovariectomised rats (Table 5.3). The release of LH induced by
PDBu (300 nM) from both E2-treated and -untreated ovariectomised rat pituitary
tissue was significantly inhibited by 300 nM staurosporine (p < 0.05). However, in
contrast to previous results obtained with pro-oestrous pituitary tissue, where 100 nM
PDBu-induced LH release was readily blocked by H7 (IC50 = 1.7 ± 1.5 |iM, n = 5)
(Chapter 3), H7, at concentrations up to 30 |iM, was unable to significantly inhibit
either DOG- or PDBu-induced LH release from anterior pituitary tissue taken from
either E2-treated or -untreated ovariectomised rats (Table 5.3). Phorbol-ester induced
GH release was similarly inhibited by staurosporine, but was insensitive to H7 at
concentrations up to 30 (iM (Table 5.3). Neither staurosporine nor H7 at the
concentrations used had any significant effect on basal LH or GH release.
The effect of E2 treatment on PKC activity and [3H]-PDBu binding site number
in cytosol from ovariectomised rat anterior pituitary tissue
The possibility that E2 treatment may enhance PKC-induced LH release
by altering anterior pituitary PKC activity was investigated. Using histone HIS as a
substrate, PDBu (1 |lM) was able to elicit approximately equal proportions of Ca2+-
dependent and -independent PKC activity in pituitary cytosol from untreated
ovariectomised rats (Table 5.4). With E2 treatment there was an approximate 2-fold
increase in both Ca2+-dependent and -independent, PDBu-induced PKC activity. In
115
both treatment groups, DOG (100 pM) apparently induced relatively less Ca2+-
dependent and -independent cytosolic kinase activity than PDBu (Table 5.4).
However, direct comparisons of the kinase activity elicited by DOG and PDBu cannot
be made unless comprehensive concentration response curves are available for each
of these agents. Similar to the results seen using PDBu, DOG- stimulated Ca2+-
dependent PKC activity approximately doubled with E2 treatment. Whilst there was
also a slight increase in DOG-stimulated, Ca2+-independent PKC activity with E2
treatment, this was not statistically significant.
Studies were carried out to examine the actions ofH7 and staurosporine
on PDBu-stimulated PKC activity in anterior pituitary tissue cytosol (Figure 5.4,
Table 5.5). In anterior pituitary cytosol from untreated ovariectomised animals,
PDBu (1 pM)-stimulated, Ca2+-dependent PKC activity was much more sensitive to
inhibition by H7 than Ca2+-independent activity. In E2-treated tissue, although
PDBu-stimulated activity was greater in magnitude, Ca2+-dependent, PDBu-
stimulated kinase activity was also found to be more sensitive to H7 than Ca2+-
independent activity. In contrast, the potency of staurosporine at inhibiting both
Ca2+-dependent and -independent PKC activity did not differ significantly and was
unaltered by E2 treatment (Table 5.5). Since PDBu-induced LH and GH release from
E2-treated and -untreated tissue are relatively insensitive to inhibition by H7 at
concentrations of 30 JJ.M (Table 5.3), the results from the PKC activity assays suggest
that those PKC(s) which induce both LH and GH release may not be dependent upon
raised intracellular Ca2+ for their effective activation by phorbol esters.
Binding studies showed that the number of specific [3H]-PDBu binding
sites in anterior pituitary cytosol significantly increased by approximately 2-fold upon
E2 treatment without any significant change in site affinity for PDBu (Table 5.6). It
seems likely therefore, that the increase in PDBu-stimulated PKC activity observed
after E2 treatment may occur as a result of an increase in pituitary PKC content, and
not as a result of a change in the affinity of existing PKC(s) for PDBu.
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The effect of E2 treatment on ionomycin-induced LH and GH release from
ovariectomised rat anterior pituitary tissue in vitro
It is possible that the facilitatory actions of E2 treatment on PKC-induced
LH release may involve steroid-mediated enhancement of other steps in the process
by which PKC can induce LH secretion, in addition to altering cytosolic PKC activity
and content. To examine the possibility that E2 treatment can enhance LH release by
increasing the amount of gonadotrophin available for release, we measured hormone
release in response to maximally raised intracellular Ca2+ levels using ionomycin, a
procedure which may be taken as an indirect measure of releasable pituitary hormone
content. Over 3 consecutive hourly incubations, ionomycin (30 (iM) significantly
increased LH and GH release from anterior pituitary tissue from both E2-treated and
-untreated ovariectomised animals (Figure 5.5). However, in contrast to the effect of
PDBu on LH release, ionomycin-induced LH release from either E2-treated or
-untreated tissue was not significantly different at any hour of incubation (Figure
5.5a). This result suggests that E2 does not enhance PKC-induced LH release by
increasing the size of the releasable LH pool. Ionomycin-induced GH release was
also found to be unaltered with E2 treatment (Figure 5.5b), suggesting that E2 does
not alter the readily-releasable pool of GH.
The effect of quinacrine on PDBu-induced LH and GH release from anterior
pituitary tissue removed at different stages of the oestrus cycle
The experiments described in Chapter 4 suggest that PKC-dependent
modulation of PLA2 activity is an integral component in the induction of LHRH
priming. To test for possible oestrous cycle-dependent changes in PLA2 involvement
in PKC-elicited LH responses, the effect of quinacrine was examined on PDBu-
induced LH release, and as a comparison, GH release (Figures 5.6 and 5.7). On
metoestrus, when tissue LH responses to PDBu are at their minimum, quinacrine had
no significant inhibitory effect on PDBu-induced LH release during any hour of
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phorbol incubation (Figure 5.6). Similarly, PDBu-induced LH release from tissue
removed at dioestrus was not significantly altered by the presence of quinacrine at
any hour of incubation, although the 3rd h of LH release was slightly reduced by the
presence of this inhibitor. On pro-oestrus, where hemipituitary LH responses are at
their greatest, 3rd h PDBu-induced LH release was significantly reduced in the
presence of quinacrine (p < 0.05). Second h PDBu-induced LH release from pro-
oestrous tissue was also reduced by quinacrine, although not to significant levels.
Quinacrine also significantly inhibited 3rd h PDBu-induced LH release from
hemipituitaries which had been removed on oestrus. It is of interest that the
inhibitory actions of quinacrine on LH release were detected on the more responsive
days of the oestrous cycle (i.e. pro-oestrus and oestrus) and that quinacrine reduced
LH release on these days to PDBu-stimulated levels measured on the least responsive
days (metoestrus and dioestrus), but never to baseline levels. Therefore, enhanced
LH responsiveness to PDBu measured over the oestrous cycle may, in part, result
from cycle-dependent changes in the involvement of PLA2 in the mechanism of PKC-
induced LH release.
In contrast to the effects of quinacrine on PDBu-induced LH release,
PDBu-induced GH release, measured at any hour of incubation, was not significantly
altered by the presence of quinacrine on any day of the oestrous cycle. These results
further support previous observations made in Chapter 3 which indicate that the
kinase(s) that induce GH release do not produce the release of this hormone by a
mechanism involving PLA2 activation.
The effect of E2 treatment on the involvement of PLA2 in responses measured in
ovariectomised rat anterior pituitary tissue and in 5 day cultures of dispersed
anterior pituitary cells from random cycling female rats
Since the involvement of PLA2 in PDBu-induced LH release was oestrous
cycle day-dependent, it is possible that gonadal steroids, and E2 in particular, can
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modulate the ability of PKC activators to elicit PLA2 activity. To test this hypothesis,
we examined the effect of quinacrine on PDBu-induced LH and GH release from
hemipituitaries removed from long-term ovariectomised rats which had received
treatment with either E2 or no steroid (Table 5.7). Using untreated ovariectomised rat
tissue, 3rd h PDBu (300 nM)-induced LH release was not inhibited in the presence of
quinacrine (50 pM). The secretory responsiveness of gonadotrophs to PDBu was
much greater in tissue removed from rats which had received prior treatment with E2,
and was significantly inhibited by quinacrine (p < 0.05). These results indicate that
E2 can modulate the mechanism by which phorbol esters induce LH release, possibly
by having an effect on the extent of PLA2 involvement in this response. Consistent
with this hypothesis, [3H]-AA pre-labelled hemipituitaries from untreated
ovariectomised rats did not release significant levels of [3H]-AA in response to 15
minutes exposure to PDBu (Table 5.8). However, PDBu could induce a significant
increase in [3H]-AA release from pre-labelled anterior pituitary tissue that had been
removed from E2-treated ovariectomised animals. The magnitude of 1st h PDBu-
induced GH release was not altered by prior E2 treatment of the animal, nor was it
blocked by quinacrine.
Oestrogen may, in principle, modulate the involvement of PLA2 in PDBu-
mediated LH responses by having a number of actions. For example, E2 may
modulate the activity of PLA2 itself and/or the PKC(s) which control PLA2 activity
and/or alter the protein synthesis-dependent mechanism by which PKC modulates
PLA2 activity. To gain an insight into which of these possible effects may contribute
to the actions of E2 on PLA2 involvement, a preliminary study was carried out. In the
presence of ionomycin (30 |iM), [3H]-AA release from pre-labelled dispersed anterior
pituitary cell cultures was increased by approximately 40 - 50% above basal levels in
both 48 h E2-treated and -untreated cells (Table 5.9). However, in the presence of
PDBu (300 nM), [3H]-AA release from steroid-untreated cells was not different from
baseline levels of release. In contrast, in E2-treated cultures, PDBu induced an almost
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2-fold increase in [3H]-AA release. These results suggest that E2 does not directly
modulate PLA2 activity, since ionomycin-induced activity was not significantly
changed by steroid treatment, but that E2 may modulate the mechanism by which
phorbol esters act to bring about PLA2 activation.
5.4 Discussion
The results presented in this Chapter suggest that E2 may modulate LHRH
priming by altering PKC isoform expression and action in gonadotrophs. The
magnitudes of the priming response to LHRH and the secretory response to PDBu,
measured in vitro, were seen to alter with the stage of the oestrous cycle (Table 5.1,
Figure 5.1), consistent with previous results (Aiyer et al, 1974a, 1974b; Castro-
Vazquez and McCann, 1975; Waring and Turgeon, 1980). This variation in anterior
pituitary responsiveness to LHRH and PDBu correlated with changes in circulating
levels of E2 that are measured in vivo. Ovariectomised rat hemipituitaries did not
exhibit the biphasic LH release response to LHRH which is characteristic of priming
unless the animals had received prior treatment with E2 (Table 5.2). These
observations support a number of reports (Aiyer and Fink, 1974; Greeley et al, 1975;
Fink and Henderson, 1977; Speight and Fink, 1981; Cover and Buckingham, 1989),
and suggest that E2 may confer on the gonadotroph at least one component of the
capacity to prime.
Interestingly, both baseline and LHRH-induced LH release from E2-
treated ovariectomised rat tissue (Table 5.2) was several-fold greater than equivalent
responses measured using tissue from intact female rats at any stage of the oestrous
cycle (Table 5.1). There is evidence that the rat gonadotroph is maintained in a low
state of responsiveness to LHRH by non-steroidal factors which are released from the
ovary (Danforth et al, 1987; de Koning et al, 1987; Busbridge et al, 1990; Koppenaal
et al, 1991). The absence of this inhibitory influence is suggested to account for the
high rate of LH release that is observed following ovariectomy (van Dieten et al,
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1989). Ovariectomised rat gonadotroph may, therefore, already exist in a state of
increased responsiveness analogous to a 'primed' state, which may explain why a
biphasic secretory response to LHRH was not observed in ovariectomised rat tissue.
However, the 1st h LH release response to LHRH measured in ovariectomised rat
tissue (Table 5.2) was not different from that observed using pro-oestrous rat tissue
(Table 5.1), suggesting that there is no apparent increase in gonadotroph
responsiveness to LHRH following ovariectomy. In fact, the 2nd h response to
LHRH is reduced following ovariectomy, suggesting that the ovary can have a
positive influence on gonadotroph responsiveness. Although these non-steroidal
factors may not be essential for conferring the ability to prime on the gonadotroph,
their negative actions may be important for controlling the magnitude of LHRH-
induced gonadotrophin release and LHRH priming in steroid-'primed' animals
(Culler, 1992).
The results presented here suggest that E2 may have a positive influence
on gonadotroph responsiveness to LHRH by having an effect on the activity and
actions of the H7-resistant PKC, or PKC-like kinase, that is involved in the
mechanism of LHRH priming. Preliminary evidence indicated that the enhanced 2nd
h 'primed' response to LHRH measured in hemipituitaries from E2-treated
ovariectomised rats was inhibited by staurosporine, but not H7 (Table 5.2), although
the statistical significance of this action could not be determined due to the small
sample size. Nevertheless, these results do suggest that the enhanced 2nd h secretory
response to LHRH, observed in tissue from E2-treated ovariectomised rats, is
dependent upon the actions of an H7-resistant, staurosporine-sensitive kinase.
However, using hemipituitaries from steroid-untreated ovariectomised rats, 2nd h
LHRH-induced LH release was also partially inhibited by staurosporine although a
primed response to LHRH was not apparent (Table 5.2). Protein kinase C inhibitors
can also block later responses to LHRH in dispersed anterior pituitary cells, cultured
in E2-free conditions, although they do not exhibit a secretory response to LHRH
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which is typical of priming (Hirota et al, 1985; Chang et al, 1987b; Stojilkovic et al,
1991). It would seem, therefore, that PKC activation may be required, in part, for
later responses to LHRH in both ovariectomised rat tissue and dispersed anterior
pituitary cells. The involvement of PKC in later secretory responses to LHRH in
ovariectomised rat tissue was not entirely unexpected since PKC activators can
induce LH release from ovariectomised rat tissue by a staurosporine-sensitive (albeit
an H7-resistant) process (Table 5.3). Thus, the H7-resistant PKC involved in LHRH
priming may still have a role in LH release responses in ovariectomised rat tissue, but
this is amplified upon treatment with E2.
Consistent with a facilitatory effect of E2 on gonadotroph PKC action,
following E2 treatment of ovariectomised rats, the magnitude of PDBu-induced LH
release was greatly enhanced (Figure 5.2). Furthermore, the amount of PDBu-
stimulated anterior pituitary cytosolic PKC activity was significantly greater in tissue
from E2-treated, compared to untreated ovariectomised rats (Table 5.4), supporting
previous data (Drouva et al, 1990; Joubert-Bression et al, 1990) and an increase in
pituitary PKC content was revealed by the [3H]-PDBu binding studies (Table 5.6).
These results, when considered together with evidence that the facilitatory action of
E2 on LH responses can be prevented by protein synthesis inhibitors (Debeljuk et al,
1978; Fahmy et al, 1989), suggest that E2 enhances LH responses by inducing
synthesis of additional PKC(s) molecules. These additional E2-induced PKC(s) are
pharmacologically distinct from those which mediated PKC-induced LH release prior
to E2 treatment (Figure 5.2, Table 5.3). That is, in tissue from untreated
ovariectomised rats, those PKCs which induce LH release are activated by both PDBu
and DOG, whereas, with E2 treatment, there is the additional involvement of PDBu-
sensitive but DOG-insensitive kinases. Correspondingly, in pro-oestrous rats, both
DOG-insensitive, and DOG-activated kinases were also involved in the LH release
response (Chapter 3). Protein kinase C(s) that are resistant to activation by DOG are
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also involved in PDBu-induced GH release in from ovariectomised and pro-oestrous
rat tissue (Figure 5.3, Chapter 3).
The PKCs which mediate PKC activator-induced LH and GH release from
ovariectomised rat hemipituitaries are relatively resistant to H7 (Table 5.3).
Correspondingly, in anterior pituitary cytosol from ovariectomised rats, a PDBu-
induced, Ca2+-independent component of PKC activity was detected which was
relatively H7-resistant. Following E2 treatment, the amount of Ca2+-independent,
H7-resistant PKC activity was increased (Figure 5.4, Table 5.5), the LH release
response to PDBu was also increased (Table 5.3) and an H7-resistant LHRH priming¬
like effect was observed using E2-treated ovariectomised rat tissue (Table 5.2). Thus,
E2 treatment may enhance the activity and actions of the H7-resistant PKC(s) that is
involved in LHRH priming and PKC activator-induced LH release.
In contrast to the reduced potency of H7 on anterior pituitary Ca2+-
independent PKC activity, PDBu-elicited, Ca2+-dependent and -independent PKC
activities measured in cytosol from ovariectomised rat hypothalamus and
hippocampus had the expected sensitivities to H7. The IC50 values for the inhibition
of Ca2+-dependent and -independent activities by H7 in ovariectomised rat
hypothalamus cytosol were 18 ± 8 p.M and 14 ± 4 |iM (means ± SEM, n = 4),
respectively. Corresponding IC50 values for H7 measured in hippocampus cytosol
were 20 ± 4 fiM and 21 ± 1 [iM (n = 4) for Ca2+-dependent and -independent
activities respectively. Oestrogen treatment had no significant effect upon the H7
sensitivity of PDBu-induced PKC activity in either hippocampus or hypothalamus.
Interestingly, E2 treatment of ovariectomised rats also enhanced the
amount of Ca2+-dependent, H7-sensitive, PDBu-induced PKC activity in anterior
pituitary cytosol (Tables 5.4 and 5.5), suggesting that E2 treatment may facilitate the
actions of other PKC(s) in addition to those involved on LHRH priming and PDBu-
induced LH release. Although a component of PDBu-induced LH release from pro-
oestrous rat tissue was readily blocked by H7, the LH release response to PDBu in
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tissue from ovariectomised rats with or without E2 treatment showed no obvious
sensitivity to H7 (Table 5.3). Ovarian factors other than E2 may influence the
involvement of the H7-sensitive PKCs in the mechanism of phorbol ester-induced LH
release. For example, progesterone can further enhance the actions of E2 on LHRH-
induced gonadotropin release (Mann and Barraclough, 1973; Turgeon andWaring,
1981, 1990) suggesting that this steroid may also regulate gonadotroph
responsiveness and may possibly influence the activity of the H7-sensitive PKCs.
Androgens can have inhibitory effects on LHRH-induced LH release in cultured cells
in vitro (Drouin and Labrie, 1975; Tibolt and Childs, 1985). Testosterone
replacement of castrated male rats apparently restores LHRH priming in vivo not by
facilitating later responses to LHRH as is the case for E2, but by reducing the initial
response to LHRH (Nazian, 1986). Thus, in the intact rat, a combination of steroidal
and non-steroidal gonadal factors may be responsible for controlling gonadotroph
responsiveness. Clearly, additional studies are required to ascertain the effect of other
gonadal factors on the cellular mechanisms which induce priming and on the actions
of the H7-sensitive PKC form(s) involved in PDBu-induced LH release. Dispersed
anterior pituitary cells, maintained in culture, may prove to be a useful model for such
future studies since culture conditions can be easily defined and manipulated, unlike
the whole animal model which has been used in the present experiments. It will be of
interest to alter the culture conditions to mimic the levels and combination of gonadal
steroids, non-steroidal factors and LHRH pulses to which the pituitary is exposed on
pro-oestrus and to examine their effect on the LHRH priming mechanism. However,
the dispersed cell model of anterior pituitary function can suffer from a number of
drawbacks. Enzymatic dispersion can change in receptor characteristics and cause
cell membrane damage (Naor et al, 1980) which will affect gonadotroph
responsiveness. In addition, there is evidence that a specific cellular association
exists between lactotrophs and gonadotrophs in rat anterior pituitary (Nakane, 1970;
Fletcher et al, 1975) and that physiological interactions may occur between these cell
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types (Denef and Andries, 1983). The secretory profiles of dispersed cells may be
altered due to disruption of these interactions between gonadotrophs and
mammotrophs.
Oestrogen may have modulatory actions on several factors that can be
involved in cellular signalling mechanisms. For example, E2 treatment of rat anterior
pituitary cell cultures can enhance LH release in response to the voltage-sensitive
Ca2+ channel agonist, BAY K 8644, suggesting that E2 treatment can facilitate some
means of activating gonadotroph voltage-sensitive Ca2+ channels (Drouva et al,
1988). In addition, E2 treatment of long-term ovariectomised ewes and of ovine
anterior pituitary cell cultures can cause a long-term increase in pituitary LHRH
receptor number (Gregg and Nett, 1989; Laws et al, 1990). In the rat ventromedial
hypothalamus, E2 treatment can also induce the synthesis of a characteristic 70 kDa
protein of yet unspecified function (Mobbs et al, 1991). Therefore, it is likely that E2
modulation of cellular signalling within gonadotrophs can occur at sites other than
PKC and thereby contribute to the facilitatory actions of E2 on gonadotrophin release.
It is possible that the modulatory effect of E2 on these factors may, in part, contribute
to the change in the time course of PDBu-induced LH release observed in
ovariectomised rat tissue after E2 treatment.
In some in vitro models, E2 treatment has positive effects on LH-(3 gene
transcription (Shupnik et al, 1989). Since pituitary and serum concentrations of LH-(3
subunit mRNA correlate with pituitary content of LH (Fetherston and Boime, 1982),
this action of E2 may have positive effects on LH pool size. However, in vivo
replacement of E2 in long-term ovariectomised animals (as here) seems instead to
prevent the increase of LH-(3 mRNA levels that occurs following ovariectomy
(Counis et al, 1983; Gharib et al, 1988; Papavisiliou et al, 1986). Furthermore, there
is no change in total pituitary LH content in long-term E2-treated ovariectomised rats
(Marchetti et al, 1982). Instead, E2 can enhance LHRH-induced LH synthesis and
glycosylation, as assessed by the incorporation of radiolabelled amino acids or
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glucosamine respectively, into LH released from cultured cells (Liu and Jackson,
1977; Tang, 1980; Ramey etal, 1987; Liu and Jackson, 1990). However, the
experiments here with ionomycin (Figure 5.5) indicated that the facilitatory actions of
E2 on phorbol ester-induced LH secretion are not the result of an E2-induced increase
in releasable gonadotrophin content prior to a stimulus. It is, of course, possible that
Ca2+-independent release processes or release mechanisms involving factors
additional to Ca2+, such as GTP-dependent processes, could be modified by E2
treatment. However, these effects of E2 may remain undetected in these experiments.
Although the induction of LHRH priming is dependent upon PLA2
activation down-stream of PKC action (Chapter 4), and cycle-dependent changes in
the involvement of PLA2 in the mechanism of PKC-induced LH release were
observed (Figure 5.6), the experiments described here suggest that E2 does not
directly influence anterior pituitary PLA2. The magnitude of ionomycin-induced
[3H]-AA release from dispersed rat anterior pituitary cells was not altered by E2
treatment suggesting that this steroid does not directly modulate PLA2 activity
elicited by directly raising intracellular Ca2+ levels (Rosenthal et al, 1989) (Table
5.8). These results are in agreement with a previous report which showed that neither
PLA2 nor melittin-induced LH release from anterior pituitary cell cultures was altered
by E2 treatment (Liu and Jackson, 1989). It would seem, however, that E2 treatment
may have an effect on the cellular mechanisms which control gonadotroph PLA2
activity. In anterior pituitary tissue from ovariectomised rats, PDBu-induced LH
release was not altered by the PLA2 inhibitor, quinacrine (Table 5.7), suggesting that
the PKC(s) involved in this response do not target PLA2, unlike the pro-oestrous rat
model of gonadotroph function (Figure 5.6, Chapter 4). In agreement with this
hypothesis, PDBu was unable to elicit a significant increase in [3H]-AA release from
pre-labelled ovariectomised rat anterior pituitary tissue or from cells maintained under
E2-free culture conditions (Tables 5.8 and 5.9). In contrast, [3H]-AA release from E2-
treated pre-labelled cells or from tissue removed from E2-treated ovariectomised rats
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was significantly increased by PDBu (Tables 5.8 and 5.9). In addition, PDBu-
induced LH release from E2-treated, ovariectomised rat tissue was sensitive to
quinacrine (Table 5.7). These results suggest that E2 may have an indirect influence
on the actions of PLA2 in gonadotroph secretory responses perhaps by modulating the
actions and activity of the PKC(s), or some other intermediate step which is involved
in the control of anterior pituitary PLA2 activity. In contrast, acute progesterone
treatment of E2 pre-treated cells can enhance melittin-induced LH release (Ortmann et
al, 1992) indicating that progesterone may either have a direct modulatory influence
on PLA2 action in gonadotrophs, or an action on some process subsequent to PLA2
activation.
Some studies have suggested that gonadectomy or steroid treatment can
alter GH release patterns measured in the female rat in vivo (Jansson et al, 1984).
However, in the model described here, E2 did not regulate either PKC actions on GH
release (Figure 5.3) or the size of the releasable pool of GH (Figure 5.5) and E2
treatment of ovariectomised rats had no effect on either pituitary GH synthesis or
mRNA content (Shupnik et al, 1979). Furthermore, there appeared to be no clear
relationship between GH secretory patterns in intact female rats and the stage of the
oestrous cycle in vivo (Clark et al, 1987b) and in vitro (Figure 5.1), consistent with
our evidence which suggests that E2 does not play an important role in modulating
anterior pituitary gland responsiveness with respect to PKC-mediated GH release.
Oestrogen treatment of cultured pituitary cells in vitro has correspondingly been
shown to enhance phorbol ester-induced LH, but not GH, release (Drouva et al,
1990). It is likely, therefore, that action of E2 on GH secretory patterns described by
Jansson and co-workers (1984) may be due to an action of the steroid at a site other
than the pituitary, perhaps at the level of the hypothalamus or at other regions of the
CNS. Quinacrine was unable to inhibit PDBu-induced GH release from either E2-
treated or -untreated ovariectomised rat tissue (Table 5.7), suggesting that PLA2 is not
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involved in the mechanism of PDBu-induced GH release, supporting the observations
made using tissue from intact rats (Chapter 4, Figure 5.7).
The PKC isoforms which have been sequenced (a, ft, ft,, y, 8, e, £, T|, 0
and X) have distinct tissue distributions (Nishizuka, 1988; Osada et al, 1990; Y.
Nishizuka, personal communication), indicating that the expression of each isoform is
differentially regulated in different tissues. However, little is known about the effects
of gonadal steroids on the expression of each isoform. Androgens may modulate the
synthesis of the a, and to a lesser extent, the p PKC isoform in the male rat prostate
(Goueli, 1990). Since both Ca2+-dependent and -independent PKC activities were
increased by E2 treatment, it seems that other PKCs may be induced by E2, in
addition to the Ca2+-independent, H7-resistant PKC relevant here in the increased
responsiveness of gonadotrophs. Although the E2-induced H7-resistant PKC would
initially appear to be a B series (or related) isoform, this kinase may represent a
modified A series isoform since it is clear that the classification of the known PKC
isoforms according to their Ca2+-dependency may be less clear cut than when
originally conceived (see Chapter 3, section 3.4 for further discussion). Data obtained
using highly purified expressed recombinant protein have shown that the 5 and e
isoforms of PKC are more sensitive to H7 (Schaap and Parker, 1990; Uchida et al,
1991) than those E2-induced forms that mediate LH and GH release in this model,
suggesting that neither 8 nor e PKC is significantly involved in the release of these
hormones in tissue from ovariectomised rats. Furthermore, the £, and X PKC isoforms
are reported to be unresponsive to phorbol esters (Ono et al, 1989, Y. Nishizuka,
personal communication), suggesting that neither of these PKC isoforms represent the
E2-induced PKC. It would seem, therefore, that the E2-induced PKC isoform(s)
which mediate PDBu-induced LH release from ovariectomised rat anterior pituitary
tissue and that is involved in LHRH priming, may be a modified form of a known
PKC isoform, a poorly characterised Ca2+-independent isoform, such as r) or 0 or an
isoform of PKC (or closely related protein kinase) which has not yet been sequenced.
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Recently, antibodies for several of the known isoforms of PKC have become
commercially available such that Western blot analysis may be able to reveal which
isoforms are induced by steroid treatment. Alternatively, Northern blot studies, using
mRNA probes with sequences specific to different PKC isoforms, could be used to
identify the PKC isoforms that are induced by E2 treatment. In addition, further
experiments are required to confirm that the E2-induced PKC(s) involved in PDBu
responses are the same as those involved in LHRH priming. Following identification
of the E2-induced PKC isoform(s) using the methods described above, it may be
possible to use either selective antisense oligonucleotide sequences to this PKC or




The effect of phorbol 12,13-dibutyrate (PDBu) on LH and GH release from
female rat hemipituitaries removed on different stages of the oestrous cycle
Hemipituitaries were incubated for a basal h with no drug, followed by
consecutive hours in the presence of PDBu (300 nM) and both LH (•) and GH (■)











































The effect of (a) phorbol 12,13-dibutyrate (PDBu) and (b) 1,2-dioctanoyl-s/i-
glycerol (DOG) on LH release from anterior pituitary tissue taken from
oestrogen (E2)-treated and untreated ovariectomised (OVX) rats
Tissue removed from ovariectomised rats with (hatched bars) or without
(open bars) E2 treatment was incubated with medium only in the basal h followed by
3 consecutive hourly incubations (1st, 2nd, 3rd h) in the presence of either (a) 300 nM
PDBu or (b) 200 (lM DOG. The data represent net hormone release, i.e. baseline
release was subtracted. Luteinizing hormone release from both E2-treated and
-untreated tissue was increased above baseline levels during all hours of incubation
with either PDBu or DOG. Phorbol 12,13-dibutyrate- but not DOG-induced LH
release was significantly enhanced by E2 treatment (*p < 0.05, **p < 0.01 comparing
E2-treated tissue with E2-untreated tissue, Mann-Whitney U-test). Values are means


















Figure 5.2 * * □ ovx









The effect of (a) phorbol 12,13-dibutyrate (PDBu) and (b) 1,2-dioctanoyl-sn-
glycerol (DOG) on GH release from anterior pituitary tissue taken from
oestrogen (E2)-treated and -untreated ovariectomised (OVX) rats
Tissue was removed from ovariectomised rats which had received either
E2 treatment (hatched bars) or no steroid (open bars) and was incubated with medium
only in the basal h followed by 3 consecutive hourly incubations (1st, 2nd, 3rd h) in
the presence of either 300 nM PDBu or 200 (iM DOG. Growth hormone release was
increased in the presence of PDBu, but not DOG (p < 0.05, Duncan's New Multiple
Range test). There was no significant difference in the magnitude of GH release
between E2-treated and -untreated tissue (Mann-Whitney U-test). Values are means ±
SEM (n = 4 - 10).
Figure 5.3
□ ovx




The effect of H7 on phorbol 12,13-dibutyrate (PDBu) -stimulated Ca2+-
independent and Ca2+-dependent cytosolic PKC activity from ovariectomised
(OVX) rat anterior pituitary tissue with or without oestrogen (E2) treatment
Anterior pituitary tissue was removed from ovariectomised rats which had
either received E2 replacement (closed symbols) or no steroid (open symbols).
Cytosolic PKC activity was partially purified and the phosphatidylserine-dependent,
histone HIS kinase activity measured with 1 |iM PDBu and various concentrations of
H7 in the presence (100 (iM) (O/#) or absence (< 3 nM) (□/■) of Ca2+. Calcium-
independent, PDBu-induced PKC activity in ovariectomised rat anterior pituitary
cytosol was less sensitive to H7 block than Ca2+-dependent activity. This profile of
H7-sensitivity was not significantly altered by E2 treatment. Each point on the curve
is the mean ± SEM of 4 - 6 determinations.
% PDBu-stimulated activity remaining
Figure 5.5
The effect of ionomycin on (a) LH and (b) GH release from anterior pituitary
tissue taken from oestrogen (E2)-treated and -untreated ovariectomised (OVX)
rats
Tissue was removed from ovariectomised rats which had received either
E2 treatment (hatched bars) or no steroid (open bars) and was incubated with medium
only in the basal h followed by 3 consecutive hours in the presence of 30 [iM
ionomycin. The data represents net hormone release, i.e. baseline release was
subtracted. Release of both LH and GH in the presence of ionomycin was not





































The effect of quinacrine on phorbol 12,13-dibutyrate (PDBu)-induced LH
release from female rat hemipituitaries removed at different stages of the
oestrous cycle
Hemipituitaries were incubated for a basal h with either no drug (open
bars) or with quinacrine (50 (iM) (hatched bars), followed by consecutive hours in the
additional presence of PDBu (300 nM). Data was calculated as a fold of basal h
release. The statistical significance of the inhibitory effect of quinacrine was
determined (* p < 0.05, Mann-Whitney U-test). Each value represents the mean ±































The effect of quinacrine on phorbol 12,13-dibutyrate (PDBu)-induced GH
release from female rat hemipituitaries removed at different stages of the
oestrous cycle
Hemipituitaries were incubated for a basal h with either no drug (open
bars) or with quinacrine (50 |lM) (hatched bars), followed by consecutive hours in the
additional presence of PDBu (300 nM). Quinacrine had no significant inhibitory
effect on GH release measured at any hour on any stage of the oestrous cycle. Each


















The effect of staurosporine on LHRH-induced LH release over the days of the
rat oestrous cycle
Hemipituitaries were incubated in vitro for 3 consecutive hours. In the
basal h either medium alone (controls) or staurosporine (300 nM) was present. In the
following 2 h there was, in addition, LHRH (1 nM). The statistical significance of the
inhibitory effect of staurosporine was determined, *p < 0.05, **p < 0.01, Student's t-
test. Values given are the mean ± SEM (number of determinations in parentheses).
LH release (jug/1)
Days of
cycle basal h 1st h 2nd h n
oestrus control 8.4 ± 1.6 14.2 ± 1.7 35.9 ± 2.3 4
staurosporine 6.2 ± 0.7 9.5 ± 1.1 9.2 ± 1.1* 4
metoestrus control 4.9 ± 1.2 5.3 ±0.4 25.1 ±2.2 4
staurosporine 6.1 ±1.4 4.6 ± 1.0 5.8 ± 1.3* 4
dioestrus control 5.3+1.2 8.6 ± 1.0 55.7 ± 4.9 6
staurosporine 2.9 ± 0.6 4.6 ± 0.4 6.2 ± 0.6** 6
pro-oestrus control 5.3 ±0.7 27.0 ± 2.6 159.7 ±14.4 6
staurosporine 6.6 ±0.8 25.4 ± 3.0 30.7 ±4.3** 6
Table 5.2
The effect of PKC inhibitors on LHRH-induced LH release from anterior
pituitary tissue taken from ovariectomised (OVX) rats with or without oestrogen
(E2) treatment
Hemipituitaries were incubated in vitro for 3 consecutive hours. In the
basal h there was either medium only or staurosporine (300 nM) or H7 (30 |lM). In
the 1st h and 2nd h there was, in addition, LHRH (1 nM) or no drug (baseline). The
statistical significance of the effects caused by PKC inhibitors is indicated by * (p <




1st h 2nd h
OVX
baseline 20.6 ± 1.8 (4) 13.3 ±2.5 (4) 10.0 ±1.3 (4)








20.5 ± 7.5 (3) 33.8 ±3.7 (3) 40.9 ± 5.7 (3)
OVX + E2
baseline 36.3 ± 3.0 (4) 34.8 ± 5.2 (4) 22.9 ±7.8 (4)








39.9 ±7.1 (3) 290.2 ± 12.0 (3) 535.1 ±19.6 (3)
Table 5.3
The effect of PKC inhibitors on PKC activator-induced LH and GH release from
anterior pituitary tissue taken from ovariectomised (OVX) rats with or without
oestrogen (E2) treatment
Hemipituitaries were incubated in vitro for 4 consecutive hours. In the
basal h there was either medium only or staurosporine (300 nM) or H7 (30 fiM). In
1st, 2nd and 3rd h there was, in addition, either DOG (200 |lM) or PDBu (300 nM).
The data show net LH release (i.e. with baseline subtracted) measured in the 3rd h
and net GH release measured in the 1st h. All values are mean ± SEM (number of
determinations in parentheses). The statistical significance of the effects caused by
PKC inhibitors is indicated by * (p < 0.05, Mann-Whitney U-test).
LH release (jag/1)
OVX-untreated E2-treated
PDBu 30.9 ±4.1 (10) 308.0 ±35.1 (6)
PDBu + staurosporine *8.0 ± 4.6 (8) *94.6 ±18.4 (8)
PDBu + H7 29.8 ± 4.8 (6) 328.5 ± 25.2 (6)
DOG 22.0 ± 2.9 (5) 24.9 ± 2.8 (8)
DOG + staurosporine *8.9 ± 3.0 (4) *9.9 ± 4.4 (4)
DOG + H7 24.7 ± 2.9 (6) 21.9 ±7.6 (6)
GH release (jLtg/1)
PDBu 1828.5 ±256.6 (6) 1871.7 ±290.1 (10)
PDBu + staurosporine *138.5 ±56.9 (6) *240.8 ± 184.6 (5)
PDBu + H7 2079.2 ± 374.5 (6) 1866.8 ±312.2 (5)
Table 5.4
Phorbol 12,13-dibutyrate (PDBu)- and 1,2-dioctanoyl-s/i-glyceroI (DOG)-
stimulated PKC activity in anterior pituitary cytosol from ovariectomised (OVX)
rats with or without oestrogen (E2) treatment
These data show the PKC-activator-evoked phosphatidylserine-dependent,
histone HIS kinase activity, measured in the presence of either PDBu (1 |iM) or DOG
(100 pM) at either < 3 nM or 100 nM free Ca2+. All data are shown as mean ± SEM
of 5 - 7 determinations, *p < 0.05 compared with the effect of E2 on activator-





OVX OVX + E2-treated
PDBu Ca2+-independent 3056 ±551 *4829 ± 420
Ca2+-dependent 2806 ±651 *4535 ±714
DOG Ca2+-independent 95 ±36 138 ± 18
Ca2+-dependent 398 ± 26 *807 ± 17
Table 5.5
The IC50 values for H7 and staurosporine on phorbol 12,13-dibutyrate (PDBu)-
induced PKC activity in anterior pituitary cytosol from ovariectomised (OVX)
rats with or without oestrogen (E2) treatment
Cytosolic PKC in anterior pituitaries removed from ovariectomised rats,
with or without E2 treatment, was partially-purified and the phosphatidylserine-
dependent, histone HIS activity was measured, using 1 |iM PDBu as a PKC activator.
Kinase activity was assayed either in the absence (< 3 nM) or presence (100 |iM) of
Ca2+. The IC50 values for H7 and staurosporine were determined for the Ca2+-
independent activity and for the incremental activity induced by Ca2+. Each point on
the curves from which the IC50 values were derived was the mean ± SEM of 4 - 6
determinations.
IC50 values for H7 (j±M)
Ca2+-independent Ca2+-dependent
OVX 104 ± 23 27 ±4
OVX + E2 113 ± 25 32 ± 3
IC50 values for staurosporine (nM)
OVX 132 ±46 139 ±65
OVX + E2 137 ±51 100 ± 10
Table 5.6
The number and affinity of specific [3H]-phorbol 12,13-dibutyrate (PDBu)
binding sites in anterior pituitary cytosol from ovariectomised (OVX) rats with
and without oestrogen (E2) treatment
Non linear, direct fitting Scatchard analysis of the data (with error
weighting) was carried out using the programme, P.fit (Biosoft, Cambridge, UK). All
data are shown as mean ± SEM, n = 4.
E2-untreated E2-treated
Maximum number of specific
[3H]-PDBu binding sites 8.3 ±0.6 18.7 ± 1.4
(pmol/mg protein)
[3H]-PDBu binding site 15.7 ±3.4 12.6 ±0.8
dissociation constant (nM)
Table 5.7
The effect of quinacrine on phorbol 12,13-dibutyrate (PDBu)-induced LH and
GH release from anterior pituitary tissue removed from oestrogen (E2)-treated
and -untreated ovariectomised (OVX) rats
Hemipituitaries were incubated in vitro for 4 consecutive hours. In the
basal h there was either medium only or quinacrine (50 pM). In the 1st, 2nd and 3rd
h there was, in addition, PDBu (300 nM). The data shows net LH release measured in
the 3rd h and net GH release measured in the 1st h of PDBu incubation. All values
are mean ± SEM (number of determinations in parentheses). The statistical
significance of the effects caused by quinacrine is indicated by * (p < 0.05, Mann-
Whitney U-test).
net LH release (pg/1)





28.6 ± 5.4 (6)
32.9 ± 5.2 (6)
431.7 ±45.1 (6)
* 247.3 ± 36.7 (6)





2540.9 ± 347.0 (6)
3105.0 ±295.1 (4)
2271.6 ± 199.5 (6)
2761.4 ± 409.1 (4)
Table 5.8
The effect of oestrogen (E2) treatment on phorbol 12,13-dibutyrate (PDBu)-
induced [3H]-arachidonic acid (AA) release from ovariectomised (OVX) rat
anterior pituitary tissue
Pre-labelled pairs of pituitary quarters were incubated for 15 minutes
either in medium containing no drug (basal) or PDBu (300 nM). The statistical
significance of the effects caused by PDBu incubation compared to baseline is
indicated by * (p < 0.05, Mann-Whitney U-test). Data are means ± SEM for the
number of determinations shown in parentheses.
[3H]-AA release
(% of total label incorporated)
OVX OVX + E2
baseline 1.46 ±0.08 (6) 1.43 ±0.04 (6)
PDBu 1.35 ±0.07 (8) *1.74 ±0.04 (6)
Table 5.9
The effect of oestrogen (E2) treatment on phorbol 12,13-dibutyrate (PDBu)- and
ionomycin-induced [3H]-arachidonic acid (AA) release from 5 day cell cultures
of dispersed rat anterior pituitary glands
Dispersed cells from female rats were treated for 48 h with either no
steroid or with E2 (1 nM). Cells were then incubated in medium containing either no
drug (baseline), ionomycin (30 |iM) or PDBu (300 nM), with steroids if appropriate,
and [3H]-AA release was determined. The statistical significance of the effects of
ionomycin and PDBu were compared to baseline [3H]-AA release (*p < 0.05, Mann-
Whitney U-test). Values are means ± SEM for the number of determinations shown
in parentheses.
[3H]-AA release
(% total label incorporated)
no steroid e2
baseline 0.60 ± 0.02 (12) 0.70 ± 0.04 (7)
ionomycin * 0.88 ± 0.05 (8) * 1.12 ± 0.10 (5)




Approach to Characterise Pharmacologically
Distinct Forms of Protein Kinase C
6.1 Introduction
In previous chapters, H7-resistant PKC-like kinases were described,
together with evidence for their role in PKC-activator induced LH and GH release
and in the LHRH priming phenomenon in pro-oestrous rat anterior pituitary tissue.
However, the relationship of these H7-resistant forms of PKC to the known isoforms
is not clear. The known PKC isoforms have distinct tissue distributions and it may be
possible to correlate this pattern with the tissue distribution of the H7-resistant form.
For example the H7-sensitivity of PKCs purified from different tissue sources could
be determined using a cell-free assay of PKC activity, in the same way as we
examined the H7-sensitivity of anterior pituitary Ca2+-independent and -dependent
PKCs in Chapter 3 (Thomson, Johnson, MacEwan and Mitchell, submitted).
Alternatively, since both staurosporine and H7 interfere with enzyme activity by
interacting with, or near to, the ATP binding site (Nakadate et al, 1988), it may be
possible to determine the tissue distribution of the H7-resistant PKC by H7
displacement of binding of the radiolabeled derivative of staurosporine, [3H]-N, N-
dimethylstaurosporine (pH]-DMS) to PKC. In this chapter, experiments are
described in which radioligand binding studies, using [3H]-DMS, were used in an
attempt to characterise PKCs with respect to any differential pharmacology of PKC
inhibitors.
6.2 Specific Methodology
Equilibrium displacement of [3H]-DMS binding by PKC inhibitors to sites
in different tissues was carried out as described in Chapter 2, section 2.2.7. Male rat
lung or midbrain was homogenised in 5 vol of homogenisation buffer, and cytosol
was prepared as described in section 2.2.7. Staurosporine and Ro 31-8220 were made
up as stock solutions at 10~3 M in DMF and H7 was made up as a stock solution at
10"3 M in distilled H2O. Further dilutions were carried out in assay buffer. Total
binding (TB) was measured in the absence of unlabelled PKC inhibitor and non-
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specific binding (NSB, which was approximately 25% of TB) was determined in the
presence of 3 |iM staurosporine.
6.3 Results
Figure 6.1 shows the displacement by staurosporine of [3H]-DMS binding
to specific recognition sites in cytosolic preparations from male rat lung and
midbrain. These tissues were chosen because rat midbrain contains mRNA for a wide
range of different PKC isoforms (Scott-Young III, 1989) and lung, like anterior
pituitary, contains a PKC activity which is unusually resistant to H7 (MacEwan,
Johnson, Ison, Thomson and Mitchell, in preparation). Staurosporine displaced [3H]-
DMS binding to sites in lung and midbrain cytosol with Hill slopes of much less than
one (Table 6.1) consistent with both tissues having more than one site with distinctly
different affinities for staurosporine. Midbrain cytosol contained sites sensitive to
particularly low concentrations of staurosporine (with 27 ± 4% displacement at just
0.02 nM) that were apparently absent in lung. At concentrations of staurosporine of
200 nM and above, a further phase of displacement of binding was observed in both
midbrain and lung; the specificity of this component is not clear.
The staurosporine derivative, Ro 31-8220, which shows greater selectivity
for PKC than staurosporine, also displaced [3h]-DMS binding to sites in male rat
lung and midbrain cytosol with a Hill number of less than 1 (Figure 6.2 and Table
6.2) suggesting that Ro 31-8220 can bind to several sites within these tissues with
different affinities. Although displacement studies using Ro 31-8220 did not reveal
any sites in midbrain cytosol which can obviously recognise Ro 31-8220 with
particularly high affinity, Ro 31-8220 displayed slightly greater potency at sites in
midbrain than in lung (Table 6.2).
Unlike staurosporine and Ro 31-8220, H7 displaced [3H]-DMS binding to
sites in both lung and midbrain cytosol with similar potencies (Figure 6.3). The
potency of H7 in comparison to staurosporine was extremely low, with 500 pM H7
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displacing only approximately 40% of total binding. It was clear that these drugs
recognise sites on the enzyme which are not identical and that any effect of high
concentrations of H7 on binding could well be attributed to completely non-specific
actions, rather than allosteric modulation of the [3H]-DMS binding domain.
Therefore, no further studies were carried out.
6.4 Discussion
The purpose of these [3H]-DMS binding studies was to characterise the
H7-resistant PKC-like kinase, described in earlier experiments to be involved in
LHRH priming, PKC activator-induced LH and GH release and in the control of
PLA2 activity in the anterior pituitary, by correlating its tissue distribution with that
of the known PKC isoforms. However, H7 only weakly displaced [3H]-DMS binding
to sites in both lung and midbrain cytosol, supporting other data (Gross et al, 1990;
Herbert et al, 1990b), and was unable to distinguish sites unique to either tissue. As a
consequence, under the present experimental conditions, H7 is unlikely to have any
allosteric modulatory effects on the characteristics of [3H]-DMS binding, except at
high, possibly non-specific concentrations. Since these results indicate that the
recognition sites for staurosporine and H7 on the protein are clearly not identical it
was not possible to use this technique to characterise the distribution of the H7-
resistant PKC(s). Interestingly, other workers have observed that [3H]-DMS binding
to purified PKC is enhanced in the presence of Mg2+ and histone substrate, but not
Ca2+ or phosphatidylserine (Gross et al, 1990). It is possible that the characteristics
of H7 binding to PKC may also be altered in the presence of factors involved in
enzyme catalysis, and it will be of interest to determine whether these factors can also
modulate the ability of H7 to displace [3H]-DMS binding.
The observation that H7 is unable to displace [3H]-DMS binding is of
interest since, although both staurosporine and H7 are suggested to inhibit enzyme
activity by acting close to the ATP-binding site of the protein, these results would
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suggested that different binding sites for each inhibitor exist on the catalytic domain
of the kinase. Consistent with this hypothesis, H7, but not staurosporine is suggested
to be a competitive inhibitor with respect to ATP. The concentrations of
staurosporine required to inhibit PKC-mediated cellular responses are much lower
than would have been predicted for competitive inhibition with ATP (Riiegg and
Burgess, 1989). However, although H7 has been suggested to act in a kinetically
competitive manner with respect to ATP (Hidaka et al, 1984), it is not entirely clear
whether the H7 recognition site is completely concurrent with that of ATP, since H7
can only provide partial protection against denaturation of the ATP site by covalent
chemical reagents (Ohta et al, 1988).
These binding studies have also shown that lung and midbrain cytosol
have more than one binding site for staurosporine and Ro 31-8220 with different
affinities (Figure 6.1 and Table 6.1). Binding to midbrain sites was more sensitive to
displacement by staurosporine than binding to lung sites suggesting that midbrain, but
not lung, expresses a kinase (or group of kinases) which is highly sensitive to
staurosporine; much more so than has been previously reported for staurosporine on
purified PKC activity (Chapter 3, Gross et al, 1990). A further phase of displacement
of [3H]-DMS binding by staurosporine occurring at concentrations of 200 nM and
above suggested that there may be a minor population of specific binding sites
(-15%), present in both midbrain and lung, that are particularly insensitive to
staurosporine. Since staurosporine has relatively little selectivity for PKC and can
inhibit the activity of other kinases (see Riiegg and Burgess, 1989 for review), it is
likely that these multiple recognition sites for staurosporine may represent binding to
one or more of a number of kinases. It is not yet clear which of these binding site
components represent ligand bound to PKC, although both [3H]-DMS binding to
purified preparations of PKC and the enzymatic activity of purified PKC are inhibited
by staurosporine over a concentration range of 1 - 5 nM (Tamaoki et al, 1986; Gross
et al, 1990; Herbert et al, 1990b). However, staurosporine can inhibit the activity of
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other protein kinases with IC50 values in the same range as the inhibition of PKC
activity. For example, staurosporine has been reported to inhibit PKA activity with
an IC50 of 8 nM, Ca2+/calmodulin-dependent protein kinases with an IC50 of 10 - 40
nM, pp60v-src anci pp70trk tyrosine kinases with IC50 values over a range of 3 - 10 nM,
PKG with an IC50 of 8.5 nM, and myosin light chain kinase with an IC50 of 1.3 nM
(Tamaoki et al, 1986; Davis et al, 1989; Riiegg and Burgess, 1989; Herbert et al,
1990b; Hidaka and Kobayashi, 1992; Ohmichi et al, 1992). Furthermore,
staurosporine displaces [3H]-DMS binding to purified PKA and Ca2+/calmodulin-
dependent protein kinase with IC50 values of 1 and 5 nM respectively (Herbert et al,
1990b). It would seem, therefore, that staurosporine displacement of [3H]-DMS
binding over a concentration range of 1 - 40 nM may represent interactions with a
number of different kinases, including PKC. In addition, the high and low affinity
sites for staurosporine that were detected in rat midbrain do not overtly appear to
represent binding to PKC, or any of the other kinases described above. Interestingly,
staurosporine is reported to inhibit cell proliferation with an IC50 value of 4 pM,
which is much lower than the IC50 of 3 nM quoted for the inhibition of PKC activity
(Tamaoki et al, 1986). Although the identity of the staurosporine-sensitive kinase
involved in cell proliferation is unknown, this enzyme may be a member of the
growth factor-associated tyrosine kinases that are involved in cell division. The
identity of the rat brain kinase which displays high affinity for staurosporine is also
unclear, but it may be related to the enzyme involved in cell proliferation. A number
of kinases have been described which are inhibited by staurosporine with lower
potency. For example, mitogen-activated protein kinase (MAP kinase) activity from
rat hippocampus is inhibited by staurosporine with an IC50 value of 1.5 ± 1.2 pM
(Leslie, Johnson and Mitchell, unpublished observations). Furthermore,
staurosporine, at a concentration as high as 1 pM, is unable to inhibit the epidermal
growth factor receptor-associated tyrosine kinase (Ohmichi et al, 1992). Thus, the
low affinity [3H]-DMS binding sites may represent binding to either certain growth
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factor-receptor tyrosine kinases, a member of the MAP kinase family or other
unspecified kinase enzymes, perhaps including novel species.
Since it is clear that [3H]-DMS binds to protein kinase, other than PKC,
we attempted to distinguish binding to PKC from binding to other kinases by
displacement studies using the selective PKC inhibitor, Ro 31-8220. Although Ro
31-8220 is reported to inhibit PKC action with 100-fold greater selectivity than
staurosporine (Davis et al, 1989), these studies did not reveal any binding sites with
obvious selectivity for Ro 31-8220. It is likely that the relative potencies of Ro 31-
8220 on various types of protein kinase are not sufficiently different for this inhibitor
to clearly distinguish between various different kinases in the displacement of [3H] -
DMS binding, and perhaps ligand binding to authentic PKC may represent a very
small fraction of the sites labelled here. Recently developed staurosporine analogues,
such as Ro 31-8425, show 350-fold greater selectivity for PKC (Nixon et al, 1992)
and may prove to be a more useful tool to pursue the approach attempted here.
Ideally, the use of radiolabelled PKC-selective analogues of staurosporine (such as
the Ro compounds) would greatly simplify the analysis of specific radioligand
binding to PKC. However, until these selective radioligands are developed, it may be
possible to dissociate [3H]-DMS binding to PKC from binding to other kinases by a
number of different approaches. For example, phorbol ester treatment of the tissue,
prior to homogenisation, will cause PKC (at least the A series isoforms) to translocate
to the membrane, depleting the cytosol of PKC. [3H]-Dimethylstaurosporine binding
studies to phorbol ester-treated cytosol will provide a profile which represents binding
more predominantly to kinases other than PKC. However, this approach has a
number of drawbacks since it is clear that the £ and X PKC isoforms do not respond
overtly to phorbol esters (Ono et al, 1989; Y. Nishizuka, personal communication).
In addition, these studies are clearly limited since they will not allow further study of
selective binding to PKC itself. Alternatively, it may be possible to examine selective
[3H]-DMS binding to PKC by preparing samples of purified enzyme. For example,
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PKC activity can be partially purified from cell homogenates by passage through
DEAE cellulose (as was described for the PKC activity assays in Chapter 3) and this
can be further resolved into different peaks of enzymatic activity by hydroxyapatite
column chromatography (Kikkawa et al, 1987). Possible contamination of the
purified PKC preparation by other kinases could then be assessed by comparing the
number of [3H]-DMS binding sites in the preparation to the number of [3H]-PDBu
binding sites. Alternatively, preparations of specific purified PKC isoforms can be
obtained by expressing the cDNA for the appropriate isoform in a suitable system, for
example, the baculovirus expression system, following which, the enzyme can be
purified. It will be of interest to see whether the profile of [3H]-DMS binding and
displacement varies between different isoforms of PKC.
Although these experiments did not provide an answer as to the identity of
the H7-resistant PKC form that has a function in gonadotroph and somatotroph
responses, [3H]-DMS binding studies may be useful in other investigations. For
example, the site of action on PKC of new pharmacological tools may be determined
by comparing the displacement of [3H]-DMS binding to the catalytic domain of the
enzyme with displacement of [3H]-PDBu binding to the regulatory domain. It should
be said, however, that this approach was not successful when considering the site of
action of H7 which, like staurosporine, is though to act on the catalytic domain, in
close proximity to the ATP recognition site (Nakadate et al, 1988). In equivalent
experiments, displacement of [3H]-PDBu binding by PKC activators such as DOG,
which can mimic some actions of phorbol esters but not others (Chapters 3 and 5),
may provide an insight into the identity of PKCs which differ in their PKC activator
pharmacology (MacEwan et al, 1992a).
Since these [3H]-DMS binding studies were carried out, the distribution of
the H7-resistant PKC has been determined by an alternative means (D. MacEwan,
PhD Thesis, University of Edinburgh). In these studies, the effect of H7 was
examined on PDBu-induced, phosphatidylserine-dependent, histone HIS kinase
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activity that was partially-purified from different tissue sources. Of the tissues
examined, male and female rat anterior pituitary and rat lung cytosol, but not male rat
frontal cerebral cortex, cerebellum, spleen, midbrain or COS 7 cells, contained Ca2+-
independent, PDBu-induced, H7-resistant kinase activity. This tissue distribution
does not correlate with the distribution of any of the characterised isoforms of PKC.
Since the H7-resistant PKC form detected in these cell-free assays does not require
Ca2+ for activation, it would seem that this enzyme may represent a member of the B
series isoforms. However, histone is reported to be a poor substrate for the B series
PKC isoforms (Ohno etal, 1988; Schaap et al, 1989; Schaap and Parker, 1990;
Olivier and Parker, 1991) thus the Ca2+-independent, H7-resistant histone kinase
activity in anterior pituitary and lung cytosol does not correlate well with the activity
of a B series isoform. Furthermore, it is clear that the Ca2+ dependency of the A
series isoforms may change under certain assay conditions (Wolf et al, 1984; Bazzi
and Nelsestuen, 1987) and according to the phosphorylation state of the enzyme
(Pelech et al, 1991), suggesting that the H7-resistant form could be a modified state
of an A series isoform. Using purified recombinant preparations, the 8 and e PKC
isoforms have been shown to be much more sensitive to H7 than the Ca2+-
independent kinase activity detected in lung and anterior pituitary (Schaap and Parker,
1990; Uchida et al, 1991). The H7-resistant PKC here was also readily activated by
PDBu, suggesting that the phorbol ester-insensitive C, and X PKC isoforms (Ono et al,
1989; Y. Nishizuka, personal communication) do not represent the H7-resistant PKC.
It would seem then that the H7-resistant kinase is either a poorly characterised B
series PKC, such as r| or 0, a modified A series isoform or is a kinase which has not
been fully characterised. Further studies are required to determine the identity of this
H7-resistant PKC. Experiments exploring immunodepletion of certain PKC isoforms,
using specific polyclonal antipeptide antibodies and their precipitation with protein A
Sepharose, followed by assessment of the H7-sensitivity of the remaining enzymes,
may eliminate some of the candidates for the H7-resistant kinase.
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Figure 6.1
Displacement of [3H]-N,N-dimethylstaurosporine (PHJ-DMS) binding to sites in
(a) midbrain and (b) lung cytosol by staurosporine
Data were calculated as a % of total binding (TB), and the curve was fitted
using the non-linear, error-weighted iterative curve fitting programme, P.fit (Biosoft,
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Figure 6.2
Displacement of [3H]-N,N-dimethylstaurosporine ([3HJ-DMS) binding to sites in
(a) midbrain and (b) lung cytosol by Ro 31-8220
Data were calculated as a % of total binding (TB), and the curve was fitted
using the non-linear, error-weighted iterative curve fitting programme, P.fit (Biosoft,
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Figure 6.3
Displacement of [3H]-N,N-dimethyIstaurosporine ([3H]-DMS) binding to sites in
(a) midbrain and (b) lung cytosol by H7
Data were calculated as a % of total binding (TB), and the curve was fitted
using the non-linear, error-weighted iterative curve fitting programme, P.fit (Biosoft,





























Hill slope and IC50 values for staurosporine displacement of [3H]-N,N-
dimethylstaurosporine (pH]-DMS) binding to sites in rat lung and midbrain
cytosol
Values were obtained by fitting the data using the non-linear, error-
weighted iterative curve fitting programme, P.fit. The IC50 value was defined as
being that concentration of staurosporine which displaced 50% of total binding. All
values are shown as mean ± SEM or 4 - 12 determinations.
midbrain lung
Hill slope 0.22 ± 0.05 0.58 ± 0.07
IC50 (nM) 0.23 ± 0.06 9.38 ± 1.93
Table 6.2
Hill slope and IC50 values for Ro 31-8220 displacement of [3H]-N,N-
dimethylstaurosporine ([3H]-DMS) binding to sites in rat lung and midbrain
cytosoi
Values were obtained by fitting the data using the non-linear, error-
weighted iterative curve fitting programme, P.fit. The IC50 value was defined as
being that concentration of Ro 31-8220 which displaced 50% of total binding. All
values are shown as mean ± SEM for 4 - 12 determinations.
midbrain lung
Hill slope 0.66 ±0.1 0.56 ±0.1




The involvement of PKC in the signal transduction system of the LHRH
receptor in anterior pituitary gonadotrophs has been a controversial issue for a number
of years (see Conn, 1989 for review). Although LHRH can stimulate the
redistribution of PKC activity from the cytosolic to the particulate fraction in anterior
pituitary cell cultures (Hirota et al, 1985; McArdle and Conn, 1986), and PKC
activators can induce LH release (Conn et al, 1985; Naor and Eli, 1985; Chang et al,
1986a, 1986b; Turgeon and Waring, 1986; Johnson and Mitchell, 1989; Chapter 3), it
has been difficult to assess the involvement of PKC in LHRH action since selective
inhibitors of this kinase have not been available until recently. However, we have
shown here that the recently developed highly selective PKC inhibitor, Ro 31-8220,
and a number of older PKC inhibitors (staurosporine, K252a and H7) could prevent
the induction of LHRH priming, measured in pro-oestrous rat anterior pituitary tissue
in vitro, without inhibiting the initial secretory response to LHRH (Chapter 3). These
results are in agreement with previous observations using less selective PKC
inhibitors which suggest that PKC activation is not essential for acute gonadotrophin
release in response to LHRH (McArdle et al, 1987), but may be required, in part, for
later responses to LHRH (Hirota et al, 1985; Chang et al, 1987b; Fink et al, 1990). In
addition to having a role in LHRH priming as shown here, PKC is also suggested to
mediate LHRH-induced changes in gonadotrophin gene expression and LH synthesis
in cultured, dispersed anterior pituitary cells (Andrews et al, 1988; Stojilkovic et al,
1988b). However, PKC-dependent positive actions on gonadotrophin synthesis are
not apparent until after 12 hours of LHRH treatment (Andrews et al, 1988),
suggesting that this action of PKC may not be important for LH release responses
measured over 2-3 consecutive hourly exposures to LHRH, as used in these studies.
Certainly, in pro-oestrous rat hemipituitary pieces, there is no significant change in
the total amount of gonadotrophin following an initial exposure to LHRH (Pickering
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and Fink, 1979), suggesting that, in this model of anterior pituitary cell function,
LHRH does not induce any significant change in gonadotrophin synthesis.
Most interestingly, the PKC that is involved in the induction of LHRH
priming, has unusual PKC inhibitor pharmacology. That is, the LHRH priming
response was readily inhibited by staurosporine and Ro 31-8220, but was relatively
resistant to H7 in comparison to certain other PKC-mediated responses (Hidaka et al,
1984; Chapter 3). The identity of this H7-resistant PKC with respect to the known
PKC isoforms is unknown, although evidence from biochemical assays of cytosolic
PKC activity indicate that this PKC is a Ca2+-independent type. However, of the
known B series isoforms, both 8 and e PKC are more sensitive to H7 (Schaap and
Parker, 1990; Uchida et al, 1991) than the kinase involved in priming. Furthermore,
the £ and X PKC isoforms, unlike the H7-resistant kinase in rat anterior pituitary
tissue, are not responsive to phorbol esters (Ono et al, 1989; Y. Nishizuka, personal
communication). Thus, it would appear that a poorly characterised B series PKC
isoform, such as T) or 0 PKC or some unknown PKC-like enzyme may represent the
PKC involved in LHRH priming. However, histone has been reported to be a poor
substrate for the characterised Ca2+-independent PKC forms (Ohno et al, 1988;
Huang, 1989; Schaap and Parker, 1990), suggesting that the H7-resistant, Ca2+-
independent histone kinase activity detected in anterior pituitary cytosol may not
result from the activation of a B series isoform. It is now clear that the Ca2+-
dependency of the A series PKC isoforms is not as clear-cut as might have been
perceived at first. Autophosphorylation of the [3 PKC isoform can reduce its
requirement for Ca2+ (Pelech et al, 1991) and the Ca2+-dependency of the A series
isoforms alters under different assay conditions (Wolf et al, 1984; Bazzi and
Nelsentuen, 1987). It is possible, therefore, that the priming kinase may represent a
modified A series PKC isoform.
In an attempt to further characterise this novel PKC-like kinase, H7
displacement of [3H]-DMS binding to cytosolic sites from different tissues sources
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was examined (Chapter 6) but was found to be of limited use since the binding sites
for staurosporine and H7 were clearly not identical. Nevertheless, this observation is
of interest since the difference in the potency of H7, but not staurosporine, on Ca2+-
independent compared with Ca2+-dependent PDBu-induced cytosolic PKC activity in
anterior pituitary (Chapter 3) may be accounted for by the fact that each inhibitor
binds to slightly different sites on the enzyme. It is clear that further studies are
required to identify the H7-resistant PKC involved in LHRH priming. One approach
may be to partially purify anterior pituitary PKC and immunodeplete certain PKC
isoforms using specific polyclonal antipeptide antibodies and protein A Sepharose.
The H7-sensitivity of the remaining enzymes could then be assessed, and this may
eliminate some of the candidates for the H7-resistant kinase. Following separation
and purification of the H7-resistant PKC, fragments of the protein may be
microsequenced, and oligonucleotides synthesised which could be used to probe a rat
anterior pituitary cDNA library to identify full length clones encoding this kinase.
Comparing even fragments of amino acid sequence or the nucleotide sequence of this
clone with those of the known PKC isoforms may clarify the identity of the kinase
involved in LHRH priming. However, problems may arise using this approach to
identify the priming kinase. For example, the pituitary consists of a heterogeneous
cell population, and cell types, other than gonadotrophs, may express H7-resistant
PKC-like kinases which function in processes other than LHRH priming. Indeed, an
H7-resistant form of PKC has been implicated in the dual control of anterior pituitary
L-type Ca2+ channel activity (Mitchell et al, 1990), and it is possible that this
represents a kinase which is distinct from that involved in LHRH priming. Using a
clonal cell line, such as the a T3-1 gonadotrophs, to purify and characterise the
priming kinase would, at first sight, seem to overcome the problem of contamination
from PKCs from other cell types. However, it is clear that the role of PKC in LHRH
responses in a T3-1 cells differs from that in rat anterior pituitary pieces (Chapter 4),
suggesting that this cell line may be of limited use in the identification of the priming
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kinase. However, until additional studies are carried out, it is uncertain whether the
H7-resistant form of PKC, that is involved in LHRH priming, represents one of the
known isoforms of PKC or if it is a novel, as of yet, unidentified form of PKC or a
closely related kinase.
Preliminary evidence from other studies has suggested that PLA2
activation may be required for secretory responses to LHRH in cultures of dispersed
anterior pituitary cells (Naor and Catt, 1981; Chang etal, 1986a, 1987b), leading us
to investigate a possible role of PLA2 in LHRH responses in pro-oestrous rat anterior
pituitary tissue (Chapter 4). Indeed, it appears that the induction of LHRH priming is
dependent upon the activation of PLA2 since LHRH priming, but not initial LHRH-
induced gonadotrophs release was blocked by a number of PLA2 inhibitors and
LHRH could induce an increase in [3H]-AA release from pre-labelled pro-oestrous rat
hemipituitary pieces, a response which was blocked by inhibitors of PLA2, but not of
DAG lipase activity. In addition, LHRH-induced modulation of PLA2 activity
apparently occurs by a route which is dependent upon both protein synthesis and the
actions of an H7-resistant form of PKC. One possibility is that the H7-resistant PKC,
which induces LHRH priming, controls the synthesis of a protein which can activate
phospholipase A2. Certainly, preliminary results from Northern blot analysis have
shown that LHRH treatment of pro-oestrous rat anterior pituitary tissue can increase
PLAP mRNA levels (Lutz and Mitchell, unpublished observations), implying that this
protein may, in some way, be involved in LHRH receptor responses. However,
additional experiments are required to determine the physiological relevance of PLAP
in LHRH receptor signalling. Biologically-active peptide fragments of phospholipase
A2-activating protein are available, and it would be of interest to see what affect these
have on gonadotroph PLA2 activity and gonadotroph responsiveness. Monoclonal
antibodies against PLAP and PLAP antisense oligonucleotides may, in principle, also
be useful since one could attempt to inhibit LHRH priming using these tools.
However, such studies require dispersed, permeabilised cells which, unfortunately, do
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not response to LHRH in the same manner as intact tissue (see section 1.7.3 for
discussion). It is, of course, possible that during LHRH receptor activation, a
protein, other than PLAP, is synthesised which may induce LHRH priming.
However, the identity of any such a protein is uncertain.
The results presented in this thesis have led us to postulate a simplified
model of the intracellular changes that may occur following LHRH stimulation of the
pro-oestrous rat gonadotroph, leading to gonadotrophin release and priming (Figure
7.1). Simulation of the LHRH receptor causes a G-protein-dependent activation of
PLC, inositol phospholipid breakdown and production of Ins(l,4,5)P3 and DAG. In
addition, since LHRH treatment of a T3-1 cells can activate PLD and thereby
increase PtdOH levels (Netiv et al, 1991), it is possible (by the subsequent action of
phosphatidate phosphohydrolase) that LHRH can also increase gonadotroph DAG
levels independently of Ins(l,4,5)P3 production. Inositol 1,4,5-trisphosphate will
mobilise Ca2+ from intracellular stores (Berridge and Irvine, 1984, 1989) which,
together with Ca2+ influx through plasma membrane channels, will contribute to early
secretory responses to LHRH, perhaps by affecting Ca2+/calmodulin-dependent
processes (Conn et al, 1981a). In parallel, DAG will activate the H7-resistant PKC
which is involved in the priming response. It is possible that the origin of this DAG
and its side chain composition might confer selectivity in activating particular PKCs.
By inducing the synthesis of a protein (perhaps PLAP), the H7-resistant PKC
enhances PLA2 activity and AA release. Arachidonic acid may mediate priming by
having an action on various aspects of cell function, but by a mechanism which is
perhaps not dependent upon metabolism of the fatty acid. For example, AA has been
reported to activate PLC (Irvine et al, 1979), possibly by increasing intracellular- Ca2+
levels which may alter the activity of this enzyme. Such an effect of AA on
gonadotroph PLC activity may account for the facilitated production of Ins(l,4,5)P3
and increased Ca2+ mobilisation response that is associated with priming (Mitchell et
al, 1988). Arachidonic acid can cause Ca2+ mobilisation from intracellular stores,
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including those which are sensitive to Ins(l,4,5)P3 (Beaumier et al, 1987), can
activate certain isoforms of PKC (Naor et al, 1988; Shearman, 1989a), and can
modulate the activity of certain types of ion channel. Any combination of these
cellular actions of AA may play an important role in LHRH priming. However, since
PKC inhibitors were unable to prevent LHRH-induced LH release from tissue which
had been previously primed, it is unlikely that the expression of priming is mediated
by an action of AA on PKC activity. Nevertheless, it is possible that AA may
activate other kinases involved in the induction of LHRH priming. Furthermore,
LHRH priming does not require extracellular Ca2+ (Pickering and Fink, 1979), is
unaffected by thapsigargin (a depletor of intracellular Ca2+) (Thomson, Mitchell and
Johnson, unpublished observations) and is unaffected by calmodulin antagonists or
Ca2+/calmodulin-dependent kinase inhibitors (Mitchell, Wolbers, Johnson and
Thomson, unpublished observations). Thus, changes in intracellular Ca2+ levels,
brought about by AA, AA metabolites, or by some other means may not be important
for the phenomenon of LHRH priming.
In addition to increasing cellular levels of free AA, PLA2 action will also
liberate lysophospholipid, which can be metabolised to PAF. Platelet-activating
factor can bind to its own membrane associated receptors and induce inositol
phospholipid turnover (Shulka, 1991). Northern blot analysis has shown that a small
but significant amount ofmRNA for PAF receptor is present in the dog pituitary (Bito
et al, 1992), suggesting that PAF receptor may be present on some pituitary cells.
The possibility that PAF may have an autocrine or paracrine action in the anterior
pituitary which may contribute to the LHRH priming effect is an interesting prospect.
Although the early secretory response to LHRH is dependent upon Ca2+
mobilisation from both intracellular and extracellular pools (Davidson et al, 1991),
LHRH priming can occur in Ca2+-free medium (as assessed by the ratio of LH release
measured in the 2nd h of LHRH incubation to the 1st h incubation) (Pickering and
Fink, 1979) and is unaffected by thapsigargin (Thomson, Mitchell and Johnson,
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unpublished observations). Furthermore, the H7-resistant, PKC-like kinase found in
anterior pituitary cytosol is active at extremely low (< 3 nM) Ca2+ levels, and its
activity was not obviously promoted by raising Ca2+ levels (Chapter 3). These
observations suggest that the induction of LHRH priming may be a Ca2+-independent
process. However, although increased levels of intracellular Ca2+ may not be a pre¬
requisite for the amplification of gonadotroph responsiveness, PKC action may
enhance the LHRH secretory response by reducing the Ca2+ requirement of the Ca2+-
dependent process of hormone release. Indeed, the Ca2+ levels measured in
gonadotrophs after chronic LHRH treatment (Limor et al, 1987) may be lower than
those levels that are sufficient alone to trigger secretion (Rink et al, 1982). Thus, a
possible synergy between Ca2+ and PKC may be important for low levels of Ca2+ to
be functionally significant. However, in pro-oestrous rat hemipituitaries, it was clear
that a PKC-independent release of gonadotrophin can still occur during a 2nd h
exposure to LHRH (Chapter 3). Thus, the actions of cellular processes, other than
PKC, perhaps Ca2+-dependent events, are sufficient alone to induce at least part of
the later phase of LHRH-induced LH release in this model. Nevertheless, Ca2+
ionophores and PKC activators can synergise to release levels of LH from dispersed
cells in culture that are greater than those measured in the presence of either
secretagogue alone (Harris et al, 1985; Naor and Eli, 1985), indicating that PKC may
serve to amplify hormone release induced by other cellular factors. In pro-oestrous
rat tissue, it is possible, therefore, that the actions of the 'priming kinase' may amplify
gonadotrophin release induced by the facilitated intracellular Ca2+ mobilising
response which is associated with LHRH priming (Mitchell et al, 1988). Although
the mechanism by which the actions of PKC and other factors, like Ca2+ may interact
to facilitate gonadotrophin release is unknown, studies using GH4C1 anterior pituitary
cells may provide a clue as to how this interaction occurs. During TRH stimulation
of GH4C1 cells, PKC action is important for the second phase of a biphasic prolactin
release response, a response which requires PKC phosphorylation of and subsequent
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re-organisation of the actin cytoskeleton (Kiley et al, 1992). During LHRH
stimulation of the gonadotroph, an equivalent action of PKC on the gonadotroph
cytoskeleton may account for earlier observations which have shown that priming is
dependent upon microfilament integrity and is associated with movement of the
secretory granules to the plasma membrane (Pickering and Fink, 1979; Fink, 1988).
This action of PKC on the gonadotroph cytoskeleton may render the secretory
granules more susceptible to release in response to other factors such as Ca2+.
The magnitude of the LHRH priming response is dependent upon the stage
of the rat oestrous cycle and it is, therefore, not surprising that the actions, and
probably the expression of the H7-resistant PKC which induces priming was
enhanced by E2 treatment (Chapter 6). Although anterior pituitary tissue from
ovariectomised rats did not display a visible LHRH priming response when measured
in vitro, preliminary experiments suggested that, following E2 replacement of
ovariectomised animals, the LHRH priming response was reinstated and that this
effect of E2 may be due to an action on the expression of the H7-resistant PKC.
Dispersed anterior pituitary cells, that have been maintained in E2-free culture
conditions over several days, do not exhibit LHRH priming (Speight and Fink, 1981;
Chang et al, 1987b), which may be explained by the experiments described in
Chapter 5 which show that the activity and amount of the PKC(s) involved in LH
responses to PKC activators and LHRH is reduced in an E2-free environment. It is,
therefore, perhaps not surprising that some reports have concluded that PKC
activation is not required for secretory responses to LHRH measured in dispersed
anterior pituitary cells which have been maintained in relatively prolonged culture.
In addition to the H7-resistant PKC-like kinases involved in LHRH
priming, a number of other distinct PKCs forms were found to be involved in the
process of PKC activator-induced LH and GH release. These PKCs differed in their
PKC inhibitor and activator pharmacology (Chapter 3). Of some interest, we found
that certain PKC activators could induce LH release by a process which involved H7-
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sensitive PKCs in addition to H7-resistant PKCs that were, presumably, involved in
the LHRH receptor signal transduction mechanisms. Thus, following LHRH receptor
stimulation, selective activation of only certain PKC forms which can modulate LH
release occurs. It is possible that selective activation of one or more PKC forms by an
agonist may be controlled by the particular species of DAG released following
receptor stimulation, in combination with other factors such as free fatty acids and
changes in intracellular Ca2+ concentrations or by the relative abundance of different
isoforms or by compartmentalisation of certain isoforms. The difference in the PKC
inhibitor and activator pharmacology of the LH and GH secretory response is of great
interest since it would add further weight to evidence that the development of agents
which selectively inhibit or activate certain PKC isoforms may be possible. Drugs
which selectively intervene with PKC isoforms that are specifically involved in
particular disease states may be novel and powerful therapeutic agents.
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Figure 7.1
A summary of the LHRH receptor signal transduction mechanisms in the pro-








































APPENDIX I Preparation of tissue culturemedia
1.1 Preparation of stripped foetal calf serum
(i) Removal of thyroid hormones
Dowex 1 x 8 - 400 resin (chloride form) was washed extensively in
distilled water, then passed through a 0.22 |im filter. The resin was then incubated
with heat-inactivated foetal calf serum (100 mg wet wt/ml serum) for 5 hours on a
rotor. The resin was removed by centrifugation (1000 g, 10 min). Fresh resin was
added to the supernatant (100 mg wet wt/ml serum) the incubated for 15 - 18 h at
room temperature. The resin was removed by centrifugation (1000 g, 10 min)
followed by passing the supernatant through a 0.8 |im filter.
(ii) Removal of steroids
Activated charcoal was mixed with distilled H2O and centrifuged (3000 g)
for 20 min. The water was discarded and the charcoal was incubated with the thyroid
hormone-stripped foetal calf serum (0.02 g wet wt/ml serum), initially at 37°C for 40
min followed by 30 min at 55°C. The charcoal was removed by centrifugation (10
min, 300 g) followed by passage through filters of 0.8 Jim, 0.45 jim and 0.22 Jim in
succession.
1.2 Preparation of steroid-free DMEM
Powdered DMEM (Sigma) with 1000 mg/ml glucose and 1-glutamine, but
without phenol red was made as a solution, as per the manufacturers instructions, and
was adjusted to pH 7.1. Arachidonic acid, docosahexaenoic acid were added as stock
solutions in BSA to give final concentrations of 1 mg/1, 0.5 mg/1 and 25 mg/1
respectively. Penicillin and streptomycin were added to give a final concentration of
100 units/1 and 0.1 mg/ml respectively. Stripped foetal calf serum was added to give
a 10% final concentration. The medium was then sterilised by passing through a
0.22 Jim filter.
APPENDIX II Radioimmunoassay for LH, FSH and GH
II. 1 Stock solutions





per litre distilled H20, pH 7.5
(ii) antiserum buffer
500 ml 0.01 PBS
9.306g ethylenediamine tetra-acetic acid disodium salt
2.5 ml normal rabbit serum for LH, FSH or 1.66 ml normal human serum for GH
pH to 7.0 with sodium hydroxide pellets
(iii) assay buffer (0.01 M PBS/1 % BSA)
1 litre 0.01M PBS
10 g bovine serum albumin
(iv) 0.5 M phosphate buffer
12.5 g NaH2P04.2H20
59.7 g Na2HP04 anhydrous
per litre distilled H20, pH 7.5
II.2 Iodination
Columns: LH 15 x 1 cm column Sephadex G50 fine coated
with 1.5 ml egg white (5% in PBS). Eluted with
0.01 M PBS.
FSH 15 x 1 cm column Sephadex G50 fine coated
with 1.5 ml ovalbumin (5% in PBS). Eluted
with 0.01 M PBS.
GH 50 x 1 cm Sephadex G75 fine coated with 900
pi human albumin (4.5% in PBS). Eluted with
0.05M sodium barbitone buffer (pH 8.6).
Hormones: LH 10 pi aliquots of 250 pg/ml in 0.01M PBS.
FSH 10 pi aliquots of 100 pg/ml in 0.01 M PBS.
GH 10 pi aliquots of 250 pg/ml in 0.01 NaHC03.
Na125I: 0.5 mCi in 5 pi for each iodination.
(Specific activity, approximately 14 mCi/pg).
2.5 mg/ml in 0.01 M PBS. 10 pi used.
2.5 mg/ml in 0.01 M PBS. 10 pi used.
0.5 mg/ml in H2O. 10 pi used.
2.5 mg/ml in 0.01 M PBS. 25 pi used.
2.5 mg/ml in 0.01 M PBS. 25 pi used.










(ii) Add 0.5 mCi Na125l
(iii) Add chloramine T, mix gently
(iv) Reaction times: LH 1 min
FSH 45 sec
GH 25 sec
(v) Add Na2S2C>5, mix gently
(vi) Transfer to column
(vii) Elute with 0.01 M PBS
(viii) Collect fractions: 0.9 ml into 0.1 ml PBS/5% BSA for GH. 0.5 ml
into 0.5 ml 0.01 M PBS/5% ovalbumin for LH and FSH.
Count radioactivity per fraction. Retain peaks protein fractions.
In all cases, iodinated hormone eluted before free iodine.
11.3 Standards
LH: NIH-LH-SI8 (0.25, 0.5, 0.75, 1.2, 2, 5, 8, 16 ng/ml in 0.01 M
PBS/1% BSA) or NIDDK-rat LH-RP-2 (0.1, 0.25, 0.5, 1.0, 2.5
and 5.0 ng/ml in 0.01 M PBS/1% BSA).
FSH: NIDDK rat FSH-RP-2 (1.25, 2.5, 5.0, 10, 20, 40 ng/ml in 0.01 M
PBS/1% BSA).
GH: NIDDK rat-GH-RP-2, (0.1, 0.2, 0.4, 0.8, 1.6, 3.2, 6.4 ng/ml in
0.01 M PBS/1% BSA).
11.4 Antisera
LH: NIDDK-r-LH-S-9 or NIDDK r-LH-S-10, V45,ooo dilution (stock).
FSH: NIDDK r-FSH-S-11, Vi5,600 dilution (stock)
GH: NIDDK r-GH-S-4, Vi2,000 dilution (stock)
11.5 Timetable of radioimmunoassay
Day 1 All assays: 200 (il sample/standards (final dilutions in 0.01
M PBS/1% BSA)
200 (il 0.01M PBS/1% BSA
200 (il antiserum in buffer all dilutions in 0.1 M
PBS/1% BSA
LH and FSH: Incubate at 4°C
GH: Incubate at room temperature.
Day 2 All assays: 200 (il 125I-hormone in PBS/1% BSA
~ 10,000 cpm for LH/FSH
~ 12,000 cpm for FSH
~ 6,000 cpm for GH
LH and FSH: Incubate at 4°C
GH: Incubate at room temperature after addition of
label.
GH only: 200 pi V30 dilution of AHGG in 0.01 M PBS added
approximately 7 h after label. Incubate at 4°C.
Day 3 GH only: Centrifuge tubes (30 min at 2000 g, 4°C),
aspirate supernatant and count pellet.
Day 4 LH and FSH: 200 pi of a V20 dilution of ARGG in 0.01 M
PBS. Incubate at 4°C.
Day 5 LH and FSH: Centrifuge, aspirate and count.
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Lithium enhances the inhibitory effect of protein kinase C on LHRH-
induced 45Ca2+ influx into rat anterior pituitary tissue in vitro
By M. S. Johnson, D. J. MacEwan, R. Mitchell and F. J. Thomson MRC Brain
Metabolism Unit. 1 George Square, Edinburgh EH8 9JZ
The metabolism of inositol phosphates is modified by Li+ (Allison et al. 1976), and
it has been suggested that this may underlie the therapeutic effects of Li+ in manic-
depressive disorders (Berridge et al. 1982). However, agonist-induced diacylglycerol
production is enhanced by Li+ (Drummond & Raeburn, 1984), suggesting that Li+
may modify several aspects of responses to Ca2+-mobilizing receptors, including the
activation of protein kinase C (PKC).
The influx of 45Ca2+ into prisms ofmale rat anterior pituitary tissue was measured
by an assay involving quenching of uptake after 30 s and extensive washing in ice-
cold EGTA-containing medium (Fink et al. 1986). The 45Ca2+ influx induced by
100 nM luteinizing hormone-releasing hormone (LHRH) but not by 300 nM
thyrotrophin-releasing hormone (TRH) was inhibited by low concentrations (3-
300 nM) of the PKC activator phorbol 12-myristate, 13-acetate (Mitchell et al. 1989).
The concentration-response curve to LHRH but not TRH was biphasic, and the
downturn at high LHRH concentrations was reversed by inhibitors of PKC (Fink
et al. 1986). Therefore the mechanism of 45Ca2+ influx induced by LHRH but not
TRH can apparently be inhibited by hormone-induced activation of PKC. In the
presence of LiCl (45 min pre-incubation), the 45Ca2+ influx due to 100 nM-LHRH, but
not 300 nM TRH or basal accumulation, was reduced, with 50% inhibition at
1-0 + 0-2 mM (mean + s.e.m., n = 4). This effect was reversed by the PKC inhibitor H7
(30 /im) but not by HA 1004 (Hidaka & Hagiwara, 1987). The biphasic concen¬
tration-response curve to LHRH was suppressed by 3 mM-Li+ such that the maximal
response was inhibited by approximately 50% and the downturn phase (from 100 to
1000 nM-LHRH) was amplified. It is possible that enhanced activation of PKC, as
well as modified inositol phosphate metabolism, may contribute to the therapeutic
actions of Li+ in vivo.
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Effects of calmodulin antagonists on neurohormone-induced 45Ca2+ influx
into rat anterior pituitary tissue in vitro
By M. S. Johnson, D. J. MacEwan, R. Mitchell and F. J. Thomson. MRC Brain
Metabolism Unit, 1 George Square, Edinburgh EH8 9JZ
Luteinizing hormone-releasing hormone (LHRH) and thyrotrophin-releasing
hormone (TRH) both induce 45Ca2+ influx into rat anterior pituitary tissue, but
utilize different routes, which are regulated differentially by protein kinase C
(Mitchell et al. 19896). The 45Ca2+ influx induced by LHRH is largely sensitive to
nimodipine (suggesting that it may occur indirectly through voltage-sensitive Ca2+
channels), whereas the response to TRH is resistant to blockers of the known voltage-
sensitive Ca2+ channels or of the Na+/Ca2+ exchanger (Mitchell et al. 19896).
Receptor-activated Ca2+ entry (perhaps such as the response to TRH here) may
involve a synergistic action of inositol 1,3,4,5-tetrakisphosphate (InsPJ and inositol
1,4,5-trisphosphate (InsP3) (A. P. Morris et al. 1987). The production of InsP4 from
lnsP3 by a 3-kinase may be calmodulin (CM)-dependent (A. J. Morris et al. 1987).
We have therefore investigated effects of CM antagonists on neurohormone-induced
Ca2+ entry.
The rapid influx of 45Ca2+ into prisms of tissue from male rats was measured in
30 s incubations with stimuli, as described previously (Mitchell et al. 1989a). At this
time point, the stimulus-induced influx had reached a maximal increment over the
basal 45Ca2+ accumulation in each case. The influx of 45Ca2+ induced by LHRH
(100 nM) or TRH (100 nM), but not by 60 mM-K+ medium, was inhibited by a new
selective CM antagonist, 5-iodo-l-C8 (MacNeil et al. 1988) at 1-30/im. The related,
but less selective compounds W7 and W5 (MacNeil et al. 1988) had similar effects
with lower potencies. At concentrations of 100 /i.m, W7 and W5 also caused
significant reduction of K+-induced 45Ca2+ influx (as did pimozide at just 10 jim),
indicating that the specificity of these compounds is uncertain at such concentrations.
The present results suggest that an unknown CM-dependent step is indeed involved
in neurohormone-induced 45Ca2+ influx regardless of whether this occurs via known
voltage-sensitive Ca2+ channels (in the case of LHRH) or via some other route of
receptor-activated Ca2+ entry (in the case of TRH).
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effect on either LH or FSH secretion). Phorbol
12,13-dibutyrate (PDBu) was kept in the dark as
a stock solution in DMF at 1 mM. Stock solutions
of l-(5-isoquinolinesulphonyl)-2-methyl-pipera-
zine hydrochloride (H7) (Gibco, Paisley, UK) were
prepared in distilled water at a concentration of
10 mM and kept at — 20°C. Luteinizing hor¬
mone-releasing hormone was from Peninsula
Laboratories Europe (St. Helens, Merseyside,
UK) and was used from an aliquoted stock solu¬
tion (10 ng/ml) in 0.9% (w/v) NaCl kept at
-40°C. Ionomycin (Novabiochem, Nottingham,
UK), genistein (ICN Biochemicals, Cleveland,
OH, USA) and 5-iodo-C8; lV-(8-aminooctyI)-5-
iodonaphthalene-l-sulphonamide (a gift from












Sheffield, UK) were used from stock solution of
10 mM in DMF. Calmidazolium (R24571, stock 1
mM, DMF) and 48/80 (stock 10 mg/ml, HzO)
were obtained from Sigma Chemical Co. Finally,
ML-7 (Novabiochem) was diluted from a stock of
10 mM in dilute acetic acid.
Statistics
Data are expressed as means + SEM. When
appropriate, statistical analyses were carried out
using the Student's f-test or the Mann-Whitney
U-test. The IC50 values for the kinase inhibitors
were obtained from fitting the data with the
non-linear, error-weighted iterative curve fitting
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Fig. 1. Concentration-response curves for the effect of the protein kinase C inhibitors staurosporine (a), K252a (b), H7 (c) and Ro
31-8220 (d) on LHRH-induced release of LH. The squares (■) represent the release of gonadotropins from proestrous
hemipituitaries in the 1st h of exposure to LHRH (0.85 nM) and the circles (•) release in a 2nd h of exposure to the peptide. The
greater release in the 2nd h is a result of LHRH priming, which, unlike the initial release effected by this peptide, is inhibited by
staurosporine. Values are mean ± SEM and each point is 4 < n > 6.Corresponding basal release of LH was between 5.2-14.8 ng/ml
and was unaffected by any of the inhibitors or their vehicles at the concentrations used.
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Results
Consecutive hourly incubations of proestrous
hemipituitaries with LHRH (0.85 nM) induced a
relatively small release of both LH and FSH in
the 1st h, followed by augmented release of go¬
nadotropin during a 2nd h with LHRH, due to
the self-priming effect of LHRH (Figs. 1 and 2).
Inclusion of staurosporine (10 nM-2 yttM), which
by itself had no effect on basal gonadotropin
release over several hours, had no effect on the
release of gonadotropins seen in the 1st h of
incubation with LHRH (see Figs. 1 a and 2a).
However, exposure to staurosporine caused a
concentration-dependent inhibition of the greater
release of gonadotropins brought about by prim¬
ing. Luteinizing hormone release in the 2nd h
with LHRH was significantly decreased {p < 0.05)
compared to control at concentrations of 30 nM
staurosporine and above; results were similar for
FSH. The concentration of staurosporine at which
50% inhibition (IC50) occurred was 26.3 + 7.0 nM
for LH and 37.0 ± 7.1 nM for FSH. In the pres¬
ence of staurosporine at concentrations of 300
nM and above, release of both LH and FSH was
decreased to levels seen in the 1st h with LHRH
but not to the basal levels of release. Table 1
shows the effect of staurosporine on LHRH-in-
duced gonadotropin release from anterior pitu¬
itary tissue obtained on different days of the
estrous cycle. The magnitude of the priming ef¬
fect of LHRH was dependent on the stage of the
estrous cycle, being largest on proestrus and
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Fig. 2. Concentration-response curves for the effect of staurosporine (a), K252a (£>) and H7 (c) on LFIRH-induced release of FSH.
The squares (■) represent the release of gonadotropins from proestrous hemipituitaries in the 1st h of exposure to LHRH (0.85
nM) and the circles (•) release in a 2nd h of exposure to the peptide. The greater release in the 2nd h is the result of the
LHRH-priming effect which, unlike the release in the 1st h with LHRH, is inhibited by K252a. Values are mean + SEM and at each
point 4 < n > 6. Corresponding basal release of FSH was between 3.3-4.6 ng/ml and was unaffected by any of the inhibitors or
their vehicles at the concentrations used.
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TABLE 1
EFFECT OF STAUROSPORINE ON LHRH-INDUCED LH RELEASE OVER THE DAYS OF THE ESTROUS CYCLE
AND IN MALES
Hemipituitaries were incubated in vitro for 3 consecutive hours. In the basal hour either medium alone (controls) or staurosporine
(300 nM) was present. In the following 2 h there was, in addition, LHRH (0.85 nM). Values given are the mean + SEM.
Days of cycle Inhibitor LH (ng/ml)
Basal hour 1st hour 2nd hour
n
Estrus Control 8.4 +1.6 14.2 +1.7 35.9 + 2.3 4
Staurosporine 6.2 ±0.7 9.5 ±1.1 9.2 ± 1.1 ** 4
Metestrus Control 4.9 +1.2 5.3 +0.4 25.1 ± 2.2 4
Staurosporine 6.1 ±1.4 4.6 ±1.0 5.8 ± 1.3 ** 4
Diestrus Control 5.25 + 1.17 8.63 + 0.99 55.70+ 4.94 6
Staurosporine 2.92 + 0.56 4.63 + 0.37 6.15+ 0.56 ** 6
Proestrus Control 5.25 + 0.67 27.03 + 2.59 159.7 ±14.43 6
Staurosporine 6.58 + 0.78 25.4 ±3.03 30.70+ 4.26 ** 6
Males Control 6.10+1.40 10.15 + 1.77 21.03+ 4.85 4
Staurosporine 8.04 + 1.04 8.70 + 0.69 5.74+ 0.45 * 4
*
p < 0.05 significantly different compared to control.
**
p < 0.01 significantly different compared to control.
TABLE 2
EFFECTS OF SOME PROTEIN KINASE INHIBITORS ON LHRH-INDUCED LH AND FSH RELEASE AND PRIMING
Hemipituitaries were incubated in vitro for 3 h. In the basal hour there was medium alone (control) or a protein kinase inhibitor. In
hours 1 and 2 there was, in addition, LHRH (0.85 nM). Values given are mean + SEM.
Inhibitor LH (ng/ml) n
Basal hour 1st hour 2nd hour
Control 20.7 + 2.8 81.9+ 8.3 285.1 + 21.2 8
Genistein (50 pM) 14.0 + 3.3 79.0+14.8 336.3 + 35.2 4
Control 8.5 + 1.8 36.2+ 8.2 191.7 + 26.7 6
5-Iodo-C8 (10 yuM) 15.6 + 3.0 92.0+11.7 ** 282.5 + 20.2 * 6
Control 7.7+1.7 123.4 + 13.5 283.0+ 6.0 5
48/80 (30 pg/ml) 10.6 + 2.6 184.7 + 10.9 * 299.5+11.2 5
Control 4.2 + 0.6 37.7+ 5.0 134.3 + 12.0 5
Calmidazolium (1 pM) 5.8+1.5 71.0 + 11.8 * 215.6 + 22.4 * 6
Control 7.9 + 3.1 46.9+ 6.3 159.0+12.7 4
ML-7 (3 p,M) 4.2 + 0.5 57.0+ 5.4 212.7 + 26.8 4
FSH (ng/ml)
Basal hour 1st hour 2nd hour
Control 5.01 + 0.29 9.93 + 0.96 25.47 + 3.52 8
Genistein 4.29 + 0.44 7.75 + 0.97 22.59 + 3.97 4
Control 3.55 + 0.38 5.89 + 0.64 17.76 + 2.29 4
5-Iodo-C8 5.08 + 0.34 10.27 + 0.82 * 28.57 + 3.28 6
Control 2.63 + 0.28 10.11 + 2.38 41.72+1.23 5
48/80 4.18 + 0.47 18.16 + 0.94 * 45.83 + 3.62 5
Control 2.76 + 0.23 7.50+1.15 17.85 + 2.09 4
ML-7 2.68 + 0.19 8.49 + 0.59 25.09 + 2.29 * 4
*
p < 0.05 significantly different compared to control.
**
p < 0.01 significantly different compared to control.
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1974b and Table 1). At each stage of the cycle,
staurosporine (300 nM) blocked LHRH-induced
gonadotropin release in the 2nd h but only to a
level equivalent to that seen in the 1st h of
LHRH incubation.
The less active congener of staurosporine
K252a (30 nM-10 ytxM) also caused a concentra¬
tion-dependent inhibition of the 2nd h of
LHRH-induced gonadotropin release (Figs, lb
and 2b) again without affecting initial go¬
nadotropin release. There was a significant de¬
crease (p<0.05) in LHRH-induced release of
both LH and FSH compared to control at K252a
concentrations of 3 ytxM and above. The IC50 for
inhibition of LHRH-induced release by K252a
was 2.9 ±0.4 ytxM for LH and was 2.3 + 0.5 /xM
for FSH.
Figs, lc and 2c show the effect on LHRH
priming of a PKC inhibitor of quite different
structure, H7 (10-300 jiM). At concentrations
above 30 ytxM H7 there was significant (p < 0.05)
inhibition of both LH and FSH release in the 2nd
h with LHRH, with no effect on LHRH-induced
gonadotropin release in the 1st h. The IC50 for
inhibition of the 2nd h of LHRH-induced release
by H7 was 71.6 ± 13.3 ytxM for LH and 88.1 ± 20.4
/u.M for FSH. The novel and highly-selective PKC
inhibitor, Ro 31-8220 (0.1-50 /xM), also caused a
concentration-dependent inhibition of the primed
but not the unprimed gonadotropin secretion in¬
duced by LHRH (Fig. Id). At concentrations of
10 ytxM and above, the inhibition was statistically
significant (p < 0.05) and gave an IC50 for inhibi¬
tion of the 2nd h of LHRH-induced LH release
of 19.0 ± 6.8 /xM.
A range of inhibitors of different classes of
kinases (used at concentrations described in the
literature to cause more than 50% inhibition of
the relevant kinase in whole cells) were compared
(Table 2). Genistein (50 /xM), an inhibitor of
several tyrosine kinases (Akiyama et al., 1987),
had no effect on either initial LHRH-induced
gonadotropin release or priming. Calmidazolium
(R24571), 48/80 (Gietzen, 1983) and 5-iodo-C8
(MacNeil et ah, 1988), which inhibit Ca2+/ca\-
modulin-dependent kinases, all significantly in¬
creased LHRH-induced release of LH and FSH
in either the 1st, 2nd or both hours with LHRH,
but did not block the priming effect. Similarly,
ML-7 which is a selective inhibitor of Ca2+/cal-
modulin-dependent myosin light chain kinase
(MLCK) acting at a site other than the calmod¬
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Fig. 3. Effect of staurosporine on the induction/expression of LHRH priming. Release of LH from proestrous hemipituitaries was
measured over either 2 or 3 consecutive hours with LHRH (0.85 nM). In part a, staurosporine (300 nM) was included (dotted bars)
in the basal h and 1st h of LHRH (i.e. that hour during which priming takes place). Between the 1st and 2nd h with LHRH, the
tissue was washed twice with MEM to remove the staurosporine before incubating the tissue with LHRH alone for a 2nd h.
Although staurosporine was not present in the 2nd h, primed release was significantly inhibited (p < 0.05). Part b shows the effect
of staurosporine (300 nM) on LHRH-stimulated LH release from previously-primed proestrous tissue. Hemipituitaries were primed
by incubating with LHRH for 1 h. They then received a further 2 consecutive hours of incubation in the presence of LHRH and
300 nM staurosporine (dotted bars). Staurosporine was unable to inhibit LHRH-stimulated LH release from previously-primed
tissue.Values are mean ± SEM (n = 4).
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In order to determine whether the stau-
rosporine-sensitive step was in the induction of
the priming effect rather than its expression, sev¬
eral experiments were carried out. Firstly, stau-
rosporine (300 nM) was included in the basal and
1st h of LHRH incubation (i.e. that hour during
which priming takes place), after which stau-
rosporine was removed and the tissue was exten¬
sively washed before a second hourly incubation
in the presence of LHRH only (see Fig. 3a). As
observed previously, staurosporine did not alter
initial LHRH-induced LH release. However,
LHRH-induced release of LH in the 2nd h of
LHRH was still fully blocked to a level equivalent
to that in the 1st h responses to LHRH. Two
pieces of evidence indicated that this washing
procedure was successful in substantially reduc¬
ing the staurosporine concentration in the tissue:
(i) an identical procedure using [3H]7V,./V-di-
methyl staurosporine (a close structural analogue
of staurosporine) resulted in a reduction of the
tissue concentration to 8 ± 2% (n = 4) of the
initial level; (ii) in tissue incubated with stau¬
rosporine and washed as above, the facilitation of
K+-induced 45Ca2+ influx caused by 300 nM
PDBu (MacEwan and Mitchell, 1991) was not
reduced from that in control tissue (108 ± 10% of
the facilitation in vehicle-incubated controls, n =
3). In the second series of experiments we investi¬
gated whether staurosporine affected LHRH-in¬
duced LH release from previously-primed tissue
(Fig. 3b). In this experiment, tissue was primed
with LHRH for 1 h before including stau¬
rosporine (300 nM) during the 2nd and 3rd h
LHRH incubations. Even over a period of 2 h (to
allow for the slow development of any possible
effect) staurosporine did not block LHRH-in¬
duced gonadotropin release from previously-
primed tissue. The results of these two experi¬
ments show clearly that staurosporine blocks the
priming but not the gonadotropin-releasing ac¬
tion of LHRH. The time course of the action of
staurosporine is shown in Table 3. When stau¬
rosporine was added over four 30 min incubation
periods with LHRH, the increment in LH release
due to priming seen in periods 2, 3 and 4 of
control (LHRH alone) incubations was abolished
completely. However, when staurosporine was
added later, at the beginning of periods 2 or 3,
primed release was progressively less inhibited.
The ability of LHRH priming to escape inhibition
by staurosporine if the tissue is exposed to LHRH
for 30 min prior to the inhibitor is in agreement
with data using the protein synthesis inhibitor
cycloheximide, which also prevents LHRH prim¬
ing with similar temporal characteristics (Picker-
TABLE 3
EFFECT OF STAUROSPORINE ON THE TIME COURSE OF LHRH-INDUCED LH RELEASE
Release of LH was measured from hemipituitaries that were incubated in vitro for a basal 30 min and then four consecutive 30 min
periods with LHRH (0.85 nM). The basal release of LH was stripped from the values for LHRH-induced LH release in the time
periods 1-4. The PKC inhibitor, staurosporine (300 nM) was added into the incubation series at the beginning of the time period at
which + is indicated in the row above the data and was present to the end of the experiment. Values given are mean±SEM (n = 4).
LH (ng/ml)
30 min incubations
1 2 3 4
Staurosporine - - - -
LHRH 17.6 + 10.5 52.7+14.5 104.6+10.2 137.2+16.4
Staurosporine - - + +
LHRH 6.8+ 3.4 35.8+ 2.9 84.9+ 8.6 76.5+ 3.9 *
Staurosporine - + + +
LHRH 8.2+ 3.7 30.7+11.4 57.2+17.1 62.9 + 20.4 **
Staurosporine + + + +
LHRH 17.3+ 7.0 25.5+ 9.8 20.8+ 8.3 ** 20.5+ 8.4 **
*
p < 0.05 significantly different compared to control (LHRH alone).
**
p < 0.01 significantly different compared to control (LHRH alone).
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ing and Fink, 1976). Some priming still occurred
if pituitaries were exposed to LHRH for as little
as 15 min before a concentration of cyclohex-
imide was added that was sufficient to abolish
priming if given in conjunction with LHRH.
To confirm that staurosporine has no in¬
hibitory activity upon the secretory apparatus of
the cell, we investigated the effect of this drug on
ionomycin (50 yuM)-induced release of LH and
FSH. In the presence of 300 nM staurosporine,
there was clearly no significant alteration in LH
or FSH release induced by a 1st h or 2nd h
incubation with ionomycin (Table 4). In the final
experiment hemipituitaries were primed with
LHRH (0.85 nM) either in the presence or ab¬
sence of staurosporine (300 nM) and ionomycin
(30 /xM) was used as a receptor-independent
secretagogue to elicit primed LH release. After
priming with LHRH, ionomycin induced a much
greater release of LH (157 +11 ng/ml) than in
control incubations with ionomycin alone (63 ± 6
ng/ml). The addition of staurosporine during the
priming hour, however, fully prevented this facili¬
tation of the response to ionomycin (LH release
of 69 ± 4 ng/ml; n = 4-6).
Discussion
The results presented here indicate that acti¬
vation of a protein kinase, probably a form of
PKC, is necessary for LHRH priming but not
initial LHRH-induced gonadotropin release.
Thus, the facilitation of gonadotropin release
brought about by LHRH priming was completely
prevented by staurosporine, leaving LHRH-in-
duced release equivalent to that of unprimed
responses, regardless of the degree of priming
that had occurred (Table 1). The absolute po¬
tency of staurosporine here (26.3 ± 7.0 nM) is
similar to that reported in thoroughly-char¬
acterised PKC-mediated cellular responses, for
example, in platelets, T cells and spinal afferent
nerve terminals (Davis et al., 1989; Dunn and
Rang, 1990) and in cell-free assays of the activity
of partially- or extensively-purified PKCs (Naka-
date et al., 1988; Schaap and Parker, 1990; John¬
son and Mitchell, unpublished). Indeed, under
equivalent conditions to the present experiments,
the release of LH elicited by 100 nM PDBu was
similarly inhibited by staurosporine with a IC50 of
44.0 ± 17.2 nM (n = 4). The potency ratio for the
inhibitory effects of staurosporine and K252a on
LHRH priming (62- and 111-fold for FSH and
LH respectively) is of a similar order to that
reported for their inhibition of PKC in cell-free
systems (36-fold) but contrasts with the corre¬
sponding values for cAMP-dependent (PKA) and
cGMP-dependent (PKG) protein kinases of 2.5
and 2.3 respectively (Kase et al., 1986; Tamaoki
et al., 1986). A novel PKC inhibitor, Ro 31-8220
(which is reported to show selectivity for PKC
over PKA and Ca2+/calmodulin-dependent ki¬
nase of 2-3 orders of magnitude; Davis et al.,
1989), also inhibited LHRH priming of LH re¬
lease, with an IC50 value of 19.0 + 6.8 /r,M, simi¬
lar to that for inhibition of PDBu (300 nM)-in-
duced LH release (15.6 + 4.5 yuM, n = 5). The
isoquinoline inhibitor of PKC, H7, also inhibited
LHRH priming. There was, however, an interest¬
ing disparity between the IC50 of H7 on LHRH
priming (71.6+13.3 yuM) and on PDBu (100
nM)-induced LH release (1.7 ± 1.5 yuM, n = 6).
We have previously described several other in¬
stances where phorbol ester-induced effects were
inhibited with unusually low potency of H7 but
not of staurosporine (Johnson and Mitchell, 1989;
Johnson et al., 1989; Fink et al., 1990; MacEwan
and Mitchell, 1991; Thomson et al., 1991a) and
the ability of staurosporine but not H7 to inhibit
some phorbol ester effects has also been de¬
scribed by others (Watson et al., 1988; Nakadate
et al., 1989). Indeed when the PDBu-induced
kinase activity of PKCs partially purified from
anterior pituitary but not brain tissue was mea¬
sured in a mixed micelle assay (Johnson et al.,
1991), a Ca2+-independent component of the ac¬
tivity was apparent which displayed a reduced
potency towards H7 but not staurosporine. Both
Ca2+-dependent and Ca2+-mdependent PDBu-
induced activity were inhibited by staurosporine
with similar IC50 values (114 ± 65 nM and 107 ±
41 nM respectively), but H7 inhibited Ca2 ^de¬
pendent activity (9 + 4 yuM) much more effec¬
tively than Ca2+-independent activity (47 + 20
yu,M). In brain and a number of peripheral tissues,
staurosporine and H7 both displayed identical
IC50 values on Ca2+-dependent and -independent
activity.
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Since both staurosporine and H7 are consid¬
ered to act close to the ATP-binding site of
PKCs, which is quite highly conserved in a num¬
ber of kinases, such disparities in the potency of
H7 but not staurosporine are at first sight unex¬
pected. However, the sites of action of these
inhibitors appear to be non-identical. While
K252a has been reported to be a competitive
inhibitor with respect to ATP (Kase et al., 1987)
there is evidence to the contrary for stau¬
rosporine (Tamaoki et al., 1986; Riiegg and
Burgess, 1989) and the binding of [3H]lV,)V-di-
methyl staurosporine is displaced with only ex¬
tremely low potency by H7 (IC50 > 500 ^.M)
(Thomson et al., 1991b). Although kinase in¬
hibitors of the isoquinoline type do appear to act
in a kinetically competitive manner with respect
to ATP (Hidaka et al., 1984), certain analogues
(for example HA 1004 and H7) demonstrate dis¬
tinct relative selectivity for or against particular
kinases (Hidaka and Hagiwara, 1987) indicating
that a degree of recognition specificity is possible
at this site. Furthermore, it is not clear that the
H7 recognition site is entirely concurrent with
that for ATP, since H7 provides only partial
protection against denaturation of the ATP site
by covalent chemical reagents (Ohta et al., 1988).
Finally, in some cases, the relationship between
H7 and ATP recognition may be complex since
the sequences of a and [3 isoforms of PKC con¬
tain a second consensus recognition motif for
ATP (Huang, 1989). It is unclear whether the
relatively H7-resistant kinase involved in LHRH
priming might represent a particular PKC
isozyme, some modified form of PKC, a distinct
but related kinase or the influence of other as yet
quite unknown factors. Whichever is the case, the
consensus of inhibition of LHRH priming by four
PKC inhibitors, taken with the ineffectiveness of
an array of inhibitors of other types of kinase,
strongly suggests that a form of PKC or related
kinase is required for LHRH priming.
Staurosporine and K252a can have inhibitory
actions on tyrosine kinases (Yamaguchi and
Kathuria, 1988), PKA (Tamaoki et al., 1986),
myosin light chain kinase and Ca2+/calmodulin-
dependent (CaM II) kinase (Watson et al., 1988).
However, the action of staurosporine on LHRH
priming seems unlikely to involve these kinases
TABLE 4
EFFECT OF STAUROSPORINE ON IONOMYCIN-IN-
DUCED LH AND FSH RELEASE
Hemipituitaries were incubated in vitro for 3 h. In the basal
hour there was medium alone (controls) or staurosporine (300
nM). In the next 2 consecutive hours there was, in addition,
ionomycin (50 p,M). Values given are the mean + SEM (n = 7).
Inhibitor LH (ng/ml)











Basal hour 1st hour 2nd hour
Control 2.47 + 0.16 8.65 + 0.90 6.52 + 0.67
Staurosporine
(300 nM) 2.45 + 0.14 7.66 + 0.63 5.27 + 0.38
since inhibitors of tyrosine kinase (genistein),
CaM II kinase (the calmodulin antagonists:
calmidazolium, 5-iodo-C8 and 48/80) and MLCK
(ML-7) were ineffective and both the potency
ratio of staurosporine versus K252a on LHRH
priming and the identical potency of Ro 31-8220
on priming and PDBu-induced responses argue
against a role of cyclic nucleotide-dependent ki¬
nases. Interestingly, both initial LHRH-induced
release and/or that from primed tissue were
enhanced by a number of the CaM II kinase
inhibitors. Evidence supporting a role of CaM II
kinase in LHRH-induced gonadotropin release
has been provided by several laboratories (Conn
et al., 1984; Das et al., 1989) but recent evidence
(Van der Merwe et al., 1990b) suggests that it is
only the more non-specific of the calmodulin
antagonists used that inhibit LHRH-induced LH
release. Certainly raised intracellular Ca2+ is an
effective secretagogue for LH, yet it will not
mimic the priming effect of LHRH (Table 4).
Interestingly, removal of extracellular Ca2+ dur¬
ing an initial hour of incubation with LHRH,
while reducing LH release in that hour, does not
prevent LHRH priming if Ca2+ is replaced in a
second hour with LHRH (Pickering and Fink,
1979). If CaM II kinase is involved in the first
phase of LHRH-induced release it is unclear why
our results show an increase of LH release in the
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presence of CaM II kinase inhibitors. The Ca2+/
calmodulin-dependent phosphatase, calcineurin
(Armstrong, 1989) has been detected in pituitary
cells (Farber et ah, 1987), so if raised Ca2+ levels
in gonadotropes were to increase both calmod¬
ulin-dependent phosphorylations and dephos-
phorylations then interpretation of the overall
effects of calmodulin antagonists would be com¬
plex.
Staurosporine exerts its inhibitory effects on
primed gonadotropin release if present during
that hour in which LHRH priming takes place
(i.e. the 1st h), but is removed for the hour of
further challenge with LHRH, showing that its
action is on the induction rather than the expres¬
sion of LHRH priming (Fig. 3a). Furthermore,
the response of previously-primed tissue to
LHRH was unaltered by staurosporine (Fig. 3b).
Since staurosporine will also prevent the facili¬
tated response to ionomycin seen in previously-
primed tissue, staurosporine cannot simply be
acting as a slowly-acting inhibitor of a late com¬
ponent of LHRH responses. Additional evidence
that staurosporine was not acting by a delayed,
non-specific action on the secretory apparatus of
the gonadotrope was provided by its lack of effect
alone on secretion induced by the Ca2+ iono-
phore, ionomycin (Table 3). In an analogous fash¬
ion to its role here in LHRH priming, PKC has
been implicated in the induction but not expres¬
sion of another phenomenon of increased cellular
responsiveness, long-term potentiation (LTP) of
synaptic transmission in hippocampus (Malinow
et ah, 1989). The induction of LTP can be pre¬
vented by selective peptide inhibitors of CaM II
kinase as well as by PKC inhibitors (Malinow et
ah, 1989), but it is not yet possible to say with any
certainty whether such factors, in addition to
PKC, serve any role in LHRH priming.
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Summary
The priming effect of LHRH in vitro (which results in increased responsiveness of gonadotropes to
both LHRH receptor-mediated and receptor-independent stimuli) is brought about by an unknown
mechanism. The present results indicate that induction of the LHRH priming effect is inhibited in a
concentration-dependent manner by the protein kinase C (PKC) inhibitors staurosporine, K252a, H7 and
by the novel highly-selective PKC inhibitor, Ro 31-8220. In contrast, a range of other compounds that are
relatively selective inhibitors of other kinases such as tyrosine kinases and Ca2+/calmodulin-dependent
kinases were unable to prevent priming. The PKC inhibitors prevented priming without affecting initial
LHRH-induced gonadotropin secretion. Thus, the priming-elicited increment in secretion was selectively
removed, restoring hormone release to the level measured during an initial response to LHRH. Similar
results were obtained on different days of the estrous cycle where the magnitude of the priming effect
varies. Experiments on the time course of PKC inhibitor action revealed that the critical period was in
the induction of the priming effect, not its expression. The PKC inhibitors had neither acute nor delayed
effects on gonadotropin secretion induced by ionomycin. Staurosporine, K252a and Ro 31-8220 inhibited
LHRH priming with identical potencies to their inhibition of phorbol ester-induced gonadotropin
secretion. The reduced potency of H7 seen on LHRH priming compared to phorbol ester-induced
gonadotropin release parallels results seen with this inhibitor on phorbol ester-induced secretion of
growth hormone (Johnson and Mitchell (1989) Biochem. Soc. Trans. 17, 751-752) and on the pharmaco¬
logical characteristics of PKCs partially purified from anterior pituitary tissue. In all aspects of this study,




(LHRH) has the ability to increase the respon-
Correspondence to: Melanie S. Johnson, MRC Brain
Metabolism Unit, University Department of Pharmacology, 1
George Square, Edinburgh EH8 9JZ, UK.
siveness of gonadotropes to itself; an action known
as the priming effect of LHRH (Aiyer et al.,
1974). As a result, the release of luteinizing hor¬
mone (LH) and follicle stimulating hormone
(FSH) in response to LHRH is greatly enhanced
after an initial exposure to the peptide hormone.
The mechanism by which this increase in pitu¬
itary responsiveness to LHRH occurs is unknown
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but the effect is dependent both on protein syn¬
thesis and the integrity of microfilaments (Picker¬
ing and Fink, 1979). We have previously shown
that a facilitation of LHRFl-induced second mes¬
senger production (and subsequent intracellular
events) occurs in LHRH priming (Mitchell et ah,
1988). In addition, the priming effect involves a
general facilitation of stimulus-secretion coupling
in gonadotropes such that receptor-independent
secretagogues will also elicit greater release of
gonadotropins after LHRH priming (Pickering
and Fink, 1979; Johnson and Mitchell, 1991). The
present experiments were carried out in order to
clarify the second messenger pathways involved
in the induction of the priming effect.
Activation of LHRH receptors on gonado¬
tropes results in phosphoinositide hydrolysis
(Schrey, 1985; Andrews and Conn, 1986), and so
it seems likely that the priming phenomenon is
dependent on production of either inositol 1,4,5-
trisphosphate (IP3) or diacylglycerol (DAG)
(which lead to release of Ca2+ from intracellular
stores and activation of protein kinase C (PKC)
respectively). There is considerable evidence for
Ca2+ having a major role in LHRH-induced go¬
nadotropin release (see Huckle and Conn, 1988,
for review). In contrast, the consensus (McArdle
et ah, 1987; Johnson et ah, 1988; Van der Merwe
et ah, 1990a) but not all (Stojilkovic et ah, 1988)
reports indicate little involvement of PKC in acute
LHRH-induced gonadotropin release. We previ¬
ously described that although PKC activation
could augment the response to LHRH in a
slowly-developing manner analogous to priming,
it did not fully pre-empt priming elicited by
LHRH. Furthermore, the PKC inhibitor H7
(Hidaka and Hagiwara, 1987) had no apparent
effect on LHRH priming at a concentration (10
/u,M) which effectively reversed the effects of
phorbol esters on gonadotropin release (Johnson
et ah, 1988). However, we now report that the
PKC inhibitor staurosporine (Tamaoki et ah,
1986), its congener K252a (Kase et ah, 1986), the
novel highly-selective PKC inhibitor Ro 31-8220
(Davis et ah, 1989), and somewhat higher concen¬
trations of H7 are able to inhibit LHRH priming
without affecting initial LHRH-induced go¬
nadotropin release.
Materials and methods
The methods and experimental design were
based on those described by Pickering and Fink
(1976) with some modifications. Female COB
Wistar rats (200-250 g; Charles River UK) were
maintained under controlled conditions with free
access to food pellets (CRM, Labsure, Manea,
Cambs., UK) and water. Vaginal smears were
examined for at least two regular 4-day estrous
cycles before sacrificing the rats at 13.30 h on the
appropriate day of the estrous cycle. Pituitary
glands were removed and the anterior lobes sepa¬
rated and hemisected. These hemipituitaries were
allocated one/flask such that hemipituitaries
from the same rat were in different treatment
groups. They were incubated in 2 ml of pre-
warmed and gassed (95% 02/5% COz) Hepes-
buffered minimal essential medium (MEM) with
Earle's salts at 37°C in a shaking water bath
under an atmosphere of 95% Oz/5% C02. After
a preincubation of 30 min, and every subsequent
hour thereafter, the medium was changed for
fresh MEM. Replacement medium contained ei¬
ther a kinase inhibitor or no drug for the initial
basal hour and then, in addition, LHRH (0.85
nM) or ionomycin (50 fiM) in the subsequent
hours (1st, 2nd, and 3rd h). To investigate the
effect of staurosporine on the time course of the
development of priming, the incubation periods
were reduced to 30 min, and there were five
consecutive incubations.
The medium removed at the end of each incu¬
bation period was kept at -40°C until assayed
for LH and FSH by radioimmunoassay (Niswen-
der et ah, 1968; Daane and Parlow, 1971) as used
previously in this laboratory (Johnson et al., 1988).
The standards used were NIADDK-rat FSH-RP2
and NIH-LH-S18 for the majority of figures and
tables, although NIADDK-rat LH-RP2 was used
for the data in Table 1 and Fig. 3.
Drugs
Staurosporine, K252a (from Kyowa Medex Co.,
Tokyo, Japan) and Ro 31-8220 (Roche Products,
Welwyn, UK) were made up as stock solutions at
2-10 mM in dimethylformamide (DMF) (the
maximum concentration of DMF (0.5%, v/v) used
was included in control experiments and had no
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effect on either LH or FSH secretion). Phorbol
12,13-dibutyrate (PDBu) was kept in the dark as
a stock solution in DMF at 1 mM. Stock solutions
of l-(5-isoquinolinesulphonyl)-2-methyl-pipera-
zine hydrochloride (H7) (Gibco, Paisley, UK) were
prepared in distilled water at a concentration of
10 mM and kept at -20°C. Luteinizing hor¬
mone-releasing hormone was from Peninsula
Laboratories Europe (St. Helens, Merseyside,
UK) and was used from an aliquoted stock solu¬
tion (10 yug/ml) in 0.9% (w/v) NaCl kept at
— 40°C. Ionomycin (Novabiochem, Nottingham,
UK), genistein (ICN Biochemicals, Cleveland,
OH, USA) and 5-iodo-C8; ,/V-(8-aminooctyl)-5-
iodonaphthalene-l-sulphonamide (a gift from
G.M. Blackburn and S. MacNeil, University of
Sheffield, UK) were used from stock solution of
10 mM in DMF. Calmidazolium (R24571, stock 1
mM, DMF) and 48/80 (stock 10 mg/ml, H20)
were obtained from Sigma Chemical Co. Finally,
ML-7 (Novabiochem) was diluted from a stock of
10 mM in dilute acetic acid.
Statistics
Data are expressed as means ± SEM. When
appropriate, statistical analyses were carried out
using the Student's f-test or the Mann-Whitney
{7-test. The IC50 values for the kinase inhibitors
were obtained from fitting the data with the
non-linear, error-weighted iterative curve fitting
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Fig. 1. Concentration-response curves for the effect of the protein kinase C inhibitors staurosporine (a), K252a (b), H7 (c) and Ro
31-8220 id) on LHRH-induced release of LH. The squares (■) represent the release of gonadotropins from proestrous
hemipituitaries in the 1st h of exposure to LHRH (0.85 nM) and the circles (•) release in a 2nd h of exposure to the peptide. The
greater release in the 2nd h is a result of LHRH priming, which, unlike the initial release effected by this peptide, is inhibited by
staurosporine. Values are mean + SEM and each point is 4 < n > 6.Corresponding basal release of LH was between 5.2-14.8 ng/ml
and was unaffected by any of the inhibitors or their vehicles at the concentrations used.
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Results
Consecutive hourly incubations of proestrous
hemipituitaries with LHRH (0.85 nM) induced a
relatively small release of both LH and FSH in
the 1st h, followed by augmented release of go¬
nadotropin during a 2nd h with LHRH, due to
the self-priming effect of LHRH (Figs. 1 and 2).
Inclusion of staurosporine (10 nM-2 p,M), which
by itself had no effect on basal gonadotropin
release over several hours, had no effect on the
release of gonadotropins seen in the 1st h of
incubation with LHRH (see Figs, la and 2a).
However, exposure to staurosporine caused a
concentration-dependent inhibition of the greater
release of gonadotropins brought about by prim¬
ing. Luteinizing hormone release in the 2nd h
with LHRH was significantly decreased (p < 0.05)
compared to control at concentrations of 30 nM
staurosporine and above; results were similar for
FSH. The concentration of staurosporine at which
50% inhibition (IC50) occurred was 26.3 ± 7.0 nM
for LH and 37.0 + 7.1 nM for FSH. In the pres¬
ence of staurosporine at concentrations of 300
nM and above, release of both LH and FSH was
decreased to levels seen in the 1st h with LHRH
but not to the basal levels of release. Table 1
shows the effect of staurosporine on LHRH-in-
duced gonadotropin release from anterior pitu¬
itary tissue obtained on different days of the
estrous cycle. The magnitude of the priming ef¬
fect of LHRH was dependent on the stage of the
estrous cycle, being largest on proestrus and
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Fig. 2. Concentration-response curves for the effect of staurosporine (a), K252a (b) and H7 (c) on LHRH-induced release of FSH.
The squares (■) represent the release of gonadotropins from proestrous hemipituitaries in the 1st h of exposure to LHRH (0.85
nM) and the circles (•) release in a 2nd h of exposure to the peptide. The greater release in the 2nd h is the result of the
LHRH-priming effect which, unlike the release in the 1st h with LHRH, is inhibited by K252a. Values are mean + SEM and at each
point 4 < n > 6. Corresponding basal release of FSH was between 3.3-4.6 ng/ml and was unaffected by any of the inhibitors or
their vehicles at the concentrations used.
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TABLE 1
EFFECT OF STAUROSPORINE ON LHRH-INDUCED LH RELEASE OVER THE DAYS OF THE ESTROUS CYCLE
AND IN MALES
Hemipituitaries were incubated in vitro for 3 consecutive hours. In the basal hour either medium alone (controls) or staurosporine
(300 nM) was present. In the following 2 h there was, in addition, LHRH (0.85 nM). Values given are the mean + SEM.
Days of cycle Inhibitor LH(ng/ml) n
Basal hour 1st hour 2nd hour
Estrus Control 8.4 +1.6 14.2 ±1.7 35.9 ± 2.3 4
Staurosporine 6.2 +0.7 9.5 ±1.1 9.2 ± 1.1 ** 4
Metestrus Control 4.9 ± 1.2 5.3 ±0.4 25.1 ± 2.2 4
Staurosporine 6.1 ±1.4 4.6 ±1.0 5.8 ± 1.3 ** 4
Diestrus Control 5.25 + 1.17 8.63 + 0.99 55.70+ 4.94 6
Staurosporine 2.92 + 0.56 4.63 + 0.37 6.15+ 0.56 ** 6
Proestrus Control 5.25 + 0.67 27.03 + 2.59 159.7 ±14.43 6
Staurosporine 6.58 + 0.78 25.4 ±3.03 30.70+ 4.26 ** 6
Males Control 6.10+1.40 10.15 + 1.77 21.03+ 4.85 4
Staurosporine 8.04+1.04 8.70 + 0.69 5.74+ 0.45 * 4
*
p < 0.05 significantly different compared to control.
**
p < 0.01 significantly different compared to control.
TABLE 2
EFFECTS OF SOME PROTEIN KINASE INHIBITORS ON LHRH-INDUCED LH AND FSH RELEASE AND PRIMING
Hemipituitaries were incubated in vitro for 3 h. In the basal hour there was medium alone (control) or a protein kinase inhibitor. In
hours 1 and 2 there was, in addition, LHRH (0.85 nM). Values given are mean + SEM.
Inhibitor LH (ng/ml) n
Basal hour 1st hour 2nd hour
Control 20.7 + 2.8 81.9+ 8.3 285.1 + 21.2 8
Genistein (50 /rM) 14.0 + 3.3 79.0 + 14.8 336.3 + 35.2 4
Control 8.5 + 1.8 36.2+ 8.2 191.7 + 26.7 6
5-Iodo-C8 (10 /rM) 15.6 + 3.0 92.0+11.7 ** 282.5 ± 20.2 * 6
Control 7.7+1.7 123.4 + 13.5 283.0+ 6.0 5
48/80 (30 jug/ml) 10.6 + 2.6 184.7 + 10.9 * 299.5 + 11.2 5
Control 4.2 + 0.6 37.7+ 5.0 134.3 + 12.0 5
Calmidazolium (1 (iM) 5.8+1.5 71.0 + 11.8 * 215.6 + 22.4 * 6
Control 7.9 + 3.1 46.9+ 6.3 159.0+12.7 4
ML-7 (3gM) 4.2 + 0.5 57.0+ 5.4 212.7 + 26.8 4
FSH (ng/ml)
Basal hour 1st hour 2nd hour
Control 5.01+0.29 9.93 + 0.96 25.47 + 3.52 8
Genistein 4.29 + 0.44 7.75 + 0.97 22.59 + 3.97 4
Control 3.55 + 0.38 5.89 + 0.64 17.76 + 2.29 4
5-Iodo-C8 5.08 + 0.34 10.27 + 0.82 * 28.57 + 3.28 6
Control 2.63 + 0.28 10.11 + 2.38 41.72+1.23 5
48/80 4.18 + 0.47 18.16 + 0.94 * 45.83 + 3.62 5
Control 2.76 + 0.23 7.50 + 1.15 17.85 + 2.09 4
ML-7 2.68 + 0.19 8.49 + 0.59 25.09 + 2.29 * 4
*
p < 0.05 significantly different compared to control.
**
p < 0.01 significantly different compared to control.
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1974b and Table 1). At each stage of the cycle,
staurosporine (300 nM) blocked LHRH-induced
gonadotropin release in the 2nd h but only to a
level equivalent to that seen in the 1st h of
LHRH incubation.
The less active congener of staurosporine
K252a (30 nM-10 p,M) also caused a concentra¬
tion-dependent inhibition of the 2nd h of
LHRH-induced gonadotropin release (Figs. 1 b
and 2b) again without affecting initial go¬
nadotropin release. There was a significant de¬
crease (/? < 0.05) in LHRH-induced release of
both LH and FSH compared to control at K252a
concentrations of 3 /xM and above. The IC50 for
inhibition of LHRH-induced release by K252a
was 2.9 + 0.4 /xM for LH and was 2.3 + 0.5 p,M
for FSH.
Figs, lc and 2c show the effect on LHRH
priming of a PKC inhibitor of quite different
structure, H7 (10-300 /xM). At concentrations
above 30 /xM H7 there was significant (p < 0.05)
inhibition of both LH and FSH release in the 2nd
h with LHRH, with no effect on LHRH-induced
gonadotropin release in the 1st h. The IC50 for
inhibition of the 2nd h of LHRH-induced release
by H7 was 71.6 ± 13.3 /xM for LH and 88.1 ± 20.4
/xM for FSH. The novel and highly-selective PKC
inhibitor, Ro 31-8220 (0.1-50 /xM), also caused a
concentration-dependent inhibition of the primed
but not the unprimed gonadotropin secretion in¬
duced by LHRH (Fig. 1 d). At concentrations of
10 p,M and above, the inhibition was statistically
significant (p < 0.05) and gave an IC50 for inhibi¬
tion of the 2nd h of LHRH-induced LH release
of 19.0 ± 6.8 /xM.
A range of inhibitors of different classes of
kinases (used at concentrations described in the
literature to cause more than 50% inhibition of
the relevant kinase in whole cells) were compared
(Table 2). Genistein (50 /xM), an inhibitor of
several tyrosine kinases (Akiyama et al., 1987),
had no effect on either initial LHRH-induced
gonadotropin release or priming. Calmidazolium
(R24571), 48/80 (Gietzen, 1983) and 5-iodo-C8
(MacNeil et ah, 1988), which inhibit Ca2+/cal-
modulin-dependent kinases, all significantly in¬
creased LHRH-induced release of LH and FSH
in either the 1st, 2nd or both hours with LHRH,
but did not block the priming effect. Similarly,
ML-7 which is a selective inhibitor of Ca2+/cal-
modulin-dependent myosin light chain kinase
(MLCK) acting at a site other than the calmod¬
ulin recognition site (Saitoh et ah, 1987), failed to
block LHRH priming.
basal h 1 st h
control
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Fig. 3. Effect of staurosporine on the induction/expression of LHRH priming. Release of LH from proestrous hemipituitaries was
measured over either 2 or 3 consecutive hours with LHRH (0.85 nM). In part a, staurosporine (300 nM) was included (dotted bars)
in the basal h and 1st h of LHRH (i.e. that hour during which priming takes place). Between the 1st and 2nd h with LHRH, the
tissue was washed twice with MEM to remove the staurosporine before incubating the tissue with LHRH alone for a 2nd h.
Although staurosporine was not present in the 2nd h, primed release was significantly inhibited (p < 0.05). Part b shows the effect
of staurosporine (300 nM) on LHRH-stimulated LH release from previously-primed proestrous tissue. Hemipituitaries were primed
by incubating with LHRH for 1 h. They then received a further 2 consecutive hours of incubation in the presence of LHRH and
300 nM staurosporine (dotted bars). Staurosporine was unable to inhibit LHRH-stimulated LH release from previously-primed
tissue.Values are mean + SEM (n = 4).
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In order to determine whether the stau-
rosporine-sensitive step was in the induction of
the priming effect rather than its expression, sev¬
eral experiments were carried out. Firstly, stau-
rosporine (300 nM) was included in the basal and
1st h of LHRH incubation (i.e. that hour during
which priming takes place), after which stau-
rosporine was removed and the tissue was exten¬
sively washed before a second hourly incubation
in the presence of LHRH only (see Fig. 3a). As
observed previously, staurosporine did not alter
initial LHRH-induced LH release. However,
LHRH-induced release of LH in the 2nd h of
LHRH was still fully blocked to a level equivalent
to that in the 1st h responses to LHRH. Two
pieces of evidence indicated that this washing
procedure was successful in substantially reduc¬
ing the staurosporine concentration in the tissue:
(i) an identical procedure using [3H]7V,TV-di¬
methyl staurosporine (a close structural analogue
of staurosporine) resulted in a reduction of the
tissue concentration to 8 + 2% (n = 4) of the
initial level; (ii) in tissue incubated with stau¬
rosporine and washed as above, the facilitation of
K+-induced 45Ca2+ influx caused by 300 nM
PDBu (MacEwan and Mitchell, 1991) was not
reduced from that in control tissue (108 ± 10% of
the facilitation in vehicle-incubated controls, n —
3). In the second series of experiments we investi¬
gated whether staurosporine affected LHRH-in¬
duced LH release from previously-primed tissue
(Fig. 3b). In this experiment, tissue was primed
with LHRH for 1 h before including stau¬
rosporine (300 nM) during the 2nd and 3rd h
LHRH incubations. Even over a period of 2 h (to
allow for the slow development of any possible
effect) staurosporine did not block LHRH-in¬
duced gonadotropin release from previously-
primed tissue. The results of these two experi¬
ments show clearly that staurosporine blocks the
priming but not the gonadotropin-releasing ac¬
tion of LHRH. The time course of the action of
staurosporine is shown in Table 3. When stau¬
rosporine was added over four 30 min incubation
periods with LHRH, the increment in LH release
due to priming seen in periods 2, 3 and 4 of
control (LHRH alone) incubations was abolished
completely. However, when staurosporine was
added later, at the beginning of periods 2 or 3,
primed release was progressively less inhibited.
The ability of LHRH priming to escape inhibition
by staurosporine if the tissue is exposed to LHRH
for 30 min prior to the inhibitor is in agreement
with data using the protein synthesis inhibitor
cycloheximide, which also prevents LHRH prim¬
ing with similar temporal characteristics (Picker-
TABLE 3
EFFECT OF STAUROSPORINE ON THE TIME COURSE OF LHRH-INDUCED LH RELEASE
Release of LH was measured from hemipituitaries that were incubated in vitro for a basal 30 min and then four consecutive 30 min
periods with LHRH (0.85 nM). The basal release of LH was stripped from the values for LHRH-induced LH release in the time
periods 1-4. The PKC inhibitor, staurosporine (300 nM) was added into the incubation series at the beginning of the time period at
which + is indicated in the row above the data and was present to the end of the experiment. Values given are mean + SEM (n - 4).
LH (ng/ml)
30 min incubations
1 2 3 4
Staurosporine - - - -
LHRH 17.6+10.5 52.7+14.5 104.6+10.2 137.2+16.4
Staurosporine - - + +
LHRH 6.8+ 3.4 35.8+ 2.9 84.9+ 8.6 76.5+ 3.9 *
Staurosporine - + + +
LHRH 8.2+ 3.7 30.7+11.4 57.2+17.1 -i. 62.9 + 20.4 **
Staurosporine + + + +
LHRH 17.3+ 7.0 25.5+ 9.8 20.8+ 8.3 ** 20.5+ 8.4 **
*
p < 0.05 significantly different compared to control (LHRH alone).
**
p < 0.01 significantly different compared to control (LHRH alone).
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ing and Fink, 1976). Some priming still occurred
if pituitaries were exposed to LHRH for as little
as 15 min before a concentration of cyclohex-
imide was added that was sufficient to abolish
priming if given in conjunction with LHRH.
To confirm that staurosporine has no in¬
hibitory activity upon the secretory apparatus of
the cell, we investigated the effect of this drug on
ionomycin (50 /rM)-induced release of LH and
FSH. In the presence of 300 nM staurosporine,
there was clearly no significant alteration in LH
or FSH release induced by a 1st h or 2nd h
incubation with ionomycin (Table 4). In the final
experiment hemipituitaries were primed with
LHRH (0.85 nM) either in the presence or ab¬
sence of staurosporine (300 nM) and ionomycin
(30 fxM) was used as a receptor-independent
secretagogue to elicit primed LH release. After
priming with LHRH, ionomycin induced a much
greater release of LH (157 + 11 ng/ml) than in
control incubations with ionomycin alone (63 + 6
ng/ml). The addition of staurosporine during the
priming hour, however, fully prevented this facili¬
tation of the response to ionomycin (LH release
of 69 + 4 ng/ml; n = 4-6).
Discussion
The results presented here indicate that acti¬
vation of a protein kinase, probably a form of
PKC, is necessary for LHRH priming but not
initial LHRH-induced gonadotropin release.
Thus, the facilitation of gonadotropin release
brought about by LHRH priming was completely
prevented by staurosporine, leaving LHRH-in¬
duced release equivalent to that of unprimed
responses, regardless of the degree of priming
that had occurred (Table 1). The absolute po¬
tency of staurosporine here (26.3 + 7.0 nM) is
similar to that reported in thoroughly-char¬
acterised PKC-mediated cellular responses, for
example, in platelets, T cells and spinal afferent
nerve terminals (Davis et al., 1989; Dunn and
Rang, 1990) and in cell-free assays of the activity
of partially- or extensively-purified PKCs (Naka-
date et al., 1988; Schaap and Parker, 1990; John¬
son and Mitchell, unpublished). Indeed, under
equivalent conditions to the present experiments,
the release of LH elicited by 100 nM PDBu was
similarly inhibited by staurosporine with a IC50 of
44.0 + 17.2 nM (n = 4). The potency ratio for the
inhibitory effects of staurosporine and K252a on
LHRH priming (62- and 111-fold for FSH and
LH respectively) is of a similar order to that
reported for their inhibition of PKC in cell-free
systems (36-fold) but contrasts with the corre¬
sponding values for cAMP-dependent (PKA) and
cGMP-dependent (PKG) protein kinases of 2.5
and 2.3 respectively (Kase et al., 1986; Tamaoki
et al., 1986). A novel PKC inhibitor, Ro 31-8220
(which is reported to show selectivity for PKC
over PKA and Ca2+/calmodulin-dependent ki¬
nase of 2-3 orders of magnitude; Davis et al.,
1989), also inhibited LHRH priming of LH re¬
lease, with an IC50 value of 19.0 ± 6.8 p,M, simi¬
lar to that for inhibition of PDBu (300 nM)-in-
duced LH release (15.6 + 4.5 q,M, n = 5). The
isoquinoline inhibitor of PKC, H7, also inhibited
LHRH priming. There was, however, an interest¬
ing disparity between the IC50 of H7 on LHRH
priming (71.6 ± 13.3 /xM) and on PDBu (100
nM)-induced LH release (1.7 ± 1.5 yuM, n = 6).
We have previously described several other in¬
stances where phorbol ester-induced effects were
inhibited with unusually low potency of H7 but
not of staurosporine (Johnson and Mitchell, 1989;
Johnson et al., 1989; Fink et al., 1990; MacEwan
and Mitchell, 1991; Thomson et al., 1991a) and
the ability of staurosporine but not H7 to inhibit
some phorbol ester effects has also been de¬
scribed by others (Watson et al., 1988; Nakadate
et al., 1989). Indeed when the PDBu-induced
kinase activity of PKCs partially purified from
anterior pituitary but not brain tissue was mea¬
sured in a mixed micelle assay (Johnson et al.,
1991), a Ca2+-independent component of the ac¬
tivity was apparent which displayed a reduced
potency towards H7 but not staurosporine. Both
Ca2+-dependent and Ca2+-independent PDBu-
induced activity were inhibited by staurosporine
with similar IC50 values (114 ± 65 nM and 107 +
41 nM respectively), but H7 inhibited Ca2+-de-
pendent activity (9 + 4 yuM) much more effec¬
tively than Ca2+-independent activity (47 + 20
fxM). In brain and a number of peripheral tissues,
staurosporine and H7 both displayed identical
IC50 values on Ca2+-dependent and -independent
activity.
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Since both staurosporine and H7 are consid¬
ered to act close to the ATP-binding site of
PKCs, which is quite highly conserved in a num¬
ber of kinases, such disparities in the potency of
H7 but not staurosporine are at first sight unex¬
pected. However, the sites of action of these
inhibitors appear to be non-identical. While
K252a has been reported to be a competitive
inhibitor with respect to ATP (Kase et al., 1987)
there is evidence to the contrary for stau¬
rosporine (Tamaoki et ah, 1986; Riiegg and
Burgess, 1989) and the binding of [3H]A,A-di-
methyl staurosporine is displaced with only ex¬
tremely low potency by H7 (IC50 > 500 juM)
(Thomson et ah, 1991b). Although kinase in¬
hibitors of the isoquinoline type do appear to act
in a kinetically competitive manner with respect
to ATP (Hidaka et ah, 1984), certain analogues
(for example HA 1004 and H7) demonstrate dis¬
tinct relative selectivity for or against particular
kinases (Hidaka and Hagiwara, 1987) indicating
that a degree of recognition specificity is possible
at this site. Furthermore, it is not clear that the
H7 recognition site is entirely concurrent with
that for ATP, since H7 provides only partial
protection against denaturation of the ATP site
by covalent chemical reagents (Ohta et ah, 1988).
Finally, in some cases, the relationship between
H7 and ATP recognition may be complex since
the sequences of a and (3 isoforms of PKC con¬
tain a second consensus recognition motif for
ATP (Huang, 1989). It is unclear whether the
relatively H7-resistant kinase involved in LHRH
priming might represent a particular PKC
isozyme, some modified form of PKC, a distinct
but related kinase or the influence of other as yet
quite unknown factors. Whichever is the case, the
consensus of inhibition of LHRH priming by four
PKC inhibitors, taken with the ineffectiveness of
an array of inhibitors of other types of kinase,
strongly suggests that a form of PKC or related
kinase is required for LHRH priming.
Staurosporine and K252a can have inhibitory
actions on tyrosine kinases (Yamagiichi and
Kathuria, 1988), PKA (Tamaoki et ah, 1986),
myosin light chain kinase and Ca2+/calmodulin-
dependent (CaM II) kinase (Watson et ah, 1988).
However, the action of staurosporine on LHRH
priming seems unlikely to involve these kinases
TABLE 4
EFFECT OF STAUROSPORINE ON IONOMYCIN-IN-
DUCED LH AND FSH RELEASE
Hemipituitaries were incubated in vitro for 3 h. In the basal
hour there was medium alone (controls) or staurosporine (300
nM). In the next 2 consecutive hours there was, in addition,
ionomycin (50 p,M). Values given are the mean + SEM (n = 7).
Inhibitor LH (ng/ml)
Basal hour 1st hour 2nd hour
Control 5.5+1.0 95.5 + 13.8 63.1 + 12.8
Staurosporine
(300 nM) 6.1 + 0.4 108.6 + 13.0 61.9+ 8.7
FSH (ng/ml)
Basal hour 1st hour 2nd hour
Control 2.47 + 0.16 8.65 + 0.90 6.52 + 0.67
Staurosporine
(300 nM) 2.45 + 0.14 7.66 + 0.63 5.27 + 0.38
since inhibitors of tyrosine kinase (genistein),
CaM II kinase (the calmodulin antagonists:
calmidazolium, 5-iodo-C8 and 48/80) and MLCK
(ML-7) were ineffective and both the potency
ratio of staurosporine versus K252a on LHRH
priming and the identical potency of Ro 31-8220
on priming and PDBu-induced responses argue
against a role of cyclic nucleotide-dependent ki¬
nases. Interestingly, both initial LHRH-induced
release and/or that from primed tissue were
enhanced by a number of the CaM II kinase
inhibitors. Evidence supporting a role of CaM II
kinase in LHRH-induced gonadotropin release
has been provided by several laboratories (Conn
et ah, 1984; Das et ah, 1989) but recent evidence
(Van der Merwe et ah, 1990b) suggests that it is
only the more non-specific of the calmodulin
antagonists used that inhibit LHRH-induced LH
release. Certainly raised intracellular Ca2+ is an
effective secretagogue for LH, yet it will not
mimic the priming effect of LHRH (Table 4).
Interestingly, removal of extracellular Ca2+ dur¬
ing an initial hour of incubation with LHRH,
while reducing LH release in that hour, does not
prevent LHRH priming if Ca2+ is replaced in a
second hour with LHRH (Pickering and Fink,
1979). If CaM II kinase is involved in the first
phase of LHRH-induced release it is unclear why
our results show an increase of LH release in the
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presence of CaM II kinase inhibitors. The Ca2+/
calmodulin-dependent phosphatase, calcineurin
(Armstrong, 1989) has been detected in pituitary
cells (Farber et ah, 1987), so if raised Ca2+ levels
in gonadotropes were to increase both calmod¬
ulin-dependent phosphorylations and dephos-
phorylations then interpretation of the overall
effects of calmodulin antagonists would be com¬
plex.
Staurosporine exerts its inhibitory effects on
primed gonadotropin release if present during
that hour in which LHRH priming takes place
(i.e. the 1st h), but is removed for the hour of
further challenge with LHRH, showing that its
action is on the induction rather than the expres¬
sion of LFIRH priming (Fig. 3a). Furthermore,
the response of previously-primed tissue to
LHRH was unaltered by staurosporine (Fig. 3b).
Since staurosporine will also prevent the facili¬
tated response to ionomycin seen in previously-
primed tissue, staurosporine cannot simply be
acting as a slowly-acting inhibitor of a late com¬
ponent of LHRH responses. Additional evidence
that staurosporine was not acting by a delayed,
non-specific action on the secretory apparatus of
the gonadotrope was provided by its lack of effect
alone on secretion induced by the Ca2+ iono-
phore, ionomycin (Table 3). In an analogous fash¬
ion to its role here in LHRH priming, PKC has
been implicated in the induction but not expres¬
sion of another phenomenon of increased cellular
responsiveness, long-term potentiation (LTP) of
synaptic transmission in hippocampus (Malinow
et al., 1989). The induction of LTP can be pre¬
vented by selective peptide inhibitors of CaM II
kinase as well as by PKC inhibitors (Malinow et
al., 1989), but it is not yet possible to say with any
certainty whether such factors, in addition to
PKC, serve any role in LHRH priming.
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^ l°|l
Modulation by phorbol 12,13-dibutyrate of dihydropyridine-sensitive hor¬
mone release from rat anterior pituitary tissue in vitro
liy M. .S. .Johnson, It. Mitchell, I). .1. MacIOwan and F. J. Thomson. MItC Bruin
Metabolism Unit, 1 George Square. Edinburgh EH8 !)JZ
Our previous studies revealed quite dilTerent influences of activators of protein
kinase 0 (I'KC) on hormone sceretion from gonadotropics and somatotrophes
(.Johnson & Mitchell, 1989; .Johnson rial.. 19896). 1'horbol 12,13-dibutyrate (PDBu)-
indueed release of growth hormone (Oil), unlike that of luteinizing hormone (LH),
occurs rapidly and is sensitive to t he L-tyjie Cai+ channel blocker nimodipine (NMD).
It is clear from experiments measuring 45Ca2+ movements that L-channels in
pituitary cells can be directly modulated by l'KC (.Johnson el al. 1989a). In order to
investigate further t he influence of l'KC on L channels in pituitary cells we examined
phorbol ester and dihydropyridine effects on K+-induecd release of GH and LH.
Female COB/Wistar rats, that, had been maintained under controlled lighting and
tem|Hirature were killed at. 13.30 h of pro-oestrus and their anterior pituitary
glands removed and heinisected. The secretion of Lll and Gil in vitro was measured
as described previously (.Johnson el al. 19896). Incubation with 60 mM-K+ medium
for 1 h caused a 6-7-fold increase in Gil release over basal and a 9-2-fold increase in
Lll release. In the presence of 1 //m NM1) these responses were 97% and 87%
inhibited res|>cctivoly. In the presence of 100 iim-1'DBu, K+-induccd GH release was
unaltered, showing a mean increment of 5733+1236 ng GH/ml compared to
5438 + 531 ng GH/ml in controls (mean±s.b.m.. n = 5). In contrast K + -induced LH
release was amplified almost 2-fold by l'DBu, showing a mean increment of
174-6 + 10-8 ng LH/ml compared to 90-5+1 I t) ng LH/ml in controls. The K+-
induccd release of GH in the presence of l'DBu was reduced by 5355 + 718 ng/ml
by 1/iM-NMD whereas the corresponding LH response was oidy reduced by
97-3 + 8-7 ng/ml (an amount similar to the K+-indueed release without I'DBu
amplification). However, when I'DBu-induccd hormone release was studied in the
presence of 3 /tM BAY K8644 (which had no cll'ect alone during 1 h of incubation),
the LH res|>onse was greatly potentiated with an increment of 2-56-fold over that of
PDBu-induced LII release alone. The release of GH was completely unaffected. It is
possible that in gonadotropics but not in somatotrophes, L-ty|»e Ca2+ channels are
recruited by I'DBu in a form (Hess el al. 1984) which requires the additional influence
of another factor such as BAY K8644 before optimal activity is expressed.
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I) 124 T THE ACTIVATION OF PROTEIN KINASE C ISOFORMS BY 1,2-DIOCTANOYL-
sn-GLYCEROL (DOG) COMPARED WITH PHORBOL 12,13-DIBUTYRATE (PDBu).
M.S. Johnson, R. Mitchell, D.J. MacEwan and F.J. Thomson, MRC Brain Metabolism Unit,
1 George Square, Edinburgh, UK.
To investigate the possibility that phorbol esters and diacylglycerols may display some
selectivity in the activation of protein kinase C (PKC), we used a mixed-micelle histone IIIS
kinase assay to determine PKC activity. Phosphatidyl serine-dependent kinase activity
partially-purified from cytosol was measured in the presence (100 pM) or absence (< 3 nM)
of free Ca2+. EC50 values were determined for PDBu and DOG using tissue sources rich in
particular isoforms; i.e. midbrain (most isoforms), spleen (13, with some 5) and COS 7 cells
(a). With Ca2+ present, PDBu activated PKC from all three sources similarly, with EC50 s
(nM):77 ± 10 (spleen), 148 ± 73 (COS 7) and 104 ± 128 (midbrain). The corresponding
values without Ca2+ were 620 ±117, 2270 ± 1595 and 875 ±131. When DOG was used as
activator the corresponding EC50S (pM) were 17.3± 11.7, 19.0 ± 5.4 and 2.1 ± 0.4, in the
presence of Ca2+. Without Ca2+, the EC50 values were 84.5 ± 23.0, no activation (COS 7)
and 41.3 ± 14.7 respectively. The total PKC activity evoked without Ca2+ was greater for
PDBu than DOG, but was similar with Ca2+ present, suggesting that PDBu, (but not DOG, at
aPKC at least) can activate some Ca2+-dependent PKC isoforms in a Ca2+-independent
fashion. However, DOG is more effective at activating a Ca2+-dependent PKC isoform in
midbrain that is not a or 8 and thus may well be y
D 173 T PHARMACOLOGICALLY DISTINCT FORMS OF PROTEIN KINASE C
REGULATE ARACHIDONIC ACID RELEASE FROM ANTERIOR PITUITARY CELLS.
F.J. Thomson, D.J. MacEwan, M.S. Johnson & R. Mitchell, MRC Brain Metabolism Unit,
1 George Square, Edinburgh, UK.
Activation of protein kinase C (PKC) can induce arachidonic acid (AA) release from anterior
pituitary cells. Since different forms of PKC may display selective pharmacology, we
investigated the actions of activators and inhibitors of PKC on [3H]AA release from
prelabelled rat anterior pituitary pieces. [3H]Arachidonic acid release from anterior pituitary
tissue was significantly increased in the presence of either phorbol 12,13-dibutyrate (PDBu),
mezerein or 1,2-dioctanoyl sn-glycerol. The [3H]AA release induced by PKC activators was
readily blocked by staurosporine and Ro 31-8220. However, blockade by another PKC
inhibitor, H7, was biphasic, consisting of H7-sensitive and insensitive components.
Furthermore, concentrations of H7 as high as 100 pM could only block PDBu-induced AA
release to a level 23 ± 9 % above basal. PKC activity, partially-purified from anterior pituitary
cytosol, was measured in a mixed micelle assay using histone IIIS as a substrate.
Phosphatidylserine-dependent, PDBu-induced, Ca2+-independent activity was relatively
resistant to block by H7 (IC50 = 121 ± 18 pM) in comparison to Ca2+-dependent activity (IC50
= 17 ± 4 pM). Corresponding values for staurosporine were 101 ±30 nM and 171 ±46 nM,
respectively. Clearly both H7-resistant, Ca2+-independent and H7-sensitive, Ca2+-
dependent PKCs (or related kinases) can participate in the control of AA release.
3 102 F INVERSE REGULATION OF L-TYPE Ca2+ CHANNELS BY TWO DISTINCT
FORMS OF PROTEIN KINASE C. R. Mitchell, D.J. MacEwan, M.S. Johnson, F.J.
Thomson, MRC Brain Metabolism Unit, 1 George Square, Edinburgh, UK.
In order to investigate kinase regulation of Ca2+ channels in pituitary cells we measured
effects of kinase activators and inhibitors on the depolarisation-induced rapid influx of
45Ca2+. Phorbol esters such as phorbol 12,13-dibutyrate (PDBu) elicited inverse effects on
nimodipine-sensitive K+-induced 45Ca2+ influx in GH3 cells (inhibition) and anterior pituitary
prisms (facilitation). Both influences were stereospecific and readily blocked by
staurosporine (3 - 1000 nM) and also by Ro 31-8220. H7 showed clear selectivity between
the responses, with an IC50 in GH3 cells of 7 ± 4 pM but in pituitary prisms of 62 ± 6 pM. 1,2
Dioctanoyl-sn-glycerol and a number of atypical phorbol esters could elicit the facilitatory but
not the inhibitory effect, whereas mezerein caused similar facilitation in both tissues. The
effect of mezerein in GH3 cells was blocked by staurosporine, Ro 31-8220 and H7 with
IC50S of 23 ± 9 nM, 7 ± 4 pM and 59 ± 8 pM. This suggests that mezerein may be a
selective activator of one or more form of PKC (which is relatively resistant to H7) and can
select a distinct facilitatory component out of the combination of inhibition and facilitation
elicited by a broad-spectrum activator such as PDBu.
J. Physio!. (1992) Vol. 449. Proceedings of The Physiological Society
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Differential actions of protein kinase C modulators on the release of hormones
from rat anterior pituitary tissue in vitro
M.S. Johnson, F.J. Thomson, J.L. Avery, D.J. MacEwan and P.R. Mitchell
MRC Brain Metabolism Unit. 1 George Square, Edinburgh EH8 9JZ
We have previously reported that phorbol 12,13-dibutyrate (PDBu)-induced
release of luteinizing hormone (LH) and growth hormone (GH) from rat
anterior pituitary in vitro show different time courses and different sensitivity
to the protein kinase C (PKC) inhibitors H7 and staurosporine (Johnson &
Mitchell, 1989). In view of the possibility that distinct forms of PKC may be
involved, we have examined the effects of another PKC activator, mezerein
(MEZ), known to mimic only some of the effects of phorbol esters (Slaga et al.
1980).
The release of LH and GH from pro-oestrous rat hemipituitaries was
measured according to Johnson & Mitchell (1989). The magnitude of GH
release induced by MEZ was similar to that seen with PDBu, thus in the
presence of either 100 nM PDBu or 100 nM MEZ. GH release was 2.32 ± 0.33 or
2.33 ±0.33 (mean ± S.E.M., n = 4-6) fold of basal. However, MEZ (100 nM)
was more effective at releasing LH. where the equivalent figures were 3.52 ± 0.28
and 13.35 ± 1.92 fold of basal LH release respectively (n = 4-6). The release of
CH induced by MEZ or by PDBu (300 nM) was unaffected by H7 (30 pM). In
contrast, 10 gM H7 inhibited the release of LH induced by MEZ and PDBu by
35 ± 10 and 64 ± 15% respectively (n = 4-6).
To compare the actions of these PKC modulators on kinase activity,
partially purified PKCs from male rat midbrain (reported to contain messen¬
ger RXA for all of the known PKC isoforms: Scott Young III, 1989) were
investigated using a phosphatidyl serine-dependent, histone III-S kinase as¬
say. similar to that described by Huang et al. (1988). The Ca2+-independent
activity induced by MEZ and PDBu was inhibited similarly by H7 (IC50s of
27 ± 7 and 49 ± 4 pM, n = 4-8). The Ca2+ -dependent activity induced by MEZ
was notably more sensitive to H7 than that induced by PDBu (IC5os of 4 ± 2
and 47 ± 9 pM, n - 3-8). Taken together, these data suggest that MEZ may
show some selectivity for activation of a Ca2+-dependent PKC, which is highly
sensitive to H7. Both this and other PKCs may participate in the LH release
induced by PKC activators.
REFERENCES
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PHARMACOLOGY OF PROTEIN KINASE C ISOFORMS AND THEIR
CELLULAR ACTIONS IN ANTERIOR PITUITARY CELLS.
David MacEwan, Rory Mitchell, Melanie Johnson and Fiona Thomson.
MRC Brain Metabolism Unit, 1 George Square, Edinburgh, EH8 9JZ, UK.
The multiple isoforms of protein kinase C (PKC) may have a range of
distinct functions. We are interested in whether they can be differentially
manipulated pharmacologically in anterior pituitary cells. A number of
distinct pharmacological profiles emerge from experiments on PKC
regulation of secretion and ion fluxes in pituitary cells. Arachidonic acid
(AA), like phorbol dibutyrate (PDBu).acts through PKC in GH3 cells to
attenuate 45Ca2+ influx through 'L'-type Ca2+ channels. However, in
anterior pituitary tissue, AA, cannot mimic the PDBu-induced enhancement
of 45Ca2+ influx through 'L'-channels. Likewise, in pituitary tissue, PDBu-
induced secretion of luteinizing hormone (LH), but not growth hormone
(GH), is mimicked by AA. These PKC-mediated effects are all sensitive to
the PKC inhibitor staurosporine. However, only the influences of PKC on
GH3 (but not pituitary) Ca2+ influx and LH (but not GH) secretion were H7-
sensitive. Selectivity of dioctanoyl glycerol (DOG) and deoxyphorbol
isobutyrate (DPB) will also be discussed. These activators and inhibitors of
PKC may be selective for PKC-isoforms in functional pituitary cells.
J. Physiol. (1992) Vol. 446. Cambridge Meeting 18-19-20 July 1991
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Protein kinase C may be required to maintain activity of nimodipine-sensitive Ca2+
channels in rat anterior pituitary cells in vitro
D.J. MacEwan. M.S. Johnson. F.J. Thomson and R. Mitchell
MRC Brain Metabolism Unit, 1 George Square, Edinburgh EH8 9JZ
Potassium-induced release of growth hormone (GH) from anterior pituitary
tissue in vitro is inhibited by nimodipine (Johnson et al. 1991). Correspond¬
ingly, K+-induced 4oCa2+ influx into anterior pituitary prisms and into cells of
the GH3 line is nimodipine-sensitive (Johnson et al. 1991; Johnson et al. 1989).
The protein kinase C (PKC) activator phorbol 12,13-dibutyrate (PDBu) also
releases GH and the response is largely inhibited by nimodipine (97 ± 9%
inhibition at 1 gM. mean±S.E.M., n — 6), suggesting that a PKC in
somatotropics can enhance the activity of dihydropyridine-sensitive Ca2+
channels. The K+-induced influx of 4oCa2+ in anterior pituitary prisms is facili
tated by PDBu and both this response and the effect of PDBu on GH releas<
were acutely reversed by the PKC inhibitor staurosporine (3-300 nM) but no
H7 (1-30 pM) (Johnson et al. 1989; Johnson & Mitchell. 1989). The presen
experiments were carried out to investigate whether there is a tonic influene
of PKC on these Ca2+ channels.
Measurements of GH secretion and K+-induced 4oCa2+ influx were made a
previously described (Johnson & Mitchell, 1989; MacEwan & Mitchell. 1990
Staurosporine (300 nM) reduced 60 mM K+-induced GH release during
consecutive hours to 44 ±13 and 10 ±14% of controls after lh addition!
preincubation with the drug (mean ± S.E.M.. n — 8). There was no effect <
10 gM H7 (114 ± 15% of control; mean ± S.E.M.. n = 5). nor did staurosporir
reduce ionomycin (50 pM)-induced release (107 ± 14 and 100 ± 12% of contrc
in 2 consecutive hours. mean±S.E.M.. n = 7). Correspondingly, several sele
tive PKC inhibitors reduced K+-induced 4oCa2+ influx into pituitary prist
after preincubation for 60 min but not 10 min: for example, 300 nM staurospori
caused 84 ± 7 and 7 ± 5% inhibition at the two time points respective
(mean ± S.E.M., n — 4). Ionomycin (30 pM)-induced 4oCa2+ influx was un.
fected by staurosporine (300 nM for 60 min) and K+-induced 4oCa2+ influx v
slightly enhanced bv H7 to 138 ±10% of control by 20 pM H7 for 60 n
(mean ± S.E.M.. n = 4). Furthermore, presumed down-regulation of PKC lev
in GH3 cells by treatment with PDBu (300 nM) for 24 h reduced 60 mM 1
induced 4oCa2+ influx to 29 ± 10% of control levels (mean ± S.E.M.. n = 6).
These results support the hypothesis that PKC activity in somatotrop
may normally contribute to maintaining nimodipine-sensitive Ca2+ channel
a relatively activated state.
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1 90 SELECTIVITY 0T PROTEIN KINASE C ACTIVATES IN THE REGULAT ION OF Ca24-CIIANNELS IN RAT
INTERIOR prruTTAKrTEurc
0..1. Macfwan, R. Mitchell, M.S. Johnson and F.J. Tlionison, MRC Brain Metabolism Unit, 1
George Square, Edinburgh EHO 9JZ.
Protein kinase C (PKC) can be activated not only by diacylglyccrols and |>horhol esters
hut also by arachidonic acid (AA) which can selectively activate certain PKC-isoforms.
Phorbol 12,13-dibutyrate (PI)Bu) has previously been shown to enhance depo 1 arisation-
induced ^Ca?4 influx into rat anterior pituitary pieces, but inliibits *5Ca<?*
influx into GII3 clonal cells under similar conditions'. This influx occurs through
an L-type Ca'4-channel in both pituitary pieces and GII3 cells. Amongst a range of
PKC activators tested, 011 K4-induced ^Ca^4 influx in these models, 1,2-d ioctanoyl
glycerol (DOG), 17-deoxyphoi bo 1 13-isobulyrale (11111) and AA could selectively elicit
just one of the responses. K4-induced ^Ca?4 influx into pituitary pieces was
increased by Klfl *■ 101 in the presence of lOtltiM DOG and by 30 1 SX in the presence of
I11H DI'll. DOG and DI'B were inactive in GII3 cells. In contrast, AA inhibited
K -induced ^Ca?4_jnf lux into ("1II3 cells (K'yj = 20|iM) tlirouyh activation of
PKC? but was inactive in pituitary pieces up to 300iiM. There is evidence that both a-
and ft- hut not y- isoforms of IKE are present in the pituitary'. It is possible that
the selective actions of certain PKC activators here may be due to their preferential
activation of particular PKC isoforms.
1. Johnson, M.S. et al. (19R9) J. Physiol, (in press).
2. MacEwan, D. and Mitchell, R. Biochcm. Sue. Trans, (in press).
3. Naor, I. el al. (19(1(1) Mol. Endocrinol. 2, 1013-loio.
3. Endocrinol. 124(Suppl) : 190
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Protein kinase C-dependent and -independent
actions of arachidonic acid in GH3 cells
DAVID J. MACEWAN, RORY MITCHELL, MELANIE S.
JOHNSON and FIONA J. THOMSON
MRC Brain Metabolism Unit, University Department of
Pharmacology, 1 George Square, Edinburgh EH8 9JZ, UK
The influx of 45Ca2.+ evoked by exposure of GH3 cells to
high K+-containing medium is mainly (-85%) through a
nimodipine-sensitive route [1]. Pre-exposure of GH3 cells to
arachidonic acid (AA) causes a time- and concentration-
dependent inhibition of K+-induced 45Ca2+ influx which is
reversed by selective inhibitors of protein kinase C (PKC) [2]
and attenuated by down-regulation of PKC levels by 24 h
pre-treatment with phorbol-12 13-dibutyrate (PDBu). The
inhibition of K+-induced 45Ca2+-influx by AA and other
unsaturated fatty acids occurred in the folowing order of
magnitude at 30 pM: AA > linoleic acid > AA methyl ester,
which agrees with their order of potency in activation of PKC
[3]. A similar inhibition of K+-induced 46Ca2+ influx was
seen with 10 min PDBu treatment prior to the depolarising
stimulus [2]. Either PDBu or 48 (but not a) -phorbol 12,13-
didecanoate, however, caused a maximal inhibition of
depolarisation-induced 45Ca2+ influx of -50%, whereas AA
«' inhibited K+-induced 45Ca2+ influx at a concentration ofpM. A selective inhibitor of PKC, H7 [4], fully reversedinhibit on seen with either PDBu or AA, but HA1004, a
less potent and unselective kinase inhibitor, could not
reverse the effect of PDBu or AA. The same distinction was
apparent with the PKC-selective and -unselective kinase
-inhibitors staurosporine [5] and K252a [6] respectively.
Therefore, the involvement of PKC in AA-induced inhibition
of K+-evoked 45Ca2+ influx into GH3 cells seems likely, but
an additional (non PDBu-like) action of AA must account for
the full inhibition of 45Ca2+-influx seen with AA and not
PDBu.
Fluorimetric studies to determine the cytosolic calcium
concentrations within GH3 cell populations were performed
using the fluorescent dye lndo-1 [7], Briefly, GH3 cells were
loaded with 10 pM lndo-1 acetoxy methyl ester (lndo-1-AM)
for 45 min in culture medium (Hams F-10, 15% foetal bovine
serum, 1 mM l-glutamine, 100 u/ml penicillin and 0.1 mg/ml
streptomycin) at 37°C, 5% CO2, 95% air. Cells were
harvested, washed and resuspended in Hank's Balanced
Salt Solution (HBSS (Gibco, Paisley, U.K.)). A 30 min
incubation in the dark at room temperature was allowed to
provide more complete hydrolysis of intracellular indo-1-AM.
Cells were washed by resuspension-centrifugation (1,000 g,
10 min, 25°C) and again resuspended in HBSS to a density
of 5 x 106 cells/ml. A sample (2.5 ml) was aliquoted to a
jj^rtz cuvette (37°C, stirred magnetically) and the^Prescence was measured in a Shimadzu RF-5000
spectrofluorophotometer interfaced with an IBM PS/2 55 SX
microcomputer. Excitation (332 nm, band width 5 nm) and
emission (400 nm, band width 5 nm) wavelengths were kept
constant so as to reduce the possibility of significant auto
fluorescence artefacts in the final signal [8] and a data point
was taken every 2 s.
AA (17 pM) induced a rise in GH3 cytosolic calcium
concentrations which was unaffected by the cyclo-
oxygenase and lipoxygenase inhibitor nordihydroguaiaretic
acid (NDGA, 30 pM) and to H7 (30 pM). Higher
concentrations of AA could not be tested because of vehicle
and solubility artefacts. No rise in cytosolic Ca2+ level was
apparent with 300 nM PDBu. If a 40 mM K+ challenge was
applied to the cells 5 min after addition of AA, then the K+-
stimulated rise in cytosolic Ca2+ concentration was greatly
diminished, concurring with the 45Ca2+ influx data. In the
additional presence of H7 (30 pM), the K+-induced response
was fully restored. Therefore, the initial AA-induced rise in
cytosolic calcium was insensitive to H7, whereas, the
inhibition by AA of K+-induced elevation of cytosolic Ca2+
levels was prevented by H7.
In 45Ca2+ efflux studies, where the prelabelled cells were
exposed to a 50 pM AA challenge, there was a marked
increase in the rate of 45Ca2+ release from the cells. This
increase in Ca2+ efflux seen with AA was not mimicked by
PDBu (300 nM) nor blocked by H7 (30 pM) or cyclo-
oxygenase and lipoxygenase inhibitors (indomethacin (10
pM), eicosatetraynoic acid (10 pM) or NC)GA (10 pM)). The
increased 45Ca2+ efflux due to AA was blocked by the Ca2+
ATPase inhibitor Na3V04 (1 mM) but was unaffected by
replacing Na+ in the medium with N-methyl d-glucamine (in
order to inhibit the Na+/Ca2+ exchanger).
The inhibition of depolarisation-induced 45Ca2+ influx by
AA seems to be mediated by PKC activation just like the
PDBu-induced inhibition of Ca2+-influx [1]. Unlike PDBu, AA
can cause a rise in cytosolic calcium concentrations which is
not due to metabolism of AA, but is presumably due to AA
itself releasing intracellularly stored Ca2+, as seen in other
cellular systems [9-11]. It seems likely that it is this AA-
induced rise in cytosolic calcium that underlies the activity of
AA in the 45Ca2+ efflux studies. Thus the AA-stimulated rise
in Ca2+ efflux may simply reflect the calcium handling
processes of GH3 cells whereby raised cytosolic calcium is
extruded from the cells via a Ca2+-ATPase, but not a
Na+/Ca2+ exchange mechanism. Both the fluorimetric and
45Ca2+ efflux studies have shown that this AA-induced rise
in cytosolic calcium is unaffected by cyclo-oxygenase or
lipoxygenase inhibitors and is not mimicked by PDBu. Our
theory, therefore, is that the additional inhibition of K+-
stimulated 45Ca2+ influx in GH3 cells when comparing AA to
PDBu action, is due to the additional ability of AA to release
intracellularly stored Ca2+. This raised cytosolic calcium
concentration could act to potentiate the activation of PKC
by AA and lead to a full inhibition of nimodipine-sensitive
Ca2+ entry. Other Ca2+-stimulated mechanisms of
diminishing the K+-stimulated 45Ca2+ entry apart from PKC
cannot be ruled out, although thd inhibition of Ca2+ entry
caused by both AA and PDBu are fully H7- and
staurosporine-reversible (but not fully reversed with their
inactive congeners, HA1004 and K252a respectively, at the
same concentrations).
AA can be metabolised to a wide range of cellular
mediators which may be involved in the action of
exogenously applied AA in GH3 anterior pituitary cells, but
in the present study have remained uninvestigated. It is
likely that AA-induced release of intracellularly stored Ca2+
may have a necessary role in the enhanced PKC-mediated
inhibition of 'L'-type Ca2+ channel activity seen with AA
rather than phorbol esters. A dual intracellular calcium
release and PKC activating response may be required to
see the full inhibition of 'L'-type Ca2+ channel activity. Such
synergistic dual actions of AA may result in an ability of AA
to act as a far more important physiological activator of PKC
than has been previously recognised.
References
1. Johnson, M.S.. MacEwan, D.J. & Mitchell, R. (1989) J.
Physiol. 418, 186P
2. MacEwan, D. & Mitchell, R. (1990) Biochem. Soc.
Trans. 18, 433-434
3. Seifert, R., Schachtele, C., Rosenthal, W. & Schultz, G.
(1988) Biochem. Biophys. Res. Commun. 154, 20-26
4. Hidaka, H. & Hagiwara, M. (1987) Trends Pharmacol.
Sci. 8, 162-164
5. Tamaoki, T., Nomoto, H., Takahashi, I.. Kato, Y.,
Morimoto, M. & Tomita, F. (1986) Biochem. Biophys.
Res. Commun. 135, 397-402
6. Kase, H., Iwahashi, K., Nakanashi, S., Matsuda, Y.,
Yamada, K., Takahashi, M., Murakata, C., Sato, A. &
Kaneko, M. (1987) Biochem. Biophys. Res. Comm.
142, 436-440
7. Grynkiewicz, G., Poenie, M. & Tsien, R.Y. (1985) J.
Biol. Chem. 260, 3440-3450
8. Luckhoff, A. (1986) Cell Calcium 7, 233-248
9. Chan, K.-M. & Turk, J. (1987) Biochim. Biophys. Acta
928, 186-193
10. Beaumier, L., Faucher N. & Naccache, P.H. (1987)
FEBS Lett. 221, 289-292
11. Chow, S.C. & Jondal, M. (1990) J. Biol. Chem. 265,
902-907
346 Biochimica et Biophysica Acta, 1094(1991)346-354
© 1991 Elsevier Science Publishers B.V. All rights reserved 0167-4889/91/$03.50
ADONIS 0167488991002538
BBAMCR 13008
Inhibition of depolarisation-induced calcium influx into GH3
cells by arachidonic acid: the involvement of protein kinase C
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The influx of 45Ca2 + induced in GH3 cells by exposure to 60 mM K+ medium was inhibited by arachidonic acid
(AA) in a concentration-dependent manner. This action of AA was not prevented by inhibitors of its metabolism but
was reversed by the inhibitors of protein kinase C (PKC), H7 and staurosporine but not their less active congeners
HA 1004 and K252a, respectively. Presumed down-regulation of PKC by pretreatment with phorbol 12,13-dibutyrate
(PDBu) also greatly diminished the effect of AA. Experiments to assess effects of AA on 4SCa2+ efflux and on
cytosolic Ca2+ concentrations indicated that an additional PKC-independent action of AA involving the release of
intracellularly stored calcium was present. Both direct activation of certain PKC isoform(s) by AA and the
synergistic influence on PKC activity by its concomitant raising of intracellular Ca2+ concentrations, may be
physiologically important in the regulation of depolarisation-induced Ca2+ entry.
Introduction
Arachidonic acid (AA) can be metabolised to a
range of bioactive compounds by means of cyclo-
oxygenase, lipoxygenase and other pathways. A num¬
ber of these metabolites appear to be involved in
inflammatory responses, and may also have roles in
neural excitation and contraction of smooth muscle [1],
For example, in Aplysia sensory neurons, where the
neurotransmitter FMRFamide is known to generate
AA [2], an unknown AA-metabolite was indicated in
having a role in synaptic transmission [3]. The
leukotriene, LTC4 and/or a related metabolite has
been implicated in the opening of potassium channels
[4,5] in guinea-pig and rat heart.
Abbreviations: PKC, protein kinase C; AA, arachidonic acid; IP3,
inositol 1,4,5-trisphosphate; NDGA, nordihydroguaiaretic acid;
ETYA, eicosa-5,8,ll,14-tetraynoic acid; 8-Br-cyclic GMP, 8-
bromoguanosine-3': 5'-cyclic monophosphate; A-methyl TRH, A-
methylthyrotrophin releasing hormone; H7, l-(5-isoquinoline-
sulfonyl)-2-methylpiperazine dihydrochlorine; HA 1004, N-(2-
guanidinoethyl)-5-isoquinolinesulfonamide hydrochloride; DTPA, di-
ethylenetriamine-pentaacetic acid; lndo-1-AM, indo-l-acetoxymeth-
ylester.
Correspondence: R. Mitchell, MRC Brain Metabolism Unit, 1
George Square, Edinburgh, EH8 9JZ, U.K.
It is increasingly clear that AA production occurs
when a number of transmitters act on their receptors;
for example the Ml and M3 muscarinic [6], NMDA [7]
and GABAb, bradykinin, a,-adrenergic and vasoactive
intestinal peptide [8] receptors all stimulate production
of free AA in receptive cells. Whether this is secondary
to phospholipase C activation is unclear, but a func¬
tional interaction of G-protein /3y-subunits with phos¬
pholipase A 2 has been described in bovine retina rod
outer segments [9]. Thus, it seems quite possible that
either AA itself or its metabolic products may have an
important role in cellular signalling by certain neuro¬
transmitters.
It may be that AA itself also has a significant role in
signalling processes. Arachidonic acid has been shown
to release calcium from hepatocyte microsomes [10,11].
However, the relationship between the AA-sensitive
pool and the inositol 1,4,5-trisphosphate (IP3)-sensitive
pool is not entirely clear [12], It has further been
shown that AA can inhibit IP3 production in pancre¬
atic cells [13] perhaps through an ATP-depleting pro¬
cess, and evoke IP3 accumulation in astrocytes [14] an
effect which may be due to a raised intracellular cal¬
cium level. Both AA and its metabolite 12-hydro-
peroxyeicosatetraenoic acid (12-HPETE) have also
been described to markedly inhibit type II calcium/
calmodulin-dependent kinase in rat forebrain synapto-
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somes [15]. Transport processes such as glutamate up¬
take into glial cells may also be influenced by AA [16]
possibly by increasing membrane fluidity.
A further putative target for AA and its metabolites
is protein kinase C (PKC); of which at least seven
distinct isoforms have been identified so far [17].
Nishizuka and his co-workers have shown that AA
itself can selectively activate the y-and a-isoforms of
PKC in cell-free systems [18]. Little is known however,
of whether such events may be of physiological impor¬
tance.
In anterior pituitary cells, AA has been reported to
increase the secretion rates of several hormones.
Luteinizing hormone and follicle stimulating hormone
secretion were enhanced in response to exposure to
AA [19]. Prolactin secretion [20] and adrenocorti-
cotrophic hormone secretion [21] are also increased by
an AA stimulus.
In the present experiments we investigated some of
the cellular influences of AA on the GH3 clonal ante¬
rior pituitary cell line; in particular the effects on
depolarisation induced Ca2+ influx. In view of the
quantitative differences observed in the influences of
AA and other PKC activators on depolarisation-in-
duced 45Ca2+ influx, we carried out further studies
(Ca2+ fluorimetry; 45Ca2+ efflux) to clarify any addi¬
tional action of AA.
Materials and Methods
Materials
GH3 cells and foetal bovine serum were obtained
from Flow Laboratories, Irvine, Strathclyde, U.K.
Ham's F-10 medium and Hanks' balanced salt solution
were supplied by Gibco-BRL, Paisley, Strathclyde, U.K.
Penicillin, streptomycin, L-glutamine, essential fatty
acid-free bovine serum albumin, arachidonic acid
(sodium salt), arachidonic acid-methyl ester, linoleic
acid, phorbol 12,13-dibutyrate, NDGA, 8-bromo cyclic
GMP (sodium salt), (V-methyl-D-glucamine, sodium or-
thovanadate, indomethacin and Indo-l-AM were all
purchased from the Sigma, Poole, Dorset, U.K. Piper-
onyl butoxide was supplied by the Aldrich, Gillingham,
Dorset, U.K. SKF-525A ('Proadifen') was obtained
from Research Biochemicals, Natick, MA, U.S.A. N-
Methyl TRH was purchased from Peninsula Laborato¬
ries, St. Helens, Merseyside, U.K. H7 and HA 1004
were obtained from Seikagaku America, St. Peters¬
burg, FL, U.S.A. Staurosporine and K252a were sup¬
plied by Kyowa Medex Co., Tokyo, Japan. Ionomycin
was bought from Novabiochem (U.K.), Nottingham,
U.K. ETYA was a gift from Roche Products, Welwyn
Garden City, U.K. and 45Ca2+ (specific activity, 17
mCi/mg) was purchased from Amersham Interna¬
tional, Amersham, U.K. All other chemicals were of
Analar grade.
Methods
Cell culture. GH3 cells were grown in Ham's F-10
medium supplemented with 15% foetal bovine serum,
1 mM L-glutamine, 100 U/ml penicillin and 0.1 mg/ml
streptomycin in a humidified atmosphere of 5% C02,
95% air at 37 °C. Cells were harvested by agitation,
washed by resuspension centrifugation (1000 Xg, 10
min, 25°C) and finally resuspended at the appropriate
density in the required medium.
Calcium influx studies. Cells were diluted to a den¬
sity of 5 • 106 cells/ml in 'calcium uptake medium'
(concentrations in mM: NaCl, 154/KC1, 5.4/CaCl2,
1.5/D-glucose, 11/Hepes, 6 (pH adjusted to 7.4 with
Tris-base) and with 0.05% fatty acid-free bovine serum
albumin). Aliquots of this suspension (0.5 ml/tube)
were preincubated (30 min, 37°C, 02 atmosphere) be¬
fore a 10 min incubation (37°C, Oz) with drugs or
solvent alone. Cells were then exposed to 1 ml of
calcium uptake medium containing either low K+ (5.4
mM final concentration) or high K+ (60 mM) with 4
liM 45CaCl2 (« 3 iiCi/tube). After 30 s (37 ° C), 45Ca2+
uptake was halted by quenching with 3 ml of ice-cold 2
mM EGTA (Ca2+-free) calcium uptake medium and
tissue was separated by vacuum-filtration through Mil-
lipore SCWP cellulose acetate/nitrate filters (8 ^m
pore size) underlain by GF/B filters on Millipore 1225
sampling manifolds (Millipore, Harrow, U.K.). Samples
were washed once immediately with 3 ml ice-cold
EGTA calcium uptake medium and then washed a
further three times for 2 min each in the same medium.
The radioactivity associated with the cellulose filters
and cells was determined by liquid scintillation count¬
ing. Preliminary experiments on GH3 cells and exten¬
sive similar studies on anterior pituitary prisms [22]
revealed that these conditions gave the optimal signal-
to-noise ratio. The stimulus-induced influx of 45Ca2+ in
excess of basal controls was maximal within 30 s, sug¬
gesting that it represented specific response-triggered
flux rather than adsorption or steady accumulation by
storage pools. Vehicle (ethanol up to 0.4% ) was always
included in controls as appropriate and was indepen¬
dently determined to have no effect on either basal or
K+-induced 45Ca2+ accummulation.
Calcium efflux studies. Harvested GH3 cells were
resuspended at a concentration of 1 • 107 cells/ml in
calcium uptake medium containing 0.05% essential
fatty acid-free bovine serum albumin and incubated for
20 min (37°C, 02) before addition of 1 ml of medium
containing 6 /rM 45Ca2+ (=4.5 /xCi/tube). Samples
were incubated for 1 h at 37°C under 02 before
loading onto separate GF/B filters pre-washed with
calcium uptake medium and under vacuum on a Milli¬
pore 1225 sampling manifold. Cells were then washed
three times for 2 min with 3 ml of pre-warmed (37°C)
calcium uptake medium alone. There then followed a
further eight washes with pre-warmed calcium uptake
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medium containing the appropriate inhibitor or solvent
for controls. Each successive 2 min wash with 3 ml of
calcium uptake medium ( +inhibitor) was collected.
The 4th and subsequent washes contained 50 yuM AA.
Radioactivity in each fraction was measured by liquid
scintillation counting.
Cytosolic calcium measurements. Cytosolic Ca2+ con¬
centrations were measured by use of the calcium fluo¬
rescent dye Indo-1 [23], GH3 cells were loaded with 10
fiM Indo-l-AM for 45 min in culture medium at 37°C,
5% COz/95% air. Cells were then harvested, washed
and resuspended in Hanks' balanced salt solution. A
30 min incubation in the dark at room temperature was
then given to allow more complete hydrolysis of intra¬
cellular Indo-l-AM. The suspension was then cen-
trifuged (1000 Xg, 10 min, 25°C) and the cell pellet
was again resuspended in Hanks' balanced salt solution
at a concentration of 5- 106 cells/ml. A sample (2.5
ml) of the cell suspension was loaded into a quartz
cuvette which was stirred magnetically and maintained
at a constant temperature of 37°C. Fluorescence was
measured in a Shimadzu RF-5000 spectrofluoropho-
tometer. Excitation was at 332 nm (band width = 5 nm)
and emission was at 400 nm (band width = 5 nm).
Emission wavelengths were not ratioed between 400
and 490 nm so that the possibility of introducing signif¬
icant autofluorescence artefacts in the final signal [24]
would be reduced. A fluorescence value was taken
every 2 s and at the end of each experiment, 10 jiM
ionomycin followed by 10 mM MnCl2 (final concentra¬
tions) were added to give a measure of the maximum
and minimum fluorescent values of the cuvette con¬
tents, respectively. An assessment of extracellular fluo¬
rescence resulting from dye leakage was made accord¬
ing to the method proposed by Rink and Pozzan [25],
Thus, appropriate corrections were made for the small
changes in basal fluorescence induced by the addition
of 100 yuM MnCl2 which were rapidly and fully re¬
versed by 200 yuM DTPA. The experimental values for
cytosolic Ca2+ concentrations were calculated accord¬
ing to Grynkiewicz et al. [23] and Luckhoff [24], In view
of the limited solubility of AA in aqueous media, we
carried out experiments to assess light-scattering using
excitation and emission wavelengths of 520 nM and
maximum sensitivity of the fluorimeter. Under our
conditions (calcium uptake buffer containing 0.4%
ethanol vehicle) there was no detectable increase in
light-scattering up to and including 32 yuM AA. At 38
yuM AA, irreversible turbidity was detectable and by 44
/rM this was very marked. All cell Ca2+ fluorescence
experiments were thus carried out with AA at concen¬
trations below the threshold for turbidity (Fig. 6).
Data analysis. Statistical significance of effects was
assessed by a non-parametric method (Mann-Whitney
U-test). Concentration-response curves were analysed
by a non-linear iterative curve-fitting program ('P-fit';
Biosoft, Cambridge, U.K.). The calculated concentra¬
tion which inhibits 50% of the maximal response (IC50)
is expressed, with the errors representing standard
errors of the mean.
Results
Depolarisation with 60 mM K+ medium caused a
marked influx of 45Ca2+ (see Table I) which was inhib¬
ited in a time-dependent manner by 30 yuM AA. The
inhibitory effect of AA was apparent without any
preincubation but an additional 1 min preincubation
produced a maximal inhibitory effect. At concentra¬
tions up to 100 ytxM, AA had no effect on basal
accumulation of 45Ca2+ (104 + 8% of control at 100
/U.M). Inhibition of K+-induced 45Ca2+ influx by AA
was concentration-dependent (Fig. 1) with an IC50
(concentration that gives 50% inhibition of maximal
response) of 19 + 3 yuM. Agents with some structural
similarity to AA; AA-methyl ester (30 and 100 yu.M)
and linoleic acid (30 yiM) were unable to mimic the
inhibition seen with AA (30 yuM). The inhibitory effect
of AA was virtually maximal by the concentration (38
yuM) at which AA reached the limit of its solubility
under these conditions. Higher concentrations of AA
did not significantly affect basal 45Ca2+ accumulation
(Table I) or that induced by ionomycin or A-methyl
TRH (Table IV) suggesting that even exceeding the
solubility limit of AA had little influence on the results
of 45Ca2+ influx experiments. Furthermore, it was clear
that AA-methyl ester (which was less soluble than AA
under our conditions; showing marked light-scattering
TABLE I
Time-course of inhibition of depolarisation-induced calcium influx by
arachidonic acid (AA) into GH3 cells
Values represent means+ S.E., n = 4-6. The total 45Ca2 + accumu¬
lated in the presence of 60 mM K+ was typically around 1600 dpm
per assay, whereas basal 45Ca2+ accumulation was around 600 dpm,
of which non-specific adsorbtion to the filter and cell surfaces
(determined in zero-time blanks) was responsible for around 400
dpm. 45Ca2+ accumulation was measured over 30 s and the incuba¬
tion times with AA are inclusive of the 30 s influx measurement
period. Incubations were at 37 °C and 45Ca2+ influx was stopped as
described under Materials and Methods. Statistically significant inhi¬
bition of K+-jnduced 45Ca2+ influx is indicated by (* P < 0.05).
Conditions 45Ca2+
accumulation
(fmol/106 cells per min)
Non-specific adsorbtion
(zero-time blank) 34 + 2
Basal 50 + 4
Basal, 100 /xM AA (10 min) 54 + 6
60 mM K+ 120 + 8
60 mM K+, 30yuM AA (30 s) 86 + 6 *
60 mM K+, 30 yuM AA (45 s) 64 + 3 *
60 mM K+, 30 gM AA (90 s) 52 + 3 *
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Fatty acid concentration (^M)
Fig. 1. Concentration-response data for the inhibition of depolarisa-
tion-induced calcium influx by fatty acids. Cells were exposed "to
45Ca2+ for 30 s at 37 ° C and calcium influx was stopped as described
under Materials and Methods. Cells were preincubated with arachi-
donic acid (AA, circles), arachidonic acid-methyl ester (AA-methyl
ester, triangles) and linoleic acid (square) for 10 min at 37 ° C before
exposure to 60 mM K+ and 45Ca2+. Values represent means+ S.E.,
n = 4-12. Statistically significant inhibition of K+-induced 45Ca2 +
influx is indicated by (* P < 0.05).
artefacts by 24 ytiM) failed to mimic the inhibition of
K+-induced 45Ca2+ influx caused by AA, even when
tested at concentrations of 30 and 100 /tM (Fig. 1).
Flowever, 30 yitM AA-methyl ester in the presence of
300 nM PDBu reduced K+-induced 45Ca2+ influx lev¬
els to 14 + 2% of control K+-induced influx (n = 4).
The inhibitory effect of 30 gM AA on K+-mduced
calcium influx (a reduction to 23 ± 9% of control K+-
induced influx) was reversed by the protein kinase C
inhibitor H7 (Fig. 2), with an IC50 of 14 + 4 yuM. A
congener of H7, HA1004, with much reduced activity
as a PKC inhibitor [26] was inactive at similar concen¬
trations. Similarly, the potent PKC inhibitor stau-
rosporine also reversed the effect of 30 gM AA on
K+-induced 45Ca2+ influx (IC50 of 52 + 15 nM, see Fig.
3), but its less active congener K252a [27,28] failed to
cause reversal. The reversibility of the effect of AA by
these means rules out any simple physicochemical ac¬
tions of AA or any chemical oxidation products that
may arise during the experiment. Down-regulation of
PKC by treatment of GH3 cells with 300 nM phorbol
ester for 24 h results in more than 50% reduction in
PKC levels [29], Using a similar protocol for PKC
down-regulation [30] by treatment of GH3 cells with
300 nM PDBu for 24 h, reduced the ability of AA to
inhibit K+-induced 45Ca2+ influx (Fig. 4).
The inhibition of K+-induced 45Ca2+ influx by 30
yuM AA was not influenced by inhibitors of its
metabolism (Table II). The cyclo-oxygenase and lipoxy¬
genase inhibitor ETYA (10 /rM), the lipoxygenase in-
Kinase inhibitor (nM)
Fig. 2. Reversal by H7 but not HA1004 of the inhibition by AA of
depolarisation-induced calcium influx. GH3 cells were exposed to
45Caz+ for 30 s at 37 ° C and calcium influx was stopped as described
under Materials and Methods. H7 (filled squares) and HA1004 (open
squares) were added immediately prior to addition of AA (30 gM),
then cells were preincubated for 10 min at 37 °C before exposure to
60 mM K+ and 45Ca2+. Control K+-induced 45Ca2+ influx data in
the presence of AA is shown by the circle. Values represent means +
S.E., n = 8-12. Both H7 and HA1004 at 50 gM had no effect alone
on basal or K+-induced 45Ca2+ influx. The inhibition of K+-induced
Ca influx due to AA was significantly reversed by 50 gM F17
(P < 0.05).
Kinase Inhibitor (nM)
Fig. 3. Reversal by staurosporine but not K252a of the inhibition by
AA of depolarisation-induced calcium influx. GH3 cells were ex¬
posed to 45Ca2+ for 30 s at 37 ° C and calcium influx was stopped as
described under Materials and Methods. Staurosporine (filled
squares) and K252a (open squares) were added immediately prior to
addition of AA (30 ytiM) then cells were preincubated for 10 min at
37°C before exposure to 60 mM K+ and 45Ca2+. Control K+-in-
duced 45Ca2+ influx data in the presence of AA is shown by the
circle. Values represent means+ S.E., n = 4-8. Both staurosporine
and K252a at 300 nM had no effect alone on basal or K """-induced
45Ca2+ influx. The inhibition of K+-induced 45Ca2+ influx due to




Fig. 4. Effect of PKC-down regulation on arachidonic acid inhibition
of depolarisation-induced calcium influx. GH3 cells were cultured
for 24 h with 300 nM PDBu in dimethylformamide (0.01% final
volume, filled circles), dimethylformamide alone (open circles) or
nothing (triangles) and then extensively washed by centrifugation and
resuspension in 'calcium uptake medium' (three times 10 min, 1000
X g, 25°C). Arachidonic acid was added 10 min before a 30 s
exposure to 60 mM K+ and 45Ca2+. Values represent means ±S.E.,
n — 6. The reduction in 45Ca2+ influx caused by AA (30 /xM) was
significantly attenuated (*) by prolonged preincubation with PDBu
compared to its solvent alone (P < 0.05).
hibitor NDGA (30 p,M) and the cytochrome P-450
inhibitors piperonyl butoxide (30 /u.M) and SKF 525A
(10 /u,M) did not significantly modify the effect of AA.
Whereas 50 p.M AA inhibited the influx induced by
60 mM K+ to 3 + 1% of control, the influx responses
to 1 /u,M (V-methyl TRH and 30 /iM ionomycin were
reduced by AA to only 77 ± 16% and 83 ± 10% of the
TABLE II
Effect of inhibitors of arachidonic acid metabolism on its inhibition of
depolarisation-induced calcium influx
GH3 cells were exposed to 30 /xM alone, or in combination with 10
fiM ETYA, 30 p.M NDGA, 10 fiM SKF 525A or 30 juM piperonyl
butoxide for 10 min before and during addition of 60 mM K+ plus
45Ca2+ medium. None of these drugs caused any significant alter¬
ation in the inhibition of KT-induced 43Ca2+ accumulation due to 30
p.M AA or had any apparent effect on basal K+-induced 45Ca2 +
influx alone. Values represent the means+ S.E., n = 4-8.




60 mM K+ medium alone 100
+ 30 p.M arachidonic acid 23 + 9
+ 30 /xM arachidonic acid+ 10 p.M ETYA 23 + 4
+ 30 p.M arachidonic acid + 30 p.M NDGA 35 + 8
+ 30 p.M arachidonic acid + 10 p.M SKF 525A 26 + 3
+ 30 pM arachidonic acid + 30 /xM piperonyl 29 + 5
Butoxide
TABLE III
Effect of inhibitors of calcium extrusion processes on ability of arachi¬
donic acid to reduce depolarisation-induced calcium influx
GH3 cells were harvested and then resuspended in either normal
'calcium uptake medium' with or without 1 mM Na3V04 or sodium-
free 'calcium uptake medium' with V-methyl-D-glucamine replacing
sodium (154 mM). Cells were incubated with or without 100 /xM
arachidonic acid for 10 min before exposure to 60 mM K+ and
45Ca2 + medium. Values represent the means+ S.E., n = 4. Neither
K+-induced 45Ca2+ nor the inhibition of that response by AA were
significantly altered by Na,V04 or V-methyl-D-glucamine.




60 mM K + 100
60 mM K+, (V-methyl-D-glucamine + Na3V04 130 + 8
60 mM K+, 100 p.M AA 8 + 6
60 mM K+, 100 /xM AA, (V-methyl-D-glucamine 30 + 6
60 mM K+, 100 p.M AA, Na3VQ4 16 + 2
respective control responses (Table IV). The effect of
AA on K+-mduced 45Ca2+ influx therefore relates (at
least mostly) to a modulation of the specific entry route
involved in that response, not just a general alteration
of Ca2+-handling by the cell.
The cell-permeable activator of cyclic GMP-depen-
dent protein kinase, 8-Br-cyclic GMP, was unable to
mimic the effect of AA at any concentration from
3-100 yU.M (data not shown). Throughout this concen¬
tration range of 8-Br-cyclic GMP the maximum devia¬
tion from control K+-mduced 45Ca2+ influx was 14 +
14% (mean ± S.E., n = 8). Sodium orthovanadate
(Na3V04) and replacement of sodium with A-methyl-
D-glucamine will effectively inhibit plasma membrane
Ca2+-ATPases and the Na + /Ca2+ exchanger, respec¬
tively [31,32]. Neither 1 mM Na3V04 nor sodium re¬
placement could prevent the inhibition of K+-mduced
calcium influx caused by 100 /xM AA (see Table III).
The minor elevation of Ca2+ accumulation due to K +
in the presence of AA that was seen with sodium
orthovanadate and (V-methyl-D-glucamine was also
seen with K+alone. It seems likely, therefore, that
these small effects reflect influences of the Ca2+-
ATPase and the Na + /Ca2+ exchanger on redistribu¬
tion of elevated Ca2+ and we could thus find no
evidence that these Ca2+ transporters are involved in
any specific way in the AA-induced inhibition of K+-
stimulated 45Ca2+ influx. Since the effect on influx of
AA (Table III) was unaltered in the presence of a
concentration of Na3V04 which fully blocked 45Ca2 +
extrusion (see Fig. 5) it seems unlikely that PKC modu¬
lation of Ca2+-ATPase activity [33] plays any major role
in the inhibition of 45Ca2+ influx observed here.
In the 45Ca2+ extrusion experiments, a clear in¬




Measurement of 45Ca2+ efflux was performed as described under
Materials and Methods. Cells were batch-perfused in either the
presence (triangles) or absence (filled circles) of 10 p.M NDGA.
Arachidonic acid (50 fiM) in ethanol (or ethanol alone for control
(open circles)) was added to the medium from 6-16 min where
indicated by the line. Values represent the means + S.E., n = 3.
to 50 yuM AA (Fig. 5). This response was transient,
being over within four efflux fractions, despite the
continued presence of AA, suggesting that it originated
from the discharge of a discrete stored pool. The effect
of 50 /rM AA was considerably less than (about 36%
of) the efflux caused by 100 yuM ionomycin. In the
presence of 10 /tM NDGA the response to AA ap¬
peared to be slightly attenuated and was completely
prevented in the presence of 1 mM Na3V04 (data
omitted for clarity). There was no increase in 45Ca2 +
efflux rate in response to 300 nM PDBu suggesting the
lack of involvement of PKC activation in this effect of
AA. The 45Ca2+ efflux response to AA was unaltered
by 10 yuM ETYA, 10 yuM indomethacin, 30 yuM H7 or
in sodium-free medium (data not shown).
The fluorimetric studies revealed that basal cytosolic
calcium concentrations were clearly elevated by quite a
low concentration (17 yuM) of AA alone (Fig. 6b and c),
but as also reported by Drummond [33], phorbol esters
were ineffective. This response to AA was not inhib¬
ited by 30 yuM H7 (Fig. 6c) or 30 /rM NDGA (data not
shown) but quite unlike the inhibition of K+-induced
45Ca2+ influx caused by AA, was mimicked by AA-
methyl ester at an equivalent concentration. The incre¬
ments in calcium concentration due to AA (17 yuM),
PDBu (300 nM) and AA-methyl ester (17 yuM) were
43 ± 11, 6 + 8 and 52 + 9 nM respectively (means ±
S.E., n = 3-5). The rise in cytosolic calcium induced by
40 mM K+ medium was markedly reduced to 14 ± 9%
of control (mean ± S.E., n = 4) by previous addition of
AA (Fig. 6b) paralleling the 45Ca2+ influx data. In the
presence of 30 yuM H7, the rise in basal cytosolic
calcium level induced by 17 yuM AA was unaltered, but
the inhibitory effect of AA on subsequent responses to
40 mM K+ was markedly attenuated (Fig. 6c); the
mean response to K+ now being 89 ± 10% of control
(mean ± S.E., n = 3). In accordance with this, pre¬

















Fig. 6. Effect of arachidonic acid on the cytosolic calcium concentra¬
tion in GH3 cells. Cells were prepared and intracellular Ca2+ levels
estimated by Indo-1 fluorescence as described under Materials and
Methods. Arachidonic acid (AA, 17 /uM) in ethanol (b and c) or
ethanol alone (a) were added where indicated by the first (shorter)
arrows. Ethanol at concentrations of up to 0.4% (as used) had no
apparent effect on basal or K+-induced increments in calcium con¬
centrations. At the concentration used, AA produced no turbidity
artefact in fluorescence records made in the absence of cells. At the
second (longer) arrow, KC1 was added to a final concentration of 40
mM. Addition of 40 mM NaCl rather than KC1 had no effect. Part
(a) illustrates a typical response to K+ in the presence of ethanol,
the vehicle for AA (0.4%). In (b), AA induced a rise in basal Ca2 +
levels and a diminution of the subsequent response to 40 mM K+. In
(c), when 30 p.M H7 had been present from the start of the record,
the AA-induced rise in basal Ca2+ levels was still present, but the
diminution by AA of the response to K+ was reversed. There was no
apparent effect of H7 alone. Staurosporine could not be tested
because of the unfavourable fluoresence spectrum of the compound.
Each trace is representative of at least three similar results. The
abscissa represents time with each scale bar indicating 1 min.
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longed preincubation with PDBu (300 nM) greatly di¬
minished the effect of AA on the response to K+ but
not its elevation of basal calcium levels (data not
shown).
Discussion
Previous work has shown that activation of PKC
with phorbol esters reduces depolarisation-induced cal¬
cium entry into GH3 cells [33-35]. Activation of PKC
in GH3 cells produces a reduced probability of 'L'- and
'T'-type calcium channel opening [34]. Indeed, the di-
hydropyridine-binding a, subunit of L-channels can be
multiply phosphorylated by PKC [36] indicating the
possibility of direct modulatory effects of PKC on
L-channels. Since 'T'-type calcium channels open only
very transiently to a depolarisation, their contribution
towards the total 45Ca2+ influx response over 30 s here
is likely to be minimal and this idea is supported by the
K+-induced 45Ca2+ influx into GH3 cells being over
85% inhibited by the selective L-channel blocker ni-
modipine [35], Unlike the strain of GH4C, cells de¬
scribed by Albert et al. [37], GH3 cells exhibit no rise
in cytosolic calcium levels or in basal accumulation of
45Ca2+ in response to activators of PKC. Whilst indeed
the operation of L-type Ca2+ channels can be directly
enhanced by PKC activators in some cell types includ¬
ing anterior pituitary cells [35,38], any contribution of
such a phenomenon in the GH3 cell line is minor.
Interestingly, phorbol esters such as PDBu can only
partially inhibit depolarisation-induced calcium influx
showing a concentration-dependent and stereo-specific
maximal inhibition of 50 + 4% at 300 nM PDBu [35], in
contrast to the total inhibition observed here with AA.
Arachidonic acid-methyl ester (30 gM), which raises
cytosolic calcium concentrations without activating
PKC, did not significantly reduce K+-induced 45Ca2 +
influx (Fig. 1). However, 30 /iM AA-methyl ester en¬
hanced the reduction of K+-induced 45Ca2+ influx
caused by 300 nM PDBu to 86 ± 4%.
Furthermore, unlike PDBu, AA also has the ability
to raise cytosolic calcium concentrations in GH3 cells.
This effect is apparent in the fluorimetric studies and
probably underlies the increase in 45Ca2+ efflux rate
induced by AA. Down-regulation of PKC in GH3 cells
leads to reduced PKC-mediated responses [29]. Al¬
though the potency of AA at inhibiting K+-induced
45Ca2+ influx was greatly reduced by presumed down-
regulation of PKC, the effect was not completely pre¬
vented. This probably reflects incomplete down-regu¬
lation (as would occur with the present protocol [29]),
and the contribution of an additional effect of AA,
other than direct activation of PKC. In summary, it
seems likely that AA may inhibit 45Ca2+ influx into
GH3 cells by a mechanism with at least two compo¬
nents: a direct activation of PKC which may reduce
voltage-sensitive calcium channel activity by channel
phosphorylation together with an additional release of
intracellularly-stored calcium. The latter action would
raise cytosolic calcium concentrations (possibly in addi¬
tion to other non-PKC-mediated actions of AA) lead¬
ing to an apparently reduced response to stimuli. The
ability of AA (and its methyl ester) to elevate cytosolic
calcium levels would explain why the inhibitory effect
of AA is greater than that of PDBu, and why AA-
methyl ester together with PDBu fully mimic the total
inhibition of influx seen with AA. Nevertheless, several
lines of evidence dictate that raising cytosolic calcium
levels alone does not underlie the major part of the
greater effect of AA (rather than PDBu) in inhibiting
K+-induced 45Ca2+ influx: (i) influx responses to other
stimuli, TRH and ionomycin (which should be equally
susceptible to the effects of a raised cytosolic calcium
concentration) were almost unmodified by AA, and (ii)
the whole of the effect of AA was reversed by H7 and
staurosporine (but not their less active congeners) in a
manner suggesting critical involvement of PKC. The
simplest unifying explanation of the data would seem
to be that the additional release of Ca2+ by AA serves
to promote the efficiency with which AA can induce
activation of PKC. Other explanations may of course
be possible.
Arachidonic acid and some of its metabolites have
been reported to open potassium channels in heart
[4,5] resulting in a hyperpolarisation. As here, these
effects took seconds to minutes to develop, but in
contrast were prevented by lipoxygenase inhibitors.
Such relatively slow development of the effect of AA
here is consistent with the involvement of an enzymic
mechanism such as kinase action. Similarly, maximal
effects of PDBu on GH3 cells were observed only after
a preincubation of at least 1 min. These facts coupled
to the selective H7 and staurosporine reversal of the
AA effect (Figs. 2 and 3) support the idea that activa¬
tion of PKC by AA mediates the effects observed here.
In cell-free systems, AA can selectively activate the
a- and -y-isoforms of PKC [18]. Our observations indi¬
cate that material immunoreactive with polyclonal anti¬
bodies for a-, (3- and e-isoforms of PKC, is present in
GH3 cells (Simpson, J., MacEwan, D.J., Mitchell, R.,
Johnson, M.S., Thomson, F.J. and Parker, P.J., unpub¬
lished data), similar to the profile reported in the
GH4C, cell line where the -y-isoform has also been
shown to be absent [39]. This suggests that it may be
the a-isoform of PKC which mediates AA action in
GH3 cells, although any role of any further PKC iso-
forms in these cells cannot yet be excluded.
Linoleic acid and AA-methyl ester are less potent
activators of PKC than AA [40], but do cause Ca2 +
release from intracellular stores [10,12], Linoleic acid
and AA-methyl ester only poorly mimic AA in the
calcium influx studies (see Fig. 1) but AA-methyl ester
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can robustly mimic AA in the fluorimetric studies,
further indicating that AA-inhibition of calcium influx
cannot simply be due to release of calcium from intra¬
cellular stores.
It has been suggested [41] that lowered cytosolic
calcium may result from activation by AA of guanylate
cyclase and thus, activation of cyclic GMP-dependent
protein kinase. This appears not to be a major factor in
the AA inhibition of calcium influx seen here since
8-Br-cyclic GMP is totally without effect up to 100 /zM.
Arachidonic acid and certain of its metabolites can also
inhibit Ca2+/calmodulin-dependent protein kinase II
[15], but the lack of effect of calmodulin antagonists on
K+-induced 45Ca2+ influx in pituitary pieces [42] and
also in GH3 cells (Mitchell, R. and MacEwan, D.J.,
unpublished data) suggests that any action does not
contribute significantly to the inhibition of influx caused
by AA here.
The components of the response to AA in GH3
cells may well be direct actions of AA, since inhibitors
of AA metabolism are without effect (Table II and Fig.
5). Although NDGA caused a slight inhibition of AA-
induced 45Ca2+ efflux, any specific action was in doubt
because of the lack of effect with ETYA in the same
studies. The increased extrusion of 45Ca2+ occuring in
response to AA (Fig. 5) may be almost exclusively
mediated by a Ca2+-ATPase as it was completely
blocked by sodium orthovanadate [31], whereas Na +
removal was without effect [32]. Table IV shows that
AA does not inhibit all stimulus-induced calcium influx
to the same degree suggesting that the AA site(s) of
action is at a specific route of Ca2+ entry rather than
on calcium extrusion.
In summary, arachidonic acid inhibits depolarisa-
tion-induced calcium influx into GH3 cells by activa¬
tion of PKC (perhaps a-isoform in particular) and by
TABLE IV
Effect of arachidonic acid on calcium influx induced by 60 mM K +,
N-methyl TRH and ionomycin
GH3 cell 45Ca2+ influx was measured as described under Materials
and Methods. Cells were preincubated with 50 )rM arachidonic acid
10 min before exposure to either 60 mM K+-, 1 (iM IV-methyl TRH-
or 30 ,uM ionomycin-containing 45Ca2 + 'calcium uptake medium' for
30 s at 37°C. Values represent the means+ S.E., n = 4-12. The effect
of AA on the response to K+, but not ionomycin or V-methyl TRH
was statistically significant (* P < 0.05).
Stimulus Ca accummulation % Inhibition of
(fmol/106 cells per min) stimulus-evoked
increment in 45Ca2 +
influx by 50 /iM AA
-AA -50/rM AA
Nil 50 + 10 49+15 -
60 mM KC1 120+18 52+18 97+16
1 ^M (V-methyl
TRH 72+ 6 66 + 4 23 + 11
30 ixM ionomycin 230 + 28 198+19 17+10
raising cytosolic calcium concentrations. Both of these
mechanisms seem to contribute to a reduction in cal¬
cium influx. It is likely that it is arachidonic acid itself,
and not a metabolite, which mediates these effects.
This appears to be the first clear evidence linking
activation of PKC by AA with a physiologically-relevent
consequence. Further work is required to characterise
the exact PKC isoform(s) which mediate the effects of
AA here and indeed what specific substrate sites this
isoform might have. It seems clear that not only diacyl-
glycerols, but also AA may be important in the physio¬
logical activation of PKC.
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properties and [32P] phosphorylation targets of a
novel form of protein kinase C in pituitary
David J. MacEwan, James Simpson, Rory Mitchell, Melanie
S. Johnson, Fiona J. Thomson and George Fink
MRC Brain Metabolism Unit, University Department of
Pharmacology, 1 George Square, Edinburgh EH8 9JZ, UK
We have described a number of cellular responses in
anterior pituitary cells which are elicited by what appears to
be a distinct form of protein kinase C (PKC), distinguished
by its resistance to isoquinoline-type but not other PKC
inhibitors [1 - 4], Phorbol ester-induced facilitation of L-type
Ca2+ channel function, secretion of growth hormone (GH),
activation of phospholipase A2 (PLA2) and the
endogenously-occurring self priming effect of LHRH are all
readily inhibited by staurosporine and more PKC-selective
indolocarbazoles but all show relatively low potency of
inhibition by isoquinolines such as H7. Compared to other
PKC-mediated responses examined in the same
experimental conditions, the kinase in question displays
diminished potency of 6 to > 20-fold for H7. In contrast,
closely matched inhibitory potencies of staurosporine were
seen in all our PKC response models.
The present experiments were carried out to examine
the properties of this kinase at a biochemical level. Two
kinds of experiments were carried out:
(1) An in vitro kinase activity assay using partially purified
cytosolic PKCs and
(2) An analysis of PKC-mediated [32P] phosphorylation of
endogenous substrates in whole pituitary cells.
For the kinase activity assay, tissues were homogenised
at 4°C in 0.5 ml of buffer (20 mM Tris HCI (pH 7.5) 50 mM 2-
mercaptoethanol, 2 mM EDTA and 1 mM
phenylmethylsulphonyl fluoride) containing 0.01%
leupeptin + 20 pM E-64 and centrifuged (16,000 g, 20 min,
4°C). The supernatant was collected (pellet discarded) and
recentrifuged (16,000 g, 5 min, 4°C). The supernatant from
the second spin was partially purified on diethylaminoethyl
cellulose (DE52), prewashed with buffer containing
leupeptin and E-64. After loading, columns were washed
with 9 column volumes of buffer before the majority of the
partially purified PKC activity was eluted with 3 column
volumes of buffer containing 150 mM NaCI. Phosphatidyl
serine was prepared as mixed micelles with Nonidet P-40.
The assay was performed in 20 mM Tris HCI (pH 7.5) with
0.5 mM EGTA containing (final concentrations): 12.5 mM
MgCI2, 100 pg/ml phosphatidyl serine + 0.04% Nonidet P-
40, 1.25 mg/ml histone lll-S as substrate, 100 pM ATP-y-35S
(7 - 20 kBq/tube) and partially purified PKCs. The PKCs
were activated by 1 pM phorbol 12,13-dibutyrate (PDBu)
with either 600 pM CaCI2 (= 100 pM final free Ca2+) or 5
mM EGTA (< 3nM final free Ca2+). After 15 min at 30°C,
reactions were stopped by addition of 20 pi of ice-cold 0.1 M
ATP in 0.1 M EDTA (pH 7.0) and aliquots were spotted onto
Whatman P81 paper (to bind [35S] thiophosphoryiated
histone) and extensively washed with 75 mM H3PO4.
The Ca2+-dependent and Ca2+-independent activities
from anterior pituitary showed a marked disparity in their
sensitivity to H7. The IC50S of Ca2+-dependent and Ca2+-
independent kinase activity for H7 were 17 ± 4 and 121 ±
18 pM respectively, while as predicted the IC50S for
staurosporine were identical; 101 ±39 and 117 ± 46 nM,
respectively (n > 4). Less marked, but similar results were
found in lung but not in a range of other tissues from the
CNS and periphery.
For studies on endogenous phosphorylation targets,
hemipituitary glands from female rats on the morning of pro-
oestrus were preincubated for 30 min in 1 ml phosphate-
free buffer at 37°C. After addition of 14.1 MBq 32P-
orthophosphoric acid for 3 h, incubations were terminated
by insertion of the tissues into lysis buffer containing 9 M
urea and 2% Nonidet P-40. After homogenisation, tissue
samples containing equal amounts of trichloroacetic acid-
precipitable 32P were loaded onto isoelectric focusing gels
(pH gradient approximately pH 4.8 - 7.1, linear within pH 5.3
- 6.9) and two-dimensional gel electrophoresis performed
using a modified O'Farrell technique [5] with 12.5%
(acrylamide, w/v) slab gels. Radiolabelted proteins were
detected by direct autoradiography with Hyperfilm-
Betamax' film (Amersham). Approximately 400 spots were
consistently resolved.
If present for 1 h, PDBu (300 nM, added 120 min after
the 32P) increased the phosphorylation of 6 pituitary
proteins (approximate molecular weight/pi: 1 = 69 kDa/pl
6.1, 2 = 65 kDa/pl 7.0 - 7.1, 3 = 36 kDa/pl 6.9, 4 = 25 kDa/pl
7.0 - 7.1, 5 = 16 kDa/pl 6.2, 6 = 16 kDa/pl 6.7) compared
with saline controls. Protein 6 was an abundant tissue
protein and 1 - 5 were minor proteins. A seventh (minor)
protein (7 = 19kDa/pl 6.0) showed increased
phosphorylation only in some experiments. A 10 min
incubation with phorbol (added 170 min after the 32p) had a
similar effect to the 1 h incubation. In experiments in which
phorbol was present in all incubation media for 1 h, the PKC
inhibitor staurosporine (300 nM), but not H7 (30 pM) when
added 30 min prior to the phorbol, reduced phosphorylation
of 11 proteins (2, 4, 5, 8 = 76 kDa/pl 7.0, 9 = 66 kDa/pl 7.0,
10 = 28 kDa/pl 7.0 - 7.1, 11 =30 kDa/pl 6.3, 12 = 22 kDa/pl
6.6, 13=13 kDa/pl 6.0, 14 = 15.5 kDa/pl 5.3, 15 = 76 kDa/pl
6.9) when compared to the group treated with phorbol
alone.
These results thus describe both distinct kinase activity
and endogenous phosphorylation targets of an H7-resistant
species of PKC (or PKC-like kinase). This kinase appears
to utilise histone lll-S as substrate in a Ca2+-independent
manner and to have a restricted tissue distribution distinct
from that of any of the so far characterised PKCs.
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183 STU01ES ON THE MECHANISM OF UAH-INDUCED "SCa?* INfLUX IN RAT ANTERIOR PITUITARY CELLS
R. Mitchell, M.S. Johnson, 0. MacEwan & F. Thomson, MRC Brain Metabolism Unit,
University Department of Pharmacology, 1 George Square, Edinburgh, EH8 9JZ.
The secretion of qonadotrophins in response to IIRM is attenuated by removal of
extracellular Ca? , indicating a partial requirement for Ca?+ influx in LERH action.
Both LlRM-induced 111 secretion in vitro and the rapid influx of 45Ca^+ induced by L1RH
in anterior pituitary slices^ are inhibited (the former only partially) by
dihydropyridines. In bullfrog sympathetic ganglia and gonadotrophes, LIRH-induced
membrane depolarisation, perhaps by inhibition of preactivated outward K* ('M')
currents, may be the means of activation of voltage-sensitive Ca?* currents. Indeed the
'M' current blocker uridine 5"-triphosphate (10-300gM) caused a concentration-dependent,
nimodipine-sensitive ^ca2+ influx here. This response could not be mimicked by
phorbol ester (phorbol 12-myristate 13-acetate (rMA) at concentrations below 10gM).
Furthermore, the ''Sea?* influx induced by LIRH (l-100nM) was unaffected by protein
kinase C inhibitors H7 and polymyxin B (10gM), and inhibited by PMA (10-300nM) or by the
diacylglycero1 kinase inhibitor R 59022 (10gM). Although our results suggest that
Unit-induced Ca?+ influx in gonadotrophes may indeed be secondary to 'M' current
inhibition, they contrast with those in bullfrog sympathetic ganglia and NG 108-15 cells
(but not hippocampal pyramidal cells), where PKC is suggested to mediate M current
closure^.
(1) Mitchell et al. (1989) Ann. N.Y. Acad. Sci 560, 451-453.
(2) lligashida S Brown (1988) Nature 323, 333-335.
3. Endocrinol. 124(§uppl) : 103.
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PHARMACOLOGY AND CELLULAR ACTIONS OF PROTEIN KINASE C
ISOFORMS {Eur. J. Pharmacol. 183, 750-751)
Rory Mitchell, David MacEwan, Melanie Johnson and Fiona Thomson, MRC Brain
Metabolism Unit, 1 George Square, Edinburgh EH8 9JZ, UK
Protein kinase C (PKC) and phorbol ester binding sites are widely distributed
and are likely to play a major role in signal transduction/cellular regulation in a
number of systems. It is now clear that at least 7 isoforms of the enzyme are
encoded. However, very little is known of the physiological roles of the isoforms
and whether they display pharmacological differences that may permit selective
intervention. We have developed a number of cellular models of PKC action
allowing us to explore in a physiological context the putative selective
pharmacology of different isoforms.
Experiments were carried out on anterior pituitary cells from rat or on the GH^
cell line. It has been reported that a and (3, but not y isoforms of PKC are present in
pituitary and that the pituitary-derived GH3 contains two forms of PKC mRNA.
K+-induced 45Ca2+ influx into GH3 cells and pituitary pieces (both through L
channels) are influenced quite differently by phorbol esters; the former being
inhibited and the latter enhanced by 43 but not 4a-phorbol 12, 13-didecanoate
(PDD)(Johnson, MacEwan and Mitchell, 1989). While both effects were readily
blocked by staurosporine, only that in GH3 cells was readily blocked by H7 (IC50 =
10 pM). We sought selective agonists for the two effects, finding that arachidonic
acid (AA) mimicked the effect in GH3 cells but not pituitary (being both H7- and
staurosporine-sensitive) whereas sn-1,2 dioctanoyl glycerol (DOG) and
12-deoxyphorbol 13-isobutyrate (DPB) were effective only in pituitary. Since AA
activates a and y isoforms but (3 is not considered to be present here, we suggest
that the effect shown by AA is via aPKC. Ligand binding studies to cytosolic PKC
showed an allosteric enhancement of [3H]-PDBu binding in a-rich but not (3-or
y-rich organs and CNS regions, supporting this hypothesis. In contrast, the IC50S
for a range of diacyl glycerols, particularly DOG, in displacing [3H]-PDBu were
much lower in B-rich (or y-rich) regions than in a-rich regions, suggesting that the
facilitatory, H7-resistant profile on 45Ca2+ influx in pituitary pieces was through
B-PKC.
Models at the level of hormone secretion parallel these observations (Johnson
and Mitchell, 1989). PDBu-induced secretion of luteinising hormone (LH) but not
growth hormone (GH) is mimicked by AA. Again the former effect is H7-sensitive
but the latter resistant. Staurosporine is effective on both. The priming effect of
LH-releasing hormone (LHRH) is a unique phenomenon of increased secretory
responsiveness (Mitchell, Johnson, Ogier & Fink, 1988). This can be mimicked in
some aspects by phorbol esters and is sensitive to staurosporine yet not H7. This
profile is reminiscent of the extremely high levels of H7 required to block long-term-
potentiation and we suggest that this is characteristic of the 6-isoform of PKC. It is
clear that less well-characterised isoforms may also contribute to these
phenomena to an as yet unknown extent.
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SELECTIVE PHARMACOLOGY OF PROTEIN KINASE C
Rorv Mitchell. David MacEwan, Melanie Johnson and Fiona Thomson
MRC Brain Metabolism Unit, 1 George Square, Edinburgh EH8 9JZ
Activation of protein kinase C (PKC) by diglyceride (derived in part from the
action of phospho-inositidase C) appears to play a major role in signal
transduction/cellular regulation in many systems. More than seven isoforms of PKC are
now known, which fall into two series: A; Ca2+ dependent and B; Ca2+ independent.
However whilst many targets of 'PKC' have been described, very little is known of the
physiological roles of particular isoforms and indeed whether they display
pharmacological differences that may permit selective intervention. We have
developed a number of cellular models of PKC action allowing us to explore, in a
physiological context, the putative selective pharmacology of different isoforms. With
the aim of assigning identities to the kinases active in particular models, we have
further assessed the actions of particular drugs in ligand binding and kinase activity
assays for PKC using cells and tissues enriched in particular isoforms.
One of our models for PKC(s) action is the regulation of 45Ca2+ influx through L
channels in the GH3 cell line and in anterior pituitary cells. K+- induced 45Ca2+ into
these different cells is influenced quite differently by phorbol esters; the former being
inhibited and the latter enhanced by 4 p- but not 4a-phorbol 12, 13-didecanoate (PDD)
(Johnson, MacEwan and Mitchell, 1989). While both effects were readily blocked by
staurosporine, only that in GH3 cells was readily blocked by H7 (IC50 = 10pM). We
sought selective agonists for the two effects, finding that arachidonic acid (AA)
mimicked the effect in GH3 cells but not pituitary (being both H7- and staurosporine-
sensitive) whereas sn-1,2 dioctanoyl glycerol (DOG) and 12-deoxyphorbol 13-
isobutyrate (DPB) were effective only in pituitary. It is known that a, 8, e and not y
isoforms are present in both tissues, with GH3 cells being rather more enriched in a.
Since AA is reported to activate a and y isoforms, but y is not considered to be present
here, we suggest that the effect shown by AA is via aPKC. In support of this hypothesis
ligand binding studies to cystosolic PKC showed an allosteric enhancement of [3H]-
PDBu binding by AA, the magnitude of which correlates with the a content of tissue. In
contrast, the affinities for a range of diacylglycerols, particularly DOG, in displacing [3H]-
PDBu showed if anything an inverse correlation with a content suggesting that the
facilitatory, H7-resistant profile on 45Ca2+ influx in pituitary pieces was through
something other than aPKC.
Models at the level of hormone secretion parallel these observations (Johnson
and Mitchell, 1989). PDBu-induced secretion of luteinising hormone (LH) but not
growth hormone (GH) is H7-sensitive but the latter resistant, whilst staurosporine is
effective on both. The priming effect of LH-releasing hormone (LHRH) is a unique
phenomenon of increased secretory responsiveness (Mitchell, Johnson, Ogier & Fink,
1988). This can be mimicked in some aspects by phorbol esters and is sensitive to
staurosporine yet not H7. This profile is reminiscent of the very high levels of H7
required to block long-term potential (LTP). It appears that e as well as a, B and y
isoforms are H7-sensitive (Schaap and Parker, 1990) so some other form of PKCiar
related kinase may mediate the H7 resistant events observed.
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Does Inositol hexaklsphosphate Induce Ca2+ entry
into GH3 cells?
RORV MITCHELL. DAVID MACEWAN, LYNNE DOUGAN,
MELANIE JOHNSON and FIONA THOMSON.
MRC Brain Metabolism Unit. 1 George Square. Edinburgh
EH89JZ
A variety of cells have recently been described to
synthesise inositol 1,3.4.5,6-pentakisphosphate (InsPs) and
inositol hexakisphosphate (InsPe). (see [1] for review). In
contrast to the lower inositol phosphates, the levels of these
inositol polyphosphates do not change rapidly in response
to Ca2+-mobilising hormones [2], However, marked
excitatory effects were reported when microinjected into the
Nucleus Tractus Solitarius of the brain stem (1), consistent
with an extracellular site cf action. Inositol polyphosphates
are known to be produced in the GH3 clonal pituitary cell
line [2], We have used the GH3 cell line to investigate
whether inositol polyphosphates might act extracellularly on
these cells to influence their mobilisation of Ca2*. The
present report describes several series of experiments,
begun originally in 1988, and our persistent difficulties in
making an unequivocal interpretation of the data.
GH3 cells were cultured and 45Ca2+ accumulation
determined as described previously [3], After 30 s at 37*C
with 2 pM 4SCa2+ .accumulation was quenched with cold
EGTA-medium before rapid filtration and washing.
Concentration-dependent increases in 45Ca2+ influx
were induced by TRH, K+ and ionomycin with peak
increments over basal controls of 148 ± 23% (100 nM TRH)
262 ± 30% (60mM K+1 and 1059 ± 51% (100 pM
ionomycin). (mean ± SEM n = 4-8). lnsP6 but not its non-
physiological analogue, inositol hexasulpfiate, induced a
marked accumulation of 45Ca2+, much greater than that due
to TRH or K+, but still clearly less than that due to ionomycin.
The effect of lnsP6 was concentration-dependent showing a
statistically significant increment at 3 pM and above, and
was saturable with a maximum response of 519 ± 70%
increase over basal at 30 pM (n = 6). The 45Ca2+
accumulation due to 20 pM InsPg was reduced by 78 ± 4%
(n = 4) on inclusion of 100 pM digitonin in the EGTA wash
medium. Cell viability {assessed with 0.2% Trypan Blue or
0.5 pg/ml fluorescein diacetate) was 93-100% following
incubation with 150 pM lnsP6 for 30 min, (n = 4). The effect
of lnsP6 could not be mimicked by NasPO*, Na glutamate,
EGTA, EDTA, 2,3-diphosphogtycerate or Na hydroxide fall
at ImM). At 150 pM, lnsP6 caused no change in the pH ofthe medium, although stock solutions of lnsP6 (K+salt) were
extremely alkaline.
The effect of 20 pM lnsP6 was unaltered by blockers of
L-and N-type voltage-sensitive Ca2+ channels (nimodipine,
9 ± 11% inhibition at 1pM and ra-conotoxin, 15 ± 8%
inhibition at 1 pM; n = 6 in each case). Polyvalent cations
however showed the following ICso's (pM concentrations
producing 50% inhibition): Gd3+, 1.2 ± 0.5; La3+, 5.7 ± 2 3 -
Cd2+. 112 ± 16 ; Co2+, 550 ± 75 ; Ni2+. 956 ± 132 . The
low potency of Ni2+ is inconsistent with the involvement of a
T-type Ca2+ channel. Replacement of Na+ with N-methyl
glucamine or the selective inhibitor of the Na+/Ca2+
exchanger (5-(N-4-chlorobenzyl)-2',4'-dimethylbenzamil) at
a concentration of 30 pM. had no effect on the response to
lnsP6- It seemed unlikely that lnsP6 was acting by
depolarising cells in view of the greater maximal response
to lnsP6 than to K+. Indeed when GH3 cells were loaded
with the potential-sensitive dye, 3,3'-dihexyl-
oxacarbocyanine iodide, the change in fluorescence
(excitation 484 nm, emission 510 nm) induced by 60 mM K+
could not be mimicked by 20 pM lnsP6- Seeking support for
the idea that cytosolic Ca2+ levels would be raised in
response to lnsP6. further experiments were carried out with
the Ca2+ fluorophore INDO-1 AM. with excitation at 332 nm
and emission at 400 nm (Ca2+-bound) and 483 nm (freeform of INDO-1). Using GH3 cells or rat hippocampal
synaptosomes, 100 pM InsPg but not Ins (SO^, produced
a clear rise in fluorescence at 400 nm or in the 400:483 nm
ratio, comparable to the response to 60 mM K+. Withoutcells present lnsP6 caused an increase in fluorescence of
INDO-1 salt but this could be largely suppressed by 100pM
Mn2+- Using extracellular Mn2+ to suppress dye leakage
artefacts, a clear response to lnsP6 .Still occurred with GH3
cells or synaptosomes. Surprisingly, the response to 100
pM lnsP6 was similar even if preceded by 100 pM
ionomycin. Unfortunately, lnsP6 (3-100pM) caused a clear
concentration-dependent increase in emission at 400 nm
when only medium (containing 1.5 mM Ca2+), without cells
or INDO-1 was present. Spectral analysis revealed a fairly
uniform response from 350-600 nm,indicating a non-specific
physical phenomenon.We then looked further at the
possibility of low-solubility artefacts arising in the 45Ca2+
experiments.
A hypotonic EGTA wash solution (2 mM EGTA, 6 mM
HEPES) failed to release any of the lnsP6-induced 45Ca2t
accumulation. Filters alone showed a small increase in
45Ca2;^etention due to 100 pM InsPg but less than 10% of
the response in the presenc^)f GH3 cells. The effect of
lnsP6 on cellular Ca2+ accumulation was not reduced by
carrying out the experiment at 0°C rather than 37°C and
some 60-105% of the normal response was apparent in
zero time blanks. Preincubation of cells at 80"C for 5 min
tailed to reduce the effect of lnsP6. although increasing the
temperature to 100°C caused more than 50% reduction, as
did pretreatment with 2% paraformaldehyde. Incubation
under N2 with 100 pM carbonyl cyanide m-chlorophenyl
hydrazone reduced the effect of 100 pM lnsP6 by around
60%. Although obvious turbidity could rarely be detected
by eye, 10-300 pM lnsP6 in the experimental medium
showed clear concentration-dependent increases in ODs20-
Another anion which forms low-solubility complexes with
Ca2*, oxalate, had similar effects from 100-10000 pM.
When 45Ca2* experiments were carried out with oxalate,
large accumulations of 45Ca2+ were induced at equivalent
concentrations. Clear accumulation of 45Ca2+ in the
presence of oxalate was seen with filters alone. In the
presence of GH3 cells (just like with InsPg) there was a
marked increase (in the order of 5 fold) in the amount of
45Ca2+ retained. All of the effects of lnsP6 observed in our
laboratory can thus be explained as physical phenomena
without the need to invoke bio-activity.
The combination of chelation and solubility properties
shown by lnsP6 and InsPs but to a much lesser extent by
lower inositol phosphates [4] is bound to confound any
investigation of their influence on cellular Ca2+ movements.
In our opinion, both the present results and those provided
in recent reports on 45Ca2+ accumulation [5,6] and Ca2+
fluorimetry [7] cannot be considered with any validity to
demonstrate biological effects of inositol polyphosphates on
cellular Ca2+ movements.
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SUMMARY
The protein kinase C (PKC) activator, phorbol 12,13-dibutyrate
(PDBu) can induce the release of both luteinizing hormone (LH) and
growth hormone (GH) from proestrous rat anterior pituitary pieces, in
vitro. Phorbol 12,13-dibutyrate-induced LH, but not GH release was
readily inhibited by the phospholipase A2 (PLA2) inhibitors, quinacrine, p-
bromophenacyl bromide and aristolochic acid. Furthermore, PDBu could
induce a quinacrine-sensitive release of [3H]arachidonic acid ([3H]AA)
from pre-labelled anterior pituitary tissue. The protein synthesis inhibitor,
cycloheximide, inhibited the release of both [3H]AA and LH that was
induced by PDBu, whereas, LH release induced by the PLA2 activator,
melittin, was cycloheximide-insensitive. These results suggest that PKC
activators may induce LH but not GH release from anterior pituitary tissue
by a mechanism involving activation of PLA2 by a process which is reliant
on protein synthesis.




Activation of the Ca2+/phospholipid-dependent protein kinase,
protein kinase C (PKC) is important for cellular responses to certain
hormones (Nishizuka, 1984,1988) including luteinizing hormone-releasing
hormone (LHRH) (Johnson et al., 1992a). Protein kinase C exists as a
family of at least 8 different isoforms, each having distinct tissue
distributions suggesting that each isoform may have discrete cellular
targets and actions (Nishizuka, 1988; Osada et al., 1990). Consistent with
this hypothesis, PKC forms which display distinct pharmacology, with
respect to PKC activators (such as phorbol esters) and PKC inhibitors,
appear to be involved in the induction of LHRH self-priming, luteinizing
hormone (LH) release and growth hormone (GH) release in proestrous rat
anterior pituitary tissue (Johnson et al., 1989,1992a, 1992b; Thomson et al,
1992). Since the temporal patterns of phorbol ester-induced LH and GH
release are different (Johnson et al, 1989) the sequence of events that lead
from PKC activation to hormone release from gonadotropes is probably
very different from that in somatotropes. Thus, the PKC forms that induce
LH and GH release may phosphorylate different cellular targets. One
potential target for the PKC(s) which induce LH release may be
phospholipase A2 (PLA2), or an intermediate leading to the activation of
PLA2.
The release of LH can be induced from primary cultures of rat
gonadotropes by the PLA2 activator, melittin, and by exogenously added
snake venom PLA2 (Kiesel et al., 1985). The actions of LHRH are
accompanied by an increased release of arachi 'onic acid (AA), a product
of PLA2 action, and AA metabolites (Naor and Catt, 1981; Catt et al., 1985).
Furthermore, exogenously added AA, and several AA metabolites, can
induce LH release from dispersed anterior pituitary cells (Naor et al., 1983;
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Hulting et al., 1984; Kiesel et al., 1987). In other cell types, phorbol esters
can induce an increase in free AA levels (Halenda and Rehm, 1987; Parker
et al., 1987) suggesting that PLA2 activity may be modulated as a
consequence of PKC activation. In these experiments, we examined a
possible role for PLA2 in the mechanism of PKC-induced LH and GH
release from proestrous rat anterior pituitary and the possible involvement
of protein synthesis in this response.
MATERIALS AND METHODS
Animals
Adult female COB Wistar rats (200 g - 250 g body weight; Charles
River UK Ltd) were maintained under controlled lighting and temperature
with free access to food pellets (CRM, Labsure, Manea, Cambs, UK) and
tap water. Vaginal smears were examined and rats with a minimum of
two regular estrous cycles were anaesthetised with sodium pentabarbitone
(30 mg/kg; Sagatal; May and Baker Ltd Dagenham, Essex) by 11.30 arrfon
proestrus.
Chemicals
Luteinizing hormone-releasing hormone, cycloheximide, quinacrine
dihydrochloride, (Sigma Chemical Co, Poole, Dorset, UK) l-(5-
isoquinolinesulphonyl)-2-methyl-piperazine dihydrochloride (H7) (Gibco
Brl, Paisley, Scotland) and aristolochic acid sodium salt (Biomol, c/o
Semat, St Albans, Herts, UK) were made up as stock solutions in distilled
H2O. Staurosporine (Novabiochem, Nottingham, UK) and Ro 31-8220 (a
gift from Roche Products Ltd, Welwyn Garden City, Herts UK) were made
up as stock solutions in dimethylformamide (DMF). p-Bromophenacyl
bromide (BrPheBr) (Sigma) was made up as a stock solution in ethanol.
The maximum concentration of DMF or ethanol (0.05 % v/v) was used in
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control experiments and had no effect on either LH or GH release or
[3H]AA release. [5,6,8,9,11,12,14,15-3H(N)]Arachidonic acid ([3H]AA)
(specific activity approximately 240 Ci/mmol) was purchased from Du
Pont, Dreieich, Germany. All other chemicals were of analar grade and ~
were purchased from BDH (Poole, Dorset, UK).
Hormone Release Experiments
The methods used were based upon those described by Pickering
and Fink (1976). Anterior pituitary glands were hemisected and each
hemipituitary placed into a flask containing 2 ml of pre-warmed (37°C)
and gassed (95%C>2/5%C02) Hepes-buffered minimal essential medium
(MEM) (Gibco Brl, Paisley, UK) with Earles' salts.
After a 30 minute pre-incubation period in a shaking water bath
(37°C, 95%02/5%CC>2), and every subsequent hour thereafter, the medium
was replaced. In the initial, basal hour, the medium contained either an
inhibitor or no drug. For each subsequent hour, medium also contained
PDBu (300 nM).
The medium removed at the end of each incubation period was kept
at -20°C until it was radioimmunoassayed for LH and GH (Niswender el
al, 1968; Daane and Parlow, 1971; Johnson et al, 1988). The standards used
were NIADDK-rat LH-RP2 and NIADDK-rat-GH-RP2.
[3H]Arachidonic Acid Release Measurements
[3H]Arachidonic acid release was measured from pre-labelled
anterior pituitary tissue as follows. Anterior pituitary glands were
removed, hemisected and each hemipituitary cut into two equal quarters.
Pairs of pituitary quarters were then placed into a silanised flask
containing 1 ml of pre-warmed (37°C) and pre-gassed (95%02/5%C02)
MEM and pre-incubated in a shaking water bath (37°C, under
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95%02/5%CC>2) for 30 minutes. The medium was then replaced with fresh
MEM containing 0.5 pCi of [3H]AA and the tissue incubated for a further 2
hours. The tissue was then washed three times in MEM containing 1%
essential fatty acid-free bovine serum albumin (BSA; Sigma) to remove
unesterified [3H]AA.
For studies of [3H]AA release, the tissue was incubated in MEM +
0.5% BSA (as a trap for released [3H]AA) in the presence or absence of
PDBu. After 15 min, the incubation medium was removed and the
medium [3H]AA levels were determined by lipid extraction and reverse-
phase liquid chromatography on octadecyl silica (ODS) using the solvent
system described by Powell (1982) as follows. Ethanol was added to the
incubation medium to give a final ethanol concentration of 30% v/v. The
medium was centrifuged (10', 5°C, 3000 g) and the supernatant was
acidified with 1M HC1 to pH 3. The acidified medium (4 ml) was loaded
onto a pre-washed (5 ml ethanol followed by 5 ml of dH20) 1.25 cm ODS
column (sep-pak Ci8 cartridge,Waters Chromatography, Watford,
Hertfordshire, UK). Solvents were then passed through the column in the
following order; 30% ethanol (20 ml), distilled H2O (20 ml), petroleum
ether (10 ml), petroleum ether: CHCI3 (1:1, 20 ml). The solvent fraction
taken to represent [3H]AA released from the tissue (petroleum ether:
CHCI3) contained over 83% of standard authentic [3H]AA that had been
incubated with inactivated tissue (previously homogenised in 30% ethanol)
and carried through the extraction procedure.
The radioactivity remaining in the tissue was determined by
washing the tissue twice in 1 ml MEM containing 1 % BSA. The tissue was
then homogenised in 1 ml MEM + 0.5% BSA using a hand held tissue
grinder and diluted in ethanol to a final concentration of 30% v/v. The
homogenate was then spun (10 min, 5°C, 3000 g) and the supernatant
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acidified to pH 3. Aliquots of the supernatants from the tissue
homogenate and the incubation media were counted and the total amount
of label incorporated into the tissue was determined.
In the experiments where the effects of inhibitors were examined on
PDBu-induced [3H]AA release, the tissue was pre-incubated for 15
minutes with the appropriate inhibitor, the medium was discarded and the
tissue incubated with medium containing, in addition, PDBu for a further
15 min as described above.
Statistics
Data are expressed as means ± standard error of the mean (S.E.M.).
Statistical analyses were carried out using the MannWhitney U-test. The
EC50 values (the effective concentration which produces 50 % of the
maximal response) for the PDBu and the IC50 values (the concentration
which inhibits 50 % of the maximal response) for the kinase inhibitors and
PLA2 inhibitors were obtained from fitting the data with the non-linear,
error-weighted iterative curve fitting programme, P.fit (Biosoft,
Cambridge, UK) and are given as mean ± S.E.M.
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Results
Over consecutive hourly incubations with PDBu (300 nM), both LH
and GH release from proestrous rat hemipituitaries were significantly
increased above basal h levels, but with different temporal patterns (Figure
1). That is, the release of GH was maximal during the 1st h of PDBu
incubation (Figure lb), whereas, LH release did not increase significantly
above basal h levels until the 2nd h of PDBu incubation and then increased
further in the 3rd h (Figure la). Third h PDBu-induced LH release was
significantly inhibited in the presence of the PLA2 inhibitor quinacrine
(Markus and Ball, 1969; Loffler et al., 1985) (Figure la and 2) with an IC50
value of 20 ± 9 pM. In contrast, GH release measured during any hour of
phorbol incubation was unaltered by quinacrine (Figure lb), even at
concentrations as high as 100 pM where PDBu-induced LH release was
decreased to levels which were approximately 10% of control (Figure 2).
Aristolochic acid (100 pM) and BrPheBr (50 pM), at concentrations which
are reported to cause over 50 % inhibition of PLA2 activity in whole cells
but which have minimal effects on other enzymes (Drenth et ah, 1976;
Vishwanath et ah, 1988), also inhibited PDBu-induced LH release but not
PDBu-induced GH release (Table 1). The actions of these inhibitors
suggest that PLA2 may be a target for the PKC(s) which induce LH release,
but not those which induce GH release.
Neither quinacrine (100 pM), aristolochic acid (150 pM), nor
BrPheBr (50 pM) had any significant effect on baseline LH or GH release
when measured over several hours of incubation.
The influence of PKC activators on anterior pituitary PLA2 activity
was examined, more directly, by measuring [3H]AA release from pre-
labelled anterior pituitary tissue. After a 15 min incubation with PDBu
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(100 nM - 1 pM), [3H]AA release from proestrous tissue was significantly
increased above baseline levels (Figure 3) (EC50 = 79 ±27 nM). An increase
in the release of free [3H]AA levels from cellular phospholipids may result
from the action of PLA2 or by the sequential actions of phospholipase C,
which releases diacylglycerol (DAG), and DAG lipase, which will catalyse
the removal of a fatty acid from the glycerol backbone of DAG (Naor,
1991). To determine the pathway leading to [3H]AA release in this system,
we examined the effect of quinacrine and the DAG lipase inhibitor, RHC
80267 on the PDBu response. The inhibitors were used at concentrations
reported to selectively inhibit the activity of their targets with minimum
side-effects (Sutherland and Amin, 1982; Hoffman et al., 1982). Quinacrine
(50 pM), but not RHC 80267 (80 pM), inhibited PDBu (300 nM)-induced
[3H]AA release (Table 2), indicating that this phorbol ester effect on
proestrous rat anterior pituitary tissue [3H]AA release occurs through a
PLA2-dependent route.
The PKC inhibitors, staurosporine and Ro 31-8220 (Davis et al, 1989)
both fully inhibited 300 nM PDBu-induced [3H]AA release from pre-
labelled tissue with IC50 values of 28 ± 18 nM and 7 ± 3 pM respectively
(Figure 4a and 4b). Phorbol ester-induced AA release was also inhibited
by H7 (Figure 4c), but in a clearly biphasic manner. Although more than
50% of the response to PDBu was blocked by H7 concentrations as little as
1 pM, no further inhibition was observed until the H7 concentration was
then further increased by over 30-fold, suggesting that the PKC form
mediating some 40% of this response was highly resistant to H7. These
results indicate that both H7-resistant and -sensitive forms of PKC may be
involved in the mechanism of PDBu-induced [3H]AA release. Neither
quinacrine (50 pM), RHC 80267 (200 pM), staurosporine (300 nM), H7 (100
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pM) nor Ro 31-8220 (30 pM) had any significant effect on baseline [3H]AA
release (data not shown).
Since a previous report has indicated that phorbol ester-induced LH
release from rat anterior pituitary pieces is dependent upon protein
synthesis (Bourne et al., 1989), we investigated the possible involvement of
protein synthesis in the mechanism of PKC-activator induced PLA2
activation. The protein synthesis inhibitor, cycloheximide (Obrig et al.,
1971) (50 pM) significantly inhibited PDBu (300 nM)-induced LH release,
but not GH release during all hours of incubation (Figure 5).
Cycloheximide also inhibited PDBu-induced [3H]AA release (Table 3). In
contrast, cycloheximide had no effect on LH release induced by the PLA2
activator, melittin (Habermann, 1972) during any hour of incubation
(Figure 6). This suggests that the phase of protein synthesis essential for
phorbol ester-induced LH release may occur following the activation of
PKC, but prior to the actions of PLA2. "
Discussion
Previous reports suggest that stimulation of rat gonadotrope LHRH
receptors can lead to activation of PKC (Johnson et al., 1992a) and of PLA2
(Naor and Catt, 1981) leading to LH release. The present evidence
suggests, that in proestrous rat hemipituitary pieces, activation of PLA2
may be required for the mechanism of PKC activator-induced LH but not
GH release. The PLA2 inhibitors, quinacrine, BrPheBr and aristolochic acid
blocked PDBu-induced LH release, but not GH release (Figures 1, 2 and
Table 1), with potencies similar to their effects on PLA2-mediated
responses in other cell types (Loffler et al., 1985; Rosenthal et al., 1989;
Vallee et al., 1978). Notably, the concentration of quinacrine which was
reported to inhibit long-term secretory responses to LHRH in primary
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cultures of anterior pituitary cells (IC50 = 20 pM) (Naor and Catt, 1981) is
within the range described here for the inhibition of PDBu-induced LH
release from proestrous rat anterior pituitary pieces (IC50 = 20 ± 9 |iM).
The specificity of both quinacrine and BrPheBr as inhibitors of PLA2
has been questioned in a number of studies (Irvine, 1982; Dise et al., 1982;
Chang et al., 1987). However, quinacrine does not inhibit LH release
induced by depolarising concentrations of K+ or by Ca2+ ionophores
(unpublished observations), suggesting that a non-specific action of this
drug is unlikely to be responsible for its effects on PDBu responses.
Although BrPheBr and quinacrine are putative inhibitors of PLC activity
(Hofmann et al., 1982), these compounds are unable to prevent the
presumed PLC-dependent, initial LH release response to LHRH, measured
in proestrous rat tissue (unpublished observations). In addition, at the
concentrations used here, these compounds have been reported to inhibit
PLA2 in other systems without affecting PLC activity (Lazarewicz€f al,
1988). Aristolochic acid can inhibit the activity of PLA2 from snake venom,
human synovial fluid and platelets (Vishwanath et al., 1988; Rosenthal et
al., 1989) by interacting directly, but non-covalently with the enzyme,
inducing a change in the secondary structure of the protein (Vishwanath et
al., 1987). This mechanism of interaction between PLA2 and aristolochic
acid would imply that this agent may have specificity for PLA2 over other
phospholipases.
In agreement with this pharmacological evidence, suggesting that
PKC activation by phorbol esters modulates anterior pituitary PLA2
activity, PDBu induced a relatively rapid (15 min) increase in [3H]AA
release from proestrous rat anterior pituitary pieces (Figure 3); a response
which was blocked by inhibitors of PLA2, but not DAG lipase action (Table
2). Unfortunately, due to the small population of gonadotropes in anterior
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pituitary tissue, it was not possible to measure changes in the cellular
content of [3H]AA after stimulation. The exact relationship between
medium [3H]AA levels (as measured in these experiments) and
intracellular-free AA levels within the gonadotrope is therefore unclear.
Although, PKC-dependent phorbol ester-modulation of PLA2
activity has been described in other cell types (Parker et al., 1987; Akiba et
al., 1990), there are some suggestions that phorbol esters may directly
activate phospholipases (Billah et al., 1989; Billah and Anthes, 1990). It is
unlikely that direct activation of PLA2 can account for the effects of PDBu
on anterior pituitary [3H]AA release since this effect required protein
synthesis, implying that the mechanism of activation is complex.
Furthermore, PDBu-induced [3H]AA release from hemipituitaries was
readily inhibited by staurosporine and Ro 31-8220, suggesting that PKC is
involved in this response (Figure 4). The PDBu-induced [3H]AA release
response showed two components of inhibition by H7, suggesting that
both H7-resistant and H7-sensitive kinases may participate in this
response. We, and others, have previously reported that certain cellular
responses to phorbol esters display unusual resistance to H7 (Watson et al.,
1988; Johnson and Mitchell, 1989; Nakadate et al., 1989; MacEwan and
Mitchell, 1991; Johnson et al., 1992a, 1992b; Thomson et al., 1992).
Furthermore, in enzyme assays of anterior pituitary cytosol PKC activity,
we have detected a PDBu activated, phosphatidylserine-dependent, Ca2+-
independent kinase activity which is relatively resistant to inhibition by H7
(MacEwan et al., 1992). Interestingly, we have found that activation of an
H7-resistant, but staurosporine- and Ro 31-8220-sensitive, PKC is required
for the induction of LHRH priming (Johnson et al., 1992a) and that this
kinase may bring about the priming response by a mechanism involving
increased PLA2 activity in the gonadotrope (unpublished observations).
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Phorbol ester-induced LH release was verymarkedly inhibited by
cycloheximide (Figure 5a), consistent with a previous observation (Bourne
et al., 1989), and suggested that synthesis of an unknown critical protein(s)
is elicited in these cells by PKC activation. The present results provide
evidence which suggests that the protein synthesis-dependent step is the
mechanism by which PKC modulates PLA2 activity. Phorbol 12,13-
dibutyrate-induced [3H]AA release was blocked by cycloheximide,
whereas, melittin-induced LH release was not affected by the inhibitor.
However, melittin can induce voltage-dependent ion conductances in
planar lipid bilayers and, at high concentrations, can cause cell membrane
damage (Tosteson and Tosteson, 1981), thus melittin-induced LH release
may not occur by an entirely PLA2~dependent process. Nevertheless, these
results do suggest that PKC modulates PLA2 activity in a protein
synthesis-dependent manner. In smooth muscle and epithelial cells, PKC
can regulate the rapid synthesis of an endogenous, melittin-like protein
which activates PLA2 (Clark et al., 1987,1991). This PLA2-activating
protein (PLAP) has been shown to have a role in the leukotriene D4
receptor signalling system (Crooke et al., 1989). Further investigations are
required to examine the possible involvement of PLAP in the control of
gonadotrope PLA2 activity by PKC.
Arachidonic acid, and its lipoxygenase and epoxygenase
metabolites, have been suggested to have a role in the mechanism of LH
release (Naor andXIatt, 1981; Naor et al., 1983; Hulting et al., 1984; Kiesel et
al., 1987, Snyder et al, 1983). Arachidonic acid has a number of cellular
actions, and any combination of these may be involved in the mechanism
of PKC activator-induced LH release. For example, AA can induce Ca2+
release from non-mitochondrial stores (Wolf et al., 1986; Chan and Turk,
1987) resulting in a promotion of Ca2+-dependent processes such as
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gonadotropin release. Arachidonic acid has been reported to act both
directly and synergistically with other lipid products in the activation of
certain PKC isoforms (McPhail et al., 1984; Shearman et al., 1991). In
addition, AA, and perhaps lipoxygenasemetabolites, can modulate the
activity of voltage-sensitive ion channels permeable to Ca2+ or K+ (Kim
and Clapham, 1989; Kurachi et al., 1989; Ordway et al., 1991). The
relevance of these actions of AA in the mechanism of PDBu-induced LH
release is unclear and obviously requires further investigation.
Interestingly, endogenous AA production can be dissociated from
exocytosis in certain cell types (Churcher et al., 1990; Morgan and
Burgoyne, 1990; Cockcroft, 1991) suggesting that AA may not be a direct
mediator of secretion. Indeed, in cell-free systems, AA can enhance fusion
of secretory granules into membranes in a Ca2+-dependent manner
modulating exocytosis (Creutz, 1981). It is possible that an equivalent
action of AA in gonadotropes may enhance Ca2+-induced LH release.
Neither cycloheximide nor any PLA2 inhibitor tested blocked PDBu-
induced GH release indicating that neither protein synthesis nor PLA2
activation is required for the mechanism of PKC activation-induced GH .
release. Instead PDBu-induced GH release is suggested to occur by a route
involving direct modulation of 'L'-type voltage-sensitive Ca2+ channels by
PKC (Johnson et al., 1991).
In conclusion, these experiments show that PDBu-induced LH but
not GH release from proestrous rat anterior pituitary pieces, in vitro,
requires PLA2 activation and protein synthesis. The relationship of the
PKC forms which control PLA2 activity to the known isoforms of PKC is
unclear. However, it would appear that more than one form of PKC (both
H7-resistant and -sensitive types) is involved in the process of PKC
activator -induced [3H]AA release (as shown here) and in PKC-activator-
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induced LH release (Johnson et al. ,1989,1992b). Thus, the PKCs that
induce LH and GH release, as well as being pharmacologically distinct
(Johnson et al., 1989,1992b), may have distinct cellular targets which may,
in part, account for the difference in the time course of PDBu-induced
release for each of these hormones.
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The effect of PLA2 inhibitors on PDBu-induced LH and GH release from
proestrous rat anterior pituitary tissue
Hemipituitaries were incubated for a basal h either in with no drug
or with a PLA2 inhibitor (BrPheBr, 50 pM) or aristolochic acid (100 pM). In the
following hours (1st h, 2nd h, 3rd h), the incubation medium contained, in
addition, PDBu (300 nM) or no drug (baseline). The data shown here
represents LH release measured during the 3rd h of incubation and GH release
measured during the 1st h of incubation with PDBu. The statistical
significance of the effects of PLA2 inhibitors on PDBu-induced hormone release
is represented by * (p < 0.05, Mann-Whitney U-test). Values shown are the
means ± S.E.M. and the number of determinations are shown in parentheses.
LH release (pg/1) GH release (pg/1)
baseline 4.9 ± 0.9 (4) 259.1 ± 14.1 (4)
PDBu 32.3 ± 2.7 (6) 1964.3 ± 108.8 (6)
PDBu + BrPheBr *15.8 ± 2.1 (4) 2072.3 ±368.7 (4)
PDBu + aristolochic acid *14.2 ±1.5 (4) 2239 ± 207.8 (4)
Table 2
The effect of quiriacrine and RHC 80267 on PDBu-induced [3H]AA release
from pre-labelled proestrous rat anterior pituitary pieces
[3H]Arachidonic acid-labelled pairs of anterior pituitary quarters
were pre-incubated for 15 minutes in medium only, or with quinacrine (50 (iM)
or RHC 80267 (80 pM), the medium was discarded and replaced with fresh
medium containing either no drug (baseline) or PDBu (300 nM), or PDBu and
either quinacrine or RHC 80267. After the second 15 min incubation, the
medium was removed and the [3H]AA was extracted. The statistical
significance of the effects of quinacrine and RHC 80267 on LHRH-induced
[3H]-AA release was determined (*p < 0.05, Mann-Whitney U-test). Values
shown are the means ± S.E.M. and the number of determinations are shown in
parentheses.
[3H]AA release
(% total label incorporated)
baseline 1.59 ±0.07 (10)
PDBu 2.73 ± 0.16 (8)
PDBu
+ *1.65 ±0.02 (5)
quinacrine
PDBu
+ 2.53 ± 0.22 (4)
RHC 80267
Table 3
The effect of cycloheximide on PDBu-induced [3H]AA release from
proestrous rat anterior pituitary pieces
Pairs of pituitary quarters, pre-labelled with [3H]AA, were pre-
incubated for 15 min in medium containing either no drug or cycloheximide
(50 pM). The medium was discarded and replacement medium contained, in
addition, either no drug (baseline) or PDBu (300 nM). After incubation for 15
min, the medium was removed and [3H]AA release was determined. Phorbol
12,13-dibutyrate-induced [3H]AA release was significantly inhibited by
cycloheximide (*p < 0.05, Mann-Whitney U-test). Values are means ± S.E.M.










Effect of quinacrine on the time-course of PDBu-induced LH and GH release
from proestrous rat hemipituitaries
Iiemipituitaries were incubated for an initial basal h either with no
drug (open bars ) or with quinacrine (50 [iM) (hatched bars). In the following
consecutive hourly incubations (1st h, 2nd h, 3rd h), the incubation medium
contained, in addition, PDBu (300 nM). The statistical significance of the
inhibitory effects of quinacrine on PDBu-induced hormone release at each
incubation period was determined (*p < 0.05, Mann-Whitney U-test). Data are
the means ± S.E.M. for 4 - 6 determinations.
Figure 2
Concentration response curve for the effect of quinacrine on PDBu-induced
LH and GH release from proestrous rat hemipituitaries
Hemipituitaries were incubated for a basal h in either medium only
or with various concentrations of quinacrine (1 - 100 pM). Over the following
consecutive hourly incubations, the medium contained, in addition, PDBu (300
nM). The data represents LH release (•) measured during the 3rd h of PDBu
incubation and GH release (■) measured in the 1st h of phorbol incubation.
Quinacrine caused a dose-dependent inhibition of PDBu-induced LH but not
GH release (*p < 0.05, Mann-Whitney U-test). Each point on the graph
represents the mean ± S.E.M. for 4-8 determinations.
Figure 3
Concentration response curve for the effect of PDBu on [3H]AA release from
pre-labelled proestrous rat anterior pituitary tissue.
Anterior pituitary tissue, which had been pre-labelled with [3H]AA
and then extensively washed, was incubated in medium containing various
concentrations of PDBu (10 nM- 1 pM). The levels of [3H]AA released into the
medium were then determined. The statistical significance of the effect of
PDBu was determined (*p < 0.05, Mann-Whitney U-test). Data are means ±
S.E.M. for 6-8 determinations.
Figure 4
Concentration-response curves for the effect of (a) staurosporine, (b) Ro 31-
8220 and (c) H7 on PDBu-induced [3H]AA release from proestrous rat
anterior pituitary tissue
Pairs of pre-labelled anterior pituitary quarters were pre-incubated
for 15 minutes with medium only or the appropriate concentration of PKC
inhibitor. The medium was discarded and replaced with fresh medium
containing either no drug (basal) or PDBu (300 nM) only or PDBu with various
concentrations of inhibitor. After 15 minutes, [3H]AA release into the medium
was determined. Both staurosporine and Ro 31-8220 fully reversed the effect of
PDBu. However, PDBu-induced [3H]AA release apparently displayed 2
components of inhibition by H7. Each point on the graphs represents the mean
± S.E.M. for 4-8 determinations.
Figure 5
Effect of cycloheximide on PDBu-induced LH and GH release from
proestrous rat anterior pituitary tissue
Hemipituitaries were incubated for a basal h in either medium only
(open bars) or with cycloheximide (50 pM, hatched bars). Over a further 3
consecutive hourly incubations, the medium contained, in addition, PDBu (300
nM). Cycloheximide inhibited 2nd and 3rd h PDBu-induced LH but not GH
release (*p < 0.05). The S.E.M. values for the cycloheximide treated samples are
within a range of 0.4 to 0.6 pg/1 and are not obvious from the scale used here.
Each point on the graph represents the mean ± S.E.M. for 6 determinations.
Figure 6
Effect of cycloheximide on melittin-induced LH release from proestrous rat
hemipituitaries _ ~~ ~ ~
Hemipituitaries were incubated for a basal h in medium containing
either with no drug (open bars) or cycloheximide (50 pM, hatched bars). In the
following consecutive hourly incubations, the medium contained, in addition,
melittin (3 pM). Melittin-induced LH release was clearly unaffected by the
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Cellular actions of pharmacologically distinct forms of Protein Kinase C
r.J. Thomson*, M.S. Johnson*, D.J. MacEwan*, G. Fink and R. Mitchell*
^RC Brain Metabolism Unit, 1 George Square, Edinburgh EH8 9JZ, U.K.
We have developed various cellular models of protein kinase C action which have
allowed us to explore, in a physiological context, the selective pharmacology of different
species of PKC.
Depolarisation-induced 45Ca2+ influx into anterior rat pituitary tissue and into GH3
sells (both of which occur through dihydropyridine-sensitive Ca2+ channels) were
differently influenced by phorbol esters and putative PKC inhibitors. In GH3 cells, 4I3-, but
■not 4a-phorbol 12,13-didecanoate (PDD) inhibited K+-induced 45Ca2+ influx in a
staurosporine- and H7-sensitive manner. In contrast, PDD enhanced K+-induced 45Ca2+
influx into pituitary tissue in a staurosporine-sensitive, but H7-insensitive manner. We have
also found certain PKC actions in other models to show differential sensitivity to H7. For
example, H7 blocked phorbol 12,13-dibutyrate (PDBu)-induced release of luteinizing
hormone (LH) but not growth hormone (GH), whereas staurosporine inhibited both. These
results were paralleled by measurements of partially purified PKC activity from anterior
pituitary gland. Both Ca2+-independent and Ca2+-dependent PDBu-stimuiated kinase
activity were blocked with similar potency by staurosporine, whereas Ca2+-independent
kinase activity was found to be relatively much more resistant to H7. These
pharmacologically different PKCs in anterior pituitary also differ in their cellular targets.
Phospholipase A2 (PLA2) inhibitors (eg quinacrine) blocked PDBu-induced LH but not GH
release suggesting that in gonadotrophes, but not somatotrophes, an H7 sensitive-PKC(s)
can act to modulate PLA2 activity.
This data suggests that PKC species may differ in their sensitivity to PKC inhibitors,
and that they may have distinct cellular targets.
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To investigate the pharmacology of the protein kinase C (PKC)
forms that modulate rat anterior pituitary hormone release,
hemipituitaries were incubated in the presence of various PKC activators
and inhibitors and luteinizing hormone (LH) and growth hormone (GH)
release were measured. Activators of PKC induced LH release with the
following order of potency; mezerein > phorbol 12,13-dibutyrate (PDBu)
» 1,2-dioctanoyl-Stt-glycerol (DOG). Mezerein and PDBu were
equipotent, but DOG was ineffective, on GH release. The PKC inhibitor,
staurosporine, blocked PKC activator-induced LH and GH release. A
component of PDBu- and mezerein-induced LH release was also blocked
with high potency by l-(5-isoquinolinesulphonyl)-2-methylpiperazine
dihydrochloride (H7). However, a second H7-insensitive-component
was detected. 1,2-Dioctanoyl-sn-glycerol-induced LH and mezerein- and
PDBu-induced GH release consisted of the H7-resistant component only.
These results are consistent with the existence of pharmacologically-
distinct PKC forms in rat anterior pituitary tissue.




The activation of receptors for many different hormones and
neurotransmitters is known to result in phosphoinositide hydrolysis
and subsequent production of diglycerides and inositol phosphates
(Nahorski et al., 1986). Inositol 1,4,5-triphosphate (Ins 1,4,5 P3)
mobilises intracellular Ca2+ from specific stores (Berridge and Irvine,
1984), whilst diglyceride activates the Ca2+/phospholipid dependent
protein kinase, protein kinase C (PKC). Both Ca2+ mobilisation and PKC
activation are important for cell responses to certain hormones
(Nishizuka, 1984), including a number that act on anterior pituitary cells.
At least 8 structurally different PKC isoforms (a, Pi, pn, y, 5, e, T|)
have been identified (Nishizuka, 1988; Parker et al., 1989; Osada et al.,
1990). EachTKC form displays somewhat different activation profiles in
terms of their requirement for co-factors, such as different phospholipids
(Bazzi and Nelsestuen, 1987; Nishizuka, 1988; Parker et al., 1989) and fatty
acids (Naor et al., 1988; Murakami and Routtenberg, 1985). Each PKC
isoform also differs in its dependence upon Ca2+ for activation; the a, Pi,
pn, and y forms (A series) being Ca2+-dependent and the y, 8, e, C, and r\
isoforms (B series) being Ca2+-independent (Nishizuka, 1988; Huang,
1989; Parker et al., 1989; Osada et al., 1990). Since the PKC isoforms have
different patterns of tissue^distribution (Brandt et al., 1987; Nishizuka,
1988; Osada et al, 1990), each isoform may have distinct cellular targets
and specific physiological roles. Consistent with this hypothesis, studies
using cell-free preparations have shown that PKC isoforms can differ in
their ability to phosphorylate various artificial and endogenous
substrates (Huang, 1989; Parker et al., 1989; Schaap et al., 1989 ).
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We have previously reported that the PKC activator, phorbol
12,13-dibutyrate (PDBu), induces the release of both luteinizing hormone
(LH) and growth hormone (GH) from rat anterior pituitary tissue, in
vitro (Johnson and Mitchell, 1989). However, the temporal patterns of
PDBu-induced LH and GH release are quite different, suggesting that
distinct intracellular mechanisms and possibly distinct PKC isoforms
may be involved in the release of each of these hormones. There is good
evidence that PKC is the main cellular receptor for phorbol esters, and
that diglycerides interact competitively with the phorbol ester binding
domain of PKC (Castagna et al., 1982; Leach et al., 1983; Niedel et al.,
1983). However, it is now apparent that PKC isoforms can display
different profiles of activation by various species of diglyceride and
phorbol ester (Johnson and Mitchell, 1989; Nakadate et al., 1988; MitchelL
et al., 1990; MacEwan and Mitchell, 1991; MacEwan et al., 1991; Ryves et
al., 1991). We have used our model of anterior pituitary hormone
release as a biologically assay of PKC function to examine the possibility
that pharmacologically-distinct PKC forms exist in anterior pituitary.
The present experiments assessed the effects of various activators and
inhibitors of PKC action on LH and GH release from rat anterior
pituitary tissue and suggest that a number of pharmacologically-distinct
species of PKC are involved in the control of LH and GH release. Some
of these data have been previously presented in abstract form (Johnson
and Mitchell, 1989).
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2. MATERIALS AND METHODS
2.1 Hormone secretion experiments
The methods and experimental design were based on those
reported by Pickering and Fink (1976) with the following modifications.
Female COB/Wistar rats (Charles River UK Ltd, Margate, Kent), 200-250g
body weight, were maintained under controlled lighting (lights on from
0500 to 1900 h) and temperature (22°C) with free access to food pellets
(CRM; Labsure, Manea, Cambs, UK) and tap water. Female rats, which
had at least two regular 4 day oestrous cycles, were anaesthetised with
sodium pentobarbitone (30 mg/kg; Sagatal; May & Baker Ltd, Dagenham,
Essex) immediately before being decapitated between 1030 and 1200 h on
pro-oestrus. The anterior lobes of the pituitary glands were separated
and hemisected. Hemipituitary glands were incubated (one/flask) in 2
ml of Hepes-buffered minimal essential medium with Earles salts
(MEM) (Gibco BRL, Paisley, U.K.) at 37°C in a shaking water bath under
an atmosphere of 95%02/5%C02- Hemipituitaries from the same rat
were allocated to treatment groups at random. After a preincubation for
30 min the medium was changed for fresh pre-warmed and gassed MEM
every hour thereafter. In the initial hour (basal hour), the tissue was
incubated with MEM only, followed by consecutive hours (1 h, 2 h, 3 h)
in the presence of a PKC activator (PDBu, DOG or mezerein). In the
experiments where the effects of PKC inhibitors (staurosporine, H7 or
psychosine) were examined, the inhibitor was included throughout all
hours of incubation (i.e. basal hour, 1st, 2nd and 3rd hour).
All the media removed from the flasks was stored at -20°C until
they were radioimmunoassayed for LH or GH (Niswender et al., 1968).
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The standards used were NIH-LH-S18 (Figs 1, 2, 4, 5a and Table 1),
NIADDK-rat LH-RP2 (Figs 3, 5b, 5c and Tables 2 and 3) and NIADDK-rat-
GH-RP-2.
2.2 Cytosolic PKC activity assay
Anterior pituitary PKC activity was determined as described by
Johnson et al., (1992b) using methods modified from those described by
Wise et al., (1982) and Huang et al., (1988). Anterior pituitary tissue was
homogenised in 2 vol of 20 mM Tris HC1 (pH 7.5) containing 50 mM 2-
mercaptoethanol, 2 mM ethylenediaminetetraacetic acid (EDTA), 1 mM
PMSF, 0.01% (w/v) leupeptin and 20 pM E64. The homogenate was
centrifuged (16,000 g 20 min, 4°C) and the supernatant was collected and
recentrifuged (16,000 g, 5 min, 4°C). The second supernatant was taken to
represent cytosol and was partially purified by loading onto 0.5 ml of
DE52 diethylaminoethyl cellulose matrix (Whatman International Ltd,
Maidstone, Kent, UK) in a Bio-Rad Poly-Prep chromatography column
(Bio-Rad Laboratories, Richmond, C.A., USA) at 4°C. The cytosol was
then washed with 6 column vols of homogenisation buffer before
eluting the partially-purified PKC with 3 column vols of buffer
containing 150 mM NaCl. Partially-purified cytosolic PKC activity was
measured in an assay mixture containing (final concentrations): 1.25 mM
MgCl2, 100 pg/ml phosphatidyl serine + 0.04% Nonidet P-40,1.25 mg/ml
histone III-S, 100 |iM ATP-y-35S (0.18 pCi/tube) and cytosol. Phosphatidyl
serine vesicles were prepared by drying the lipid from
chloroform/methanol under a stream of N2. The subsequent film of
phosphatidyl serine was scraped into 20 mM Tris HC1 (pH 7.5) + 0.5 mM
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EGTA at a stock concentration of 400 pg/ml, sonicated, then 0.16%
Nonidet P-40 was added. The mixture was vortexed before use. Assay
tubes also contained either 600 pM CaCl2 (100 pM free Ca2+) or 5 mM
ethyleneglycol-bis-(p-aminoethyl ether) N, N, N',N'-tetraacetic acid
(EGTA) (less than 3 nM free Ca2+). Protein kinase C activity was
measured either in the absence of activator (i.e. basal activity) or in the
presence of 1 pM PDBu with or without Ca2+ and with or without
various concentrations of either H7 or staurosporine. All assay
components and drugs were dissolved in 20 mM Tris HC1 (pH7.5) + 0.5
mM EGTA. Reactions were carried out at 30°C for 15 min and were
stopped by quenching with 20 pi of 0.1 mol/1 ATP in 0.1 mol/1 EDTA (pH
7.0). The quenched reaction mixture (50 pi) was spotted onto a 4 cm2
piece of P-81 cellulose phosphate ion-exchange chromatography paper
(Whatman International Ltd) and washed (3 x 10 ml, 2 min, room
temperature) in 75 mM H3PO4, dried and counted by liquid scintillation.
2.3 Drugs
Phorbol 12,13-dibutyrate, 1,2-dioctanoyl-sn-glycerol,
galactosylsphingosine (psychosine) (Sigma Chemical Co Ltd, Poole,
Dorset), mezerein and staurosporine (Calbiochem, San Diego, CA, USA)
were all made up as stock solutions in dimethylformamide (DMF) and
kept in the dark, on ice, before final dilution in MEM for experiments.
The maximum concentration of DMF used was 0.5 % v/v and this was
shown in control experiments to have no effect. l-(5-
Isoquinolinesulphonyl)-2-methylpiperazine (H7) (Gibco BRL, Paisley,
Scotland, UK), leupeptin (Boehringer Mannheim, Lewes, UK) and trans-
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epoxysuccinyl-L-leucylamido-(4-guanidino) butane (E64, Sigma) were
made up as stock solutions in distilled H2O. Phenylmethlysulphonyl
fluoride (PMSF) and histone III S were obtained from Sigma, Nonidet P-
40 and unlabelled ATP-y-S were from Calbiochem. Phosphatidyl serine
(sodium salt) was from Lipid Products, Nutfield, Surrey and ATP-y-35S
(specific activity = 1256 Ci/mmol) was purchased from DuPont, Dreiech,
Germany. Analar grade laboratory chemicals were obtained from BDH,
Dagenham, Essex, UK.
2.4 Statistics
Data are expressed as means ± standard error of the mean (S.E.M).
Statistical analyses were carried out using the Mann Whitney U-test.
The EC50 values for the PKC activators and the IC50 values for the kinase
inhibitors were obtained from fitting the data with the non-linear, error-
weighted iterative curve fitting programme, P.fit (Biosoft, Cambridge,
UK) and are given as mean ± S.E.M.
3. RESULTS
3.1 The effect of PKC activators on anterior pituitary hormone release
When rat hemipituitary pieces were incubated for consecutive
hours in the presence of PDBu (100 nM), both LH and GH release
significantly increased above basal h levels. However, the time course of
PDBu-induced release was very different for each hormone (Fig 1). The
release of GH was maximal during the 1st h of PDBu incubation, with
release increasing by 2.1 ± 0.3 fold over basal h levels. In contrast, LH
release in the 1st h of incubation with PDBu was not significantly
different from LH release measured during the basal h. During the 2nd
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h of incubation with PDBu, LH release increased to 2.9 ±1.0 fold of basal
h levels (p < 0.05) and increased further in the 3rd h of incubation (5.3 ±
0.9 fold of basal h levels, p < 0.01).
Another PKC activator, mezerein, induced both LH and GH
release from hemipituitary pieces with temporal patterns similar to
those observed using PDBu (data not shown). Increasing the
concentration of either PDBu or mezerein resulted in a concentration-
dependent increase in the magnitude of both LH (Fig 2a) and GH (Fig 2b)
release. Growth hormone release was induced by mezerein and PDBu
with similar potency (EC50 of 74 ± 62 nM and 82 ± 25 nM respectively).
Mezerein was almost as potent in releasing LH (EC50 = 152 ± 70 nM) .
However, much greater concentrations of PDBu were required to elicit
LH release, with 50% of the maximal release induced by mezerein only
being reached by a PDBu concentration of approximately 900 nM. It
appears, therefore, that PDBu is considerably less potent than mezerein
at inducing LH release. These results suggest that the PKC(s) which are
involved in LH release may be less susceptible to activation by PDBu
than mezerein.
The cell-permeable diglyceride, DOG (200 pM) induced a small but
significant increase in LH secretion from rat anterior pituitary tissue
throughout the 2nd h and 3rd h of incubation with the diglyceride (p <
0.05) (Fig 3a). However, even at this high concentration, DOG was less
effective at inducing LH release when compared to either PDBu or
mezerein. Growth hormone release was not significantly increased
above baseline levels at any hour of incubation with DOG (Fig 3b)
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suggesting that the PKC(s) which induce GH release may be relatively
resistant to activation by DOG.
3.2 The effect of PKC inhibitors on anterior pituitary hormone release
The PKC inhibitor, staurosporine, readily blocked 100 nM PDBu-
induced release of both LH and GH with similar potency (IC50 = 44 ±
17 nM and 54 ± 42 nM for LH and GH respectively) (Fig 4). At
staurosporine concentrations of 100 nM and above, both LH and GH
release were blocked to levels which were not significantly different
from basal h levels of release.
The effects of another putative endogenous PKC inhibitor,
psychosine (galactosylsphingosine) (Hannun and Bell, 1987), was
examined on PDBu-induced LH and GH release (Table 1). When
anterior pituitary tissue was incubated with psychosine alone, both LH
and GH were released to levels significantly higher than baseline (p <
0.05). Psychosine had no inhibitory action on either PDBu-induced LH
or GH release; in fact, PDBu-induced release of LH and GH were both
slightly enhanced in the presence of psychosine, although not to
significant levels, presumably indicating non-specific actions of this
substance.
Luteinizing hormone release induced by 100 nM PDBu was
significantly inhibited by another PKC inhibitor, H7, at concentrations of
3 |iM and above and with an IC50 value of 1.7 ± 1.5 pM (Fig 5a). In
contrast, 100 nM PDBu-induced GH release was unaffected by H7, even at
concentrations of 30 |iM and above which caused over 80 % inhibition of
LH release induced by 100 nM PDBu. However, when the effect of H7 (30
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pM) was examined on LH release measured over a range of PDBu
concentrations (Fig 5b), it was clear that an H7-resistant component of
this response could also be detected at higher levels of the phorbol ester.
That is, LH release induced by 30 nM PDBu was completely inhibited by
30 (iM H7, whereas, approximately 20 % of LH release measured at 1 |iM
PDBu was insensitive to H7 (30 pM). Similarly, mezerein (300 nM)-
induced LH release also consisted of H7-sensitive and resistant
components. Approximately 40 % of the LH secretory response to
mezerein was blocked by H7 at concentrations as low as 1 pM. However,
further inhibition of the response was not seen until H7 concentrations
of 30 pM. Furthermore, at H7 concentrations as high as 100 pM,
mezerein-induced LH release was not completely inhibited, with 20 % of
the response remaining. Mezerein (300 nM)-induced GH release was
completely insensitive to inhibition by H7 at concentrations up to 100
pM (Fig 5c). Both mezerein-induced LH and GH release were, however,
readily blocked by 300 nM staurosporine (Table 2).
Although 200 pM DOG-induced LH release was readily inhibited
by staurosporine (300 nM) to levels that were not significantly different
from baseline, this response was entirely resistant to block by 30 pM H7
f
(Table 3). Therefore, DOG may be a selective activator of the H7-resistant
PKC(s) which can elicit LH release.
Neither H7 (30 pM) nor staurosporine (2 pM) had any effect on
baseline LH and GH release from anterior pituitary tissue when added
alone to the incubation medium over a period of 3 consecutive hours
(data not shown).
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Anterior pituitary PKC activity, measured in a mixed micelle
assay, was used to further examine the effects of H7 and staurosporine.
Calcium-independent, cytosolic PKC activity was stimulated by PDBu
with an EC50 of 916 ± 150 nM and the additional activity evoked by
addition of Ca2+ had an EC50 for PDBu of 261 ± 86 nM. All activity was
entirely dependent on the presence of phosphatidyl serine. Calcium-
dependent activity induced by 1 pM PDBu was potently inhibited by
staurosporine and H7 (Table 4) with IC50 values similar to those found
for PKC activity measured in a range of other peripheral and central
tissues. For example, Ca2+-dependent cytosolic PKC activity from rat
midbrain was inhibited by staurosporine and H7 with IC50 values of 100
± 40 nM and 34 ± 5 pM respectively. In contrast, Ca2+-independent
anterior pituitary PKC activity was distinctly less sensitive to H7 than the
Ca2+-dependent activity measured in the same experiment (Table 4).
However, in experiments using rat midbrain, Ca2+-independent activity
had the expected sensitivity to H7 and staurosporine (IC50 = 27 ± 9 pM
and 120 ± 6 nM respectively). The Ca2+-independent activity in anterior
pituitary, however, showed the expected potency of block by
staurosporine (Table 4).
4. DISCUSSION
Several earlier reports have shown that PKC activation by phorbol
esters and diglycerides can induce hormone release from anterior
pituitary tissue, in vitro, and from anterior pituitary cells in culture
(Smith and Vale, 1980; Conn et al., 1985; Nigro-Villar and Lapetina, 1985;
Turgeon and Waring, 1986; Johnson and Mitchell, 1989). However, we
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have shown that LH release is induced more effectively by mezerein
than PDBu, suggesting that the PKC(s) involved are more readily
activated by mezerein. In contrast to their effects on LH release, PDBu
and mezerein induced GH release with equal potency, suggesting that
the PKC(s) that are involved in the latter case are activated by these two
compounds with equal effectiveness. Differences in the tumour-
promoting effects of phorbol esters, such as phorbol 12-myristate
13-acetate (PMA) ,and mezerein have been reported previously (Slaga et
al., 1980) and may also reflect the ability of these compounds to
preferentially activate certain forms of PKC.
1, 2-Dioctanoyl-sn-glycerol was unable to induce any significant
release of GH suggesting that DOG-insensitive PKC(s) are involved in
this response. Although DOG could enhance LH release, the secretory
response to DOG was much smaller than that measured using either
PDBu or mezerein. In certain other models of PKC function in pituitary
cells, for example, the facilitation of depolarisation-induced 45Ca2+ influx
into anterior pituitary prisms (MacEwan and Mitchell, 1991), a DOG
concentration of 100 |iM elicited effects of equivalent magnitude to 300
nM PDBu or 300 nM mezerein. However, the lower potency of DOG on
LH release may reflect the ability of this diglyceride to activate only a sub-
population of the PKCs that are potentially involved in LH release.
Consistent with this hypothesis, DOG appeared to be a selective activator
of an H7-resistant PKC(s) involved in LH release. In other physiological
models of PKC action, DOG has been shown to mimic some, but not all,
actions of phorbol esters (Lacerda et al., 1988; MacEwan and Mitchell,
1991; Thomson et al., 1992). Indeed, in both the hormone release and
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45Ca2+ flux models, DOG appears to selectively activate a relatively H7-
resistant PKC, which is also activated by PDBu (MacEwan and Mitchell,
1991; Thomson et al., 1992), further suggesting that DOG may be a
selective activator of certain PKC forms. Reduced potency of DOG as an
activator of the a-PKC isoform has been reported (Sekiguchi et al., 1988)
and is most marked under conditions of basal cytosolic Ca2+ (< 200 nM).
However, DOG, unlike PDBu and mezerein, is susceptible to
intracellular degradation (Kaibuchi et al., 1983), which may also partly
contribute to the low potency of DOG on LH release, especially under the
relatively long incubation periods used here.
We have demonstrated here that some actions of PKC activators
on anterior pituitary hormone release are unusually resistant to the PKC
inhibitor, H7 (Hidaka & Hagiwara, 1987), but not to staurosporine
(Tamaoki et al., 1986). Both H7-sensitive and -insensitive PKC(s) may be
involved in PKC activator-induced LH release, with DOG being a
selective activator of the H7-resistant PKC(s). In contrast, the PKC(s)
which induce GH release are of the H7-resistant type only but are not
activated by DOG. These observations suggest that at least 3 forms of
PKC (or a closely related kinase) with distinct pharmacological properties
may participate in phorbol ester-induced anterior pituitary hormone
release. Additional evidence that H7-resistant PKC forms are expressed
in anterior pituitary tissue has come from cell free assays of PKC activity.
In these experiments, a PDBu-induced, Ca2+-independent, phosphatidyl
serine-dependent component was detected which was relatively H7
resistant but readily blocked by staurosporine. In contrast, Ca2+-
dependent, PDBu-induced activity displayed relative sensitivity to block
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by H7 and staurosporine. We and others have previously described
phorbol ester-responses which show unusual resistance to H7, but not
staurosporine (Watson et al., 1988; Johnson and Mitchell, 1989; Johnson
et al., 1989; Nakadate et al., 1989; Fink et al., 1990; Johnson et al., 1992a;
Thomson et al., 1992). Furthermore, an H7-resistant PKC appears to
have a role in anterior pituitary responses to LH-releasing hormone
(Fink et al., 1990; Johnson et al., 1992a).
Although staurosporine and H7 are structurally very different,
they both appear to block PKC activity by binding at or near to the ATP
binding site (Huang, 1989), hence the contrast between the inhibitory
effects of H7 and staurosporine may at first be unexpected. However,
these two inhibitors may not have identical sites of action. Both H7 and
staurosporine have been reported to exert kinetically competitive
inhibition with respect to ATP (Hidaka et al., 1984; Tamaoki et al., 1986;
Riiegg and Burgess, 1989) although, in both cases, the precise site of
action is unclear. However, the binding of [3H]N,N-
dimethylstaurosporine (a radiolabeled staurosporine derivative) is
displaced by H7 with extremely low potency (IC50 > 500 pM) (Thomson et
al., 1991a). In addition, the a and (J PKC isoforms have both been
reported to have a second consensus recognition motif for ATP (Huang,
1989; Burns and Bell, 1991), therefore the interactions between H7 and
these isoforms may be complex. Since H7 and its congener, HA 1004, can
display relative selectivity for particular kinases (Hidaka and Hagiwara,
1987), it may be possible that these compounds can have some degree of
selectivity between different PKC isoforms.
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The different temporal patterns of PKC-activator induced LH and
GH release indicates that these pharmacologically-distinct PKCs may also
phosphorylate distinct cellular targets. For example, evidence from our
laboratory suggests that these distinct PKCs may differentially modulate
voltage-sensitive Ca2+ channels (MacEwan et al., 1991) and
phospholipase A2 (Thomson et al., 1991b). In the pituitary derived
GH4C1 cell line, a specific role has been attributed to the E isoform in
cellular responses to thyrotropin releasing hormone (Kiley et al., 1990,
1991) further indicating that specific PKC isoforms have distinct roles in
anterior pituitary cell function.
The relationship of the PKC forms involved here in LH and GH
release to the known PKC isoforms is unclear. Of the known PKC types,
a, P, e, but not y, have been described in anterior pituitary cells (Naor et
al., 1988; Kiley et al., 1990, 1991; Naor, 1990)._Our own experiments,
employing Northern blotting with 3' tailed oligonucleotide probes for
particular isoforms, indicate that the C, and 5 isoforms may also be
expressed in anterior pituitary tissue (data not shown). The T} isoform is
reported to show a broad tissue distribution (Osada et al., 1990), so it too
may potentially be a mediator of some of the effects seen here. When
added to permeabilized pituitary cells, both a and P isoforms can
stimulate LH release (Naor et al., 1989). Certainly, the results presented
here indicate that the H7-sensitive PKC(s) which are involved in LH
release may represent one or more of the Ca2+-dependent types, such as
the a and P isoforms. However, PKC-induced LH release and GH release
also involve H7-resistant PKC(s) which appear to be Ca2+-independent,
and may therefore represent one or more of the 5, e, £ and r\ isoforms.
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Since data obtained using recombinant or purified enzyme preparations
has shown that the e- and 5-isoforms of PKC display the same degree of
sensitivity to H7 (Schaap and Parker, 1990; Uchida et al., 1991), the Ca2+-
independent, H7-resistant PKC(s) that induce LH and GH in our model
may not represent either of these isoforms. However, there is increasing
evidence that the degree of Ca2+-dependency of the a, P and y isoforms,
may alter in the presence of certain fatty acids (Naor et al., 1988;
Shinomura et al., 1991) and it has also been suggested that the
phosphorylation state of the (3 isoform can alter its Ca2+ dependency
(Pelech et al., 1991). Thus, it is possible that a modified state of one or
more of the A series PKC isoforms may represent one of the apparently
Ca2+-independent, H7-resistant types which control anterior pituitary
hormone release. _
=
In Summary, we have shown here that several pharmacologically
distinct forms of kinase, with many of the properties of PKC, exist in
anterior pituitary tissue and these forms differ in their influence on
hormone release from different cell types. The relationship of these
pharmacologically distinct forms to the known PKC isoforms, is unclear.
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Table 1. Effect of psychosine on PDBu-induced LH and GH release from
rat anterior pituitary tissue. Hemipituitaries were incubated for a basal hr with
either no drug (baseline) or psychosine (50 (iM), followed by 3 consecutive hrs
with the same or, in addition, PDBu (100 nM). Values shown here are for GH
release measured in the 1st h and LH release measured in the 3rd h of treatment.
Values are mean ± S.E.M., and the number of determinations are in parentheses.
LH release (ng/ml) GH release (ng/ml)
baseline 2.5 ± 0.3 (6) 464 ±70 (5)
psychosine 22.7 ± 4.1 (6) 1424 ±109 (6)
PDBu 33.8 ± 8.3 (7) 1951 ± 216 (7)
psychosine + PDBu 60.1 ±11.7 (4) 2243 ± 226 (4)
Table 2. Effect of staurosporine on mezerein-induced LH and GH release
from rat anterior pituitary tissue. Hemipituitaries were incubated for a basal hr
with either no drug (baseline) or staurosporine (300 nM), followed by 3
consecutive hrs with the same and/or mezerein (300 nM). Values shown here are
for GH release measured in the 1st h and LH release measured in the 3rd h of
incubation. Values are mean ± S.E.M., with the number of determinations shown
in parentheses.




3.9 ± 0.4 (4)
39.1 ± 4.3 (5)
*2.9 ± 0.4 (4)
480.7 ±105.5 (4)
1820.3 ± 234.7 (4)
*510.0 ± 38.7 (4)
Table 3. The effect of PKC inhibitors on DOG-induced LH release from rat
anterior pituitary tissue. Hemipituitaries were incubated for a basal h in the
absence of drugs (baseline) or with H7 (30 pM) or staurosporine (300 nM)
followed by consecutive hours, in addition, with DOG (200 |iM). Values shown
here are for LH release measured in the 3rd h of incubation. Staurosporine, but
not H7, significantly inhibited DOG-induced LH release (*p < 0.05). Data are
means ± S.E.M. and the number of determinations are shown in parentheses.
LH release (ng/ml)
baseline 3.6 ± 0.3 (5)
DOG 8.5 ± 0.8 (6)
DOG + staurosporine *2.4 ± 0.4 (6)
DOG + H7 7.7 ±0.3 (6)
Table 4. Effect of PKC inhibitors on PDBu-induced PKC activity partially
purified from rat anterior pituitary cytosol. Phorbol 12,13-dibutyrate (1 pM)-
induced histone Ills kinase activity was measured in the presence of phosphatidyl
serine, with either the presence (100 pM free Ca2+) or absence (> 3 nM free Ca2+)
of Ca2+ as described in section 2.2.
IC50 values








Temporal profile of the effect of PDBu on LH and GH release from rat
hemipituitaries. Tissue was incubated for 4 consecutive hours, initially
with no drug (basal h), followed by 3 consecutive hours (1st h, 2nd h, 3rd
h) in the presence of PDBu (100 nM) and LH (open bars) and GH (hatched
bars) release were determined. The release of GH was maximal by the 1st
h of PDBu incubation whereas LH release was only significantly greater
than basal h levels in the 2nd h and 3rd h of PDBu incubation (p > 0.05).
Data are means ± S.E.M. for 5-11 determinations.
Figure 2
Dose response curves for the effect of (■) PDBu and (•) mezerein, on the
release of LH (a) and GH (b) from rat anterior pituitary tissue.
Tlemipituitaries were incubated for an initial basal h with no drug
followed by consecutive hours in the presence of various concentrations
of PDBu or mezerein. These graphs show LH release measured in the
3rd h and GH release measured in the 1st h of incubation with these
compounds. Data are expressed as the fold of release that occurred in the
initial basal h. Each point represents the mean ± S.E.M. for 4-11
determinations.
Figure 3
The temporal pattern of DOG-induced (a) LH and (b) GH release from rat
hemipituitary pieces. Tissue was incubated for 4 consecutive hours in
the presence of medium only (baseline, open bars) or for an initial, basal
h in medium only followed by consecutive hs with 200 |iM DOG
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(hatched bars). The release of LH was significantly greater than baseline
levels throughout the 2nd and 3rd h of DOG incubation (p < 0.05).
However, GH release was not significantly different from baseline levels
during any hour of incubation with DOG. Data are means ± S.E.M. for
4-6 determinations.
Figure 4
Concentration-response curves for the effect of the PKC inhibitor,
staurosporine, on PDBu-induced LH (•) and GH (■) release from rat
anterior pituitary tissue. Tissue was incubated over consecutive hours
(basal h, 1st h, 2nd h, 3rd h) in the presence of staurosporine (10 -
300 nM). In addition, PDBu (100 nM) was also present throughout the
1st h, 2nd h and 3rd h incubations. The data shows the effects oP
staurosporine on 3rd h PDBu-induced LH release and 1st h PDBu-
induced GH release. Staurosporine significantly inhibited (p < 0.05) both
PDBu (100 nM)-induced LH and GH release with similar potency. Each
point on the curves represents the mean ± S.E.M. for 4-6
determinations.
Figure 5
Concentration-response curves for the effect of (a) H7 on 100 nM PDBu-
induced LH and GH release (b) H7 (30 |iM) on LH release induced by
increasing PDBu concentrations and (c) H7 on mezerein-induced LH and
GH release from rat anterior pituitary tissue. (•) LH release; (■) GH
release. In parts (a) and (c), tissue was incubated for consecutive hours
(basal h, 1st h, 2nd h, 3rd h) in the presence of various concentrations of
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H7. In addition, either 100 nM PDBu (a) or 300 nM mezerein (c) was also
present throughout the 1st h, 2nd h and 3rd h incubations. The data
show GH release measured during the 1st h and LH release measured in
the 3rd h of incubation with PKC activators. Statistical significant
inhibition of hormone release by H7 is shown by * (p < 0.05). The
corresponding basal release of LH during the 3rd h of drug-free controls
was 2.5 ± 0.3 ng/ml (a) and 3.9 ± 0.4 (c). H7 alone had no effect on basal
release of LH or GH at any of the concentrations tested. In part (b), tissue
was incubated for consecutive hours with various concentrations of
PDBu (3 - 1000 nM) either in the presence or absence of H7 (30 pM). The
data shows the % of the LH response, measured during the 3rd h of
PDBu incubation, that was inhibited by H7. Each point on the graphs
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ABSTRACT
Phorbol ester-induced release of LH and GH from rat anterior pituitary tissue
in vitro is differentially inhibited by some, but not other, inhibitors of protein
kinase C (PKC), suggesting that pharmacologically distinct species of PKC may have
different functional roles in these cells. Since stimulus-induced anterior pituitary
hormone release can be enhanced by oestradiol-17fi (OE2) pretreatment, we
investigated the effect of OE2 treatment of long-term (4 weeks) ovariectomized rats
on the amount, activity and cellular actions of pharmacologically distinct PKC
species in rat anterior pituitary tissue. Here we report that OE2 treatment enhanced
phorbol 12,13-dibutyrate (PDBu)-induced LH but not GH release measured in vitro.
This effect of OE2 on LH release may involve synthesis of additional PKCs that are
not targeted by the synthetic diacylglycerol, 1,2-dioctanoyl-sn-glycerol (DOG).
Measurements of anterior pituitary PKC activity and [3H]phorbol ester-binding
studies suggested that the facilitatory action of OE2 on LH release may occur, at least
in part, by altering the quantity and activity of PKC(s). Our results also demonstrate
that the OE2-induced PKC(s) which facilitate LH release may be of the type that are
not dependent upon raised intracellular Ca2+ for their activation and display distinct
pharmacological properties (being readily activated by PDBu, but not by DOG, and
are staurosporine-sensitive but H7-insensitive). This facilitatory action of OE2 on
PKC-induced LH release does not appear to involve OE2-induced changes in the
affinity of existing PKC(s) for PDBu, or changes in the amount of releasable LH in
the pituitary prior to the stimulus.
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INTRODUCTION
The release of a number of anterior pituitary hormones can be induced in
vitro by activators of protein kinase C (PKC), such as phorbol esters (Smith & Vale,
1981; Johnson & Mitchell, 1989) and diacylglycerols (Conn, Ganong, Ebeling et al.
1985; Negro-Villar & Lapetina, 1985), suggesting that PKC activation may have a
physiological role in triggering pituitary hormone release (McArdle, Huckle &
Conn, 1987; Stojilkovic, Chang, Ngo & Catt, 1988). There is increasing evidence that
different PKC-mediated responses (and perhaps certain isoforms of PKC) may be
distinguished by their differential sensitivity towards various activators and
inhibitors (Johnson & Mitchell, 1989; Nakadate, Yamamoto, Aizu et al. 1989;
Mitchell, MacEwan, Johnson & Thomson, 1990; MacEwan & Mitchell, 1991;
MacEwan, Mitchell, Johnson & Thomson, 1991; Ryves, Evans, Olivier et al. 1991;
MacEwan, Simpson, Mitchell et al. 1992). We have shown, for example, that
phorbol ester-induced luteinizing hormone (LH) but not growth hormone (GH)
release from pro-oestrous rat anterior pituitary tissue can be readily inhibited by low
concentrations of the PKC inhibitor, H7, despite the release of both hormones being
similarly sensitive to other PKC inhibitors such as staurosporine (Johnson &
Mitchell, 1989).
The responsiveness of gonadotrophs to secretagogues, such as luteinizing
hormone-releasing hormone (LHRH) (Aiyer & Fink, 1974; Drouin, Legace & Labrie,
1976; Kamel, Balz, Kubajak & Schneider, 1987; Turgeon & Waring, 1981),
depolarizing concentrations of potassium (Liu & Jackson, 1988) and activators of
PKC (Liu & Jackson, 1988; Fahmy, Das & Bourne, 1989; Audy, Boucher & Bonnin,
1990; Drouva, Gorenne, Laplante et al. 1990) can be markedly altered by the prior
presence of gonadal steroids, suggesting that steroids modulate several aspects of
stimulus-secretion coupling in these cells. We therefore investigated the possibility
that steroid modulation of pituitary responsiveness may involve an action on the





Adult female COB Wistar rats (approximately 200 g, Charles River U.K. Ltd,
Margate, Kent, U.K.) were maintained under controlled lighting and temperature
with free access to food pellets (CRM, Labsure, Manea, Cambs, U.K.) and tap water.
Rats were bilaterally ovariectomized under halothane anaesthesia and left for a
period of 4 weeks before being randomly divided into two experimental groups.
The group treated with oestradiol-17fi (OE2) received subcutaneous implants in the
dorsal neck with 1 cm long silicone elastomer capsules (Dow-Corning Corporation,
Midland, MI, USA), with an external diameter of 0.125 inches and internal diameter
of 0.078 inches, containing 0.5 cm of crystallized oestradiol-17fi, and the control (i.e.
OE2 untreated) group received equivalent implants but with empty capsules (Dzuik
& Cook, 1966; Henderson, Baker & Fink, 1977). Animals were killed in the morning
of the 5th day after implantation.
Chemicals
Phorbol 12,13-dibutyrate (PDBu), 1,2-dioctanoyl-sn-glycerol (DOG) (Sigma
Chemical Co Ltd, Poole, Dorset, U.K.), ionomycin and staurosporine (Novabiochem,
Nottingham, Notts, U.K.) were made up as stock solutions in dimethylformamide
(DMF). The maximum concentration of DMF (0.5%, v/v) was used in control
experiments and had no effect. [20-3H(N)]Phorbol 12,13-dibutyrate (specific activity =
19.1 Ci/mmol) and ATP-y-35S (specific activity = 1256 Ci/mmol) were purchased
from Du Pont, Dreieich, Germany. l-(5-Isoquinolinesulphonyl)-2-methylpiperazine
dihydrochloride (H7; Gibco-BRL, Paisley, Strathclyde, U.K.), leupeptin (Boehringer
Mannheim, Lewes, U.K.) and trans-epoxysuccinyl-L-leucylamido-(4-guanidino)
butane (E64; Sigma) were all made up as stock solutions in distilled H2O. Oestradiol-
172 and phenylmethylsulphonyl fluoride (PMSF) were obtained from Sigma and
phosphatidyl serine (sodium salt) from Lipid Products, Nutfield, Surrey, U.K.
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Nonidet P-40 was from Novabiochem and Analar grade laboratory chemicals were
obtained from BDH, Dagenham, Essex, U.K.
Hormone secretion experiments
The methods were based upon those used by Pickering and Fink (1976).
Anterior pituitary glands were bisected and preincubated for 30 min (37°C, 95%
02/5% CO2; 1 hemipituitary/flask) in 2 ml pregassed and prewarmed Hepes-buffered
minimal essential medium with Earle's salts (MEM; Gibco-BRL) after which the
medium was discarded and replaced hourly with fresh MEM over a total period of 4
h. To examine the actions of secretagogues on hormone release, the tissue was
incubated for an initial, basal hour in the presence of MEM only, followed by three
consecutive hours (1st, 2nd and 3rd h) in the presence of a PKC activator (PDBu,
DOG) or the calcium ionophore, ionomycin. In the experiments where the effects of
kinase inhibitors (staurosporine, H7) on PKC-induced hormone release were
examined, the inhibitor was present during the basal hour as well as the 1st, 2nd and
3rd hours, together with the activator. The medium was collected at the end of each
hourly incubation and was stored at -20°C until it was radioimmunoassayed for LH
and GH (Niswender, Midgley, Monroe & Reichert, 1968; Daane & Parlow, 1971). The
standards used were NIDDK-rat LH-RP2 and NIDDK-rat-GH-RP-2.
Cytosolic PKC activity assay
Anterior pituitary PKC activity was determined as the phosphatidyl serine-
dependent, histone III-S kinase activity induced by PKC activators using methods
modified from those described by Wise, Glass, Chou et al. (1982) and Huang, Huang,
Nakabayashi & Yoshida (1988). Anterior pituitary tissue was homogenized in 2
volumes of 20 mmol Tris-HCl/1 (pH 7.5) containing 50 mmol 2-mercaptoethanol/l,
2 mmol EDTA/1, 1 mmol PMSF/1, 0.01% (w/v) leupeptin and 20 pmol E64/1. The
homogenate was centrifuged (16,000 g, 20 min, 4°C) and the supernatant was
collected and recentrifuged (16,000 g, 5 min, 4°C). The supernatant from the second
spin was taken to represent cytosol and was partially purified by loading onto 0.5 ml
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DE52 diethylaminoethyl cellulose (Whatman International Ltd, Maidstone, Kent,
U.K.) in a Bio-Rad Poly-Prep chromatography column (Bio-Rad Laboratories,
Richmond, CA, USA) at 4°C. The cytosol was then washed with six column
volumes of homogenization buffer before eluting the partially purified PKC with
three column volumes of buffer containing 150 mmol NaCl/1. Partially purified
cytosolic PKC activity was measured in an assay mixture containing (final
concentrations): 1.25 mmol MgC^/l, 100 mg phosphatidyl serine (sodium salt)/l,
0.04% (v/v) Nonidet P-40, 1.25 g histone III-S/1, 100 pmol ATP-y-35S/l (0.595
pCi/tube) and cytosol. Assay tubes also contained either 600 pmol CaCl2/l (100 pmol
free Ca2+/1) or 5 mmol EGTA/1 to give Ca2+-dependent and Ca2+-independent
environments respectively. Phosphatidyl serine vesicles were prepared by drying
the lipid from chloroform/methanol under a stream of N2. The subsequent film of
phosphatidyl serine was scraped into 20 mmol Tris-HCl/1 (pH 7.5) + 0.5 mmol
EGTA/1 at a stock concentration of 400 mg/l, sonicated, then 0.16% (v/v) Nonidet P-
40 was added. The mixture was vortexed before use. Protein kinase C activity was
measured either in the absence of activator (i.e. basal activity) or in the presence of 1
pmol PDBu/1 or 100 pmol DOG/1. All assay components and drugs were dissolved
in 20 mmol Tris-HCl/1 (pH 7.5) + 0.5 mmol EGTA/1 except for DOG which was
added to each assay tube in 1 pi DMF using a Hamilton microsyringe. Reactions
were carried out at 30°C for 15 min and were stopped by quenching with 20 pi 0.1
mol ATP/1 in 0.1 mol EDTA/1 (pH 7.0). The quenched reaction mixture (50 pi) was
spotted onto a 4 cm2 piece of P-81 cellulose phosphate ion-exchange paper
(Whatman International Ltd) and washed (three x 10 ml, 2 min, room temperature)
in 75 mmol H3PO4/I.
Kinase activity measured in the presence of phosphatidyl serine, 5 mmol
EGTA/1 (i.e. low free Ca2+) and in the absence of PKC activator was taken to
represent basal activity and was subtracted from all activator-stimulated levels.
Calcium-independent kinase activity was taken to be the activity measured in the
presence of 5 mmol EGTA/1 and PKC activator (1 pmol PDBu/1 or 100 pmol DOG/1).
6
The additional kinase activity measured with samples containing CaCh + PKC
activator was taken to represent calcium-dependent kinase activity.
Cytosolic [3H]phorbol ester binding assay
The number of PKC molecules in OE2~treated and untreated pituitary cytosol
and their affinity for PDBu were assessed using a [3H]PDBu-binding method
described previously (Leach, James & Blumberg, 1983). Briefly, anterior pituitaries
were homogenized in 2 volumes of 50 mmol Tris-HCl/1 (pH 9.0) containing 1 mmol
PMSF/1 and 1 mmol MnCl2/l then centrifuged (100,000 g, 1 h, 4°C). The supernatant
was collected and recentrifuged (120,000 g, 1 h, 4°C) and the supernatant from the
second spin was regarded as cytosol. Cytosol was diluted in assay buffer (50 mmol
Tris-HCl/1 (pH 7.4), 4 g essential fatty acid-free bovine serum albumin/1, 1 mmol
CaCl2/l and 75 mmol magnesium acetate/1) to a concentration which gave total
binding of approximately 10% of total radioactivity present. The assay constituents
were 1 g phosphatidyl serine (sodium salt)/l, [3H]PDBu (2 - 500 nmol/1) and diluted
cytosol. Phosphatidyl serine vesicles were prepared by dissolving the lipid in
chloroform, drying under N2, reconstituting into assay buffer, vortexing and
sonicating. Total binding was measured in the presence of 0.5% DMF whilst non¬
specific binding was measured in the presence of 20 pmol PDBu/1. After a 30-min
incubation (37°C), protein was precipitated by adding 100 pi 12 g bovine gamma¬
globulin/1 and 300 pi 24% (w/v) polyethyleneglycol 8000 (4°C, 20 min). The
precipitate was pelleted by centrifugation (12,000 g, 5 min, 4°C), the supernatant
removed by aspiration and the radioactivity in each pellet counted.
Protein assay
Protein content in anterior pituitary cytosol, and in DEAE cellulose-purified
cytosol was measured using a Pierce protein assay kit (Pierce, Chester, Cheshire,
U.K.). This method used an assay reagent based on the Bradford method consisting
of Coomassie blue G-250, phosphoric acid, methanol, water and solubilizing agents.
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When Coomassie Blue binds to proteins in an acidic solution, an absorbance shift
from 465 to 595 nm occurs (Bradford, 1976).
Data analysis
All values are expressed as mean ± S.E.M. Statistical analyses were carried out
using the Mann-Whitney U-test or in the case of time-course data, by both 2-way
and 1-way Analysis of Variance, followed by Duncan's New Multiple Range test on
significantly different groups. The concentrations of the kinase inhibitors producing
50% inhibition of the stimulus-induced response (IC50 values) were determined by
fitting the data with a non-linear, error-weighted, iterative curve-fitting
programme, P.fit (Biosoft, Cambridge, Cambs., U.K.)
RESULTS
Effects of oestradiol-176 on hormone release induced by PKC activators
Consecutive hourly incubations with PDBu (300 nmol/1) significantly
increased_net LH and GH release from anterior pituitary tissue taken from both en¬
treated and untreated ovariectomized rats (Figs. 1 and 2). The baseline release of
both hormones was determined in parallel control incubations for 4 h and the
corresponding values were subtracted from all stimulated values to allow
presentation of net stimulus-induced responses. In OE2-treated but not untreated
tissue there was a time-dependent increase in LH release in response to PDBu
(F(3,36) = 37.35, p < 0.0001 and F(3,36) - 1.73, p = 0.178, respectively (Fig. la)).
Statistically significant increments in LH release from OE2-treated tissue occurred
progressively at each of the hours of incubation with PDBu (p < 0.05). Thus, LH
release from untreated tissue reached maximal levels by the 1st hour of PDBu
incubation, whereas LH output from OE2-treated tissue increased progressively with
each successive PDBu incubation (in a manner similar to that seen with pro-
oestrous tissue (Johnson, Mitchell & Fink, 1988)). The release of LH was
significantly greater in OE2-treated tissue than in ovariectomized controls in the 1st,
2nd and 3rd hours of PDBu stimulation (p < 0.05) but not in the basal hour (Fig. la).
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The release of GH was increased by PDBu in both OE2-treated and untreated
tissue (F(3,36) = 9.17, p < 0.0001 and F(3,36) = 5.47, p < 0.0034 respectively) with
statistically significant increments over basal (p < 0.05) in the 1st, 2nd and 3rd hours
of PDBu in each group (Fig. 2a). There were however no significant differences in
GH release between any of the hours of PDBu in either group or between en¬
treated and untreated groups at any point (Fig. 2a). These data are consistent with
OE2 having a facilitatory action on the mechanism by which phorbol ester activators
of PKC can induce LH but not GH release.
In a manner similar to PDBu, an alternative PKC activator DOG (200 pmol/l)
also induced a significant increase in LH release from pituitary tissue from both
untreated and OE2-treated animals (Fig. lb). Analysis of the raw data failed to show
a statistically significant time-dependent increase in overall LH output from either
OE2-treated or untreated tissue in the presence of DOG. However, the
corresponding basal LH release in each hour (assessed in parallel control
incubations) showed a time-dependent decrease. When these values were
subtracted to yield net DOG-induced LH release, non-parametric analysis (Mann-
Whitney U-test) revealed a significant increment in LH release at each hour of
incubation with DOG (p < 0.05). There were no significant differences between
DOG-induced LH release from OE2-treated or untreated tissue at any time point.
Using pituitary tissue from untreated ovariectomized rats, the magnitude of DOG-
induced LH release was not significantly different from PDBu-induced LH release at
any hour of incubation with PKC activator. However, DOG was unable to mimic
the enhanced effect of PDBu on LH release from OE2-treated tissue as the magnitude
of DOG-induced LH release from OE2-treated and untreated tissue was similar.
In contrast to the effects of PDBu, DOG (at concentrations up to 200 pmol/1)
was unable to induce GH release from either OE2-treated or untreated tissue (Fig.
2b), suggesting that the PKC(s) that mediate GH and LH release differ in their
susceptibility to activation by DOG.
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In a further set of experiments, we examined the effects of the kinase
inhibitors, staurosporine and H7 on PKC activator-induced hormone release from
pituitary tissue from OE2-treated and untreated ovariectomized rats (Table 1). The
release of LH induced by PDBu (300 nmol/1) from both OE2-treated and untreated
ovariectomized rat pituitary tissue was significantly inhibited by 300 nmol
staurosporine/1 (p < 0.05). However, in contrast to previous results obtained with
pro-oestrous pituitary tissue, where PDBu-induced LH release was readily inhibited
by H7 (IC50 = 15.6 ± 4.5 gmol/1, n = 5) (Johnson & Mitchell, 1989), H7, at
concentrations up to 30 gmol/l, was unable to significantly inhibit either DOG- or
PDBu-induced LH release from anterior pituitary tissue taken from either OE2-
treated or untreated ovariectomized rats (Table 1). Phorbol-ester induced GH release
was similarly inhibited by staurosporine, but was insensitive to H7 (up to 30
p.mol/1). Neither staurosporine nor H7 at the concentrations used had any
significant effect on basal LH or GH release (data not shown).
Effects of oestradiol-17£ on protein kinase C activity and [3H]phorbol ester binding
sites
We investigated the possibility that OE2 treatment may enhance PKC-induced
LH release by altering anterior pituitary PKC activity. Using histone III-S as a
substrate, PDBu (1 |imol/l) was able to elicit approximately equal proportions of
Ca2+-dependent and -independent PKC activity in pituitary cytosol from untreated
ovariectomized rats (Table 2). With OE2 treatment there was approximately a 60%
increase in both Ca2+-dependent and -independent PDBu-induced PKC activity. In
both treatment groups, DOG (100 (imol/1) apparently induced relatively less Ca2+-
dependent and -independent cytosolic kinase activity than PDBu (Table 2).
However, direct comparisons of the kinase activity elicited by DOG and PDBu
cannot be made unless comprehensive concentration response curves are available
for each of these agents . Similar to the results seen using PDBu, DOG-stimulated
Ca2+-dependent PKC activity approximately doubled with OE2 treatment. Whilst
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there was also a slight increase in DOG-stimulated Ca2+-independent PKC activity
with OE2 treatment, this was not statistically significant. It seems likely that such
PDBu-sensitive, DOG-insensitive, Ca2+-independent PKCs rather than the PDBu-
sensitive, DOG-sensitive, Ca2+-dependent PKCs are responsible for the OE2-induced
facilitation of PDBu-evoked LH release observed.
Studies were carried out to examine the actions of H7 and staurosporine on
PDBu-stimulated PKC activity in anterior pituitary tissue cytosol (Fig. 3). In anterior
pituitary cytosol from untreated ovariectomized animals, PDBu (1 pmol/1)-
stimulated, Ca2+-dependent PKC activity was much more sensitive to inhibition by
H7 (IC50 = 26.8 ± 3.8 gmol/1) than Ca2+-independent activity (IC50 = 103.7 ± 23.0
pmol/1) (mean ± S.E.M. values, n = 4). In OE2-treated tissue, although PDBu-
stimulated activity was greater in magnitude, Ca2+-dependent, PDBu-stimulated
kinase activity was also found to be more sensitive to H7 (IC50 = 32.1 ± 3.3 pmol/1)
than Ca2+-independent activity (IC50 = 112.5 ± 24.5 pmol/1) (mean ± S.E.M. values, n
= 6). In contrast, the potency of staurosporine at inhibiting both Ca2+-dependent and
-independent PKC activity did not differ significantly between any of the conditions.
In cytosol from untreated rats, the IC50 values for staurosporine on Ca2+-dependent
and Ca2+-independent PKC activity were 139 ± 65 nmol/1 and 132 ± 46 nmol/1
respectively (means ± S.E.M., n = 5). Corresponding values from OE2-treated rats
were 100 ± 10 nmol/1 and 137 ± 51 nmol/1 respectively (means ± S.E.M., n = 5). Since
PDBu-induced LH and GH release from OE2-treated and untreated ovariectomized
tissue are relatively insensitive to inhibition by H7 (with no apparent inhibition at
concentrations of 30 pmol/1 (Table 1)), the results from the PKC activity assays
suggest that those PKC(s) which induce both LH and GH release may not be
dependent upon raised intracellular Ca2+ for their activation by phorbol esters.
Saturation binding studies using [3H]PDBu at eight different concentrations
were carried out to assess the number of PKC molecules and their affinity for
phorbol ester, with or without OE2 treatment. Data were analysed by the non-linear,
error-weighted curve-fitting programme P.fit (Biosoft). Treatment with OE2
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increased (p < 0.05, Mann-Whitney U-test) the number of [3H]PDBu binding sites in
anterior pituitary cytosol approximately 2-fold from 8.3 ± 0.6 pmol/mg protein to
18.7 ± 1.4 pmol/mg protein (means ± S.E.M., n = 5). The affinity (dissociation
constant) of the binding sites for [3H]PDBu was unaltered by OE2 treatment, being 16
± 3 nmol/1 and 13 ± 1 nmol/1 in untreated and OE2-treated tissue respectively. It
seems likely therefore, that the increase in PDBu-stimulated PKC activity observed
after OE2 treatment may occur as a result of an increase in pituitary PKC content,
and not as a result of a change in the affinity of existing PKC(s) for PDBu.
Effects of oestradiol-176 on ionomycin-releasable pools of LH and GH
It is possible that the facilitatory actions of OE2 treatment on PKC-induced LH
release may involve steroid-mediated enhancement of other steps in the process by
which PKC can induce LH secretion, in addition to altering cytosolic PKC activity
and content. To examine the possibility that OE2 treatment can enhance LH release
by increasing the amount of gonadotrophin available for release, we measured
hormone release in response to maximally raised intracellular Ca2^ levels using the
Ca2+ ionophore, ionomycin; a procedure which may be taken as an indirect measure
of releasable pituitary hormone content. Over three consecutive hourly
incubations, ionomycin (30 gmol/1) significantly increased LH and GH release from
anterior pituitary tissue from both OE2-treated and untreated ovariectomized
animals (Fig. 4). In OE2-treated and untreated tissue, ionomycin (30 (imol/1) caused
significant release of LH (F(3,12) = 27.66, p< 0.001 and F(3,12) = 12.59, p < 0.005
respectively) (Fig. 4a). Compared with the pre-drug basal values, all individual time
points (except for the third hour of ionomycin in OE2-treated tissue) reached
statistical significance (p < 0.05). When net ionomycin-induced increments in LH
output were calculated by correcting for declining baseline, all increments were
significant (p < 0.05, Mann-Whitney U-test). Treatment with OE2 did not
significantly affect responses to ionomycin at any time point (Fig. 4a). This evidence
that OE2 treatment enhances PDBu but not ionomycin-induced LH release, suggests
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that OE2 does not enhance PKC-induced LH release by increasing the size of the
releasable LH pool.
Ionomycin also caused significantly increased release of GH in both en¬
treated and untreated tissue (F(3,12) = 48.27, p < 0.0001 and F(3,12) = 10.35, p < 0.0012
respectively) (Fig. 4b). All time points with ionomycin (either with or without OE2
treatment) showed significantly greater GH release than pre-drug basal (p < 0.05).
There was no significant influence of OE2 treatment on ionomycin-induced GH
release at any time point, suggesting that OE2 does not alter the readily releasable
pool of GH.
Discussion
Eight isoforms of PKC (a, fiu, y, 8, e, £ and rj) have been sequenced; each
having distinct tissue distributions (Nishizuka, 1988; Osada, Mizuno, Saido et al.
1990), indicating that the expression of various PKC isoforms is differentially
regulated in different tissues. Anterior pituitary tissue is known to express a and fi
but not y isoforms (Naor, Dan-Cohen, Hermon & Limor, 1989; Naor, 1990) and
evidence from Northern blots using oligonucleotide probes directed against unique
sequence regions of the other PKC isoforms suggests that e and but little 8 isoform
may also be present (E. Lutz, A. Ison, R. Mitchell & F.J. Thomson, unpublished
observations). The results presented here suggest that OE2 is an important regulator
of PKC isoform expression in gonadotrophs, but not somatotrophs, with respect to
the actions of PKC on hormone release in vitro. The increase in the amount of
phorbol ester-stimulated pituitary cytosolic PKC activity with OE2 treatment (Table
2) supports previous data (Drouva et al. 1990; Joubert-Bression, Brandi, Birman &
Peillon,T990) and suggests that the facilitatory action of OE2 on phorbol ester-
induced LH release involves an increase in the availability of PDBu-sensitive PKC
molecules in anterior pituitary cells, including gonadotrophs. The increase in
pituitary PKC content revealed by our [3H]PDBu-binding studies, together with
evidence that the facilitatory actions of OE2 on stimulus-induced LH release can be
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prevented by protein synthesis inhibitors (Debeljuk, Khar & Jutisz, 1978; Fahmy et
al. 1989), suggests that OE2 enhances PKC-stimulated LH release by inducing
synthesis of additional PKC molecules. However, here we provide evidence that
these additional OE2-induced PKC(s) are pharmacologically distinct from those that
mediated LH release prior to OE2 treatment (Fig. 1 and Table 1). That is, in untreated
tissue from ovariectomized rats, those PKCs that can induce LH release can be
activated by both PDBu and DOG, whereas with OE2 treatment there is an additional
involvement of PDBu-sensitive but DOG-insensitive kinases. PKCs that are
similarly resistant to activation by DOG are also involved in PDBu-induced GH
release (Fig. 2). Cellular actions of PKC, elicited by phorbol esters, but not by DOG,
have been described previously (Lacerda, Rampe & Brown, 1988; MacEwan &
Mitchell, 1991; MacEwan, Johnson, Mitchell et al. 1992) and reduced potency of DOG
as an activator of a-PKC has been reported (Sekiguchi, Tsukada, Ase et al. 1988) and
is most marked under conditions of basal cytosolic Ca2+ (< 100 nmol/1) (MacEwan,
Johnson, MitchelFcf al. 1992).
The PKCs involved in both LH and GH release in the present experiments are
also distinctive in their resistance to the PKC inhibitor H7, but not staurosporine
(Table 1). Correspondingly, a component of PKC activity (the Ca2+-independent
fraction) from the anterior pituitary cytosol of both untreated and OE2-treated
ovariectomized rats was relatively resistant to H7. In contrast, PDBu-elicited, Ca2+-
dependent and -independent PKC activities measured in cytosol from
ovariectomized rat hypothalamus and hippocampus displayed the expected
sensitivities to H7. The IC50 values for the inhibition of Ca2+-dependent and
-independent activities by H7 in hypothalamus cytosol were 17.6 ±8.1 |imol/l and
13.6 ± 4.4 (imol/1, respectively (means ± S.E.M., n = 4). Corresponding IC50 values
for H7 measured in hippocampus cytosol were 19.6 ± 4.4 pmol/1 and 21.3 ± 1.4
(imol/1 (means ± S.E.M., n = 4). Oestradiol-17fi (OE2) treatment had no significant
effect upon the H7 sensitivity of PDBu-induced PKC activity in the hippocampus or
hypothalamus. Interestingly, the priming effect of LHRH (Aiyer, Chiappa & Fink,
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1974) is mediated by PKC(s) with the same unusual profile of sensitivity to PKC
inhibitors (Johnson, Mitchell & Thomson, 1992). Phorbol 12,13-dibutyrate (PDBu)-
induced GH release from intact pro-oestrous rat anterior pituitary tissue also shows
H7 resistance (Johnson & Mitchell, 1989) whereas, in the same experiments
(Johnson et al. 1988; Johnson & Mitchell, 1989), LH release was completely inhibited
by H7 at a concentration of 30 pmol/1 (as was used here). Thus, it appears that more
than one pharmacologically distinct type of PKC(s) can mediate LH release under
different circumstances and the involvement of particular PKC forms in this
response may be dependent upon the gonadal steroid status of the animal.
Progesterone can further enhance the actions of OE2 on LHRH-induced
gonadotrophin release (Mann & Barraclough, 1973 ; Turgeon & Waring, 1990)
suggesting that gonadal steroids other than OE2 are also required to regulate
gonadotroph responsiveness. Thus, factors other than OE2 may be required to
influence the activity of the H7-sensitive PKCs that can induce LH release in the
intact rat.
Some studies have suggested that gonadectomy or steroid treatment can alter
GH release patterns measured in the rat in vivo (Jansson, Ekberg, Isaksson & Eden,
1984). However, in our model, OE2 does not regulate either PKC actions on GH
secretion or the size of the releasable pool of GH. Furthermore, there appears to be
no clear relationship between GH secretory patterns in intact female rats and stage of
the oestrous cycle (Clark, Carlsson & Robinson, 1987), consistent with our evidence
that OE2 does not play an important role in modulating anterior pituitary gland
responsiveness with respect to PKC-mediated GH release. Oestradiol-17fi (OE2)
treatment of cultured pituitary cells in vitro has correspondingly been shown to
enhance phorbol ester-induced LH but not GH release (Drouva et al. 1990).
Oestradiol-17fi (OE2) has modulatory actions on several factors that may be
involved in cellular signalling mechanisms, for example voltage-sensitive Ca2+
channels (Drouva, Rerat, Bihoreau et al. 1988) and LHRH receptor number (Gregg &
Nett, 1989). Therefore, it is likely that OE2 modulation of cellular signalling within
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gonadotrophs may also occur at sites other than PKC and thereby contribute to the
facilitatory actions of OE2 on gonadotrophin release in intact animals. It is possible
that such factors may contribute to the changes in the time-course of PDBu-induced
LH release observed after OE2 treatment. In some in vitro models, OE2 treatment
has positive effects on LH-fi gene transcription (Shupnik, Gharib & Chin, 1989), but
in vivo replacement of OE2 in long-term ovariectomized animals (as here) seems
instead to reduce levels of mRNA for LH-fi (Counis, Corbani & Jutisz, 1983; Gharib,
Bowers, Need & Chin, 1988; Papavisiliou, Zmeili, Herbon et al. 1986). Oestradiol-17fi
(OE2) can enhance LH synthesis and glycosylation and facilitate responses to LHRH
(Liu & Jackson, 1977, 1990; Tang, 1980; Ramey, Highsmith, Wilfinger & Baldwin,
1987). However, the experiments here with ionomycin (Fig. 4) indicated that the
facilitatory actions of OE2 on phorbol ester-induced LH secretion do not appear to
result from an OE2-induced increase in releasable gonadotrophin content prior to a
stimulus.
The identity of the PKC isoforms involved in LH and GH release is not yet
known. However, since the known PKC isoforms differ in their dependency upon
raised intracellular Ca2+ for activation they have been subclassified into two groups
(Parker, Kour, Marais et al. 1989). The a, fi, and y PKC forms (the A series) have been
shown to be dependent upon raised intracellular Ca2+ for their activation, whereas
activation of the 8, e, £ and r\ forms (the B series) appears to be independent of raised
Ca2+. Although the Ca2+-dependent a- and fi-PKC isoforms have been implicated as
having a role in gonadotrophin release (Naor et al. 1989), the H7-resistant PKCs
which mediate both LH and GH release from ovariectomized rat tissue are readily
activated by PDBu alone and do not overtly require elevated Ca2+ levels for
activation. Since both Ca2+-dependent and -independent PKC activities were
increased by OE2 treatment, it seems that other PKCs may be induced by OE2, in
addition to the PDBu-sensitive, DOG-insensitive, H7-resistant PKC relevant here in
the increased responsiveness of gonadotrophs. Although the H7-resistant PKC
would initially appear to be a B series (or related) isoform, there is evidence that the
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degree of Ca2+ dependency exhibited by the A series isoforms may differ in the
presence of certain fatty acids (Naor, Shearman, Kishimoto & Nishizuka, 1988;
Shinomura, Asaoka, Oka et al. 1991). Furthermore, it has been suggested that the
phosphorylation state of the 6-isoform can alter its Ca2+ dependency (Pelech,
Samieim, Charest et al. 1991), so this classification of the known PKC isoforms
according to their Ca2+ dependency may be less clear-cut than when originally
conceived. Data obtained using highly purified or expressed recombinant
preparations have shown that the 5- and e-isoforms of PKC are more sensitive to H7
(Schaap & Parker, 1990; Uchida, Hagiwara & Hidaka, 1991) than those forms that
induce LH and GH release in our model, suggesting that neither 8- nor e-PKC is
significantly involved in mediating LH or GH release in ovariectomized or en¬
treated rat pituitary tissue. Furthermore, the C, isoform is reported to be
unresponsive to phorbol esters (Ono, Fujii, Ogita, Kikkawa et al. 1989), suggesting
that C, would not contribute to the present results. It seems therefore that the PKC
isoform(s) which mediates PDBu-induced LH release from ovariectomized rat
anterior pituitary tissue (and which is induced by OE2 treatment) may be a
covalently modified form of a PKC, a poorly characterized Ca2+-independent
isoform, such as r\ or an isoform of PKC (or closely related protein kinase) which has
not yet been sequenced.
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Table 1 Effect of protein kinase C (PKC) inhibitors on PKC activator-induced
LH and GH release from anterior pituitary tissue taken from ovariectomized rats
with or without oestradiol-17fi (OE2) treatment. All values are mean ± S.E.M.










8.0 ± 4.6 (8)*
29.8 ± 4.8 (6)
22.0 ± 2.9 (5)
8.9 ± 3.0 (4)*
24.7 ± 2.9 (6)
308.0 ± 35.1 (6)
94.6 ± 18.4 (8)*
328.5 ± 25.2 (6)
24.9 ± 2.8 (8)






1828.5 ± 256.6 (6)
138.5 ± 56.9 (6)*
2079.2 ±374.5 (6)
1871.7 ± 290.1 (10)
240.8 ± 184.6 (5)*
1866.8 ±312.2 (5)
Hemipituitaries were incubated in vitro for 4 consecutive hours. In the basal hour
there was either medium only or staurosporine (300 nmol/1) or H7 (30 pmol/1). In
the 1st, 2nd, 3rd hour there was, in addition, either phorbol 12,13-dibutyrate (PDBu)
(300 nmol/1) or dioctanoyl-sn-glycerol (DOG) (200 gmol/1). The data shows net LH
release (i.e. with baseline subtracted) measured in the 3rd hour with PKC activator
and net GH release measured in the 1st hour with PKC activator. *p < 0.05
compared with corresponding release from untreated tissue.
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Table 2 Phorbol 12,13-dibutyrate- (PDBu) and 1,2-dioctanoyl-sn-glycerol (DOG)
-stimulated protein kinase C (PKC) activity in anterior pituitary cytosol from
ovariectomized rats with or without oestradiol-17fi (OE2) treatment. All data are
shown as mean ± S.E.M. with the number of determinations in parentheses.
Activator-induced PKC activity
(pmol thiophosphate/mg






3056 ± 551 (4)
2806 ± 651 (4)
95 ± 36 (4)
398 ± 26 (4)
Ovariectomized
+ OE2-treated
4829 ± 420 (7)*
4535 ± 714 (7)*
138+18(5)
807 ± 17 (5)*
These data show the PKC-activator-evoked phosphatidylserine-dependent, histone
III-S kinase activity, measured in the presence of either phorbol 12,13-dibutyrate-
(PDBu) (1 (imol/1) or 1,2-dioctanoyl-sn-glycerol (DOG) (100 p.mol/1) at either < 3
nmol free Ca2+/1 or 100 nmol free Ca2+/1. *p < 0.05 compared with corresponding
activity measured from untreated tissue (Mann-Whitney U-test).
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Figure 1
Effect of (a) phorbol 12,13-dibutyrate (PDBu) and (b) 1,2-dioctanoyl-sn-glycerol (DOG)
on LH release from anterior pituitary tissue taken from oestradiol-17fi (OE2) -treated
(hatched bars) and untreated (open bars) ovariectomized rats. Tissue was incubated
with medium only in the basal hour followed by three consecutive hourly
incubations (1st, 2nd, 3rd h) in the presence of either (a) 300 nmol PDBu/1 or (b) 200
gmol/DOG/1. Values are means ± S.E.M. (n = 4 - 10). The data represent net
hormone release, i.e. baseline release (determined in parallel control incubations
over 4 hours) was subtracted. Initial baseline secretion of LH was in the range of 12 -
35 mg/1 and was not different between tissue from OE2-treated and untreated
ovariectomized rats. LH release from both OE2-treated and -untreated tissue was
significantly increased above baseline levels during all hours of incubation with
either PDBu or DOG (*p < 0.05, Duncan's test or Mann-Whitney U-test). Phorbol
12,13-dibutyrate (PDBu)-, but not DOG-induced LH release was significantly
enhanced by OE2 treatment (+p < 0.05 comparecLwith LH release from untreated
tissue at each hour of stimulation with that PKC activator; Duncan's test or Mann-
Whitney U-test)
Figure 2
Effect of (a) phorbol 12,13-dibutyrate (PDBu) and (b) 1,2-dioctanoyl-stt-glycerol (DOG)
on GH release from anterior pituitary tissue taken from oestradiol-17fi (OE2) -treated
(hatched bars) and -untreated (open bars) ovariectomized rats. Tissue was incubated
with medium only in the basal hour followed by three consecutive hourly
incubations (1st, 2nd, 3rd h) in the presence of either 300 nmol PDBu/1 or 200 jimol
DOG/1. Values are means ± S.E.M. (n = 4 - 10). The data represent net hormone
release, i.e. baseline release (determined in parallel control incubations over 4
hours) was subtracted. Growth hormone release was increased in the presence of
PDBu, but not DOG during all hours of incubation with PKC activator (*p < 0.05,
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Duncan's test or Mann-Whitney U-test). There was no significant influence of OE2
treatment on GH release in the presence of PDBu or DOG (Duncan's test or Mann-
Whitney U-test).
Figure 3
Effect of the protein kinase C (PKC) inhibitor H7 on phorbol 12,13-dibutyrate (PDBu)
-stimulated Ca2+-independent (#/0) and Ca2+-dependent (■/□) cytosolic PKC
activity from ovariectomized rat anterior pituitary tissue with (closed symbols) or
without (open symbols) oestradiol-17fi (OE2) treatment. Cytosolic PKC activity was
partially purified and the phosphatidylserine-dependent, histone III-S kinase
activity measured with 1 (imol PDBu/1, and various concentrations of H7, in the
presence (100 pmol/l) or absence (< 3 nmol/1) Ca2+ as described in the methods
section. Each point on the curves is the mean ± S.E.M. of 4 - 6 determinations. The
IC50 values (concentration of the inhibitor causing 50% inhibition of the activator-
induced response) were obtained by using a non-linear, error-weighted curve fitting
programme (P.fit, Biosoft) and are expressed as the mean ± S.E.M. (with the number
of determinations in parentheses). Calcium-independent PDBu-induced PKC
activity in ovariectomized rat anterior pituitary cytosol was less sensitive to
inhibition by H7 than Ca2+-dependent activity, with IC50 values of 104 ± 23 (imol/1
and 27 ± 4 fimol/1 respectively (n = 4). This profile of H7-sensitivity was not
significantly altered by OE2 treatment, where the corresponding IC50 values were 113
± 25 pmol/1 and 32 ± 2 pmol/1 respectively (n = 6).
Figure 4
Effect of ionomycin on (a) LH and (b) GH release from anterior pituitary tissue taken
from oestradiol-17fi (OE2) -treated (hatched bars) and -untreated (open bars)
ovariectomized rats. Tissue was incubated with medium only in the basal hour
followed by three consecutive hours (1st, 2nd, 3rd h) in the presence of 30 pmol
ionomycin/1. Values are means ± S.E.M. (n = 4 - 6). The data represent net
27
hormone release, i.e. baseline release (determined in parallel control incubations
over 4 hours) was subtracted. Both LH and GH release were significantly increased
during all hours of incubation with ionomycin (*p < 0.05, Duncan's test or Mann-
Whitney U-test). Release of both LH and GH in the presence of ionomycin was not
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A possible role for phospholipase A2 in phorbol ester-induced release of
hormones from rat anterior pituitary tissue in vitro
By F. J. Thomson, R. Mitchell, M. S. Johnson and D. J. MacEwan (introduced
by S. Fleetwood-Walker). MRC Brain Metabolism Unit, 1 George Square,
Edinburgh, EH8 9JZ
Stimulation of luteinizing hormone (LH) and growth hormone (GH) release by
phorbol 12,13-dibutyrate (PDBu) in vitro (Johnson & Mitchell, 1989) is consistent
with a physiological role for protein kinase C (PKC) in triggering or modulating
release of these hormones. Differences in the pharmacology and time course of
PDBu-induced LH and GH release suggest that PKC(s) may influence different
targets in gonadotrophes and somatotrophes. Since arachidonic acid (AA) has been
reported to induce LH release (Naor et al. 1981), we investigated the possibility that
AA production by phospholipase A2 (PLA2) may have a role in PKC-mediated LH
and GH release.
Female COB/Wistar rats that had been maintained under controlled lighting and
temperature were killed at 13.00 h on the appropriate day of the oestrous cycle.
Anterior pituitary glands were removed and hemisected. The release of LH and
GH in vitro was measured as described previously (Johnson & Mitchell, 1989).
Phospholipase A2 activity was determined in anterior pituitary tissue preincubated
for 1 h with [3H]arachidonic acid in minimal essential medium at 37 °C under 95%
02/5% C02. After extensive washing, stimuli were applied for 1 h and the labelled
lipids and metabolites separated on octadecylsilyl silica (Powell, 1982).
Luteinizing hormone output increased progressively over three successive hourly
incubations with 300 nM-PDBu and was greatest using tissue from pro-oestrous or
oestrous rats. The PLA2 inhibitor quinacrine (50 fiM) significantly attenuated PDBu-
induced LH release from pro-oestrous and oestrous but not metoestrous or dioestrous
tissue. In contrast, the magnitude of PDBu-induced GH release was unaltered
throughout the oestrous cycle and was never reduced by quinacrine. Phospholipase
A2 activity in anterior pituitary tissue was stimulated 1-89 + 0-09-fold (mean + s.E.M.,
n = 8) by 300 nM-PDBu. These results indicate that activation of PLA2 by PKC can
occur in some pituitary cells and may have a role in influencing hormone release from
particular cell types.
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Differential activation of phospholipase A2 by
protein kinase C in pituitary cells
FIONA J. THOMSON, RORY MITCHELL, MELANIE S.
JOHNSON and DAVID J. MacEWAN
MRC Brain Metabolism Unit, University Department of
Pharmacology, 1 George Square, Edinburgh EH8 9JZ, U.K.
Phorbol esters have been shown to induce secretion of
luteinizing hormone (LH) and growth hormone (GH) from
anterior pituitary tissue in vitro [1] implicating a role for
protein kinase C (PKC) in triggering and/or modulating
release of these hormones. Using pituitary tissue from pro-
oestrous female rats, we have previously shown that phorbol
12,13-dibutyrate (PDBu) induced LH release is sensitive to
the PKC inhibitors staurosporine and H7 [1], In contrast,
PDBu-induced GH release is sensitive to staurosporine only,
thus suggesting that pharmacologically distinct forms of PKC
(perhaps different structural isoforms) are involved in the
modulation of LH release rather than GH release. Further
observations that the temporal pattern of phorbol induced-
LH release differs from that of GH release led us to consider
that PKCs might exert actions on different targets in
gonadotropics from those in somatotrophes to control
hormone secretion. Since arachidonic acid (AA) and its
metabolites have been shown to induce release of pituitary
lormones [2] we postulated that phospholipase A2 (PLA2)
ay be one such target for PKC in mediating pituitary
normone release. Here, we investigated the possibility that
pituitary PLA2 could be activated by PKC. The differential
effects of PKC- and PLA2-inhibitors on PDBu-induced
pituitary hormone release shown here suggest: (1) that only
certain forms of PKC can modulate PLA2 activity and (2) that
crosstalk between PKC and PLA2 may be an important
process in secretory responses in some but not all pituitary
cell types.
Pituitary hormone release was measured using pituitary
tissue obtained from pro-oestrous female cob wistar rats thathad been maintained under controlled lighting and
temperature. Briefly, pituitary glands were removed by
1300 h on the day of pro-oestrus and the anterior lobes
removed and hemisected. Each hemisected lobe was
placed into 2 ml of HEPES-buffered Minimal Essential
Medium containing Earle's salts (MEM). After 30 minutes
preincubation at 37°C, 95%02/5%CC>2 in a shaking water
bath, the medium was replaced. From then onwards,
medium was changed at hourly intervals with or without the
appropriate combination of drugs. Medium LH and GH
content were measured by radioimmunoassay.
Pituitary PLA2 activity was determined by measuring [3H]-
AA release from prelabelled pituitaries. Pituitary tissue was
removed from pro-oestrous rats as described above.
'interior pituitaries were quartered and placed in MEM (4 x
t per flask). After 30 minutes preincubation, the medium
was replaced with MEM containing 0.5 pCi [3H]-AA. After a
2 hour incubation period (37°C, 95% O2 5% CO2), the label
was removed and the tissue washed twice with MEM
containing 1% BSA. Tissue was then incubated for a further
hour in MEM containing 0.5% BSA with the appropriate
combination of drugs. Release of [3H]-AA was measured by
extraction of the incubation medium with octadecyl silica.
Fractions containing lipids and metabolic derivatives were
sequentially eluted with the solvents described by Powell
(1982) [3], The fraction taken to represent [3H]-AA released
from the tissue contained over 83% of authentic AA that was
added subsequent to tissue incubation and carried through
the extraction procedure.
Luteinizing hormone release from pro-oestrous anterior
pituitary tissue progressively increased over 3 consecutive
hourly incubations with PDBu (300 nM) from a level of
4.3±0.8 ng/ml (mean ±SEM,n=4) in the basal hour to
29.3±4.3ng/ml,n=4 in the third hour of incubation with PDBu.
Growth hormone release induced by PDBu was maximal by
the first hour of incubation increasing to a level of 3.14
±0.31, n = 19 fold of basal in the first hour with the phorbol.
In the presence of the PLA2 inhibitor, quinacrine (50 pM),
PDBu-induced LH release was significantly reduced by the
3rd hour of phorbol incubation from a level of secretion of
29.3±4.3ng/ml,n=4 in the absence of quinacrine to
13,2±0.9ng/ml,n=4 in the presence of quinacrine. Phorbol
12,13-dibutyrate-stimulated GH release was unaffected by
the presence of quinacrine. Similarly, PDBu (300 nM)
induced an 87 ± 8% (mean ± SEM, n = 10) increase in
pituitary PLA2 activity, an effect which was completely
blocked by quinacrine (50 pM). Phorbol 12,13-dibutyrate-
induced PLA2 activity was also significantly, but only
partially reduced to an increment of 48±11% (n=14) over
basal activity by 30 pM H7 and was completely inhibited to a
basal level of activity by 300 nM staurosporine.
The susceptibility of the PDBu-induced LH secretory
response, but not the GH secretory response, to quinacrine
indicates that in gonadotrophes, but not somatotrophes, a
PKC might act to cause hormone release by a pathway
involving increased PLA2 activity. The evidence that PLA2
may have a role in mediating phorbol-induced hormone
release is strengthened by the observation that PDBu
stimulates an increase in pituitary PLA2 activity.
Interestingly, the susceptibility of the PKC form(s) stimulating
pituitary PLA2 activity to PKC inhibitors matches the PKC-
inhibitor profile observed in induction of LH but not GH
release. That is, the actions of PDBu on LH release and
PLA2 activity are staurosporine and H7 sensitive, whereas
PDBu-stimulated GH release is susceptible to staurosporine
only. Thus it appears to be unlikely that a PKC-mediated
increase in PLA2 activity occurs in the GH secretory
response to PDBu. In contrast, in gonadotrophes. it appears
that a form of PKC is present which is capable of acting to
enhance PLA2 activity and consequently evoke hormone
release. These results lend support to other evidence [4,5]
for pharmacological heterogeneity in the functional cellular
actions of PKC(s) and further suggest that distinct forms of
PKC may have selective cellular targets.
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Abstract
The phospholipase A2 (PLA2) inhibitors, quinacrine, aristolochic acid,
p-bromophenacyl bromide and ONO-RS-082, blocked the priming effect of
luteinizing hormone releasing hormone (LHRH), but not acute LHRH-
induced gonadotrophin release measured from pro-oestrous rat anterior
pituitary pieces, in vitro. These results suggest that the intracellular
mechanisms involved in LHRH priming are distinct from those which
mediate LH release. Furthermore, neither LHRH-induced LH release from
pre-primed tissue nor Ca2+-induced LH release were attenuated by
quinacrine, indicating that this inhibitor does not interfere with the
general, Ca2+-dependent secretory apparatus of the gonadotroph.
Luteinizing hormone-releasing hormone induced the release of
[3H]arachidonic acid ([3H]AA) from [3H]AA prelabelled pro-oestrous rat
anterior pituitary tissue; a response which was sensitive to PLA2 inhibitors.
However, LHRH priming was not prevented by the inhibitors of AA
metabolism, NDGA and ETYA, except at high, non-specific concentrations,
suggesting that metabolism of AA may not be essential for LHRH priming.
These results indicate that LHRH receptors in pro-oestrous rat anterior
pituitary gonadotrophs can be coupled to PLA2 activation and that




Anterior pituitary responsiveness to luteinizing hormone-releasing
hormone (LHRH) is enhanced by prior exposure of the tissue to the peptide;
a phenomenon known as LHRH priming (Aiyer, Chiappa & Fink, 1974).
Consequently, after an initial exposure to LHRH, stimulus-induced
luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release
are both greatly enhanced. Although LHRH priming is important for the
timing and induction of pre-ovulatory surge of LH (Fink, 1988), little is
known about the intracellular mechanism by which it occurs. However,
the priming action of LHRH appears to be distinct from the mechanism by
which the peptide induces gonadotropin release (Pickering & Fink, 1976;
Fink, 1988; Johnson, Mitchell & Thomson, 1992). For example, LHRH
priming, but not initial secretory responses to LHRH may be dependent
upon protein synthesis and gonadotroph microfilament integrity (Pickering
& Fink, 1979). Recent evidence from our laboratory has suggested that
LHRH priming involves a facilitation of stimulus-secretion coupling in the
gonadotroph. Luteinizing hormone-releasing hormone receptor activation
is associated with phosphoinositide hydrolysis (Schrey, 1985; Andrews &
Conn, 1986) and production of inositol 1,4,5-trisphosphate (Ins(l,4,5)P3),
which releases Ca2+ from intracellular stores, and diacylglycerol (DAG),
which activates protein kinase C (PKC). Priming is accompanied by a
potentiation of LHRH-induced Ins(l,4,5)P3 production and Ca2+
mobilisation (Mitchell, Johnson, Ogier et al. 1988) and may be dependent
upon the activation of a distinct form of PKC, or a closely related kinase
(Johnson et al. 1992).
Several lines of evidence suggest that activation of phospholipase A2
(PLA2) is also important for responses to LHRH. The release of LH can be
induced from primary cultures of rat gonadotrophs by the PLA2 activator,
3
melittin, and by exogenously added PLA2 (Kiesel, Rabe, Hauser et al. 1985).
In addition, LHRH induces the release of arachidonic acid (AA), a product
of PLA2 action, and AA metabolites (Vanderhoek, Kiesel, Naor et al. 1984;
Catt, Loumaye, Wynn et al. 1985) and exogenously added AA can induce LH
release from dispersed anterior pituitary cells (Naor & Catt, 1981; Naor,
Vanderhoek, Lindner et al. 1983; Hulting, Lingren, Hokfelt et al. 1984;
Kiesel, Przylipiak, Emig et al. 1987) suggesting that this fatty acid may have a
second messenger function in gonadotrophs.
To investigate for any possible role of PLA2 in LHRH receptor
responses in pro-oestrous rat anterior pituitary gonadotrophs, we examined
the effects of a number of PLA2 inhibitors on LHRH-induced
gonadotrophin release and on LHRH priming. Here we report that the
induction of LHRH priming, but not initial secretory responses to LHRH, in




Adult female COB Wistar rats (200 g - 250 g body weight; Charles
River UK Ltd) were maintained under controlled lighting and temperature
with free access to food pellets (CRM, Labsure, Manea, Cambs, UK) and tap
water. Vaginal smears were examined and rats with a minimum of two
regular oestrous cycles were anaesthetised with sodium pentabarbitone (30
mg/kg; Sagatal; May and Baker Ltd Dagenham, Essex) by 11.30 am pro-
oestrus.
Chemicals
Luteinizing hormone-releasing hormone, quinacrine
dihydrochloride, (Sigma Chemical Co, Poole, Dorset, UK) l-(5-
4
isoquinolinesulphonyl-2 methylpiperazine) dihydrochloride (H7) (Gibco
Brl, Paisley, Scotland) and aristolochic acid sodium salt (Biomol Research
Laboratories, c/o Semat, St Albans, Herts, UK) were made up as stock
solutions in distilled H2O. Ionomycin, staurosporine (Novabiochem,
Nottingham, UK), 4-chloro-N-(p-pentylcinnamoyl) anthraniric acid (ONO-
RS-082) (a gift from ONO Pharmaceuticals, Osaka, Japan) and
nordihydroguaiaretic acid (NDGA) (Sigma) were made up as stock solutions
in dimethylformamide (DMF). Arachidonic acid, arachidic acid, p-
bromophenacyl bromide (BrPheBr), 4, 8, 11, 14-eicosatetraynoic acid (ETYA)
were purchased from Sigma and were made up as stock solutions in
ethanol. The maximum concentration of DMF or ethanol (0.05 % v/v) was
used in control experiments and had no effect on either baseline LH or FSH
release or [3H]AA release. [5, 6, 8, 9,11,12,13,15-3H(N)]-Arachidonic acid
(specific activity = 240 Ci/mmol) was purchased from Dupont, Dreieich,
Germany.
Hormone Release Experiments
The methods used were based upon those described by Pickering and
Fink (1976). Anterior pituitary glands were hemisected and each
hemipituitary placed into a flask containing 2 ml of prewarmed (37°C) and
gassed (95%C>2/5%C02) Hepes-buffered minimal essential medium (MEM)
(Gibco Brl, Paisley, UK) with Earles' salts. After a 30 minute pre-incubation
period in a shaking water bath (37°C, 95%C>2/5%C02), and every subsequent
hour thereafter, the medium was replaced. In the initial, basal hour, the
medium contained either a PLA2 inhibitor or no drug. For each subsequent
hour (1st h, 2nd h, 3rd h), medium also contained either LHRH (1 nmol/1)
or ionomycin (30 pmol/1) or arachidonic acid (300 (imol/1) or arachidic acid
(300 jimol/1).
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The medium removed at the end of each incubation period was kept
at -20°C until it was radioimmunoassayed for LH and FSH (Niswender,
Midgley, Monroe et al. 1968; Daane and Parlow, 1971). The standards used
were NIH-LH-S18 for the data in Figure la and NIADDK-rat LH-RP2 for the
remaining data and NIADDK-rat-FSH-RP2.
[3H]Arachidonic Acid Release Measurements
To obtain an index of anterior pituitary PLA2 activity, [3H]AA release
was measured from pre-labelled tissue as follows. Anterior pituitary glands
were removed, hemisected and each hemipituitary cut into two equal
quarters. Pairs of pituitary quarters were then placed into a silanised flask
containing 1 ml of prewarmed (37°C) and pregassed (95%02/5%C02) MEM
and preincubated in a shaking water bath (37°C, 95%02/5%C02) for 30
minutes. The medium was then replaced with fresh MEM containing 0.5
pCi of [3H]AA and the tissue incubated with the label for 2 hours. The
tissue was then washed three times in MEM containing 1% essential fatty
acid-free bovine serum albumin (BSA; Sigma, Poole, Dorset, UK) to remove
unesterified [3H]AA.
For studies of [3H]AA release, the tissue was incubated in MEM +
0.5% BSA (as a trap for released [3H]AA) in the presence or absence of
LHRH. After 15 min, the incubation medium was removed and the
[3H]AA released was measured by lipid extraction and reverse-phase liquid
chromatography on octadecyl silica (ODS) using the solvent system
described by Powell (1982). Ethanol was added to the incubation medium to
give a final ethanol concentration of 30% v/v and the medium was
centrifuged (10', 5°C, 3000 g). The supernatant was removed and adjusted to
pH 3. The acidified medium (4 ml) was loaded onto a 1.25 cm ODS column
(Sep pak Ci8 cartridge; Waters Chromatography, Watford, Hertfordshire,
UK) which had been prewashed with 5 ml ethanol followed by 5 ml of
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distilled H2O. Solvents were then passed through the columns in the
following order; 30% ethanol (20 ml), distilled H2O (20 ml), petroleum ether
(10 ml) and petroleum ether: CHCI3 (1:1, 20 ml). The fraction taken to
represent [3H]AA released from the tissue (petroleum ether: CHCI3)
contained over 83% of authentic standard [3H]AA that had been incubated
with denatured tissue (previously homogenised in 30% ethanol) and
carried through the extraction procedure.
The radioactivity remaining in the tissue was determined by washing
the tissue twice in 1 ml MEM containing 1% BSA and the tissue was
homogenised in 1 ml MEM + 0.5% BSA using a hand held tissue grinder.
Ethanol was then added to the tissue homogenate to give a final
concentration of 30% v/v. The homogenate was then centrifuged (10 min,
5°C, 3000 g) and the supernatant acidified to pH 3. Aliquots of the
supernatants from the tissue homogenate and the incubation media were
counted to give a measurement total amount of label incorporated into the
tissue for each flask.
In the experiments where the effects of inhibitors were examined on
LHRH responses, the tissue was preincubated for 15 minutes with the
appropriate inhibitor, the medium was removed and the tissue incubated
with, in addition, LHRH as described above.
Data Analysis
Data are expressed as means ± standard error of the mean (S.E.M.).
Statistical analyses were carried out using the Mann-Whitney U-test. The
concentration of PLA2 inhibitor which prevented 50 % of the maximal
response to LHRH (IC50 value) was obtained from fitting the data with the




The effect of PLA2 inhibitors on LHRH responses measured in pro-oestrous
rat anterior pituitary tissue.
Figure 1 shows the effect of the PLA2 inhibitor, quinacrine (50
pmol/1) (Markus & Ball, 1969; Loffler ,Bohn, Hesse et al. 1985) on LH
(Figure la) and FSH (Figure lb) release from pro-oestrous rat
hemipituitaries, measured over consecutive hourly incubations with
LHRH (1 nmol/1). Neither basal h, nor 1st h LHRH-induced LH release
were significantly altered in the presence of quinacrine. However, 2nd h
LHRH-induced LH release, where LHRH priming is expressed, was
significantly inhibited by quinacrine (p < 0.05) to levels that were 44.5 ± 3.1
% of control. Similarly, 2nd h, but not basal h or 1st h, LHRH-induced FSH
release was significantly inhibited by 50 pmol/1 quinacrine (Figure lb).
Quinacrine, at concentrations up to 100 pmol/1, caused a dose-dependent
inhibition of 2nd h LHRH-induced LH release to levels approaching those
measured during the 1st h of LHRH stimulus, but never to basal h levels
(Figure 2a). Another PLA2 inhibitor, p-bromophenacyl bromide (BrPheBr)
(Drenth, Enzig, Kalk et al. 1976) also blocked LHRH-induced release of
primed LH to levels approaching those measured during the 1st h of LHRH
incubation, without significantly affecting 1st hour LH release (Figure 2b).
However, at BrPheBr concentrations of 50 jimol/1 and above, basal h LH
release was elevated above control levels, suggesting that this compound
may have non-specific actions at high concentrations. Other putative
inhibitors of PLA2 activity, aristolochic acid (50 pmol/1) (Vishwanath,
Fawzy & Franson, 1988) and ONO-RS-082 (10 pmol/1) (Banga, Simons, Brass
et al. 1986) both inhibited 2nd h LHRH-induced LH release without altering
either basal h or 1st h LHRH-induced LH release (Table 1). Since 2nd h, but
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not 1st h, LHRH-induced LH release from pro-oestrous rat hemipituitaries
was inhibited these compounds, PLA2 activation may be required for LHRH
priming , but not for initial responses to LHRH.
Neither quinacrine (100 gmol/1), ONO-RS-082 (10 pmol/1) or
aristolochic acid (50 gmol/1) had any significant effect on baseline
gonadotrophin release when measured over several hours of incubation.
To examine the role of PLA2 in LHRH priming in more detail, a
number of experiments were carried out. These experiments considered
the critical period for the effect of quinacrine on pituitary responses and the
specificity of its action (Table 2, Figure 3). Firstly, hemipituitary pieces were
incubated for a basal h in medium only or with quinacrine (50 pmol/1),
followed by a 1st h incubation with, in addition, LHRH (1 nmol/1). After
the 1st h incubation, quinacrine was removed by washing the tissue three
times in fresh pre-warmed and pre-gassed MEM and the washed tissue was
incubated for a final hour (2nd h) with LHRH only. Control treatments
received identical incubations with LHRH and washing, but in the absence
of quinacrine. Consistent with the results shown in Figures 1 and 2,
quinacrine did not inhibit either basal h or 1st h LHRH-induced LH release
(Figure 3a). However, following a 1st h incubation with LHRH and
quinacrine, 2nd h LHRH-induced LH release was significantly reduced in
comparison to the controls, although the tissue had been washed to
remove the inhibitor from the 2nd h incubation period. These results
indicate that quinacrine may inhibit a PLA2-dependent induction of LHRH
priming during the 1st h of incubation, reducing 2nd h LHRH-induced LH
release as a consequence. However, it is possible that the washout
procedure was not completely effective and that a significant amount of
quinacrine was present in the tissue during the 2nd h of LHRH incubation.
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Consequently, additional experiments were carried out to further examine
the effects of quinacrine on the induction of LHRH priming
In a second experiment, the effect of quinacrine was examined on
LHRH-induced LH release from pituitary tissue which had been previously
primed (Figure 3b). Hemipituitaries were incubated for a 1st h with LHRH
(1 nmol/1) followed by a further 2 consecutive hourly incubations with
LHRH, either in the presence or absence of quinacrine (50 (imol/1).
Quinacrine had no significant inhibitory action on LHRH-induced LH
release from pre-primed tissue, even over two hours of incubation which
would allow for any possible slow-developing inhibitory effect on the
mechanism of hormone release.
To test the actions of quinacrine on the secretory apparatus of the
gonadotroph, the effects of this drug were examined on LH release induced
by raising intracellular Ca2+ levels (Table 2). In the presence of ionomycin
(30 |imol/l), LH release was increased above basal h levels, but with a
temporal pattern that did not exhibit 'priming'. Quinacrine (50 pmol/1)
had no significant inhibitory effect on ionomycin-induced LH release
measured during any hour of incubation indicating that this drug does not
inhibit the general secretory apparatus of the gonadotroph. In addition,
these results suggest that PLA2 is not involved in the mechanism of Ca2+-
induced LH release. In contrast, ionomycin-induced LH release from tissue
which had been previously primed by a 1st h incubation with LHRH was
significantly inhibited when quinacrine was present during the LHRH
incubation period.
In summary, PLA2 inhibitors prevented LHRH responses only when
present during the time when the induction of LHRH priming takes place
i.e. the 1st h of LHRH treatment (Figures 1, 2, 3 and Table 2). In addition,
quinacrine did not inhibit the actions of ionomycin; a secretagogue that
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does not elicit a priming response. These results therefore indicate an
involvement of PLA2 in the induction, but not in the expression of LHRH
priming.
The effect of LHRH on pro-oestrous rat anterior pituitary PLA2 activity.
The influence of LHRH on gonadotroph PLA2 activity was examined,
more directly, by measuring [3H]AA release from pre-labelled pro-oestrous
rat anterior pituitary tissue. After a 15 min incubation with LHRH (1
nmol/1), [3H]AA release increased by approximately 2 fold over basal levels
(Table 3). An increase in the release of free [3H]AA levels from cellular
phospholipids may result either from the action of PLA2 or by the
sequential actions of phospholipase C (PLC), which releases DAG, and DAG
lipase, which will catalyse the removal of a fatty acid from the glycerol
backbone of DAG (Naor, 1991). To determine the pathway of LHRH-
induced [3H]AA release from pro-oestrous rat anterior pituitary tissue, we
examined the effect of quinacrine and the DAG lipase inhibitor, RHC 80267,
on the LHRH response. The inhibitors were used at concentrations
reported to inhibit the activity of their targets with minimum side effects
(Hoffman, Prescott and Majerus, 1982; Sutherland and Amin, 1982). This
response was almost completely prevented by quinacrine (50 pmol/1), but
not by RHC 80267 (80 pmol/1), suggesting that the main route of [3H]AA
release induced by LHRH is via a pathway involving PLA2 but not DAG
lipase activation.
We have previously shown that the induction of LHRH priming is
dependent upon the activation of a pharmacologically distinct PKC (or
closely related kinase) which is readily inhibited by the PKC inhibitors,
staurosporine and Ro 31-8220, but not by another PKC inhibitor, H7
(Johnson et al. 1992). To test for the possible involvement of this PKC-like
kinase in the mechanism of LHRH-induced activation of PLA2 , the effects
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of H7 and staurosporine were examined on LHRH-induced [3H]AA release
(Table 4). [3H]Arachidonic acid release induced by LHRH was readily
blocked by staurosporine at a concentration (300 nmol/1) which inhibits
LHRH priming (Johnson et al. 1992). In contrast, LHRH-induced [3H]AA
release was relatively resistant to block by H7 at a concentration (30 pmol/1)
which is usually associated with the inhibition of PKC action in other cell
types (Hidaka, Inagaki, Kawamoto et al. 1984), but which is unable to inhibit
LHRH priming (Johnson et al. 1992). Thus, the induction of LHRH priming
may occur by a sequence of events which involve activation of an H7-
resistant form of a PKC-like kinase and its subsequent action to increase
PLA2 activity.
The involvement of arachidonic acid and arachidonic acid metabolites in
LHRH responses
Since PLA2 activation may be required for the induction of LHRH
priming, and LHRH induces an increase in [3H]AA release, AA may be a
mediator of LHRH action. In the presence of AA (300 p.mol/1), LH release
from pro-oestrous hemipituitaries was significantly increased during the
2nd and 3rd hs of incubation (Figure 4a). However, the saturated congener
of AA, arachidic acid (300 gmol/1), which lacks many of the biological
actions of AA (Beaumier, Faucher & Naccache, 1987; Negishi, Ito &
Hayaishi, 1990), also enhanced LH release (Figure 4b), suggesting that the
direct hormone releasing effect of AA on gonadotrophs is non-specific.
Since previous reports have suggested that lipoxygenase and
epoxygenase metabolites of AA may modulate gonadotrophin release (Naor
et al. 1983; Snyder, Capdevila, Chacos et al. 1983; Catt et al. 1985; Kiesel et al.
1987), we examined the effects of lipoxygenase inhibitors on LHRH
responses in pro-oestrous rat hemipituitary pieces. At a concentration of 10
fimol/1, where ETYA is reported to lipoxygenase and cyclo-oxygenase
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pathways of AA metabolism (Hamberg and Samuelsson, 1974), LHRH-
induced LH release was unaltered during any hour of incubation (Table 5)
suggesting that AA metabolism may not be required for LHRH responses in
pro-oestrous rat hemipituitaries. At a higher concentration, ETYA (30
jimol/1) inhibited 2nd h, but not 1st h, LHRH-induced LH release to levels
that were not significantly different from basal h measurements. Although
ETYA can inhibit the epoxygenase pathway at this higher concentration
(Capdevila, Gil, Orellana et al. 1988), ETYA, at this level, can also block PLA2
activity (Lanni and Becker, 1985). Nordihydroguaiaretic acid, when used at
a concentration (10 gmol/l) reported to inhibit the epoxygenase and
lipoxygenase pathways (Capdevila et al. 1988; Smith and Bowman, 1982)
had no effect on LHRH responses during any hour. However, when used at
a concentration of 30 gmol/l, NDGA inhibited both 1st and 2nd h LHRH-
induced LH release to baseline levels (Table 5), but at this level, ETYA can
also inhibit PLA2 activity (Lanni and Becker, 1985). Neither ETYA (10
p.mol/1) nor NDGA (10 (imol/1) had any significant effect on baseline LH
release measured over several hours of incubation.
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Discussion
Previous reports suggest that stimulation of rat gonadotroph and rat
granulosa cell LHRH receptors can lead to activation of PLA2 (Naor & Catt,
1981; Minegishi, Wang & Leung, 1987). The present evidence suggests that,
in pro-oestrous rat gonadotrophs, activation of PLA2 may be required for
the induction of LHRH priming, but not for initial LHRH-induced
gonadotrophin release. Quinacrine, BrPheBr, ONO-RS-082 and aristolochic
acid, blocked 2nd h LHRH-induced release of primed LH, but not 1st h
LHRH-induced LH release (Figures 1, 2 and Table 1), with potencies similar
to their effects on PLA2-mediated responses in other cell types (Loffler et al.
1985; Banga et al. 1986; Rosenthal, Vishwanath & Franson, 1989; Tohmatsu,
Nakashima & Nozawa, 1989). Notably, the concentration of quinacrine
which was reported to inhibit later secretory responses to LHRH in primary
cultures of anterior pituitary cells (IC50 = 20 (imol/1 (Naor and Catt, 1981)) is
within the range described here for the block of LHRH priming (IC50 = 34.0
± 10.3 (imol/1). The 2nd h response to LHRH was blocked by these drugs to
quantities that approached 1st h levels of LHRH-induced LH release, but
never to baseline levels. Thus, PLA2 activation may be required for
enhanced gonadotroph responsiveness. Consistent with this hypothesis,
LHRH-induced LH release was only inhibited if quinacrine was present
throughout the time when LHRH priming occurs i.e. the 1st h of LHRH
incubation, whereas LHRH-induced LH release from pre-primed tissue was
not blocked by quinacrine (Figure 3). Therefore, the induction, but not the
expression, of priming may be dependent upon PLA2 activation.
Quinacrine did not appear to inhibit primed LH release by affecting the later
stages in the mechanism of gonadotrophin release since this drug did not
alter ionomycin-induced LH release. However, if the tissue was primed by
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exposure to LHRH, facilitated LH release in response to the Ca2+-ionophore
was blocked by quinacrine to 'non-primed' levels (Table 2).
The specificity of both quinacrine and BrPheBr as inhibitors of PLA2
has been questioned in a number of studies (Irvine, 1982; Chang, Musser &
McGregor, 1987). High concentrations of quinacrine may perturb
membrane architecture and alter cell function (Dise, Burch & Goodman,
1982). However, quinacrine did not alter Ca2+-induced LH release (Table 2)
suggesting that a non-specific action of this drug is unlikely to be
responsible for its effects on LHRH responses. Bromophenacyl bromide
inhibits PLA2 activity by forming a covalent bond with a histidine residue
which is situated near the Ca2+-binding site of the enzyme (Volwerk,
Pieterson & de Haas, 1974; Drenth et al. 1976; Roberts, Deems, Mincey et al.
1977), but can covalently modify many other proteins (Erlanger, Vratsanos,
Wassermann et al. 1965) which may account for the effects of high
concentrations of BrPheBr on baseline LH release. Although BrPheBr and
quinacrine are putative inhibitors of PLC activity (Hofmann et al. 1982),
these compounds were unable to prevent the presumed PLC-dependent, 1st
h of LHRH-induced LH release. Furthermore, at the concentrations used
here, these compounds have been reported to inhibit PLA2 in other systems
without affecting PLC activity (Lazarewicz, Wroblewski, Palmer et al. 1988).
In agreement with the actions of quinacrine and BrPheBr on LHRH
responses, another PLA2 inhibitor, ONO-RS-082, blocked the primed
response to LHRH, at a concentration which can inhibit PLA2 activity in
platelets/ without affecting PLC activity (Tohmatsu et al. 1989; Banga et al.
1986).
In agreement with the pharmacological evidence presented here
which suggests that LHRH receptors modulate PLA2 activity, stimulation of
anterior pituitary pieces with LHRH is accompanied by a relatively rapid (15
15
min) increase in [3H]AA; a response which was blocked by inhibitors of
PLA2, but not DAG lipase action (Table 3). However, this result contrasts
with a previous report where RHC 80267, at concentrations that block DAG
lipase activity with little effect on PLA2 action, inhibited approximately 40
% of LHRH-induced LH release from dispersed anterior pituitary cells
(Chang, Morgan & Catt, 1988). The reason why DAG lipase is apparently
involved in LHRH responses in dispersed anterior pituitary cells, but not in
pro-ostrous rat anterior pituitary tissue is uncertain, but may reflect an
alteration in gonadotroph function following cell dispersal and culture.
In the LHRH receptor signal, modulation of gonadotroph PLA2
activity may be dependent upon the activity of PKC, suggesting that PLA2
activation may occur down-stream from inositol phospholipid hydrolysis.
An initial indication of a possible link between PLA2 and PKC activation in
response to LHRH came from the observation that activation of both of
these enzymes is required for LHRH priming (see also Johnson et al. 1992).
In addition, staurosporine, but not IT7, inhibited LHRH-induced [3H]AA
release at concentrations which are equivalent to their effects on LHRH self-
priming (IC50 = 26.3 ± 7.0 nmol/1 and 71.6 ± 13.3 pmol/l for staurosporine
and H7 respectively) (Johnson et al. 1992). Thus, LHRH receptor-mediated
activation of an H7-resistant, PKC-like kinase may modulate PLA2 activity,
enhancing gonadotroph responsiveness.
Although the product of PLA2-catalysed phospholipid hydrolysis, AA
could induce LH release, the saturated congener, arachidic acid, could also
elicit the same effect (Figure 4). Arachidic acid lacks many of the biological
actions of AA. For example, AA, but not arachidic acid, can induce Ca2+
release from intracellular stores (Beaumier et al. 1987) and can induce
inositol phospholipid hydrolysis (Negishi et al. 1990). It seems likely that
AA and arachidic acid may induce LH release by a non-specific action,
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perhaps by having a detergent-like effect on the gonadotroph cell
membrane (Karnovsky, Kleinfeld, Hoover et al. 1982; Kaye, van der Merwe,
Miller et al. 1992). In other cell types, endogenous AA production can be
dissociated from exocytosis (Churcher, Allan & Gomperts, 1990; Morgan &
Burgoyne, 1990) suggesting that AA is not a direct mediator of secretion. In
cell-free systems, however, AA can enhance fusion of secretory granules
into membranes in a Ca2+-dependent manner and may, therefore,
modulate exocytosis (Creutz, 1981). The possibility that an equivalent
action of AA in gonadotrophs may enhance Ca2+-induced LH release,
thereby contributing to the LHRH priming effect, is an interesting prospect.
The LHRH priming affect may not be dependent upon lipoxygenase
metabolites of AA since neither ETYA nor NDGA had any effect on LHRH
responses when either compound was used at a concentration (10 pmol/l)
which is said to inhibit lipoxygenase activity (Hamberg and Samuelsson,
1974; Capdevila et al. 1988; Smith and Bowman, 1982) (Table 5). At a higher
concentration (30 gmol/1), ETYA and NDGA did inhibit priming, but at this
concentration, both drugs also block PLA2 activity (Lanni & Becker, 1985).
We could therefore find no evidence at all that lipoxygenase metabolites of
AA have a role in LHRH responses in pro-oestrous rat anterior pituitary
tissue. However, both ETYA and NDGA can inhibit LHRH-induced LH
release from primary cultures of anterior pituitary cells (Naor et al. 1983;
Catt et al. 1985) and certain lipoxygenase metabolites can induce LH release
from dispersed anterior pituitary cells (Naor et al. 1983; Catt et al. 1985;
Kiesel et al. 1987). Furthermore, selective leukotriene receptor antagonists
can partially inhibit LHRH-induced LH release from dispersed rat anterior
pituitary cells (Catt et al. 1985; Kiesel, Przylipiak, Habenicht et al. 1991). The
discrepancy between these reports and the results presented here may be
accounted for by differences in the model of pituitary function chosen in
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each study (see Conn, Hawes & Janovick, 1992 for review). Therefore, it is
possible that lipoxygenase products have a different function in LHRH
receptor-signalling in pro-oestrous rat pituitary pieces than in dispersed
pituitary cells.
Epoxygenase metabolites have also been suggested to have a role in
LH release responses (Snyder et al. 1983). However, NDGA, at a
concentration reported to inhibit cyclo-oxygenase activity (10 pmol/1)
(Capdevila et al. 1988), had no significant inhibitory effect on LHRH
priming, suggesting that epoxygenase metabolites are not involved in this
response. Further studies using recently developed selective inhibitors of
the epoxygenase and lipoxygenase enzymes will help to clarify the role of
these pathways of AA metabolism in LHRH responses in pro-oestrous rat
anterior pituitary tissue.
In summary, these experiments show that the induction of LHRH-
priming requires PLA2 activation. The LHRH receptor controlled PLA2
activity is likely to be related to the hormonally-regulated, cytosolic forms
which have been described in other cell types (Gronich, Bonventre &
Nemenoff, 1990). Although these PLA2 forms can associate with the cell
membrane in a Ca2+-dependent manner, raised Ca2+ levels alone do not
seem to be sufficient for full activation of the gonadotroph PLA2, since
Ca2+-induced LH release was not blocked by PLA2 inhibitors. Instead, the
activity of an H7-resistant PRC is apparently required, in addition, to fully
elicit gonadotroph PLA2 activation.
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Figure 1
The effect of quinacrine on LHRH-induced LH (a) and FSH (b) release from
pro-oestrous rat anterior pituitary tissue.
Tissue was incubated for consecutive hours. In the basal h, tissue
was incubated in either medium only (open bars) or with quinacrine (50
gmol/1) (hatched bars) then, in addition, with LHRH (1 nmol/1)
throughout the following 1st and 2nd h incubations. Quinacrine had no
significant effect on either basal or 1st h gonadotrophin release, but
significantly inhibited 2nd h, LHRH-primed LH and FSH release (*p <
0.05). Data are means ± S.E.M. for 4-6 determinations.
FIGURE 2
Concentration-response curves for the effect of (a) quinacrine and (b) p-
bromophenacyl bromide on acute LHRH-induced LH release and LHRH
s
priming in pro-oestrous rat anterior pituitary tissue.
Tissue was incubated for a basal h (•) in medium only or with
increasing concentrations of either quinacrine (10 - 100 (imol/1) or p-
bromophenacyl bromide (BrPheBr) (1-100 pmol/l) followed by 2 further
consecutive hourly incubations (1st h (H) and 2nd h(A)) with, in addition,
LHRH (1 nmol/1). Both quinacrine and BrPheBr dose-dependently
inhibited 2nd h LHRH primed release of LH (*p < 0.05). Data are means ±
S.E.M. for 4-6. determinations.
Figure 3
Effect of quinacrine on the development of LHRH priming in pro-oestrous
rat anterior pituitary tissue.
Hemipituitary pieces were incubated for consecutive hours (basal h,
1st h, 2nd h, 3rd h). In part a, tissue was incubated for a basal h with
quinacrine (50 jimol/1) (hatched bars), or with no drug (open bars),
followed by a 1st h with, in addition, LHRH (1 nmol/1). The tissue was
then washed in MEM and all treatments were incubated with LHRH only
during the final 2nd h (open bars). Second h LHRH-induced LH release
was significantly inhibited (*p < 0.05) in the quinacrine treated samples. In
part b, tissue was incubated for a basal h in medium only followed by a 1st
h with 1 nmol/1 LHRH (open bars), during which LHRH priming takes
place. Throughout the 2nd and 3rd hs, tissue was then incubated with
LHRH only (open bars) or with LHRH and quinacrine (50 pmol/1)
(hatched bars). Quinacrine had no significant inhibitory effect on LHRH-
induced LH release from pre-primed tissue. Data are means ± S.E.M. for 6
determinations.
Figure 4
Effect of (a) arachidonic acid and (b) arachidic acid on LH release from pro-
oestrous rat anterior pituitary pieces.
Hemipituitary pieces were incubated for a basal h in medium only
followed by 3 consecutive hourly incubations (1st h, 2nd h, 3rd h) either in
medium only (open bars) or with (a) arachidonic acid ( 300 pmol/1) or (b)
arachidic acid (300 pmol/1). Luteinizing hormone release was significantly
increased above baseline during the 2nd and 3rd h of incubation with each
fatty acid (*p < 0.05). Values are means ± S.E.M. for 4 or 5 determinations.
Table 1
The effect of PLA2 inhibitors on initial LHRH-induced LH release and
LHRH priming in pro-oestrous rat anterior pituitary tissue.
Hemipituitaries were incubated, in vitro, for 3 hours. In the basal h
there was medium alone or a PLA2 inhibitor (ONO-RS-082 (10 (imol/1), or
aristolochic acid (50 pmol/1)). In the 1st and 2nd hs there was, in addition,
LHRH (1 nmol/1). The statistical significance of the inhibitory actions of the
PLA2 inhibitors tested was determined (*p < 0.05). Values given are the mean
± S.E.M. with the number of determinations in parentheses.
basal h
LH release (pg/1)
1st h 2nd h








2.9 ±0.6 (4) 23.4 ± 2.9 (4) *54.9 ± 9.7 (4)
Table 2
The effect of quinacrine on ionomycin-induced LH release from pro-
oestrous rat anterior pituitary tissue.
Hemipituitary pieces were incubated for consecutive hours. In the basal
h there was medium only or quinacrine (50 gmol/1). In the following hours, in
addition, the incubation medium contained ionomycin (30 pmol/1, Ii) or
LHRH (1 nmol/1, Li), followed by a 2nd h incubation with ionomycin (I2). The
statistical significance of the inhibitory effect of quinacrine was determined (*p




1st h 2nd h
I1-I2 4.5 ± 1.0(5) 26.7 ±2.0 (5) 26.8 ± 2.8 (5)
I1-I2













The effect of quinacrine and RHC 80267 on LHRH-induced [3H]arachidonic
acid release from prelabelled pro-oestrous rat anterior pituitary pieces.
Pairs of [3H]AA prelabelled anterior pituitary pieces were preincubated
for 15 minutes in medium only, or with quinacrine (50 pmol/1) or RHC 80267
(80 pmol/1). The medium was discarded and replaced with fresh medium
containing either no drug (basal) or LHRH (1 nmol/1) only or LHRH together
with either quinacrine or RHC 80267 and after a second 15 min incubation,
[3H]AA release was determined. In the presence of LHRH only, [3H]AA
release was increased to levels that were significantly greater than baseline
(+p<0.01). The statistical significance of the effect of quinacrine and RHC 80267
on responses to LHRH was determined (*p < 0.05). Values shown are the
means ± S.E.M. and the number of determinations are shown in parentheses.
[3H]AA release
(% of total label incorporated)
baseline 0.85 ± 0.06 (8)
LHRH +2.17 ±0.16 (8)
LHRH
+ *0.92 ± 0.07 (6)
quinacrine
LHRH
+ 1.66 ±0.18 (4)
RHC 80267
Table 4
The effect of PKC inhibitors on LHRH-induced [3H]arachidonic acid release
from prelabelled pro-oestrous anterior pituitary pieces.
Pairs of prelabelled anterior pituitary quarters were preincubated for 15
minutes with either no drug, or H7 (30 |imol/) or staurosporine (300 nmol/1).
The medium was replaced and fresh medium contained either no drug
(baseline), LHRH (1 nmol/1), LHRH and H7 or LHRH and staurosporine. In
the presence of LHRH only, [3H]AA release was increased to levels that were
significantly greater than baseline (+p<0.05). Staurosporine, but not H7,
significantly inhibited LHRH-induced [3H]AA release (*p< 0.05). Values
shown are the means ± S.E.M. and the number of determinations are shown in
parentheses.
[3H]AA release
(% of total label incorporated)
baseline 1.03 ±0.09 (10)
LHRH +2.33 ±0.30 (10)
LHRH
+ *0.95 ± 0.04 (10)
staurosporine
LHRH
+ 1.79 ±0.07 (8)
H7
Table 5
The effect of inhibitors of arachidonic acid metabolism on LHRH responses
measured in pro-oestrous rat anterior pituitary.
Hemipituitaries were incubated, in vitro, for consecutive hours. In the
basal h, tissue was incubated in medium only, or in the presence of ETYA, (10
or 30 (imol/l) or NDGA, (10 or 30 pmol/1). In the following hours (1st h, 2nd
h), the incubation medium contained, in addition, LHRH (1 nmol/1). The
statistical significance of the effects of each inhibitor was determined (p < 0.05)
Values shown are for means ± S.E.M. and the number of replicates are shown
in parenthesis.
LH release (pg/1)
basalh 1st h 2nd h
no drug
















3.7 ±0.4 (4) *6.3 ±1.2 (4) *6.32 ± 3.16 (4)
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